


**CUMULATIVE  
SUPPLEMENT 5  
May 2024**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

2024

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**Cumulative Supplement 5  
May 2024**

**CONTENTS**

*PAGE*

**Contents**

1.0	INTRODUCTION.....	v
1.1	HOW TO USE THE CUMULATIVE SUPPLEMENT.....	vi
1.2	CUMULATIVE SUPPLEMENT CONTENT.....	vi
1.3	APPLICANT NAME CHANGES.....	vii
1.4	LEVOTHYROXINE SODIUM.....	viii
1.5	AVAILABILITY OF THE EDITION.....	x
1.6	REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST.....	x
1.7	CUMULATIVE SUPPLEMENT LEGEND.....	xi
<b>DRUG PRODUCT LISTS</b>		
	Prescription Drug Product List .....	1-1
	OTC Drug Product List .....	2-1
	Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List .....	3-1
	Orphan Products Designations and Approvals List .....	4-1
	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution .....	5-1
<b>PATENT AND EXCLUSIVITY INFORMATION ADDENDUM</b>		
A.	Patent and Exclusivity Lists .....	A-1
B.	Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**44<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 5  
May 2024**

**1.0 INTRODUCTION**

This Cumulative Supplement is one of a series of monthly updates to the *Approved Drug Products with Therapeutic Equivalence Evaluations* (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug

Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List.

## 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and is current as of the date of publication.

Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPR) of any changes or corrections. The DOBPR can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
AKORN OPERATING CO LLC (AKORN)	EPIC PHARMA LLC (EPIC PHARMA LLC)
CADILA HEALTHCARE LTD (CADILA)	ZYDUS LIFESCIENCES LTD (ZYDUS LIFESCIENCES)
GLAXOSMITHKLINE (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE (GLAXOSMITHKLINE CONS)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS US LLC (GLAXOSMITHKLINE)	HALEON US HOLDINGS LLC (HALEON US HOLDINGS)
GLENMARK GENERICS INC USA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)

GLENMARK GENERICS LIMITED (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS INC USA (GLENMARK PHARMS INC)
GLENMARK GENERICS LTD (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK GENERICS LTD INDIA (GLENMARK GENERICS)	GLENMARK PHARMACEUTICALS LTD (GLENMARK PHARMS LTD)
GLENMARK PHARMACEUTICALS SA (GLENMARK PHARMS)	GLENMARK SPECIALY SA (GLENMARK SPECLT)
GLENMARK PHARMACEUTICALS SA SWITZERLAND (GLENMARK PHARMS SA)	GLENMARK SPECIALY SA (GLENMARK SPECLT)
LUPIN LTD (LUPIN LTD)	CHARTWELL RX SCIENCES LLC (CHARTWELL RX)
MYLAN LABORATORIES LTD (MYLAN LABS LTD)	XIROMED LLC (XIROMED)
PAR PHARMACEUTICAL (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR PHARMACEUTICAL INC (PAR PHARM INC)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
PAR STERILE PRODUCTS LLC (PAR STERILE PRODUCTS)	ENDO OPERATIONS LTD (ENDO OPERATIONS)
TARO PHARMACEUTICALS USA INC (TARO)	TARO PHARMACEUTICALS INC (TARO)
VERTICE PHARMA MANAGEMENT CORP (VERTICE)	ENCUBE ETHICALS PRIVATE LTD (ENCUBE)
ZYDUS WORLDWIDE DMCC (ZYDUS)	ZYDUS LIFESCIENCES GLOBAL FZE (ZYDUS LIFESCIENCES)

#### 1.4 LEVOTHYROXINE SODIUM<sup>1</sup>

Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to

---

<sup>1</sup> In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths.

establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code.

Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.<sup>2</sup>

- Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4).
- More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes.

TE Code	Proprietary Name	Applicant	Strength	Appl No	RLD	RS
AB1	UNITHROID	STEVENS J	0.3MG	N021210	RLD	RS
AB2	SYNTHROID	ABBVIE	0.3MG	N021402	RLD	RS
AB3	LEVOXYL	KING PHARMS	0.2MG	N021301	RLD	RS
AB4	THYRO-TABS	ALVOGEN INC	0.3MG	N021116	RLD	-
AB4	LEVOTHYROXINE SODIUM <sup>3</sup>	MYLAN	0.3MG	A076187	-	RS

<sup>2</sup> Please consult the Active Section of the Orange Book for information on other strengths.

<sup>3</sup> Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016).



## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List,  
<https://www.fda.gov/about-fda/reports-manuals-forms/forms>.

The current listing of the Orphan Product Designations and Approvals is available at <https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

## DEFINITIONS

### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

## REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES</u> <u>COUNTED</u>	<u>DEC</u> <u>2023</u>	<u>MAR</u> <u>2024</u>	<u>JUN 2024</u>	<u>SEP 2024</u>	<u>DEC 2024</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	23099 (12.1%)	23058 (12.2%)			
MULTISOURCE	20315 (87.9%)	20256 (87.8%)			
THERAPEUTICALLY EQUIVALENT	20252 (87.7%)	20198 (87.6%)			
NOT THERAPEUTICALLY EQUIVALENT	63 (0.3%)	58 (0.3%)			
EXCEPTIONS <sup>4</sup>	46 (0.2%)	46 (0.2%)			
NEW MOLECULAR ENTITIES APPROVED	32	18			
NUMBER OF APPLICANTS	1214	1219			

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

<sup>4</sup> Amino acid containing products of varying composition (see Introduction, page xx of the List).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval
NFTG	New first-time generic approval
CAHN <sup>5</sup>	Applicant holder firm name has changed
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration
CFTG	Change. A TE Code is added when a first time generic for an innovator is approved.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMKT	Change. RX to OTC marketing status switch.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug
CHRS	Change. Reference Standard
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition.

---

<sup>5</sup> The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query.

ABACAVIR SULFATE; LAMIVUDINE

TABLET;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
AB	!	CIPLA	EQ 600MG BASE;300MG	A091144	001	Mar 28, 2017	Jan	CHRS	
		EPZICOM							
	+	@ VIIV HLTHCARE	EQ 600MG BASE;300MG	N021652	001	Aug 02, 2004	Jan	DISC	
TABLET, FOR SUSPENSION;ORAL		ABACAVIR SULFATE AND LAMIVUDINE							
	+	@ MYLAN LABS LTD	EQ 60MG BASE;30MG	N204311	001	Dec 22, 2023	Jan	DISC	

ABIRATERONE ACETATE

TABLET;ORAL		ABIRATERONE ACETATE							
AB		MSN	500MG	A210686	002	Apr 24, 2024	Apr	NEWA	

ACETAMINOPHEN; BUTALBITAL

TABLET;ORAL		BUTALBITAL AND ACETAMINOPHEN							
AA		QUAGEN	300MG;50MG	A214305	001	Feb 01, 2024	Jan	NEWA	
AA			325MG;50MG	A214291	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
>D>	AA	KEY THERAP	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May	DISC	
>A>		@	300MG;50MG;40MG	A206615	001	Aug 04, 2017	May	DISC	
	AA		300MG;50MG;40MG	A206615	001	Aug 04, 2017	Apr	CAHN	
	AA	QUAGEN	300MG;50MG;40MG	A214288	001	Feb 08, 2024	Jan	NEWA	
	AA		325MG;50MG;40MG	A216376	001	Mar 12, 2024	Mar	NEWA	
	AA	SENORES PHARMS	300MG;50MG;40MG	A214087	001	Aug 13, 2021	Feb	CAHN	
	AA		325MG;50MG;40MG	A214087	002	Aug 13, 2021	Feb	CAHN	
TABLET;ORAL		BUTALBITAL, ACETAMINOPHEN AND CAFFEINE							
	AA	QUAGEN	325MG;50MG;40MG	A214287	001	Jan 18, 2024	Jan	NEWA	

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL		BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE							
>D>	AB	NOSTRUM LABS INC	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May	DISC	
>A>		@	325MG;50MG;40MG;30MG	A075929	001	Apr 22, 2002	May	DISC	

>D> ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL		TREZIX							
>D>		KEY THERAP	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May	DISC	
>A>		@	320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	May	DISC	
			320.5MG;30MG;16MG	A204785	001	Nov 26, 2014	Apr	CAHN	

ACETAMINOPHEN; CODEINE PHOSPHATE

SOLUTION;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
>D>		AKORN	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
		@	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	Feb	DISC	
>A>		@ PAI HOLDINGS	120MG/5ML;12MG/5ML	A040119	001	Apr 26, 1996	May	CAHN	
TABLET;ORAL		ACETAMINOPHEN AND CODEINE PHOSPHATE							
	AA	! SPECGX LLC	300MG;60MG	A040419	003	May 31, 2001	Apr	CHRS	
	AA	STRIDES PHARMA	300MG;15MG	A089990	001	Sep 30, 1988	Apr	CMFD	
	AA		300MG;30MG	A089805	001	Sep 30, 1988	Apr	CMFD	
	AA		300MG;60MG	A089828	001	Sep 30, 1988	Apr	CMFD	
		@ SUN PHARM INDS LTD	300MG;30MG	A085868	001		Jan	DISC	

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET;ORAL		HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
>A>		ENDO OPERATIONS	300MG;5MG	A090415	001	Jan 24, 2011	May	CAHN	
>A>		@	300MG;7.5MG	A090415	002	Jan 24, 2011	May	CAHN	
>A>		@	300MG;10MG	A090415	003	Jan 24, 2011	May	CAHN	
		@ PRINSTON INC	325MG;5MG	A214928	001	Dec 30, 2021	Mar	DISC	

TABLET;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

	@		325MG;7.5MG	A214928	002	Dec 30, 2021	Mar	DISC
	@		325MG;10MG	A214928	003	Dec 30, 2021	Mar	DISC
>D>	@	VINTAGE PHARMS	300MG;5MG	A090415	001	Jan 24, 2011	May	CAHN
>D>	@		300MG;7.5MG	A090415	002	Jan 24, 2011	May	CAHN
>D>	@		300MG;10MG	A090415	003	Jan 24, 2011	May	CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN

>A>	@	ENDO OPERATIONS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	May	CAHN
>D>	@	VINTAGE PHARMS	325MG/5ML;5MG/5ML	A203573	001	Dec 18, 2014	May	CAHN

TABLET;ORAL

OXYCODONE AND ACETAMINOPHEN

>A>	@	ENDO OPERATIONS	325MG;2.5MG	A090733	001	Jul 11, 2013	May	CAHN
>A>	@		325MG;5MG	A040105	001	Jul 30, 1996	May	CAHN
>A>	@		325MG;7.5MG	A090734	001	Jul 11, 2013	May	CAHN
>A>	@		325MG;10MG	A090734	002	Jul 11, 2013	May	CAHN
>D>	@	VINTAGE PHARMS	325MG;2.5MG	A090733	001	Jul 11, 2013	May	CAHN
>D>	@		325MG;5MG	A040105	001	Jul 30, 1996	May	CAHN
>D>	@		325MG;7.5MG	A090734	001	Jul 11, 2013	May	CAHN
>D>	@		325MG;10MG	A090734	002	Jul 11, 2013	May	CAHN

PERCOCET

AA	!	ENDO OPERATIONS	325MG;2.5MG	A040330	001	Jun 25, 1999	Apr	CAHN	
AA	!		325MG;5MG	A040330	002	Jun 25, 1999	Apr	CAHN	
>A>	+	@	325MG;5MG	A085106	002		May	CAHN	
AA	!		325MG;7.5MG	A040330	003	Nov 23, 2001	Apr	CAHN	
AA	!		325MG;10MG	A040330	004	Nov 23, 2001	Apr	CAHN	
>D>	+	@	VINTAGE PHARMS LLC	325MG;5MG	A085106	002		May	CAHN

ACETAZOLAMIDE

TABLET;ORAL

ACETAZOLAMIDE

	@	AJANTA PHARMA LTD	125MG	A211151	001	Sep 11, 2023	Feb	DISC
	@		250MG	A211151	002	Sep 11, 2023	Feb	DISC
>A>	AB	EPIC PHARMA LLC	125MG	A218023	001	May 14, 2024	May	NEWA
>A>	AB		250MG	A218023	002	May 14, 2024	May	NEWA
	@	TORRENT	125MG	A213706	001	Jan 26, 2024	Jan	DISC
AB			125MG	A213706	001	Jan 26, 2024	Jan	NEWA
	@		250MG	A213706	002	Jan 26, 2024	Jan	DISC
AB			250MG	A213706	002	Jan 26, 2024	Jan	NEWA

ACETAZOLAMIDE SODIUM

INJECTABLE;INJECTION

ACETAZOLAMIDE SODIUM

>A>	@	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	May	CAHN
>D>	@	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A205358	001	Jun 20, 2017	May	CAHN

ACETIC ACID, GLACIAL

SOLUTION/DROPS;OTIC

ACETIC ACID

AT	!	SAPTALIS PHARMS	2%	A040607	001	Feb 24, 2005	Apr	CHRS	
		VOSOL							
	+	@	HIKMA	2%	N012179	001		Apr	CRLD
	@		2%	N012179	001			Apr	DISC

ACETYLCYSTEINE

INJECTABLE;INTRAVENOUS

ACETYLCYSTEINE

>A>	AP	SOMERSET THERAPS LLC	6GM/30ML (200MG/ML)	A218397	001	Jun 07, 2024	May	NEWA	
		SOLUTION;INHALATION, ORAL							
		ACETYLCYSTEINE							
		@	EXELA PHARMA	20%	A205643	001	Nov 01, 2023	Feb	DISC

ACETYLCYSTEINE LYSINE

FOR SOLUTION;ORAL

LEGUBETI

+	!	GALEPHAR	EQ 500MG BASE/PACKET	N215040	001	Feb 13, 2024	Feb	NEWA
+	!		EQ 2.5GM BASE/PACKET	N215040	002	Feb 13, 2024	Feb	NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

	CAPSULE; ORAL						
	SEMPREX-D						
>D>	+ @	AUXILIUM PHARMS LLC	8MG; 60MG	N019806	001	Mar 25, 1994	May CAHN
>A>	+ @	ENDO OPERATIONS	8MG; 60MG	N019806	001	Mar 25, 1994	May CAHN

ACYCLOVIR

	CREAM; TOPICAL						
	ACYCLOVIR						
>A>	AB	TARO	5%	A205470	001	Jun 12, 2024	May NEWA
	OINTMENT; TOPICAL						
	ACYCLOVIR						
	@	COSETTE	5%	A205591	001	Nov 13, 2017	Mar DISC
	SUSPENSION; ORAL						
	ACYCLOVIR						
	@	HIKMA	200MG/5ML	A077026	001	Jun 07, 2005	Mar DISC
	@	VISTAPHARM LLC	200MG/5ML	A213951	001	Jan 11, 2021	Mar CAHN

ADAPALENE

>D>	LOTION; TOPICAL						
>D>	DIFFERIN						
>D>	+!	GALDERMA LABS LP	0.1%	N022502	001	Mar 17, 2010	May DISC
>A>	+ @		0.1%	N022502	001	Mar 17, 2010	May DISC

ADENOSINE

	SOLUTION; INTRAVENOUS						
	ADENOSINE						
	@	HOSPIRA	60MG/20ML (3MG/ML)	A203883	001	Mar 24, 2014	Feb DISC
	@		90MG/30ML (3MG/ML)	A203883	002	Mar 24, 2014	Feb DISC

ALBUTEROL SULFATE

	AEROSOL, METERED; INHALATION						
	ALBUTEROL SULFATE						
>A>	AB2	ARMSTRONG PHARMS	EQ 0.09MG BASE/INH	A212447	001	May 21, 2024	May NEWA
	SOLUTION; INHALATION						
	ALBUTEROL SULFATE						
	AN	LEXENPHARM	EQ 0.021% BASE	A215571	001	May 03, 2024	Apr NEWA
	AN		EQ 0.042% BASE	A215571	002	May 03, 2024	Apr NEWA
	SYRUP; ORAL						
	ALBUTEROL SULFATE						
	@	HIKMA	EQ 2MG BASE/5ML	A074749	001	Jan 30, 1998	Mar DISC

ALBUTEROL SULFATE; BUDESONIDE

	AEROSOL, METERED; INHALATION						
	AIRSUPRA						
	+!	ASTRAZENECA	EQ 0.09MG BASE/INH; 0.08MG/INH	N214070	001	Jan 10, 2023	Jan CPOT

ALENDRONATE SODIUM

	TABLET; ORAL						
	ALENDRONATE SODIUM						
>A>	AB	IPCA LABS LTD	EQ 10MG BASE	A206387	001	Jun 04, 2024	May NEWA
>A>	AB		EQ 35MG BASE	A206387	002	Jun 04, 2024	May NEWA
>A>	AB		EQ 40MG BASE	A206387	003	Jun 04, 2024	May NEWA
>A>	AB		EQ 70MG BASE	A206387	004	Jun 04, 2024	May NEWA

ALISKIREN HEMIFUMARATE

	TABLET; ORAL						
	ALISKIREN HEMIFUMARATE						
AB		ENDO OPERATIONS	EQ 150MG BASE	A206665	001	Mar 22, 2019	Apr CAHN
AB			EQ 300MG BASE	A206665	002	Mar 22, 2019	Apr CAHN

ALLOPURINOL

	TABLET; ORAL						
	ALLOPURINOL						
AB		ENDO OPERATIONS	100MG	A075798	001	Jun 27, 2003	Apr CAHN
AB			300MG	A075798	002	Jun 27, 2003	Apr CAHN
	@	LUPIN LTD	100MG	A211807	001	Dec 14, 2023	Apr DISC
	@		300MG	A211807	002	Dec 14, 2023	Apr DISC

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

ALOSETRON HYDROCHLORIDE

>A>	@ ENDO OPERATIONS	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN
>A>	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN
>D>	@ PAR PHARM INC	EQ 0.5MG BASE	A206113	001	Feb 23, 2018	May	CAHN
>D>	@	EQ 1MG BASE	A206113	002	Feb 23, 2018	May	CAHN

ALPELISIB

GRANULES; ORAL

VIJOICE

+!	NOVARTIS	50MG/PACKET	N218466	001	Apr 24, 2024	Apr	NEWA
----	----------	-------------	---------	-----	--------------	-----	------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB	CHARTWELL RX	0.25MG	A207507	001	Jul 09, 2018	Mar	CAHN
AB		0.5MG	A207507	002	Jul 09, 2018	Mar	CAHN
AB		1MG	A207507	003	Jul 09, 2018	Mar	CAHN
AB		2MG	A207507	004	Jul 09, 2018	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

>D>	@ ANCHEN PHARMS	0.5MG	A078469	001	Sep 29, 2011	May	CAHN
	@	0.5MG	A078469	001	Sep 29, 2011	Mar	DISC
>D>	@	1MG	A078469	002	Sep 29, 2011	May	CAHN
	@	1MG	A078469	002	Sep 29, 2011	Mar	DISC
>D>	@	2MG	A078469	003	Sep 29, 2011	May	CAHN
	@	2MG	A078469	003	Sep 29, 2011	Mar	DISC
>D>	@	3MG	A078469	004	Sep 29, 2011	May	CAHN
	@	3MG	A078469	004	Sep 29, 2011	Mar	DISC
>A>	@ ENDO OPERATIONS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
>A>	@	0.5MG	A078469	001	Sep 29, 2011	May	CAHN
>A>	@	1MG	A078442	002	Oct 15, 2007	May	CAHN
>A>	@	1MG	A078469	002	Sep 29, 2011	May	CAHN
>A>	@	2MG	A078442	003	Oct 15, 2007	May	CAHN
>A>	@	2MG	A078469	003	Sep 29, 2011	May	CAHN
>A>	@	3MG	A078442	004	Oct 15, 2007	May	CAHN
>A>	@	3MG	A078469	004	Sep 29, 2011	May	CAHN
>D>	@ VINTAGE PHARMS	0.5MG	A078442	001	Oct 15, 2007	May	CAHN
>D>	@	1MG	A078442	002	Oct 15, 2007	May	CAHN
>D>	@	2MG	A078442	003	Oct 15, 2007	May	CAHN
>D>	@	3MG	A078442	004	Oct 15, 2007	May	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB	ENDO OPERATIONS	0.25MG	A078088	001	Jan 09, 2009	Apr	CAHN
AB		0.5MG	A078088	002	Jan 09, 2009	Apr	CAHN
AB	!	1MG	A078088	003	Jan 09, 2009	Apr	CAHN
AB		2MG	A078088	004	Jan 09, 2009	Apr	CAHN

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ ENDO OPERATIONS	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr	CAHN
AP	+	0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr	CAHN
	+!	0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr	CAHN
AP	+	0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr	CAHN
	+!	0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr	CAHN
AP	+!	0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr	CAHN
	+!	0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr	CAHN

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

AMANTADINE HYDROCHLORIDE

>A>	@ ENDO OPERATIONS	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN
	@ GENUS	50MG/5ML	A076352	001	Sep 10, 2004	Jan	CAHN
>D>	@ VINTAGE	50MG/5ML	A077992	001	Dec 12, 2006	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

OSMOLEX ER

+	@ ADAMAS OPERATIONS	EQ 129MG BASE	N209410	001	Feb 16, 2018	Apr	DISC
+	@	EQ 193MG BASE	N209410	002	Feb 16, 2018	Apr	DISC

AMBRISENTAN

TABLET; ORAL

AMBRISENTAN

>A>	@ ENDO OPERATIONS	5MG	A209509	001	Apr 10, 2019	May	CAHN
>A>	@	10MG	A209509	002	Apr 10, 2019	May	CAHN
>D>	@ PAR PHARM INC	5MG	A209509	001	Apr 10, 2019	May	CAHN
	@	5MG	A209509	001	Apr 10, 2019	Apr	DISC
>D>	@	10MG	A209509	002	Apr 10, 2019	May	CAHN
	@	10MG	A209509	002	Apr 10, 2019	Apr	DISC

AMCINONIDE

LOTION; TOPICAL

AMCINONIDE

! GENUS

0.1%

A076329 001 Nov 06, 2002 Jan CAHN

OINTMENT; TOPICAL

AMCINONIDE

AB

! GENUS

0.1%

A076096 001 Nov 19, 2002 Jan CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP

QILU

EQ 250MG BASE/ML

A218146 001 Mar 19, 2024 Mar NEWA

AMILORIDE HYDROCHLORIDE

TABLET; ORAL

AMILORIDE HYDROCHLORIDE

AB

! ENDO OPERATIONS

5MG

A070346 001 Jan 22, 1986 Apr CAHN

AMINO ACIDS; DEXTROSE

INJECTABLE; INJECTION

CLINIMIX 8/14 SULFITE FREE IN DEXTROSE 14% IN PLASTIC CONTAINER

BAXTER HLTHCARE

8%; 14GM/100ML

N020734 019 Apr 13, 2021 Apr NEWA

AMINOCAPROIC ACID

SOLUTION; ORAL

AMICAR

+ @ HIKMA

0.25GM/ML

N015230 002

Mar DISC

AMINOCAPROIC ACID

AA

! TULEX PHARMS INC

0.25GM/ML

A212494 001 Aug 11, 2020 Mar CHRS

@ VISTAPHARM LLC

0.25GM/ML

A212814 001 Feb 26, 2020 Mar CAHN

TABLET; ORAL

AMICAR

+ @ HIKMA

500MG

N015197 001

Mar DISC

+ @

1GM

N015197 002 Jun 24, 2004

Mar DISC

AMIODARONE HYDROCHLORIDE

INJECTABLE; INJECTION

AMIODARONE HYDROCHLORIDE

>D> AP

HOSPIRA

50MG/ML

A203884 001 Nov 25, 2013

May DISC

>A>

@

50MG/ML

A203884 001 Nov 25, 2013

May DISC

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

>D>

@ AIPING PHARM INC

10MG

A212654 002 Sep 29, 2021

May CMFD

>A> AB

@

10MG

A212654 002 Sep 29, 2021

May CMFD

>D>

@

25MG

A212654 001 Apr 07, 2020

May CMFD

>A> AB

@

25MG

A212654 001 Apr 07, 2020

May CMFD

>D>

@

50MG

A212654 003 Sep 29, 2021

May CMFD

>A> AB

@

50MG

A212654 003 Sep 29, 2021

May CMFD

>D>

@

75MG

A212654 004 Sep 29, 2021

May CMFD

>A> AB

@

75MG

A212654 004 Sep 29, 2021

May CMFD

>D>

@

100MG

A212654 005 Sep 29, 2021

May CMFD

>A> AB

@

100MG

A212654 005 Sep 29, 2021

May CMFD

>D>

@

150MG

A212654 006 Sep 29, 2021

May CMFD

>A> AB

@

150MG

A212654 006 Sep 29, 2021

May CMFD

>A>

@ ENDO OPERATIONS

10MG

A040218 001 Sep 11, 1997

May CAHN

>A>

@

25MG

A040218 002 Sep 11, 1997

May CAHN

>A>

@

50MG

A040218 003 Sep 11, 1997

May CAHN

>A>

@

75MG

A040218 004 Sep 11, 1997

May CAHN

>A>

@

100MG

A040218 005 Sep 11, 1997

May CAHN



TABLET;ORAL

AMITRIPTYLINE HYDROCHLORIDE

>A>	@	150MG	A 040218	006	Sep 11, 1997	May	CAHN
>D>	@	VINTAGE PHARMS 10MG	A 040218	001	Sep 11, 1997	May	CAHN
>D>	@	25MG	A 040218	002	Sep 11, 1997	May	CAHN
>D>	@	50MG	A 040218	003	Sep 11, 1997	May	CAHN
>D>	@	75MG	A 040218	004	Sep 11, 1997	May	CAHN
>D>	@	100MG	A 040218	005	Sep 11, 1997	May	CAHN
>D>	@	150MG	A 040218	006	Sep 11, 1997	May	CAHN

AMLODIPINE BESYLATE

TABLET;ORAL

AMLODIPINE BESYLATE

@	AIPING PHARM INC	EQ 2.5MG BASE	A 077759	001	Jul 09, 2007	Feb	CAHN
@		EQ 5MG BASE	A 077759	002	Jul 09, 2007	Feb	CAHN
@		EQ 10MG BASE	A 077759	003	Jul 09, 2007	Feb	CAHN
@	SUN PHARM INDS LTD	EQ 2.5MG BASE	A 077974	001	Jul 09, 2007	Jan	DISC
@		EQ 5MG BASE	A 077974	002	Jul 09, 2007	Jan	DISC
@		EQ 10MG BASE	A 077974	003	Jul 09, 2007	Jan	DISC

AMLODIPINE BESYLATE; BENAZEPRIL HYDROCHLORIDE

CAPSULE;ORAL

AMLODIPINE BESYLATE AND BENAZEPRIL HYDROCHLORIDE

@	AMNEAL	EQ 2.5MG BASE;10MG	A 077215	001	Dec 07, 2018	Apr	CAHN
@		EQ 5MG BASE;10MG	A 077215	002	Dec 07, 2018	Apr	CAHN
@		EQ 5MG BASE;20MG	A 077215	003	Dec 07, 2018	Apr	CAHN
@		EQ 10MG BASE;20MG	A 077215	004	Dec 07, 2018	Apr	CAHN

AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL

TABLET;ORAL

AMLODIPINE AND OLMESARTAN MEDOXOMIL

AB	SCIEGEN PHARMS INC	EQ 5MG BASE;20MG	A 209010	001	Dec 03, 2018	Feb	CMFD
AB		EQ 5MG BASE;40MG	A 209010	002	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;20MG	A 209010	003	Dec 03, 2018	Feb	CMFD
AB		EQ 10MG BASE;40MG	A 209010	004	Dec 03, 2018	Feb	CMFD

AMOXICILLIN

FOR SUSPENSION;ORAL

AMOXICILLIN

>A>	AB	CHARTWELL RX	400MG/5ML	A 065319	002	Jun 18, 2007	May	CAHN
>D>	@	DAVA PHARMS INC	125MG/5ML	A 062927	001	Nov 25, 1988	May	CAHN
	@		125MG/5ML	A 062927	001	Nov 25, 1988	Mar	DISC
>D>	@		250MG/5ML	A 062927	002	Nov 25, 1988	May	CAHN
	@		250MG/5ML	A 062927	002	Nov 25, 1988	Mar	DISC
>A>	@	ENDO OPERATIONS	125MG/5ML	A 062927	001	Nov 25, 1988	May	CAHN
>A>	@		250MG/5ML	A 062927	002	Nov 25, 1988	May	CAHN
>D>	AB	WOCKHARDT BIO AG	400MG/5ML	A 065319	002	Jun 18, 2007	May	CAHN
		AMOXIL						
AB	+	US ANTIBIOTICS	400MG/5ML	N 050760	002	Apr 15, 1999	Apr	CMFD

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

ADDERALL XR 10

AB1	+	TAKEDA PHARMS USA	2.5MG;2.5MG;2.5MG;2.5MG	N 021303	001	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 15						
AB1	+	TAKEDA PHARMS USA	3.75MG;3.75MG;3.75MG;3.75MG	N 021303	006	May 22, 2002	Jan	CTEC
		ADDERALL XR 20						
AB1	+	TAKEDA PHARMS USA	5MG;5MG;5MG;5MG	N 021303	002	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 25						
AB1	+	TAKEDA PHARMS USA	6.25MG;6.25MG;6.25MG;6.25MG	N 021303	004	May 22, 2002	Jan	CTEC
		ADDERALL XR 30						
AB1	+	TAKEDA PHARMS USA	7.5MG;7.5MG;7.5MG;7.5MG	N 021303	003	Oct 11, 2001	Jan	CTEC
		ADDERALL XR 5						
AB1	+	TAKEDA PHARMS USA	1.25MG;1.25MG;1.25MG;1.25MG	N 021303	005	May 22, 2002	Jan	CTEC
		DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE						
AB1		ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A 077302	001	Jun 22, 2012	Jan	CTEC
AB1			2.5MG;2.5MG;2.5MG;2.5MG	A 077302	002	Jun 22, 2012	Jan	CTEC
AB1			3.75MG;3.75MG;3.75MG;3.75MG	A 077302	003	Jun 22, 2012	Jan	CTEC
AB1			5MG;5MG;5MG;5MG	A 077302	004	Jun 22, 2012	Jan	CTEC
AB1			6.25MG;6.25MG;6.25MG;6.25MG	A 077302	005	Jun 22, 2012	Jan	CTEC
AB1			7.5MG;7.5MG;7.5MG;7.5MG	A 077302	006	Jun 22, 2012	Jan	CTEC
AB1		ANI PHARMS	1.25MG;1.25MG;1.25MG;1.25MG	A 205401	001	Jan 22, 2019	Jan	CTEC

## CAPSULE, EXTENDED RELEASE;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A205401	002	Jan 22, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A205401	003	Jan 22, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A205401	004	Jan 22, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A205401	005	Jan 22, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A205401	006	Jan 22, 2019	Jan CTEC
AB1	ASCENT PHARMS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214959	001	Sep 29, 2021	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214959	002	Sep 29, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214959	003	Sep 29, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214959	004	Sep 29, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214959	005	Sep 29, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214959	006	Sep 29, 2021	Jan CTEC
AB1	ELITE LABS INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A212037	001	Dec 11, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A212037	002	Dec 11, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A212037	003	Dec 11, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A212037	004	Dec 11, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A212037	005	Dec 11, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A212037	006	Dec 11, 2019	Jan CTEC
>A>	@ ENDO OPERATIONS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	May CAHN
>A>	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	May CAHN
>A>	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	May CAHN
>A>	@	5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	May CAHN
>A>	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	May CAHN
>A>	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	May CAHN
AB1	GRANULES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A217027	001	Jan 23, 2023	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A217027	002	Jan 23, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A217027	003	Jan 23, 2023	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A217027	004	Jan 23, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A217027	005	Jan 23, 2023	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A217027	006	Jan 23, 2023	Jan CTEC
AB1	IMPAX LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A076852	001	Feb 16, 2016	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A076852	002	Feb 16, 2016	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A076852	003	Feb 16, 2016	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A076852	004	Feb 16, 2016	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A076852	005	Feb 16, 2016	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A076852	006	Feb 16, 2016	Jan CTEC
AB1	LANNETT CO INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A214403	001	Nov 26, 2021	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A214403	002	Nov 26, 2021	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A214403	003	Nov 26, 2021	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A214403	004	Nov 26, 2021	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A214403	005	Nov 26, 2021	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A214403	006	Nov 26, 2021	Jan CTEC
>D>	@ PAR PHARM INC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A206159	001	May 31, 2019	May CAHN
>D>	@	2.5MG; 2.5MG; 2.5MG; 2.5MG	A206159	002	May 31, 2019	May CAHN
>D>	@	3.75MG; 3.75MG; 3.75MG; 3.75MG	A206159	003	May 31, 2019	May CAHN
>D>	@	5MG; 5MG; 5MG; 5MG	A206159	004	May 31, 2019	May CAHN
>D>	@	6.25MG; 6.25MG; 6.25MG; 6.25MG	A206159	005	May 31, 2019	May CAHN
>D>	@	7.5MG; 7.5MG; 7.5MG; 7.5MG	A206159	006	May 31, 2019	May CAHN
AB1	RHODES PHARMS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A210651	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A210651	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A210651	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A210651	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A210651	005	May 17, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A210651	006	May 17, 2019	Jan CTEC
AB1	SPECGX LLC	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211547	001	Apr 22, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211547	002	Apr 22, 2019	Jan CTEC
AB2		3.125MG; 3.125MG; 3.125MG; 3.125MG	A211546	001	Aug 31, 2023	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211547	003	Apr 22, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211547	004	Apr 22, 2019	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211546	002	Aug 31, 2023	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211547	005	Apr 22, 2019	Jan CTEC
AB1		7.5MG; 7.5MG; 7.5MG; 7.5MG	A211547	006	Apr 22, 2019	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A211546	003	Aug 31, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A211546	004	Aug 31, 2023	Jan CTEC
AB2	SUN PHARM INDS INC	3.125MG; 3.125MG; 3.125MG; 3.125MG	A215997	001	Sep 27, 2023	Jan CTEC
AB2		6.25MG; 6.25MG; 6.25MG; 6.25MG	A215997	002	Sep 27, 2023	Jan CTEC
AB2		9.375MG; 9.375MG; 9.375MG; 9.375MG	A215997	003	Sep 27, 2023	Jan CTEC
AB2		12.5MG; 12.5MG; 12.5MG; 12.5MG	A215997	004	Sep 27, 2023	Jan CTEC
AB1	SUN PHARM INDUSTRIES	1.25MG; 1.25MG; 1.25MG; 1.25MG	A211715	001	May 17, 2019	Jan CTEC
AB1		2.5MG; 2.5MG; 2.5MG; 2.5MG	A211715	002	May 17, 2019	Jan CTEC
AB1		3.75MG; 3.75MG; 3.75MG; 3.75MG	A211715	003	May 17, 2019	Jan CTEC
AB1		5MG; 5MG; 5MG; 5MG	A211715	004	May 17, 2019	Jan CTEC
AB1		6.25MG; 6.25MG; 6.25MG; 6.25MG	A211715	005	May 17, 2019	Jan CTEC

CAPSULE, EXTENDED RELEASE;ORAL

DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE							
AB1		7.5MG;7.5MG;7.5MG;7.5MG	A211715	006	May 17, 2019	Jan	CTEC
AB2	TEVA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	A210876	001	Jan 31, 2022	Jan	CTEC
AB2		6.25MG;6.25MG;6.25MG;6.25MG	A210876	002	Jan 31, 2022	Jan	CTEC
AB2		9.375MG;9.375MG;9.375MG;9.375MG	A210876	003	Jan 31, 2022	Jan	CTEC
AB2		12.5MG;12.5MG;12.5MG;12.5MG	A210876	004	Jan 31, 2022	Jan	CTEC
MYDAYIS							
AB2	+ TAKEDA PHARMS USA	3.125MG;3.125MG;3.125MG;3.125MG	N022063	001	Jun 20, 2017	Jan	CTEC
AB2	+	6.25MG;6.25MG;6.25MG;6.25MG	N022063	002	Jun 20, 2017	Jan	CTEC
AB2	+	9.375MG;9.375MG;9.375MG;9.375MG	N022063	003	Jun 20, 2017	Jan	CTEC
AB2	+!	12.5MG;12.5MG;12.5MG;12.5MG	N022063	004	Jun 20, 2017	Jan	CTEC

AMPHETAMINE SULFATE

TABLET;ORAL							
AMPHETAMINE SULFATE							
AA	SENORES PHARMS	5MG	A212901	001	May 22, 2020	Feb	CAHN
AA		10MG	A212901	002	May 22, 2020	Feb	CAHN
	@ SUN PHARM INDS INC	5MG	A214574	001	Jan 27, 2021	Mar	DISC
	@	10MG	A214574	002	Jan 27, 2021	Mar	DISC
EVEKEO							
AA	AZURITY	5MG	A200166	001	Aug 09, 2012	Mar	CAHN
AA	!	10MG	A200166	002	Aug 09, 2012	Mar	CAHN
TABLET, ORALLY DISINTEGRATING;ORAL							
EVEKEO ODT							
	+ @ AZURITY	5MG	N209905	001	Jan 30, 2019	Apr	DISC
	+ @	10MG	N209905	002	Jan 30, 2019	Apr	DISC
	+ @	15MG	N209905	003	Jan 30, 2019	Apr	DISC
	+ @	20MG	N209905	004	Jan 30, 2019	Apr	DISC

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE;INJECTION							
AMPICILLIN AND SULBACTAM							
	@ ASTRAL	EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL	A090579	001	Jan 08, 2016	Apr	DISC
	@	EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL	A090579	002	Jan 08, 2016	Apr	DISC
	@	EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL	A090578	001	Jan 11, 2016	Apr	DISC

AMPICILLIN/AMPICILLIN TRIHYDRATE

FOR SUSPENSION;ORAL							
AMPICILLIN TRIHYDRATE							
>D>	@ DAVA PHARMS INC	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN
>D>	@	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN
>A>	@ ENDO OPERATIONS	EQ 125MG BASE/5ML	A062982	001	Feb 10, 1989	May	CAHN
>A>	@	EQ 250MG BASE/5ML	A062982	002	Feb 10, 1989	May	CAHN

APIXABAN

TABLET;ORAL							
APIXABAN							
>D>	AB APOTEX	2.5MG	A210091	001	Feb 16, 2024	May	DISC
>A>	@	2.5MG	A210091	001	Feb 16, 2024	May	DISC
	AB	2.5MG	A210091	001	Feb 16, 2024	Feb	NEWA
>D>	AB	5MG	A210091	002	Feb 16, 2024	May	DISC
>A>	@	5MG	A210091	002	Feb 16, 2024	May	DISC
	AB	5MG	A210091	002	Feb 16, 2024	Feb	NEWA

APREMILAST

TABLET;ORAL							
APREMILAST							
AB	MANKIND PHARMA	10MG	A211734	001	Feb 07, 2024	Jan	NEWA
AB		20MG	A211734	002	Feb 07, 2024	Jan	NEWA
AB		30MG	A211734	003	Feb 07, 2024	Jan	NEWA

APROCITENTAN

TABLET;ORAL							
TRYVIO							
	+! IDORSIA	12.5MG	N217686	001	Mar 19, 2024	Mar	NEWA

ARFORMOTEROL TARTRATE

SOLUTION; INHALATION  
ARFORMOTEROL TARTRATE

>A>	AN	CF PHARMTECH	EQ 0.015MG BASE/2ML	A216303	001	May 17, 2024	May NEWA
>A>	AN	DR REDDYS	EQ 0.015MG BASE/2ML	A215032	001	Jun 03, 2024	May NEWA
	AN	PHARMAMAX	EQ 0.015MG BASE/2ML	A214901	001	Apr 02, 2024	Mar NEWA

ARIPIPIRAZOLE

TABLET; ORAL  
ARIPIPIRAZOLE

AB		LUPIN	2MG	A205589	001	Mar 18, 2024	Mar NEWA
AB			5MG	A205589	002	Mar 18, 2024	Mar NEWA
AB			10MG	A205589	003	Mar 18, 2024	Mar NEWA
AB			15MG	A205589	004	Mar 18, 2024	Mar NEWA
AB			20MG	A205589	005	Mar 18, 2024	Mar NEWA
AB			30MG	A205589	006	Mar 18, 2024	Mar NEWA

ARIPIPIRAZOLE LAUROXIL

SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ARISTADA INITIO KIT

+	ALKERMES INC	675MG/2.4ML (281.25MG/ML)	N209830	001	Jun 29, 2018	Jan CPOT
---	--------------	---------------------------	---------	-----	--------------	----------

ASCIMINIB HYDROCHLORIDE

TABLET; ORAL  
SCEMBLIX

+	NOVARTIS	EQ 100MG BASE	N215358	003	Apr 18, 2024	Apr NEWA
---	----------	---------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL  
LANORINAL

AA	!	SANDOZ	325MG; 50MG; 40MG	A086996	002	Oct 11, 1985	Jan CAHN
----	---	--------	-------------------	---------	-----	--------------	----------

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL  
ASPIRIN AND DIPYRIDAMOLE

AB		ENDO OPERATIONS	25MG; 200MG	A207944	001	Jan 18, 2017	Apr CAHN
----	--	-----------------	-------------	---------	-----	--------------	----------

ASPIRIN; OXYCODONE HYDROCHLORIDE

TABLET; ORAL  
PERCODAN

>A>	AA	+	!	ENDO OPERATIONS	325MG; 4.8355MG	N007337	007	Aug 05, 2005	May CAHN
>D>	AA	+	!	ENDO PHARMS	325MG; 4.8355MG	N007337	007	Aug 05, 2005	May CAHN

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL  
PERCODAN

>A>		@		ENDO OPERATIONS	325MG; 4.5MG; 0.38MG	N007337	006		May CAHN
>D>		@		ENDO PHARMS	325MG; 4.5MG; 0.38MG	N007337	006		May CAHN
>A>		@		ENDO OPERATIONS	325MG; 2.25MG; 0.19MG	N007337	005		May CAHN
>D>		@		ENDO PHARMS	325MG; 2.25MG; 0.19MG	N007337	005		May CAHN

ATOMOXETINE HYDROCHLORIDE

CAPSULE; ORAL  
ATOMOXETINE HYDROCHLORIDE

AB		APOTEX	EQ 10MG BASE	A078983	001	May 30, 2017	Mar CPOT
AB			EQ 18MG BASE	A078983	002	May 30, 2017	Mar CPOT
AB			EQ 25MG BASE	A078983	003	May 30, 2017	Mar CPOT
AB			EQ 40MG BASE	A078983	004	May 30, 2017	Mar CPOT
AB			EQ 60MG BASE	A078983	005	May 30, 2017	Mar CPOT
AB			EQ 80MG BASE	A078983	006	May 30, 2017	Mar CPOT
AB			EQ 100MG BASE	A078983	007	May 30, 2017	Mar CPOT
AB		AUROBINDO PHARMA	EQ 10MG BASE	A079016	001	May 30, 2017	Mar CPOT
AB			EQ 18MG BASE	A079016	002	May 30, 2017	Mar CPOT
AB			EQ 25MG BASE	A079016	003	May 30, 2017	Mar CPOT
AB			EQ 40MG BASE	A079016	004	May 30, 2017	Mar CPOT
AB			EQ 60MG BASE	A079016	005	May 30, 2017	Mar CPOT
AB			EQ 80MG BASE	A079016	006	May 30, 2017	Mar CPOT
AB			EQ 100MG BASE	A079016	007	May 30, 2017	Mar CPOT
AB		DR REDDYS	EQ 10MG BASE	A090609	001	Feb 23, 2018	Mar CPOT
AB			EQ 18MG BASE	A090609	002	Feb 23, 2018	Mar CPOT

CAPSULE;ORAL

ATOMOXETINE HYDROCHLORIDE

AB		EQ 25MG BASE	A090609	003	Feb 23, 2018	Mar	CPOT
AB		EQ 40MG BASE	A090609	004	Feb 23, 2018	Mar	CPOT
AB		EQ 60MG BASE	A090609	005	Feb 23, 2018	Mar	CPOT
AB		EQ 80MG BASE	A090609	006	Feb 23, 2018	Mar	CPOT
AB		EQ 100MG BASE	A090609	007	Feb 23, 2018	Mar	CPOT
AB	GLENMARK PHARMS LTD	EQ 10MG BASE	A079019	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079019	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079019	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079019	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079019	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079019	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079019	007	May 30, 2017	Mar	CPOT
AB	HETERO LABS LTD V	EQ 10MG BASE	A202682	001	Mar 11, 2021	Mar	CPOT
AB		EQ 18MG BASE	A202682	002	Mar 11, 2021	Mar	CPOT
AB		EQ 25MG BASE	A202682	003	Mar 11, 2021	Mar	CPOT
AB		EQ 40MG BASE	A202682	004	Mar 11, 2021	Mar	CPOT
AB		EQ 60MG BASE	A202682	005	Mar 11, 2021	Mar	CPOT
AB		EQ 80MG BASE	A202682	006	Mar 11, 2021	Mar	CPOT
AB		EQ 100MG BASE	A202682	007	Mar 11, 2021	Mar	CPOT
	@ STRIDES PHARMA	EQ 10MG BASE	A079021	001	Feb 18, 2021	Mar	CPOT
	@	EQ 18MG BASE	A079021	002	Feb 18, 2021	Mar	CPOT
	@	EQ 25MG BASE	A079021	003	Feb 18, 2021	Mar	CPOT
	@	EQ 40MG BASE	A079021	004	Feb 18, 2021	Mar	CPOT
	@	EQ 60MG BASE	A079021	005	Feb 18, 2021	Mar	CPOT
	@	EQ 80MG BASE	A079021	006	Feb 18, 2021	Mar	CPOT
	@	EQ 100MG BASE	A079021	007	Feb 18, 2021	Mar	CPOT
AB	TEVA PHARMS USA	EQ 10MG BASE	A079022	001	May 30, 2017	Mar	CPOT
AB		EQ 18MG BASE	A079022	002	May 30, 2017	Mar	CPOT
AB		EQ 25MG BASE	A079022	003	May 30, 2017	Mar	CPOT
AB		EQ 40MG BASE	A079022	004	May 30, 2017	Mar	CPOT
AB		EQ 60MG BASE	A079022	005	May 30, 2017	Mar	CPOT
AB		EQ 80MG BASE	A079022	006	May 30, 2017	Mar	CPOT
AB		EQ 100MG BASE	A079022	007	May 30, 2017	Mar	CPOT
AB	ZYDUS PHARMS USA INC	EQ 10MG BASE	A079017	007	Apr 05, 2023	Mar	CPOT
AB		EQ 18MG BASE	A079017	001	Sep 16, 2010	Mar	CPOT
AB		18MG	A079017	001	Sep 16, 2010	Jan	CMS1
AB		EQ 25MG BASE	A079017	002	Sep 16, 2010	Mar	CPOT
AB		25MG	A079017	002	Sep 16, 2010	Jan	CMS1
AB		EQ 40MG BASE	A079017	003	Sep 16, 2010	Mar	CPOT
AB		40MG	A079017	003	Sep 16, 2010	Jan	CMS1
AB		EQ 60MG BASE	A079017	004	Sep 16, 2010	Mar	CPOT
AB		60MG	A079017	004	Sep 16, 2010	Jan	CMS1
AB		EQ 80MG BASE	A079017	005	Sep 16, 2010	Mar	CPOT
AB		80MG	A079017	005	Sep 16, 2010	Jan	CMS1
AB		EQ 100MG BASE	A079017	006	Sep 16, 2010	Mar	CPOT
AB		100MG	A079017	006	Sep 16, 2010	Jan	CMS1
	STRATTERA						
	@ LILLY	EQ 5MG BASE	N021411	001	Nov 26, 2002	Mar	CPOT
AB	+	EQ 10MG BASE	N021411	002	Nov 26, 2002	Mar	CPOT
AB	+	EQ 18MG BASE	N021411	003	Nov 26, 2002	Mar	CPOT
AB	+	EQ 25MG BASE	N021411	004	Nov 26, 2002	Mar	CPOT
AB	+	EQ 40MG BASE	N021411	005	Nov 26, 2002	Mar	CPOT
AB	+	EQ 60MG BASE	N021411	006	Nov 26, 2002	Mar	CPOT
AB	+	EQ 80MG BASE	N021411	007	Feb 14, 2005	Mar	CPOT
AB	+	EQ 100MG BASE	N021411	008	Feb 14, 2005	Mar	CPOT

ATORVASTATIN CALCIUM

TABLET;ORAL

ATORVASTATIN CALCIUM

AB	ANBISON LAB	EQ 10MG BASE	A211886	001	Jan 25, 2024	Jan	NEWA
AB		EQ 20MG BASE	A211886	002	Jan 25, 2024	Jan	NEWA
AB		EQ 40MG BASE	A211886	003	Jan 25, 2024	Jan	NEWA
AB		EQ 80MG BASE	A211886	004	Jan 25, 2024	Jan	NEWA
AB	AUROBINDO PHARMA LTD	EQ 10MG BASE	A217118	001	Feb 13, 2024	Feb	NEWA
AB		EQ 20MG BASE	A217118	002	Feb 13, 2024	Feb	NEWA
AB		EQ 40MG BASE	A217118	003	Feb 13, 2024	Feb	NEWA
AB		EQ 80MG BASE	A217118	004	Feb 13, 2024	Feb	NEWA
	@ CADILA PHARMS LTD	EQ 10MG BASE	A212103	001	Oct 16, 2023	Apr	DISC
	@	EQ 20MG BASE	A212103	002	Oct 16, 2023	Apr	DISC
	@	EQ 40MG BASE	A212103	003	Oct 16, 2023	Apr	DISC
	@	EQ 80MG BASE	A212103	004	Oct 16, 2023	Apr	DISC
	@ INVAGEN PHARMS	EQ 10MG BASE	A204846	001	Jan 09, 2017	Mar	DISC

TABLET;ORAL

ATORVASTATIN CALCIUM

	@		EQ 20MG BASE	A204846	002	Jan 09, 2017	Mar	DISC
	@		EQ 40MG BASE	A204846	003	Jan 09, 2017	Mar	DISC
	@		EQ 80MG BASE	A204846	004	Jan 09, 2017	Mar	DISC
AB		LAURUS	EQ 10MG BASE	A214513	001	Jan 22, 2024	Jan	NEWA
AB			EQ 20MG BASE	A214513	002	Jan 22, 2024	Jan	NEWA
AB			EQ 40MG BASE	A214513	003	Jan 22, 2024	Jan	NEWA
AB			EQ 80MG BASE	A214513	004	Jan 22, 2024	Jan	NEWA
>A>	AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A208480	001	Jun 03, 2024	May	NEWA
>A>	AB		EQ 20MG BASE	A208480	002	Jun 03, 2024	May	NEWA
>A>	AB		EQ 40MG BASE	A208480	003	Jun 03, 2024	May	NEWA
>A>	AB		EQ 80MG BASE	A208480	004	Jun 03, 2024	May	NEWA
AB		SHANDONG XINHUA	EQ 10MG BASE	A211886	001	Jan 25, 2024	Mar	CAHN
AB			EQ 20MG BASE	A211886	002	Jan 25, 2024	Mar	CAHN
AB			EQ 40MG BASE	A211886	003	Jan 25, 2024	Mar	CAHN
AB			EQ 80MG BASE	A211886	004	Jan 25, 2024	Mar	CAHN

ATROPINE SULFATE

SOLUTION/DROPS;OPHTHALMIC

ATROPINE SULFATE

AT1	!	AMNEAL	1%	A214752	001	Jul 14, 2022	Apr	CTEC
AT1		APOTEX	1%	A215624	001	Nov 26, 2021	Apr	CTEC
AT1		MANKIND PHARMA	1%	A218148	001	Jan 08, 2024	Apr	CTEC
AT1	+	RISING	1%	N206289	001	Jul 18, 2014	Apr	CTEC
AT2		SOMERSET	1%	A217791	001	Apr 29, 2024	Apr	NFTG
		ISOPTO ATROPINE						
AT2	+!	ALCON LABS INC	1%	N208151	001	Dec 01, 2016	Apr	CFTG

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET;ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	ANI PHARMS	0.025MG;2.5MG	A086727	001		Mar	DISC
	@	MYLAN	0.025MG;2.5MG	A085762	001		Apr	DISC

AVACINCAPTAD PEGOL SODIUM

SOLUTION;INTRAVITREAL

IZERVAY

+!	ASTELLAS	EQ 2MG BASE/0.1ML (EQ 2MG BASE/0.1ML)	N217225	001	Aug 04, 2023	Jan	CAHN
----	----------	---------------------------------------	---------	-----	--------------	-----	------

AZACITIDINE

POWDER;INTRAVENOUS, SUBCUTANEOUS

AZACITIDINE

>A>	AP	MSN LABS PVT LTD	100MG/VIAL	A212580	001	May 16, 2024	May	NEWA
-----	----	------------------	------------	---------	-----	--------------	-----	------

AZELAIC ACID

GEL;TOPICAL

AZELAIC ACID

AB		TARO	15%	A210549	001	Aug 23, 2019	Apr	CAHN
----	--	------	-----	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

	@	HIKMA	0.137MG/SPRAY	A091444	001	Oct 24, 2014	Mar	DISC
--	---	-------	---------------	---------	-----	--------------	-----	------

AZITHROMYCIN

INJECTABLE;INJECTION

AZITHROMYCIN

>D>	AP	SUN PHARM INDS LTD	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May	DISC
>A>		@	EQ 500MG BASE/VIAL	A090923	001	Apr 02, 2013	May	DISC

TABLET;ORAL

AZITHROMYCIN

	@	YUNG SHIN PHARM	EQ 250MG BASE	A211317	001	Jul 26, 2022	Feb	DISC
--	---	-----------------	---------------	---------	-----	--------------	-----	------

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES, BACITRACIN ZINC AND HYDROCORTISONE

>D>		@	AKORN	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	May	CAHN
>A>		@	SAPTALIS PHARMS	400 UNITS/GM;1%;EQ 3.5MG BASE/GM;10,000 UNITS/GM	A065213	001	Jul 25, 2012	May	CAHN

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT;OPHTHALMIC

NEOMYCIN AND POLYMYXIN B SULFATES AND BACITRACIN ZINC

@ SAPTALIS PHARMS

400 UNITS/GM;EQ 3.5MG  
BASE/GM;10,000 UNITS/GM

A065088 001 Feb 06, 2004 Apr CAHN

BACLOFEN

INJECTABLE;INTRATHECAL

BACLOFEN

@ ACIC PHARMS

0.5MG/ML

A216309 001 Aug 10, 2023 Jan DISC

@

2MG/ML

A216309 002 Aug 10, 2023 Jan DISC

TABLET;ORAL

BACLOFEN

AB ENDO OPERATIONS

10MG

A077068 002 Aug 30, 2005 Apr CAHN

AB

20MG

A077068 001 Aug 30, 2005 Apr CAHN

@ IMPAX

5MG

A077971 003 Jul 07, 2021 Mar DISC

@

10MG

A077971 001 Oct 26, 2007 Mar DISC

@

20MG

A077971 002 Oct 26, 2007 Mar DISC

AB

RUBICON

15MG

A209102 004 Feb 05, 2024 Feb CTEC

15MG

A209102 004 Feb 05, 2024 Jan NEWA

BALSALAZIDE DISODIUM

CAPSULE;ORAL

BALSALAZIDE DISODIUM

AB ZYDUS LIFESCIENCES

750MG

A217592 001 Jun 08, 2023 Mar CAHN

BENZTROPINE MESYLATE

TABLET;ORAL

BENZTROPINE MESYLATE

AA ENDO OPERATIONS

0.5MG

A040715 001 Aug 27, 2007 Apr CAHN

AA

1MG

A040715 002 Aug 27, 2007 Apr CAHN

AA

2MG

A040715 003 Aug 27, 2007 Apr CAHN

@ INVAGEN PHARMS

0.5MG

A090294 001 Mar 29, 2010 Mar DISC

@

1MG

A090294 002 Mar 29, 2010 Mar DISC

@

2MG

A090294 003 Mar 29, 2010 Mar DISC

BERDAZIMER SODIUM

GEL;TOPICAL

ZELSUVMI

+! LNHC

EQ 10.3% BASE

N217424 001 Jan 05, 2024 Jan NEWA

BETAMETHASONE DIPROPIONATE

LOTION, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

@ HIKMA

EQ 0.05% BASE

A208849 001 Oct 11, 2019 Mar DISC

OINTMENT, AUGMENTED;TOPICAL

BETAMETHASONE DIPROPIONATE

AB AUROBINDO PHARMA LTD

EQ 0.05% BASE

A218289 001 Apr 10, 2024 Mar NEWA

@ PADAGIS US

EQ 0.05% BASE

A206118 001 Nov 09, 2017 Jan CAHN

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM;TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB ! TARO

EQ 0.05% BASE;1%

A075673 001 May 29, 2001 Apr CAHN

BICALUTAMIDE

TABLET;ORAL

BICALUTAMIDE

AB CHARTWELL RX

50MG

A091011 001 Jun 10, 2015 Jan CAHN

@ RISING

50MG

A079185 001 Jul 06, 2009 Feb CAHN

BIMATOPROST

SOLUTION/DROPS;TOPICAL

BIMATOPROST

@ HIKMA

0.03%

A203051 001 Oct 09, 2018 Mar DISC

BIRCH TRITERPENES

GEL;TOPICAL  
FILSUVEZ

+! CHIESI 10% N215064 001 Dec 18, 2023 Jan CAHN

BISOPROLOL FUMARATE

TABLET;ORAL  
BISOPROLOL FUMARATE

AB HARMAN FINOCHEM 5MG A217617 001 Jan 18, 2024 Jan NEWA  
AB 10MG A217617 002 Jan 18, 2024 Jan NEWA

BIVALIRUDIN

INJECTABLE;INTRAVENOUS  
BIVALIRUDIN

>D> AP HOSPIRA 250MG/VIAL A090816 001 Jul 14, 2015 May DISC  
>A> @ 250MG/VIAL A090816 001 Jul 14, 2015 May DISC

BLEOMYCIN SULFATE

INJECTABLE;INJECTION  
BLEOMYCIN SULFATE

@ TEVA PHARMS USA EQ 15 UNITS BASE/VIAL A065033 001 Jun 27, 2000 Jan DISC  
@ EQ 30 UNITS BASE/VIAL A065033 002 Jun 27, 2000 Jan DISC

BORTEZOMIB

INJECTABLE;INTRAVENOUS, SUBCUTANEOUS  
BORTEZOMIB

AP HETERO LABS LTD VI 3.5MG/VIAL A212204 001 May 03, 2024 Apr NEWA  
>A> AP RELIANCE LIFE SCI 3.5MG/VIAL A211898 001 Oct 11, 2022 May CAHN  
>D> AP WAVERLEY PHARMA INC 3.5MG/VIAL A211898 001 Oct 11, 2022 May CAHN

BOSENTAN

TABLET;ORAL  
BOSENTAN

@ ENDO OPERATIONS 62.5MG A205699 001 Apr 26, 2019 Apr CAHN  
@ 125MG A205699 002 Apr 26, 2019 Apr CAHN

BREMELANOTIDE ACETATE

SOLUTION;SUBCUTANEOUS  
VYLEESI (AUTOINJECTOR)

+! COSETTE EQ 1.75MG BASE/0.3ML (EQ 1.75MG BASE/0.3 ML) N210557 001 Jun 21, 2019 Apr CAHN

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC  
BRIMONIDINE TARTRATE

AB SANDOZ 0.1% A203172 001 Mar 04, 2024 Feb NEWA  
>A> AT UPSHER SMITH LABS 0.15% A216772 001 Jun 12, 2024 May NEWA

BRIMONIDINE TARTRATE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
BRIMONIDINE TARTRATE AND TIMOLOL MALEATE

>A> AB GLENMARK PHARMS LTD 0.2%;EQ 0.5% BASE A214987 001 May 16, 2024 May NEWA

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC  
BROMFENAC SODIUM

AB LUPIN LTD EQ 0.075% ACID A211239 001 Feb 02, 2024 Jan NFTG  
BROMSITE  
AB +! SUN PHARM EQ 0.075% ACID N206911 001 Apr 08, 2016 Jan CFTG

BUDESONIDE

SUSPENSION;INHALATION  
BUDESONIDE

>D> AN EUGIA PHARMA 0.5MG/2ML A216667 001 Nov 29, 2023 May DISC  
>A> @ 0.5MG/2ML A216667 001 Nov 29, 2023 May DISC

SUSPENSION;ORAL  
EOHILIA

+! TAKEDA PHARMS USA 2MG/10ML N213976 001 Feb 09, 2024 Feb NEWA



BUMETANIDE

INJECTABLE; INJECTION  
BUMETANIDE

>D>	AP	HOSPIRA	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC
>A>		@	0.25MG/ML	A074332	001	Oct 31, 1994	May	DISC

BUPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP		ASPIRO	0.25%	A217821	001	Mar 27, 2024	Mar	NEWA
AP			0.5%	A217821	002	Mar 27, 2024	Mar	NEWA
AP			0.75%	A217821	003	Mar 27, 2024	Mar	NEWA

BUPIVACAINE HYDROCHLORIDE; EPINEPHRINE BITARTRATE

INJECTABLE; INJECTION  
VIVACAINE

!	SEPTODONT		0.5%;0.0091MG/ML	A077250	001	Sep 27, 2006	Jan	CTNA
---	-----------	--	------------------	---------	-----	--------------	-----	------

BUPRENORPHINE HYDROCHLORIDE

IMPLANT; IMPLANTATION  
PROBUPHINE

+	@	REACK PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Apr	CAHN
---	---	--------------	----------------------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
BUPRENORPHINE HYDROCHLORIDE

@	AM REGENT		EQ 0.3MG BASE/ML	A078331	001	Mar 27, 2007	Jan	DISC
---	-----------	--	------------------	---------	-----	--------------	-----	------

BUPROPION HYDROCHLORIDE

TABLET; ORAL

BUPROPION HYDROCHLORIDE

AB		AUROBINDO PHARMA USA	75MG	A075491	001	Apr 17, 2000	Apr	CMFD
AB			100MG	A075491	002	Apr 17, 2000	Apr	CMFD
	@	INVAGEN PHARMS	75MG	A207389	001	Sep 18, 2017	Mar	DISC
	@		100MG	A207389	002	Sep 18, 2017	Mar	DISC

TABLET, EXTENDED RELEASE; ORAL

BUPROPION HYDROCHLORIDE

>D>	@	ANCHEN PHARMS	100MG	A091459	001	Jun 09, 2011	May	CAHN
	@		100MG	A091459	001	Jun 09, 2011	Feb	DISC
>D>	@		150MG	A077284	001	Dec 14, 2006	May	CAHN
>D>	@		150MG	A091459	002	Jun 09, 2011	May	CAHN
	@		150MG	A091459	002	Jun 09, 2011	Feb	DISC
>D>	@		150MG	A091520	001	Jun 09, 2011	May	CAHN
	@		150MG	A091520	001	Jun 09, 2011	Feb	DISC
>D>	@		200MG	A091459	003	Jun 09, 2011	May	CAHN
	@		200MG	A091459	003	Jun 09, 2011	Feb	DISC
>D>	@		300MG	A077284	002	Dec 14, 2006	May	CAHN
>A>	@	ENDO OPERATIONS	100MG	A091459	001	Jun 09, 2011	May	CAHN
>A>	@		150MG	A077284	001	Dec 14, 2006	May	CAHN
>A>	@		150MG	A091459	002	Jun 09, 2011	May	CAHN
>A>	@		150MG	A091520	001	Jun 09, 2011	May	CAHN
>A>	@		200MG	A091459	003	Jun 09, 2011	May	CAHN
>A>	@		300MG	A077284	002	Dec 14, 2006	May	CAHN
	@	INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Mar	DISC
	@		150MG	A206556	001	Aug 26, 2016	Mar	DISC
	@		150MG	A206674	002	Feb 09, 2016	Mar	DISC
	@		200MG	A206674	003	Feb 09, 2016	Mar	DISC
	@		300MG	A206556	002	Aug 26, 2016	Mar	DISC
	@	RISING	150MG	A090941	001	May 03, 2010	Feb	CAHN
>D>	AB1	SUN PHARM	200MG	A078866	003	Apr 06, 2010	May	DISC
>A>	@		200MG	A078866	003	Apr 06, 2010	May	DISC
	AB3	TWI PHARMS	150MG	A210081	001	Nov 03, 2017	Mar	CAHN
	AB3		300MG	A210081	002	Nov 03, 2017	Mar	CAHN

BUSPIRONE HYDROCHLORIDE

TABLET; ORAL

BUSPIRONE HYDROCHLORIDE

AB		AIPING PHARM INC	5MG	A202087	001	Dec 16, 2015	Jan	CAHN
AB			10MG	A202087	002	Dec 16, 2015	Jan	CAHN
AB			15MG	A202087	003	Dec 16, 2015	Jan	CAHN
AB			30MG	A202087	004	Dec 16, 2015	Jan	CAHN
	@	AMNEAL PHARMS CO	5MG	A208829	001	May 24, 2017	Mar	DISC
	@		7.5MG	A208829	002	May 24, 2017	Mar	DISC

<u>TABLET; ORAL</u>							
BUSPIRONE HYDROCHLORIDE							
	@	10MG	A208829	003	May 24, 2017	Mar	DISC
	@	15MG	A208829	004	May 24, 2017	Mar	DISC
	@	30MG	A208829	005	May 24, 2017	Mar	DISC
<u>BUSULFAN</u>							
INJECTABLE; INJECTION							
BUSULFAN							
	@ NEXUS	6MG/ML	A207794	001	Jan 14, 2019	Mar	DISC
<u>CABAZITAXEL</u>							
SOLUTION; INTRAVENOUS							
CABAZITAXEL							
	+! ACTAVIS	60MG/6ML (10MG/ML)	N207970	001	Mar 14, 2024	Mar	NEWA
<u>CALCIPOTRIENE</u>							
SOLUTION; TOPICAL							
CALCIPOTRIENE							
	@ HIKMA	0.005%	A077579	001	Nov 19, 2009	Mar	DISC
<u>CALCITONIN SALMON</u>							
INJECTABLE; INJECTION							
CALCITONIN-SALMON							
AP	DR REDDYS	200 IU/ML	A215715	001	Apr 11, 2024	Apr	NEWA
SPRAY, METERED; NASAL							
CALCITONIN-SALMON							
>A>	@ ENDO OPERATIONS	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN
>D>	@ PAR PHARM	200 IU/SPRAY	A076979	001	Jun 08, 2009	May	CAHN
<u>CALCIUM ACETATE</u>							
CAPSULE; ORAL							
CALCIUM ACETATE							
AB	! INVAGEN PHARMS	667MG	A203135	001	Feb 07, 2013	Apr	CHRS
	PHOSLO GELCAPS						
	+ @ FRESENIUS MEDCL	667MG	N021160	003	Apr 02, 2001	Apr	DISC
<u>CALCIUM GLUCONATE</u>							
SOLUTION; INTRAVENOUS							
CALCIUM GLUCONATE							
>A>	AP AMNEAL	1GM/10ML (100MG/ML)	A216611	001	May 10, 2024	May	NEWA
>A>	AP	5GM/50ML (100MG/ML)	A216611	002	May 10, 2024	May	NEWA
>A>	AP	10GM/100ML (100MG/ML)	A216611	003	May 10, 2024	May	NEWA
	AP NIVAGEN PHARMS INC	10GM/100ML (100MG/ML)	A213071	003	Apr 30, 2024	Apr	NEWA
<u>CAPECITABINE</u>							
TABLET; ORAL							
CAPECITABINE							
AB	HETERO LABS LTD V	150MG	A210203	001	Mar 05, 2024	Feb	NEWA
AB		500MG	A210203	002	Mar 05, 2024	Feb	NEWA
<u>CAPTOPRIL</u>							
TABLET; ORAL							
CAPTOPRIL							
AB	INNOGENIX	12.5MG	A074677	004	May 30, 1997	Mar	CAHN
AB		25MG	A074677	002	May 30, 1997	Mar	CAHN
AB		50MG	A074677	001	May 30, 1997	Mar	CAHN
AB		100MG	A074677	003	May 30, 1997	Mar	CAHN
AB	STASON PHARMS	12.5MG	A074677	004	May 30, 1997	Feb	CAHN
AB		25MG	A074677	002	May 30, 1997	Feb	CAHN
AB		50MG	A074677	001	May 30, 1997	Feb	CAHN
AB		100MG	A074677	003	May 30, 1997	Feb	CAHN
<u>CARBAMAZEPINE</u>							
TABLET; ORAL							
CARBAMAZEPINE							
AB	BIONPHARMA	200MG	A218221	001	Feb 16, 2024	Feb	NEWA
TABLET, EXTENDED RELEASE; ORAL							
CARBAMAZEPINE							
	@ AMNEAL PHARMS	100MG	A212704	001	Sep 22, 2023	Feb	DISC
	@	200MG	A212704	002	Sep 22, 2023	Feb	DISC
	@	400MG	A212704	003	Sep 22, 2023	Feb	DISC

TABLET, EXTENDED RELEASE;ORAL  
 CARBAMAZEPINE

>D>	AB	APOTEX	100MG	A213159	001	Mar 08, 2024	May DISC
>A>		@	100MG	A213159	001	Mar 08, 2024	May DISC
	AB		100MG	A213159	001	Mar 08, 2024	Mar NEWA
>D>	AB		200MG	A213159	002	Mar 08, 2024	May DISC
>A>		@	200MG	A213159	002	Mar 08, 2024	May DISC
	AB		200MG	A213159	002	Mar 08, 2024	Mar NEWA
>D>	AB		400MG	A213159	003	Mar 08, 2024	May DISC
>A>		@	400MG	A213159	003	Mar 08, 2024	May DISC
	AB		400MG	A213159	003	Mar 08, 2024	Mar NEWA

CARBIDOPA; LEVODOPA

CAPSULE, EXTENDED RELEASE;ORAL  
 RYTARY

>A>	+	IMPAX	23.75MG;95MG	N203312	001	Jan 07, 2015	May CAHN
>A>	+		36.25MG;145MG	N203312	002	Jan 07, 2015	May CAHN
>A>	+		48.75MG;195MG	N203312	003	Jan 07, 2015	May CAHN
>A>	+		61.25MG;245MG	N203312	004	Jan 07, 2015	May CAHN
>D>	+	IMPAX LABS INC	23.75MG;95MG	N203312	001	Jan 07, 2015	May CAHN
>D>	+		36.25MG;145MG	N203312	002	Jan 07, 2015	May CAHN
>D>	+		48.75MG;195MG	N203312	003	Jan 07, 2015	May CAHN
>D>	+		61.25MG;245MG	N203312	004	Jan 07, 2015	May CAHN

TABLET, EXTENDED RELEASE;ORAL  
 CARBIDOPA AND LEVODOPA

>A>	AB	RUBICON	25MG;100MG	A217482	001	Jun 04, 2024	May NEWA
>A>	AB		50MG;200MG	A217482	002	Jun 04, 2024	May NEWA

CARBINOXAMINE MALEATE

SOLUTION;ORAL

CARBINOXAMINE MALEATE

>A>		@ ENDO OPERATIONS	4MG/5ML	A040814	001	Feb 26, 2008	May CAHN
>D>		@ VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	May CAHN

TABLET;ORAL

CARBINOXAMINE MALEATE

@ INVAGEN PHARMS

4MG

A090435 001 Apr 15, 2010 Mar DISC

CARBOPROST TROMETHAMINE

INJECTABLE;INJECTION

CARBOPROST TROMETHAMINE

AP		ANI PHARMS	EQ 0.25MG BASE/ML	A215901	001	Jan 25, 2024	Jan NEWA
AP		MICRO LABS	EQ 0.25MG BASE/ML	A218013	001	Apr 03, 2024	Mar NEWA

CARMUSTINE

INJECTABLE;INJECTION

CARMUSTINE

@ INGENUS PHARMS LLC

100MG/VIAL

A211011 001 Jun 21, 2022 Feb DISC

>D>		POWDER;INTRAVENOUS					
>D>		CARMUSTINE					
>D>	+	ACCORD HLTHCARE	50MG/VIAL	N215000	001	May 16, 2022	May DISC
>A>	+	@	50MG/VIAL	N215000	001	May 16, 2022	May DISC
>D>	+		300MG/VIAL	N215000	002	May 16, 2022	May DISC
>A>	+	@	300MG/VIAL	N215000	002	May 16, 2022	May DISC

CARVEDILOL

TABLET;ORAL

CARVEDILOL

@ MYLAN

3.125MG

A077316 001 Sep 05, 2007 Apr DISC

@ SUN PHARM INDS LTD

3.125MG

A076989 001 Sep 05, 2007 Jan DISC

@

6.25MG

A076989 002 Sep 05, 2007 Jan DISC

@

12.5MG

A076989 003 Sep 05, 2007 Jan DISC

@

25MG

A076989 004 Sep 05, 2007 Jan DISC

COREG

AB	+	WAYLIS THERAP	3.125MG	N020297	004	May 29, 1997	Apr CAHN
AB	+		6.25MG	N020297	003	Sep 14, 1995	Apr CAHN
AB	+		12.5MG	N020297	002	Sep 14, 1995	Apr CAHN
AB	+		25MG	N020297	001	Sep 14, 1995	Apr CAHN

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL  
COREG CR

AB	+	WAYLIS THERAP	10MG	N022012	001	Oct 20, 2006	Apr	CAHN
AB	+		20MG	N022012	002	Oct 20, 2006	Apr	CAHN
AB	+		40MG	N022012	003	Oct 20, 2006	Apr	CAHN
AB	+		80MG	N022012	004	Oct 20, 2006	Apr	CAHN

CASPOFUNGIN ACETATE

POWDER; INTRAVENOUS  
CASPOFUNGIN ACETATE

AP		AREVA PHARMS	50MG/VIAL	A211263	001	Oct 01, 2021	Mar	CAHN
AP			70MG/VIAL	A211263	002	Oct 01, 2021	Mar	CAHN

CEFAZOLIN SODIUM

INJECTABLE; INJECTION  
CEFAZOLIN SODIUM  
QILU

			EQ 3GM BASE/VIAL	A203661	003	Jan 24, 2024	Jan	NEWA
--	--	--	------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS

>A> CEFAZOLIN IN DEXTROSE

>A>	+	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA
>A>	+		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA
>A>	+		EQ 3GM BASE/150ML (EQ 20MG BASE/ML)	N207131	003	May 31, 2024	May	NEWA

>D> CEFAZOLIN IN PLASTIC CONTAINER

>D>	+	BAXTER HLTHCARE CORP	EQ 1GM BASE/50ML (EQ 20MG BASE/ML)	N207131	002	Feb 01, 2021	May	CTNA
>D>	+		EQ 2GM BASE/100ML (EQ 20MG BASE/ML)	N207131	001	Aug 07, 2015	May	CTNA

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION  
CEFEPIME HYDROCHLORIDE

	@	ASTRAL	EQ 1GM BASE/VIAL	A212721	001	Jul 21, 2020	Apr	DISC
	@		EQ 2GM BASE/VIAL	A212721	002	Jul 21, 2020	Apr	DISC
>A>	AP	HIKMA	EQ 1GM BASE/VIAL	A214402	001	May 22, 2024	May	NEWA
>A>	AP		EQ 2GM BASE/VIAL	A214402	002	May 22, 2024	May	NEWA

POWDER; INTRAVENOUS  
CEFEPIME HYDROCHLORIDE IN PLASTIC CONTAINER

	!	SAMSON MEDCL	EQ 100GM BASE	A209408	001	Aug 21, 2018	Apr	CHRS
--	---	--------------	---------------	---------	-----	--------------	-----	------

>D> CEFEPIME HYDROCHLORIDE; ENMETAZOACTAM

>D> POWDER; INTRAVENOUS  
>D> EXBLIFEP

>D>	+	ALLECRA THERAPS	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
>A>	+	@	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	May	DISC
>A>	+	!	EQ 2GM BASE/VIAL; 0.5GM/VIAL	N216165	001	Feb 22, 2024	Feb	NEWA

CEFOTAXIME SODIUM

INJECTABLE; INJECTION  
CLAFORAN

	+	@	STERIMAX	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
	+	@		EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
	+	@		EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
	+	@		EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN

CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER

	@	STERIMAX	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jan	CAHN
	@		EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN

CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	@	STERIMAX	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@		EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUM

INJECTABLE; INJECTION  
CEFOTAN

AP	+	PAI HOLDINGS PHARM	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
AP	+		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD

CEFOTETAN

AP	!	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A065374	001	Aug 09, 2007	Feb	CTEC
AP	!		EQ 2GM BASE/VIAL	A065374	002	Aug 09, 2007	Feb	CTEC

CEFPROZIL

TABLET;ORAL  
CEFPROZIL

AB	ALKEM LABS LTD	250MG	A 090857	001	Apr 09, 2024	Mar	NEWA
AB		500MG	A 090857	002	Apr 09, 2024	Mar	NEWA

CEFTOBIPROLE MEDOCARIL SODIUM

POWDER;INTRAVENOUS  
ZEVTERA

+	BASILEA PHARM ALLSCH	667MG/VIAL	N218275	001	Apr 03, 2024	Apr	NEWA
---	----------------------	------------	---------	-----	--------------	-----	------

CEFTRIAZONE SODIUM

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS  
CEFTRIAZONE

	@ ASTRAL	EQ 250MG BASE/VIAL	A 091049	001	Jun 11, 2018	Apr	DISC
	@	EQ 500MG BASE/VIAL	A 091049	002	Jun 11, 2018	Apr	DISC
	@	EQ 1GM BASE/VIAL	A 091049	003	Jun 11, 2018	Apr	DISC
	@	EQ 2GM BASE/VIAL	A 091049	004	Jun 11, 2018	Apr	DISC
AP	DEVA HOLDING AS	EQ 250MG BASE/VIAL	A 210197	001	Jan 12, 2024	Jan	NEWA
AP		EQ 500MG BASE/VIAL	A 210197	002	Jan 12, 2024	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A 210197	003	Jan 12, 2024	Jan	NEWA
AP		EQ 2GM BASE/VIAL	A 210197	004	Jan 12, 2024	Jan	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL  
CETIRIZINE HYDROCHLORIDE

	@ ACTAVIS MID ATLANTIC	5MG/5ML	A 078617	001	Feb 02, 2010	Feb	CDFR
AA	AMNEAL PHARMS	5MG/5ML	A 090766	001	Oct 07, 2009	Feb	CDFR
	@ APOZEAL PHARMS	5MG/5ML	A 078870	001	Apr 27, 2009	Feb	CDFR
	@ AUROBINDO PHARMA LTD	5MG/5ML	A 090751	001	Dec 16, 2009	Feb	CDFR
AA	BAJAJ	5MG/5ML	A 090191	001	Nov 12, 2009	Feb	CDFR
AA	BIONPHARMA	5MG/5ML	A 078488	001	Oct 06, 2008	Feb	CDFR
AA	CHARTWELL MOLECULAR	5MG/5ML	A 078876	001	May 11, 2012	Feb	CDFR
	@ LANNETT CO INC	5MG/5ML	A 078496	001	Sep 25, 2009	Feb	CDFR
AA	! PADAGIS US	5MG/5ML	A 078398	001	Jun 17, 2008	Feb	CDFR
AA	PHARM ASSOC	5MG/5ML	A 078412	001	Jun 18, 2008	Feb	CDFR
	@ RANBAXY LABS LTD	5MG/5ML	A 077472	001	Jun 18, 2008	Feb	CDFR
AA	TARO	5MG/5ML	A 076601	001	Jun 20, 2008	Feb	CDFR
	@ TEVA PHARMS	5MG/5ML	A 077279	001	May 27, 2008	Mar	DISC
AA		5MG/5ML	A 077279	001	May 27, 2008	Feb	CDFR
	@ WOCKHARDT	5MG/5ML	A 078757	001	Aug 28, 2009	Feb	CDFR
	ZYRTEC						
	@ J AND J CONSUMER INC	5MG/5ML	N 020346	001	Sep 27, 1996	Feb	CDFR

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	PHARM ASSOC	5MG/5ML	A 078412	001	Jun 18, 2008	Jan	CMFD
----	-------------	---------	----------	-----	--------------	-----	------

CETRORELIX ACETATE

POWDER;SUBCUTANEOUS  
CETRORELIX ACETATE

AP	GLAND	EQ 0.25MG BASE/VIAL	A 218150	001	Apr 25, 2024	Apr	NEWA
AP	LIVZON GRP	EQ 0.25MG BASE/VIAL	A 214540	001	Apr 24, 2024	Apr	NEWA
AP	QILU	EQ 0.25MG BASE/VIAL	A 217776	001	Apr 16, 2024	Apr	NEWA

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE;INJECTION  
CHLORAMPHENICOL SODIUM SUCCINATE

@	FRESENIUS KABI USA	EQ 1GM BASE/VIAL	A 062365	001	Aug 25, 1982	Feb	DISC
---	--------------------	------------------	----------	-----	--------------	-----	------

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION  
CHLOROTHIAZIDE SODIUM

@	RK PHARMA	EQ 500MG BASE/VIAL	A 202493	001	Jun 18, 2014	Mar	DISC
---	-----------	--------------------	----------	-----	--------------	-----	------

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE;INJECTION  
CHLORPROMAZINE HYDROCHLORIDE

AP	DR REDDYS	25MG/ML	A 080365	001		Apr	CMFD
AP	ZYDUS PHARMS	25MG/ML	A 217275	001	Mar 13, 2024	Mar	NEWA

SYRUP; ORAL

SONAZINE

>A>	@ CHARTWELL RX	10MG/5ML	A 083040	001			May	CAHN
>D>	@ FOSUN PHARMA	10MG/5ML	A 083040	001			May	CAHN

TABLET; ORAL

CHLORPROMAZINE HYDROCHLORIDE

AB	ZAMEER PHARMS	10MG	A 212630	001	Nov 29, 2021	Feb	CAHN
AB		25MG	A 212630	002	Nov 29, 2021	Feb	CAHN
AB		50MG	A 212630	003	Nov 29, 2021	Feb	CAHN
AB		100MG	A 212630	004	Nov 29, 2021	Feb	CAHN
AB		200MG	A 212630	005	Nov 29, 2021	Feb	CAHN

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

	@ APTAPHARMA INC	375MG	A 212053	001	Sep 14, 2020	Apr	DISC
	@	750MG	A 212053	002	Sep 14, 2020	Apr	DISC
AB	ENDO OPERATIONS	375MG	A 212743	002	Apr 29, 2021	Apr	CAHN
AB		750MG	A 212743	001	Nov 02, 2020	Apr	CAHN
AA	HAVIX	500MG	A 210961	001	Jan 22, 2024	Jan	NEWA
AA	SENORES PHARMS	250MG	A 215158	001	Jul 29, 2021	Feb	CAHN
AA		500MG	A 210961	001	Jan 22, 2024	Feb	CAHN

CHOLESTYRAMINE

POWDER; ORAL

CHOLESTYRAMINE LIGHT

>A>	AB	ENDO OPERATIONS	EQ 4GM RESIN/PACKET	A 077203	001	Aug 26, 2005	May	CAHN
>A>	AB		EQ 4GM RESIN/SCOOPFUL	A 077203	002	Aug 26, 2005	May	CAHN
>D>	AB	PAR PHARM	EQ 4GM RESIN/PACKET	A 077203	001	Aug 26, 2005	May	CAHN
>D>	AB		EQ 4GM RESIN/SCOOPFUL	A 077203	002	Aug 26, 2005	May	CAHN

CHOLINE FENOFIBRATE

CAPSULE, DELAYED RELEASE; ORAL

FENOFIBRIC ACID

>D>	@ ANCHEN PHARMS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	May	CAHN
	@	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	Mar	DISC
>D>	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	May	CAHN
	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	Mar	DISC
>A>	@ ENDO OPERATIONS	EQ 45MG FENOFIBRIC ACID	A 201573	002	Jul 18, 2013	May	CAHN
>A>	@	EQ 135MG FENOFIBRIC ACID	A 201573	001	Jul 18, 2013	May	CAHN
AB	MACLEODS PHARMS LTD	EQ 45MG FENOFIBRIC ACID	A 207796	001	Feb 08, 2024	Feb	NEWA
AB		EQ 135MG FENOFIBRIC ACID	A 207796	002	Feb 08, 2024	Feb	NEWA
AB	TWI PHARMS	EQ 45MG FENOFIBRIC ACID	A 210469	001	Jul 05, 2019	Mar	CAHN
AB		EQ 135MG FENOFIBRIC ACID	A 210469	002	Jul 05, 2019	Mar	CAHN

CICLOPIROX

CREAM; TOPICAL

CICLOPIROX

AB	TARO	0.77%	A 076790	001	Apr 12, 2005	Jan	CAHN
----	------	-------	----------	-----	--------------	-----	------

SOLUTION; TOPICAL

CICLOPIROX

	@ HIKMA	8%	A 078270	001	Sep 18, 2007	Mar	DISC
--	---------	----	----------	-----	--------------	-----	------

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

	@ RISING	50MG	A 077323	002	Apr 20, 2006	Feb	CAHN
	@	100MG	A 077323	001	Apr 20, 2006	Feb	CAHN

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

CIMETIDINE HYDROCHLORIDE

>D>	@ DAVA PHARMS INC	EQ 300MG BASE/2ML	A 074428	001	Apr 25, 1996	May	CAHN
>A>	@ ENDO OPERATIONS	EQ 300MG BASE/2ML	A 074005	001	Aug 31, 1994	May	CAHN
>A>	@	EQ 300MG BASE/2ML	A 074428	001	Apr 25, 1996	May	CAHN
>D>	@ VINTAGE PHARMS LLC	EQ 300MG BASE/2ML	A 074005	001	Aug 31, 1994	May	CAHN

SOLUTION; ORAL

CIMETIDINE HYDROCHLORIDE

	@ PAI HOLDINGS PHARM	EQ 300MG BASE/5ML	A 074664	001	Oct 28, 1997	Feb	DISC
	@ PHARM ASSOC	EQ 300MG BASE/5ML	A 074553	001	Jan 27, 1997	Feb	DISC

CIPROFLOXACIN HYDROCHLORIDE

	SOLUTION/DROPS;OPHTHALMIC							
	CIPROFLOXACIN HYDROCHLORIDE							
	@ SAPTALIS PHARMS	EQ 0.3% BASE	A076555	001	Dec 11, 2008	Mar	CAHN	
	SOLUTION/DROPS;OTIC							
	CETRAXAL							
	+! KEY THERAP	EQ 0.2% BASE	N021918	001	May 01, 2009	Apr	CAHN	
	TABLET;ORAL							
	CIPROFLOXACIN HYDROCHLORIDE							
AB	AIPING PHARM INC	EQ 250MG BASE	A076593	002	Jun 09, 2004	Apr	CMFD	
AB		EQ 500MG BASE	A076593	003	Jun 09, 2004	Apr	CMFD	
AB		EQ 750MG BASE	A076593	004	Jun 09, 2004	Apr	CMFD	

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

	TABLET, EXTENDED RELEASE;ORAL							
	CIPROFLOXACIN EXTENDED RELEASE							
>D>	@ ANCHEN PHARMS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May	CAHN	
	@	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	Mar	DISC	
>D>	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May	CAHN	
	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	Mar	DISC	
	! DR REDDYS LABS LTD	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CTEC	
AB	!	425.2MG;EQ 574.9MG BASE	A077701	001	Mar 26, 2007	Mar	CHRS	
>A>	@ ENDO OPERATIONS	212.6MG;EQ 287.5MG BASE	A078166	002	Nov 27, 2007	May	CAHN	
>A>	@	425.2MG;EQ 574.9MG BASE	A078166	001	Nov 27, 2007	May	CAHN	

CIPROFLOXACIN; DEXAMETHASONE

	SUSPENSION/DROPS;OTIC							
	CIPROFLOXACIN; DEXAMETHASONE							
AB	AMNEAL	0.3%;0.1%	A216501	001	Mar 22, 2024	Mar	NEWA	

CISATRACURIUM BESYLATE

	INJECTABLE;INJECTION							
	CISATRACURIUM BESYLATE							
	@ CAPLIN	EQ 2MG BASE/ML	A217725	001	Jun 09, 2023	Apr	DISC	
	@	EQ 10MG BASE/ML	A217725	002	Jun 09, 2023	Apr	DISC	
AP	HAINAN POLY	EQ 2MG BASE/ML	A216538	001	Mar 08, 2024	Mar	NEWA	
AP	! MEITHEAL	EQ 2MG BASE/ML	A211668	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 2MG BASE/ML	A211669	001	Apr 25, 2019	Apr	CHRS	
AP	!	EQ 10MG BASE/ML	A211668	002	Apr 25, 2019	Apr	CHRS	
AP	PIRAMAL CRITICAL	EQ 2MG BASE/ML	A215516	003	Dec 14, 2022	Mar	CMS1	
	NIMBEX							
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	001	Dec 15, 1995	Apr	DISC	
	NIMBEX PRESERVATIVE FREE							
	+ @ ABBVIE	EQ 2MG BASE/ML	N020551	003	Dec 15, 1995	Apr	DISC	
	+ @	EQ 10MG BASE/ML	N020551	002	Dec 15, 1995	Apr	DISC	

CISPLATIN

	INJECTABLE;INJECTION							
	CISPLATIN							
>A>	AP	QILU	A218868	001	May 10, 2024	May	NEWA	

CITALOPRAM HYDROBROMIDE

	TABLET;ORAL							
	CITALOPRAM HYDROBROMIDE							
AB	APOTEX	EQ 10MG BASE	A077046	001	Nov 24, 2004	Jan	CAHN	
AB		EQ 20MG BASE	A077046	002	Nov 24, 2004	Jan	CAHN	
AB		EQ 40MG BASE	A077046	003	Nov 24, 2004	Jan	CAHN	
	@ COSETTE	EQ 10MG BASE	A077048	001	Nov 16, 2004	Apr	DISC	
	@	EQ 20MG BASE	A077048	002	Nov 16, 2004	Apr	DISC	
	@	EQ 40MG BASE	A077048	003	Nov 16, 2004	Apr	DISC	
	@ TARO	EQ 10MG BASE	A077278	001	Mar 22, 2006	Jan	CAHN	
	@	EQ 20MG BASE	A077278	002	Mar 22, 2006	Jan	CAHN	
	@	EQ 40MG BASE	A077278	003	Mar 22, 2006	Jan	CAHN	

CLEMASTINE FUMARATE

	SYRUP;ORAL							
	CLEMASTINE FUMARATE							
	@ NEW HEIGHTS	EQ 0.5MG BASE/5ML	A074884	001	Dec 17, 1997	Jan	CAHN	

CLINDAMYCIN HYDROCHLORIDE

CAPSULE;ORAL

CLINDAMYCIN HYDROCHLORIDE

@ COSETTE EQ 150MG BASE  
 @ EQ 300MG BASE

A063029 001 Sep 20, 1989 Apr DISC  
 A063029 002 Aug 05, 2005 Apr DISC

CLINDAMYCIN PHOSPHATE

GEL;TOPICAL

CLINDAMYCIN PHOSPHATE

AB1 ALEMBIC EQ 1% BASE  
 @ AMNEAL EQ 1% BASE

A212466 001 Apr 02, 2024 Mar NEWA  
 A215219 001 Nov 03, 2022 Feb DISC

GEL;VAGINAL

XACIATO

+! ORGANON LLC EQ 2% BASE

N215650 001 Dec 07, 2021 Jan CAHN

SOLUTION;TOPICAL

CLINDAMYCIN PHOSPHATE

@ ENDO OPERATIONS EQ 1% BASE

A203343 001 May 29, 2015 Apr CAHN

CLOBAZAM

TABLET;ORAL

CLOBAZAM

@ BRECKENRIDGE 20MG

A209308 002 Oct 22, 2018 Jan DISC

CLOBETASOL PROPIONATE

AEROSOL, FOAM;TOPICAL

CLOBETASOL PROPIONATE

AB2 TARO 0.05%

A208563 001 Mar 14, 2024 Mar NEWA

CREAM;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%

A074139 001 Aug 03, 1994 Apr DISC

CORMAX

@ HIKMA 0.05%

A074220 001 May 16, 1997 Mar DISC

GEL;TOPICAL

EMBELINE

@ HIKMA 0.05%

A076141 001 Apr 12, 2002 Mar DISC

OINTMENT;TOPICAL

EMBELINE

@ HIKMA 0.05%

A074221 001 Mar 31, 1995 Mar DISC

SHAMPOO;TOPICAL

CLOBETASOL PROPIONATE

@ HIKMA 0.05%

A209871 001 Oct 27, 2017 Mar DISC

SOLUTION;TOPICAL

CLOBETASOL PROPIONATE

@ COSETTE 0.05%

A074331 001 Dec 15, 1995 Apr DISC

>D> @ ENCUBE 0.05%

A076977 001 Aug 05, 2005 May CMFD

>A> AT 0.05%

A076977 001 Aug 05, 2005 May CMFD

EMBELINE

@ HIKMA 0.05%

A074222 001 Dec 06, 1995 Mar DISC

SUSPENSION/DROPS;OPHTHALMIC

CLOBETASOL PROPIONATE

>A> +! EYENOVIA 0.05%

N218158 001 Mar 04, 2024 May CAHN

>D> +! FORMOSA 0.05%

N218158 001 Mar 04, 2024 May CAHN

+! 0.05%

N218158 001 Mar 04, 2024 Mar NEWA

CLOCORTOLONE PIVALATE

CREAM;TOPICAL

CLODERM

AB +! LEGACY PHARMA 0.1%

N017765 001 Apr CAHN

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

AB CHARTWELL RX 25MG

A074364 001 Mar 29, 1996 Mar CAHN

AB 50MG

A074364 002 Mar 29, 1996 Mar CAHN

AB 75MG

A074364 003 Mar 29, 1996 Mar CAHN

>D> AB MYLAN 25MG

A074947 001 Apr 30, 1998 May DISC

>A> @ 25MG

A074947 001 Apr 30, 1998 May DISC

>D> AB 50MG

A074947 002 Apr 30, 1998 May DISC

>A> @ 50MG

A074947 002 Apr 30, 1998 May DISC

>D> AB 75MG

A074947 003 Apr 30, 1998 May DISC



CAPSULE;ORAL

CLOMIPRAMINE HYDROCHLORIDE

>A>	AB	@	75MG	A074947	003	Apr 30, 1998	May	DISC
		@ RK PHARMA	25MG	A213221	001	Jun 22, 2020	Mar	DISC
		@	50MG	A213221	002	Jun 22, 2020	Mar	DISC
		@	75MG	A213221	003	Jun 22, 2020	Mar	DISC

CLONAZEPAM

TABLET, ORALLY DISINTEGRATING;ORAL

CLONAZEPAM

AB	ENDO OPERATIONS		0.125MG	A077171	001	Aug 03, 2005	Apr	CAHN
AB			0.25MG	A077171	002	Aug 03, 2005	Apr	CAHN
AB			0.5MG	A077171	003	Aug 03, 2005	Apr	CAHN
AB	!		1MG	A077171	004	Aug 03, 2005	Apr	CAHN
AB			2MG	A077171	005	Aug 03, 2005	Apr	CAHN

CLONIDINE HYDROCHLORIDE

>A>	SUSPENSION, EXTENDED RELEASE;ORAL							
>A>	ONYDA XR							
>A>	+!	TRIS PHARMA INC	0.1MG/ML	N217645	001	May 24, 2024	May	NEWA
	TABLET, EXTENDED RELEASE;ORAL							
	CLONIDINE HYDROCHLORIDE							
>D>	@	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
>D>	@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN
	@		0.1MG	A202984	001	Sep 30, 2013	Mar	DISC
>D>	@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
>D>	@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
>D>	@	BLUEPHARMA INDUSTRIA	0.1MG	A211433	001	Oct 12, 2018	May	CAHN
	@		0.1MG	A211433	001	Oct 12, 2018	Jan	CAHN
>A>	@	ENDO OPERATIONS	0.1MG	A202983	001	Apr 02, 2014	May	CAHN
>A>	@		0.1MG	A202984	001	Sep 30, 2013	May	CAHN
>A>	@		0.2MG	A202983	002	Apr 02, 2014	May	CAHN
>A>	@		0.2MG	A202984	002	Sep 30, 2013	May	CAHN
>A>	@	SOMERSET THERAPS LLC	0.1MG	A211433	001	Oct 12, 2018	May	CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>D>	AB	ACCORD HLTHCARE	EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
>A>	@		EQ 75MG BASE	A202925	001	Mar 27, 2013	May	DISC
>D>	AB		EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC
>A>	@		EQ 300MG BASE	A202925	002	Mar 27, 2013	May	DISC

CLOTTRIMAZOLE

TROCHE/LOZENGE;ORAL

CLOTTRIMAZOLE

AB	THINQ PHARM-CRO PVT		10MG	A215641	001	Feb 29, 2024	Feb	NEWA
----	---------------------	--	------	---------	-----	--------------	-----	------

COBICISTAT

TABLET;ORAL

COBICISTAT

AB	MYLAN LABS LTD		150MG	A209986	001	Feb 07, 2024	Jan	NFTG
AB	TYBOST							
AB	+!	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Jan	CFTG

COCAINE HYDROCHLORIDE

SOLUTION;NASAL

GOPRELTO

+!	NODEN PHARMA		4%	N209963	001	Dec 14, 2017	Jan	CAHN
----	--------------	--	----	---------	-----	--------------	-----	------

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETH HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE

AA	!	GENUS	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040660	001	Dec 07, 2006	Apr	CAHN
	@	HIKMA	10MG/5ML; 5MG/5ML; 6.25MG/5ML	A040674	001	Dec 23, 2014	Mar	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

@ HIKMA	10MG/5ML;6.25MG/5ML	A040151	001	Aug 26, 1997	Mar	DISC
---------	---------------------	---------	-----	--------------	-----	------

COLCHICINE

CAPSULE;ORAL

COLCHICINE

AB	ANNORA PHARMA	0.6MG	A217620	001	Apr 29, 2024	Apr	NEWA
AB	AUROBINDO PHARMA LTD	0.6MG	A215463	001	Apr 29, 2024	Apr	NEWA
AB	GRANULES	0.6MG	A210757	001	Apr 29, 2024	Apr	NEWA

TABLET;ORAL

COLCHICINE

>D>	AB	ENDO OPERATIONS	0.6MG	A203976	001	Aug 12, 2021	May	CHRS
>A>	AB	!	0.6MG	A203976	001	Aug 12, 2021	May	CHRS
		@ MYLAN	0.6MG	A209470	001	Sep 16, 2019	Apr	DISC
>D>		COLCRYS						
>D>	AB	+! TAKEDA PHARMS USA	0.6MG	N022352	001	Jul 29, 2009	May	DISC
>A>		+ @	0.6MG	N022352	001	Jul 29, 2009	May	DISC

COLESEVELAM HYDROCHLORIDE

FOR SUSPENSION;ORAL

COLESEVELAM HYDROCHLORIDE

>D>	AB	IMPAX	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC
>A>		@	3.75GM/PACKET	A212886	001	Jan 18, 2023	May	DISC

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+!	ENDO OPERATIONS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001			Apr	CAHN
----	-----------------	---	---------	-----	--	--	-----	------

CORTICOTROPIN

INJECTABLE;INJECTION

ACTHAR GEL (AUTOINJECTOR)

+!	MALLINCKRODT ARD	40 UNITS/0.5ML	N008372	003	Feb 29, 2024	Mar	NEWA
+!		80 UNITS/ML	N008372	004	Feb 29, 2024	Mar	NEWA

COSYNTROPIN

INJECTABLE;INJECTION

COSYNTROPIN

>D>	AP	MYLAN INSTITUTIONAL	0.25MG/VIAL	A090574	001	Dec 17, 2009	May	DISC
>A>		@	0.25MG/VIAL	A090574	001	Dec 17, 2009	May	DISC

CUPRIC CHLORIDE

INJECTABLE;INJECTION

CUPRIC CHLORIDE

>A>	AP	RK PHARMA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	May	CAHN
	AP	SOMERSET	EQ 0.4MG COPPER/ML	A216113	001	Apr 30, 2024	Apr	NEWA
>D>	AP	STIRA	EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	May	CAHN
	AP		EQ 0.4MG COPPER/ML	A217626	001	Apr 30, 2024	Apr	NEWA

CYANOCOBALAMIN

GEL, METERED;NASAL

NASCOBAL

>A>		@ ENDO OPERATIONS	0.5MG/INH	N019722	001	Nov 05, 1996	May	CAHN
>D>		@ PAR PHARM	0.5MG/INH	N019722	001	Nov 05, 1996	May	CAHN

SPRAY, METERED;NASAL

CALOMIST

>A>		@ ENDO OPERATIONS	25MCG/SPRAY	N022102	001	Jul 27, 2007	May	CAHN
>D>		@ PAR PHARM	25MCG/SPRAY	N022102	001	Jul 27, 2007	May	CAHN

NASCOBAL

>A>	AB	+! ENDO OPERATIONS	0.5MG/SPRAY	N021642	001	Jan 31, 2005	May	CAHN
>D>	AB	+! ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	May	CAHN

CYCLOPENTOLATE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC

CYCLOPENTOLATE HYDROCHLORIDE

@ SAPTALIS PHARMS	0.5%	A205937	001	Dec 09, 2015	Mar	CAHN
-------------------	------	---------	-----	--------------	-----	------

CYCLOPHOSPHAMIDE

	INJECTABLE; INJECTION						
	CYCLOPHOSPHAMIDE						
AP	HIKMA	500MG/VIAL	A216958	001	Dec 18, 2023	Jan	CAHN
AP		1GM/VIAL	A216958	002	Dec 18, 2023	Jan	CAHN
AP		2GM/VIAL	A216958	003	Dec 18, 2023	Jan	CAHN
	SOLUTION; INTRAVENOUS						
	CYCLOPHOSPHAMIDE						
	+ @ BAXTER HLTHCARE CORP	500MG/2.5ML (200MG/ML)	N217651	001	Jun 28, 2023	Jan	CAHN
	+ @	1GM/5ML (200MG/ML)	N217651	002	Jun 28, 2023	Jan	CAHN

CYCLOSPORINE

	EMULSION; OPHTHALMIC						
	CYCLOSPORINE						
>A>	AB	DEVA HOLDING AS 0.05%	A209811	001	May 21, 2024	May	NEWA

CYPROHEPTADINE HYDROCHLORIDE

	SYRUP; ORAL						
	CYPROHEPTADINE HYDROCHLORIDE						
	@ PATRIN	2MG/5ML	A204823	001	Dec 27, 2016	Apr	DISC
	@ PHARM ASSOC	2MG/5ML	A091295	001	Mar 28, 2013	Feb	DISC

CYSTEINE HYDROCHLORIDE

	SOLUTION; INTRAVENOUS						
	ELCYS						
	+ @ EXELA PHARMA	2500MG/50ML (50MG/ML)	N210660	002	Dec 04, 2023	Jan	DISC

DABIGATRAN ETEXILATE MESYLATE

	CAPSULE; ORAL						
	DABIGATRAN ETEXILATE MESYLATE						
>A>	AB	MSN EQ 75MG BASE	A213879	001	May 22, 2024	May	NEWA
>A>	AB	EQ 150MG BASE	A213879	002	May 22, 2024	May	NEWA

DACTINOMYCIN

	INJECTABLE; INJECTION						
	COSMEGEN						
	+ @ RECORDATI RARE	0.5MG/VIAL	N050682	001		Jan	DISC
	DACTINOMYCIN						
AP	!	EUGIA PHARMA 0.5MG/VIAL	A203385	001	Nov 09, 2017	Jan	CHRS

DANICOPAN

	TABLET; ORAL						
	VOYDEYA						
	+ ALEXION PHARMS INC	50MG	N218037	001	Mar 29, 2024	Mar	NEWA
	+!	100MG	N218037	002	Mar 29, 2024	Mar	NEWA

>D>	<u>DAPRODUSTAT</u>						
>D>	TABLET; ORAL						
>D>	JESDUVROQ						
>D>	+ GLAXOSMITHKLINE	1MG	N216951	001	Feb 01, 2023	May	DISC
>A>	+ @	1MG	N216951	001	Feb 01, 2023	May	DISC
>D>	+	2MG	N216951	002	Feb 01, 2023	May	DISC
>A>	+ @	2MG	N216951	002	Feb 01, 2023	May	DISC
>D>	+	4MG	N216951	003	Feb 01, 2023	May	DISC
>A>	+ @	4MG	N216951	003	Feb 01, 2023	May	DISC
>D>	+	6MG	N216951	004	Feb 01, 2023	May	DISC
>A>	+ @	6MG	N216951	004	Feb 01, 2023	May	DISC
>D>	+!	8MG	N216951	005	Feb 01, 2023	May	DISC
>A>	+ @	8MG	N216951	005	Feb 01, 2023	May	DISC

DAPSONE

	GEL; TOPICAL						
	DAPSONE						
	@ PADAGIS ISRAEL	5%	A215087	001	Oct 31, 2023	Jan	DISC
	@	7.5%	A212657	001	Nov 01, 2023	Jan	DISC
>D>	AB	ZYDUS 7.5%	A214019	001	May 08, 2024	May	CAHN
	AB	7.5%	A214019	001	May 08, 2024	Apr	NEWA
>A>	AB	ZYDUS LIFESCIENCES 7.5%	A214019	001	May 08, 2024	May	CAHN

DARIFENACIN HYDROBROMIDE

TABLET, EXTENDED RELEASE;ORAL  
DARIFENACIN HYDROBROMIDE

>D>	@	ANCHEN PHARMS	EQ 7.5MG BASE	A 091190	001	Mar 13, 2015	May CAHN
>D>	@		EQ 15MG BASE	A 091190	002	Mar 13, 2015	May CAHN
>A>	@	ENDO OPERATIONS	EQ 7.5MG BASE	A 091190	001	Mar 13, 2015	May CAHN
>A>	@		EQ 15MG BASE	A 091190	002	Mar 13, 2015	May CAHN

DARUNAVIR

TABLET;ORAL  
DARUNAVIR

>A>	AB	ZYDUS LIFESCIENCES	600MG	A 214085	001	Dec 13, 2023	May CAHN
>A>	AB		800MG	A 214085	002	Dec 13, 2023	May CAHN
>D>	AB	ZYDUS PHARMS	600MG	A 214085	001	Dec 13, 2023	May CAHN
>D>	AB		800MG	A 214085	002	Dec 13, 2023	May CAHN

DECITABINE

INJECTABLE;INTRAVENOUS  
DECITABINE

>A>	AP	HETERO LABS LTD VI	50MG/VIAL	A 215355	001	May 10, 2024	May NEWA
-----	----	--------------------	-----------	----------	-----	--------------	----------

DEFERASIROX

GRANULE;ORAL  
DEFERASIROX

AB		MYLAN	90MG	A 213146	001	May 03, 2024	Apr NEWA
AB			180MG	A 213146	002	May 03, 2024	Apr NEWA
AB			360MG	A 213146	003	May 03, 2024	Apr NEWA

TABLET;ORAL  
DEFERASIROX

AB		MYLAN	90MG	A 211395	001	Mar 22, 2024	Mar NEWA
AB			180MG	A 211395	002	Mar 22, 2024	Mar NEWA
AB			360MG	A 211395	003	Mar 22, 2024	Mar NEWA

TABLET, FOR SUSPENSION;ORAL  
DEFERASIROX

>A>	AB	GLENMARK SPECLT	125MG	A 209433	001	Jan 06, 2020	May CAHN
>A>	AB		250MG	A 209433	002	Jan 06, 2020	May CAHN
>A>	AB		500MG	A 209433	003	Jan 06, 2020	May CAHN
>D>	AB	ICHNOS	125MG	A 209433	001	Jan 06, 2020	May CAHN
>D>	AB		250MG	A 209433	002	Jan 06, 2020	May CAHN
>D>	AB		500MG	A 209433	003	Jan 06, 2020	May CAHN
>A>	AB	MYLAN	125MG	A 206585	001	May 17, 2024	May NEWA
>A>	AB		250MG	A 206585	002	May 17, 2024	May NEWA
>A>	AB		500MG	A 206585	003	May 17, 2024	May NEWA

DEFLAZACORT

SUSPENSION;ORAL  
DEFLAZACORT

AB		TRIS PHARMA INC	22.75MG/ML	A 217813	001	Apr 25, 2024	Apr NFTG
AB	+	PTC THERAP	22.75MG/ML	N 208685	001	Feb 09, 2017	Apr CFTG

TABLET;ORAL  
DEFLAZACORT

AB		AUROBINDO PHARMA LTD	6MG	A 217123	001	Feb 09, 2024	Feb NFTG
AB			18MG	A 217123	002	Feb 09, 2024	Feb NFTG
AB			30MG	A 217123	003	Feb 09, 2024	Feb NFTG
AB			36MG	A 217123	004	Feb 09, 2024	Feb NFTG

EMFLAZA

AB	+	PTC THERAP	6MG	N 208684	001	Feb 09, 2017	Feb CFTG
AB	+		18MG	N 208684	002	Feb 09, 2017	Feb CFTG
AB	+		30MG	N 208684	003	Feb 09, 2017	Feb CFTG
AB	+		36MG	N 208684	004	Feb 09, 2017	Feb CFTG

DEOXYCHOLIC ACID

SOLUTION;SUBCUTANEOUS  
KYBELLA

AP	+	ABBVIE	20MG/2ML (10MG/ML)	N 206333	001	Apr 29, 2015	Jan CAHN
----	---	--------	--------------------	----------	-----	--------------	----------

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL		DESIPRAMINE HYDROCHLORIDE						
AB	CHARTWELL RX	10MG		A 072103	002	May 24, 1988	Mar	CAHN
AB		25MG		A 072103	003	May 24, 1988	Mar	CAHN
AB		50MG		A 072103	004	May 24, 1988	Mar	CAHN
AB		75MG		A 072103	005	Jun 20, 1988	Mar	CAHN
AB		100MG		A 072103	001	Jun 20, 1988	Mar	CAHN
AB		150MG		A 072103	006	Jun 20, 1988	Mar	CAHN

DESLORATADINE

TABLET; ORAL		DESLORATADINE						
	@ CHARTWELL RX	5MG		A 078364	001	Dec 03, 2010	Jan	CAHN

DESMOPRESSIN ACETATE

TABLET; ORAL		DESMOPRESSIN ACETATE						
	@ ACTAVIS LABS FL INC	0.1MG		A 076470	001	Jul 01, 2005	Feb	DISC
	@	0.2MG		A 076470	002	Jul 01, 2005	Feb	DISC
AB	AUROBINDO PHARMA	0.1MG		A 213095	001	Mar 21, 2024	Mar	NEWA
AB		0.2MG		A 213095	002	Mar 21, 2024	Mar	NEWA

DESOGESTREL; ETHINYL ESTRADIOL

TABLET; ORAL-28		DESOGESTREL AND ETHINYL ESTRADIOL						
AB	NAARI PTE LTD	0.15MG; 0.03MG		A 207067	001	Sep 13, 2018	Apr	CMFD
	@ XIROMED	0.15MG; 0.03MG		A 202085	001	May 20, 2015	Apr	CAHN
	EMOQUETTE							
>A>	@ ENDO OPERATIONS	0.15MG; 0.03MG		A 076675	001	Feb 25, 2011	May	CAHN
>D>	@ VINTAGE PHARMS LLC	0.15MG; 0.03MG		A 076675	001	Feb 25, 2011	May	CAHN
	KIMIDESS							
>A> AB	ENDO OPERATIONS	0.15MG, N/A; 0.02MG, 0.01MG		A 076681	001	Apr 30, 2015	May	CAHN
>D> AB	VINTAGE PHARMS	0.15MG, N/A; 0.02MG, 0.01MG		A 076681	001	Apr 30, 2015	May	CAHN

DESONIDE

OINTMENT; TOPICAL		DESONIDE						
	@ HIKMA	0.05%		A 208836	001	Mar 27, 2017	Mar	DISC

DESOXIMETASONE

CREAM; TOPICAL		DESOXIMETASONE						
	@ COSETTE	0.25%		A 209595	001	Mar 04, 2020	Mar	DISC
	@ SAPTALIS PHARMS	0.05%		A 203787	001	Jan 06, 2017	Feb	CAHN
	@	0.25%		A 203234	001	Jun 12, 2015	Feb	CAHN
OINTMENT; TOPICAL		DESOXIMETASONE						
	@ COSETTE	0.25%		A 206740	001	Dec 23, 2016	Apr	DISC

DEUTETRABENAZINE

TABLET, EXTENDED RELEASE; ORAL		AUSTEDO XR						
>A>	+ TEVA	30MG		N 216354	004	May 29, 2024	May	NEWA
>A>	+	36MG		N 216354	005	May 29, 2024	May	NEWA
>A>	+	42MG		N 216354	006	May 29, 2024	May	NEWA
>A>		48MG		N 216354	007	May 29, 2024	May	NEWA

DEXAMETHASONE

TABLET; ORAL		DEXAMETHASONE						
>D> BP	KEY THERAP	1.5MG		A 088237	001	Apr 28, 1983	May	DISC
>A>	@	1.5MG		A 088237	001	Apr 28, 1983	May	DISC
BP		1.5MG		A 088237	001	Apr 28, 1983	Apr	CAHN
	@ PANGEA	0.25MG		A 088149	001	Apr 28, 1983	Jan	CAHN
AB	ZYDUS LIFESCIENCES	0.5MG		A 216282	001	Feb 07, 2024	Mar	CAHN
AB		0.75MG		A 216282	002	Feb 07, 2024	Mar	CAHN
>A> AB		1MG		A 216284	001	May 09, 2024	May	CAHN
AB		1.5MG		A 216282	003	Feb 07, 2024	Mar	CAHN
AB		2MG		A 216283	001	Feb 07, 2024	Mar	CAHN
AB		4MG		A 216282	004	Feb 07, 2024	Mar	CAHN

TABLET; ORAL

DEXAMETHASONE

AB		6MG	A216282	005	Feb 07, 2024	Mar	CAHN
AB	ZYDUS PHARMS	0.5MG	A216282	001	Feb 07, 2024	Jan	NEWA
AB		0.75MG	A216282	002	Feb 07, 2024	Jan	NEWA
>A>	AB	1MG	A216284	001	May 09, 2024	May	NEWA
AB		1.5MG	A216282	003	Feb 07, 2024	Jan	NEWA
AB		2MG	A216283	001	Feb 07, 2024	Jan	NEWA
AB		4MG	A216282	004	Feb 07, 2024	Jan	NEWA
AB		6MG	A216282	005	Feb 07, 2024	Jan	NEWA

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

DEXAMETHASONE SODIUM PHOSPHATE

	@ GENEYORK PHARMS	EQ 4MG PHOSPHATE/ML	A214891	001	Jul 28, 2023	Feb	DISC
	@	EQ 10MG PHOSPHATE/ML	A214890	001	Jul 07, 2023	Feb	DISC
AP	MICRO LABS	EQ 10MG PHOSPHATE/ML	A217797	001	Mar 27, 2024	Mar	NEWA

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL

DEXCHLORPHENIRAMINE MALEATE

	+ @ PAI HOLDINGS PHARM	2MG/5ML	A088251	001	Mar 23, 1984	Mar	DISC
	! CAPELLON PHARMS LLC	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CTEC
AA	!	2MG/5ML	A202520	001	Jul 16, 2018	Mar	CHRS

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE; ORAL

DEXLANSOPRAZOLE

AB	MYLAN	30MG	A205205	001	Jan 19, 2024	Jan	NEWA
AB		60MG	A205205	002	Jan 19, 2024	Jan	NEWA

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA	AZURITY	2.5MG	A090533	001	Oct 25, 2011	Mar	CAHN
AA		5MG	A090533	002	Oct 25, 2011	Mar	CAHN
AA		7.5MG	A090533	003	Oct 25, 2011	Mar	CAHN
AA		10MG	A090533	004	Oct 25, 2011	Mar	CAHN
AA		15MG	A090533	005	Oct 25, 2011	Mar	CAHN
AA		20MG	A090533	006	Oct 25, 2011	Mar	CAHN
AA		30MG	A090533	007	Oct 25, 2011	Mar	CAHN
	@ TRIS PHARMA INC	5MG	A206095	001	Aug 18, 2022	Jan	DISC
	@	10MG	A206095	002	Aug 18, 2022	Jan	DISC

DEXTROSE

INJECTABLE; INJECTION

DEXTROSE 5%

AP	AM REGENT	50MG/ML	A217263	001	Apr 08, 2024	Apr	CTNA
AP		50MG/ML	A217263	001	Apr 08, 2024	Mar	NEWA

DIAZEPAM

FILM; BUCCAL

LIBERVANT

	+ AQUESTIVE	5MG	N218623	001	Apr 26, 2024	Apr	NEWA
	+	7.5MG	N218623	002	Apr 26, 2024	Apr	NEWA
	+	10MG	N218623	003	Apr 26, 2024	Apr	NEWA
	+	12.5MG	N218623	004	Apr 26, 2024	Apr	NEWA
	+!	15MG	N218623	005	Apr 26, 2024	Apr	NEWA

INJECTABLE; INJECTION

DIAZEPAM

AP	ALEMBIC	10MG/2ML (5MG/ML)	A218450	001	Apr 25, 2024	Apr	NEWA
	@ HIKMA	5MG/ML (5MG/ML)	A070311	002	Dec 16, 1985	Jan	NEWA
	@	10MG/2ML (5MG/ML)	A070311	003	Dec 16, 1985	Jan	NEWA
AP		50MG/10ML (5MG/ML)	A070311	001	Dec 16, 1985	Jan	CPOT

TABLET; ORAL

DIAZEPAM

>D>	@ DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	May	CAHN
>D>	@	5MG	A070228	003	Sep 26, 1985	May	CAHN
>D>	@	10MG	A070228	001	Sep 26, 1985	May	CAHN
>A>	@ ENDO OPERATIONS	2MG	A070228	002	Sep 26, 1985	May	CAHN
>A>	@	5MG	A070228	003	Sep 26, 1985	May	CAHN

		TABLET;ORAL DIAZEPAM							
>A>	@		10MG	A070228	001	Sep 26, 1985	May	CAHN	
		<u>DICHLORPHENAMIDE</u>							
		TABLET;ORAL ORMALVI							
AB	TORRENT		50MG	A215924	001	Dec 29, 2022	Feb	CTNA	
		<u>DICLOFENAC POTASSIUM</u>							
		FOR SOLUTION;ORAL DICLOFENAC POTASSIUM							
>A>	AB	ENDO OPERATIONS	50MG	A202964	001	May 02, 2016	May	CAHN	
>D>	AB	PAR FORM	50MG	A202964	001	May 02, 2016	May	CAHN	
		<u>DICLOFENAC SODIUM</u>							
		SOLUTION;TOPICAL DICLOFENAC SODIUM							
AB	! LUPIN PHARMS		2%	A208021	001	Sep 20, 2022	Mar	CHRS	
	PENNSAID								
	+ @ HORIZON		2%	N204623	001	Jan 16, 2014	Mar	DISC	
		<u>DICYCLOMINE HYDROCHLORIDE</u>							
		INJECTABLE;INJECTION BENTYL							
	+ @ ABBVIE		10MG/ML	N008370	001	Oct 15, 1984	Apr	DISC	
		DICYCLOMINE HYDROCHLORIDE							
AP	! FOSUN PHARMA		10MG/ML	A210979	001	Jul 02, 2018	Apr	CHRS	
		SYRUP;ORAL DICYCLOMINE HYDROCHLORIDE							
AA	! ENDO OPERATIONS		10MG/5ML	A040169	001	Mar 24, 2005	Apr	CAHN	
		TABLET;ORAL DICYCLOMINE HYDROCHLORIDE							
AB	ANNORA PHARMA		20MG	A217566	001	May 07, 2024	Apr	NEWA	
		<u>DIFLUPREDNATE</u>							
		EMULSION;OPHTHALMIC DIFLUPREDNATE							
>A>	AB	EPIC PHARMA LLC	0.05%	A207284	001	May 14, 2024	May	NEWA	
		<u>DIGOXIN</u>							
		ELIXIR;ORAL DIGOXIN							
AA	VISTAPHARM LLC		0.05MG/ML	A213000	001	Oct 04, 2019	Feb	CAHN	
		<u>DIHYDROERGOTAMINE MESYLATE</u>							
		SPRAY, METERED;NASAL DIHYDROERGOTAMINE MESYLATE							
	@ AMNEAL		0.5MG/SPRAY	A214105	001	Jan 04, 2022	Mar	DISC	
	TRUDHESA								
	+! JN BIDCO		0.725MG/SPRAY	N213436	001	Sep 02, 2021	Feb	CAHN	
		<u>DILTIAZEM HYDROCHLORIDE</u>							
		CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE							
AB3	ENDO OPERATIONS		120MG	A074984	001	Dec 20, 1999	Apr	CAHN	
AB3			180MG	A074984	002	Dec 20, 1999	Apr	CAHN	
AB3			240MG	A074984	003	Dec 20, 1999	Apr	CAHN	
AB3			300MG	A074984	004	Dec 20, 1999	Apr	CAHN	
>A>	@		360MG	A209766	001	May 30, 2018	May	CAHN	
>D>	@ PAR PHARM		360MG	A209766	001	May 30, 2018	May	CAHN	
	@ SUN PHARM		360MG	A090492	005	Oct 28, 2011	Feb	DISC	
		INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE							
AP	HIKMA		5MG/ML	A078538	001	Dec 17, 2008	Mar	CAHN	
	@ HIKMA FARMACEUTICA		5MG/ML	A202651	001	Aug 09, 2012	Mar	DISC	

DIPHENHYDRAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DIPHENHYDRAMINE HYDROCHLORIDE

AP	GLAND PHARMA LTD	50MG/ML	A 218448	001	Mar 20, 2024	Mar	NEWA
>D>	MYLAN INSTITUTIONAL	50MG/ML	A 040498	001	Jul 12, 2005	May	CHRS
>A>	!	50MG/ML	A 040498	001	Jul 12, 2005	May	CHRS

DIPYRIDAMOLE

TABLET; ORAL

DIPYRIDAMOLE

	@ GENUS	25MG	A 040898	001	Apr 23, 2008	Jan	CAHN	
	@	50MG	A 040898	002	Apr 23, 2008	Jan	CAHN	
	@	75MG	A 040898	003	Apr 23, 2008	Jan	CAHN	
>D>	AB	IMPAX LABS	75MG	A 040782	003	Jul 18, 2007	May	CHRS
>A>	AB	!	75MG	A 040782	003	Jul 18, 2007	May	CHRS
>D>		PERSANTINE						
>D>	AB	+ BOEHRINGER INGELHEIM	25MG	N 012836	003	Dec 22, 1986	May	DISC
>A>		+ @	25MG	N 012836	003	Dec 22, 1986	May	DISC
>D>	AB	+	50MG	N 012836	004	Feb 06, 1987	May	DISC
>A>		+ @	50MG	N 012836	004	Feb 06, 1987	May	DISC
>D>	AB	+!	75MG	N 012836	005	Feb 06, 1987	May	DISC
>A>		+ @	75MG	N 012836	005	Feb 06, 1987	May	DISC

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DIVALPROEX SODIUM

>D>	@ ANCHEN PHARMS	EQ 500MG VALPROIC ACID	A 078411	001	Nov 03, 2008	May	CAHN
>A>	@ ENDO OPERATIONS	EQ 500MG VALPROIC ACID	A 078411	001	Nov 03, 2008	May	CAHN

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

>D>	@ ANCHEN PHARMS	EQ 250MG VALPROIC ACID	A 078445	001	Feb 26, 2009	May	CAHN
>D>	@	EQ 500MG VALPROIC ACID	A 078445	002	Aug 04, 2009	May	CAHN
>A>	@ ENDO OPERATIONS	EQ 250MG VALPROIC ACID	A 078445	001	Feb 26, 2009	May	CAHN
>A>	@	EQ 500MG VALPROIC ACID	A 078445	002	Aug 04, 2009	May	CAHN

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

AP	ACIC PHARMS	80MG/4ML (20MG/ML)	A 216677	002	Feb 28, 2024	Feb	NEWA
AP		20MG/ML (20MG/ML)	A 216677	001	Feb 28, 2024	Feb	NEWA

SOLUTION; INTRAVENOUS

DOCIVYX

+!	AVYXA HOLDINGS	20MG/2ML (10MG/ML)	N 215813	001	Nov 22, 2022	Apr	CMFD
+	@	20MG/2ML (10MG/ML)	N 215813	001	Nov 22, 2022	Apr	CTNA
+	@	20MG/2ML (10MG/ML)	N 215813	001	Nov 22, 2022	Jan	CAHN
+!		80MG/8ML (10MG/ML)	N 215813	002	Nov 22, 2022	Apr	CMFD
+	@	80MG/8ML (10MG/ML)	N 215813	002	Nov 22, 2022	Apr	CTNA
+	@	80MG/8ML (10MG/ML)	N 215813	002	Nov 22, 2022	Jan	CAHN
+!		160MG/16ML (10MG/ML)	N 215813	003	Nov 22, 2022	Apr	CMFD
+	@	160MG/16ML (10MG/ML)	N 215813	003	Nov 22, 2022	Apr	CTNA
+	@	160MG/16ML (10MG/ML)	N 215813	003	Nov 22, 2022	Jan	CAHN

DOLUTEGRAVIR SODIUM

TABLET; ORAL

TIVICAY

+	@ VIIIV HLTHCARE	EQ 10MG BASE	N 204790	002	Jun 09, 2016	Jan	DISC
+	@	EQ 25MG BASE	N 204790	003	Jun 09, 2016	Jan	DISC

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

>A>	@ ENDO OPERATIONS	23MG	A 202542	001	Jul 24, 2013	May	CAHN	
>D>	@ PAR PHARM	23MG	A 202542	001	Jul 24, 2013	May	CAHN	
>D>	AB	SUN PHARM INDS	5MG	A 090493	001	May 31, 2011	May	DISC
>A>	@	5MG	A 090493	001	May 31, 2011	May	DISC	
>D>	AB	10MG	A 090493	002	May 31, 2011	May	DISC	
>A>	@	10MG	A 090493	002	May 31, 2011	May	DISC	

TABLET, ORALLY DISINTEGRATING; ORAL

DONEPEZIL HYDROCHLORIDE

AB	!	MACLEODS PHARMS LTD	10MG	A 201787	002	Dec 14, 2012	Mar	CHRS
	@	SANDOZ	5MG	A 091198	001	May 10, 2011	Mar	DISC



TABLET, ORALLY DISINTEGRATING;ORAL  
DONEPEZIL HYDROCHLORIDE

@ 10MG A091198 002 May 10, 2011 Mar DISC

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE

@ HIKMA EQ 2% BASE A077846 001 Oct 28, 2008 Mar DISC

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS;OPHTHALMIC  
DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

@ HIKMA EQ 2% BASE;EQ 0.5% BASE A077847 001 Oct 28, 2008 Mar DISC

DOXAZOSIN MESYLATE

TABLET;ORAL  
DOXAZOSIN MESYLATE

AB AUROBINDO PHARMA USA EQ 1MG BASE A075509 001 Oct 19, 2000 Mar CMFD  
 AB EQ 2MG BASE A075509 002 Oct 19, 2000 Mar CMFD  
 AB EQ 4MG BASE A075509 003 Oct 19, 2000 Mar CMFD  
 AB EQ 8MG BASE A075509 004 Oct 19, 2000 Mar CMFD

DOXEPIIN HYDROCHLORIDE

CAPSULE;ORAL  
DOXEPIIN HYDROCHLORIDE

@ ENDO OPERATIONS EQ 10MG BASE A071422 002 Nov 09, 1987 Apr CAHN  
 @ EQ 25MG BASE A071422 003 Nov 09, 1987 Apr CAHN  
 @ EQ 50MG BASE A071422 004 Nov 09, 1987 Apr CAHN  
 @ EQ 75MG BASE A071422 005 Nov 09, 1987 Apr CAHN  
 @ EQ 100MG BASE A071422 001 Nov 09, 1987 Apr CAHN  
 AB ! EQ 150MG BASE A071422 006 Nov 09, 1987 Apr CAHN

DOXERCALCIFEROL

INJECTABLE;INJECTION  
DOXERCALCIFEROL

@ AMNEAL 2MCG/ML (2MCG/ML) A208974 001 May 24, 2017 Jan DISC  
 @ 4MCG/2ML (2MCG/ML) A208974 002 May 24, 2017 Jan DISC  
 AP 4MCG/2ML (2MCG/ML) A208975 001 May 24, 2017 Jan CMFD

DOXYCYCLINE

CAPSULE;ORAL  
DOXYCYCLINE

@ COSETTE EQ 50MG BASE A204446 001 May 28, 2015 Apr DISC  
 @ EQ 75MG BASE A204446 002 May 28, 2015 Apr DISC  
 @ EQ 100MG BASE A204446 003 May 28, 2015 Apr DISC  
 AB DR REDDYS 40MG A218034 001 Apr 08, 2024 Mar NFTG  
 AB LUPIN 40MG A216631 001 Apr 08, 2024 Mar NFTG  
 AB +! GALDERMA LABS LP 40MG N050805 001 May 26, 2006 Mar CFTG

DOXYCYCLINE HYCLATE

CAPSULE;ORAL  
ACTICLATE CAP  
+ @ CHARTWELL RX  
INJECTABLE;INJECTION  
DOXYCYCLINE HYCLATE

LUPIN LTD EQ 75MG BASE N208253 001 Apr 26, 2016 Jan CAHN

TABLET;ORAL  
ACTICLATE

AB + CHARTWELL RX EQ 75MG BASE N205931 001 Jul 25, 2014 Jan CAHN  
 AB +! EQ 150MG BASE N205931 002 Jul 25, 2014 Jan CAHN

DOXYCYCLINE HYCLATE

>D> AB NOSTRUM LABS INC EQ 100MG BASE A209560 001 Apr 15, 2024 May DISC  
 >A> @ EQ 100MG BASE A209560 001 Apr 15, 2024 May DISC  
 AB EQ 100MG BASE A209560 001 Apr 15, 2024 Apr NEWA  
 @ TORRENT EQ 75MG BASE A214356 001 Apr 15, 2024 Apr DISC  
 AB EQ 75MG BASE A214356 001 Apr 15, 2024 Apr NEWA  
 @ EQ 150MG BASE A214356 002 Apr 15, 2024 Apr DISC  
 AB EQ 150MG BASE A214356 002 Apr 15, 2024 Apr NEWA

TABLET, DELAYED RELEASE;ORAL  
DORYX

+ @	MAYNE PHARMA	EQ 75MG BASE	N050795	001	May 06, 2005	Feb	DISC
+ @		EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb	DISC

DOXYLAMINE SUCCINATE; PYRIDOXINE HYDROCHLORIDE

## TABLET, DELAYED RELEASE;ORAL

## DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE

AB	ENDO OPERATIONS	10MG;10MG	A208518	001	Dec 06, 2017	Apr	CAHN
----	-----------------	-----------	---------	-----	--------------	-----	------

DRONABINOL

## CAPSULE;ORAL

## DRONABINOL

@	HIKMA	2.5MG	A079217	001	Jun 20, 2014	Mar	DISC
@		5MG	A079217	002	Jun 20, 2014	Mar	DISC
@		10MG	A079217	003	Jun 20, 2014	Mar	DISC

DRONEDARONE HYDROCHLORIDE

## TABLET;ORAL

## DRONEDARONE HYDROCHLORIDE

AB	LUPIN	EQ 400MG BASE	A205904	001	Jan 31, 2024	Jan	NFTG
AB	+! SANOFI AVENTIS US	EQ 400MG BASE	N022425	001	Jul 01, 2009	Jan	CFTG

DROXIDOPA

## CAPSULE;ORAL

## DROXIDOPA

@	UPSHER SMITH LABS	100MG	A213661	001	Feb 18, 2021	Apr	DISC
@		200MG	A213661	002	Feb 18, 2021	Apr	DISC
@		300MG	A213661	003	Feb 18, 2021	Apr	DISC

DULOXETINE HYDROCHLORIDE

## CAPSULE, DELAYED REL PELLETS;ORAL

## DRIZALMA SPRINKLE

+	SUN PHARM	EQ 20MG BASE	N212516	001	Jul 19, 2019	Apr	CMFD
+		EQ 30MG BASE	N212516	002	Jul 19, 2019	Apr	CMFD
+		EQ 40MG BASE	N212516	003	Jul 19, 2019	Apr	CMFD
+!		EQ 60MG BASE	N212516	004	Jul 19, 2019	Apr	CMFD

## DULOXETINE HYDROCHLORIDE

>D>	@ ANCHEN PHARMS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May	CAHN
	@	EQ 20MG BASE	A090780	001	Oct 28, 2015	Feb	DISC
>D>	@	EQ 30MG BASE	A090780	002	Oct 28, 2015	May	CAHN
	@	EQ 30MG BASE	A090780	002	Oct 28, 2015	Feb	DISC
>D>	@	EQ 60MG BASE	A090780	003	Oct 28, 2015	May	CAHN
	@	EQ 60MG BASE	A090780	003	Oct 28, 2015	Feb	DISC
>A>	@ ENDO OPERATIONS	EQ 20MG BASE	A090780	001	Oct 28, 2015	May	CAHN
>A>	@	EQ 30MG BASE	A090780	002	Oct 28, 2015	May	CAHN
>A>	@	EQ 60MG BASE	A090780	003	Oct 28, 2015	May	CAHN
	@ MARKSANS PHARMA	EQ 20MG BASE	A090723	001	Dec 11, 2013	Feb	DISC
	@	EQ 30MG BASE	A090723	002	Dec 11, 2013	Feb	DISC
	@	EQ 60MG BASE	A090723	003	Dec 11, 2013	Feb	DISC

DUTASTERIDE

## CAPSULE;ORAL

## AVODART

AB	+! WAYLIS THERAP	0.5MG	N021319	001	Nov 20, 2001	Mar	CAHN
AB	CHARTWELL	0.5MG	A200899	001	Nov 20, 2015	Mar	CAHN
	@ VINTAGE	0.5MG	A202421	001	Nov 20, 2015	Feb	DISC

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

## CAPSULE;ORAL

## DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ENDO OPERATIONS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Apr	CAHN
AB	+! WAYLIS THERAP	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Apr	CAHN

EDARAVONE

SOLUTION; INTRAVENOUS

EDARAVONE

AP	DR REDDYS	60MG/100ML (0.6MG/ML)	A215917	001	May 06, 2024	Apr	NEWA
AP	GLAND PHARMA LTD	30MG/100ML (0.3MG/ML)	A216199	001	May 06, 2024	Apr	NFTG
AP		60MG/100ML (0.6MG/ML)	A216199	002	May 06, 2024	Apr	NFTG
AP	HIKMA	30MG/100ML (0.3MG/ML)	A215508	001	May 06, 2024	Apr	NFTG
AP	LONG GROVE PHARMS	30MG/100ML (0.3MG/ML)	A218354	001	May 06, 2024	Apr	NEWA
	RADICAVA						
AP	+! MITSUBISHI TANABE	30MG/100ML (0.3MG/ML)	N209176	001	May 05, 2017	Apr	CFTG
AP	+!	60MG/100ML (0.6MG/ML)	N209176	002	Nov 15, 2018	Apr	CFTG

EFAVIRENZ

TABLET; ORAL

EFAVIRENZ

>A>	AB	MACLEODS PHARMS LTD	600MG	A091579	001	May 10, 2024	May	NEWA
-----	----	---------------------	-------	---------	-----	--------------	-----	------

EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL

EFAVIRENZ; EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE

@ STRIDES PHARMA 600MG; 200MG; 300MG

A201802	001	Oct 03, 2023	Mar	DISC
---------	-----	--------------	-----	------

EFINAACONAZOLE

SOLUTION; TOPICAL

EFINAACONAZOLE

>D>		@ ZYDUS	10%	A212178	001	Jul 15, 2022	May	CAHN
>A>		@ ZYDUS LIFESCIENCES	10%	A212178	001	Jul 15, 2022	May	CAHN

ELTROMBOPAG OLAMINE

FOR SUSPENSION; ORAL

ELTROMBOPAG OLAMINE

AB	ANNORA PHARMA	EQ 12.5MG ACID/PACKET	A216620	001	Apr 18, 2024	Apr	NFTG
AB		EQ 25MG ACID/PACKET	A216620	002	Apr 18, 2024	Apr	NFTG
	PROMACTA KIT						
AB	+ NOVARTIS	EQ 12.5MG ACID/PACKET	N207027	002	Sep 27, 2018	Apr	CFTG
AB	+!	EQ 25MG ACID/PACKET	N207027	001	Aug 24, 2015	Apr	CFTG

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL

DESCOVY

>D>	+	GILEAD SCIENCES INC	120MG; EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG
>A>	AB	+	120MG; EQ 15MG BASE	N208215	002	Jan 07, 2022	May	CFTG
>D>		+!	200MG; EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG
>A>	AB	+!	200MG; EQ 25MG BASE	N208215	001	Apr 04, 2016	May	CFTG
>A>		EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FUMARATE						
>A>	AB	APOTEX	120MG; EQ 15MG BASE	A214053	001	May 17, 2024	May	NFTG
>A>	AB		200MG; EQ 25MG BASE	A214053	002	May 17, 2024	May	NFTG

ENALAPRIL MALEATE

FOR SOLUTION; ORAL

EPANED KIT

+	@ AZURITY	1MG/ML	N204308	001	Aug 13, 2013	Mar	CAHN
---	-----------	--------	---------	-----	--------------	-----	------

SOLUTION; ORAL

ENALAPRIL MALEATE

AB	AMNEAL	1MG/ML	A212894	001	Jun 29, 2022	Mar	CMFD
----	--------	--------	---------	-----	--------------	-----	------

ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE

@ COSETTE 5MG; 12.5MG

@ 10MG; 25MG

A075727	001	Sep 18, 2001	Apr	DISC
A075727	002	Sep 18, 2001	Apr	DISC

EPHEDRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS

REZIPRES

>D>	+	DR REDDYS LABS SA	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC
>A>		+ @	23.5MG/5ML (4.7MG/ML)	N213536	001	Jun 14, 2021	May	DISC

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS  
EPHEDRINE SULFATE

+!	ENDO OPERATIONS	25MG/5ML (5MG/ML)	N213994	002	Apr 22, 2022	Apr	CAHN
+!		50MG/10ML (5MG/ML)	N213994	001	Oct 16, 2020	Apr	CAHN

EPINEPHRINE

SOLUTION; INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
EPINEPHRINE

+!	BPI LABS	1MG/ML (1MG/ML)	N205029	005	Mar 04, 2024	Apr	NEWA
+!		30MG/30ML (1MG/ML)	N205029	004	Feb 14, 2024	Feb	NEWA

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION  
XYLOCAINE W/ EPINEPHRINE

+	@ FRESenius KABI USA	0.01MG/ML; 2%	N006488	003		Feb	CRLD
---	----------------------	---------------	---------	-----	--	-----	------

EPLERENONE

TABLET; ORAL  
EPLERENONE

	@ PRASCO	25MG	A203896	001	Feb 02, 2017	Mar	DISC
	@	50MG	A203896	002	Feb 02, 2017	Mar	DISC
AB	SLATE RUN PHARMA	25MG	A212765	001	Aug 10, 2020	Feb	CAHN
AB		50MG	A212765	002	Aug 10, 2020	Feb	CAHN

EPLONTERSEN SODIUM

SOLUTION; SUBCUTANEOUS  
WAINUA (AUTOINJECTOR)

+!	ASTRAZENECA AB	EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Feb	CTNA
+!		EQ 45MG BASE/0.8ML (EQ 45MG BASE/0.8ML)	N217388	001	Dec 21, 2023	Jan	CAHN

EPOPROSTENOL SODIUM

INJECTABLE; INJECTION  
EPOPROSTENOL SODIUM

AP1	MEITHEAL	EQ 0.5MG BASE/VIAL	A078396	001	Apr 23, 2008	Jan	CAHN
AP1		EQ 1.5MG BASE/VIAL	A078396	002	Apr 23, 2008	Jan	CAHN
>A>	AP2 MYLAN	EQ 0.5MG BASE/VIAL	A213913	001	Jun 12, 2024	May	NEWA
>A>	AP2	EQ 1.5MG BASE/VIAL	A213913	002	Jun 12, 2024	May	NEWA

EPTIFIBATIDE

INJECTABLE; INJECTION  
EPTIFIBATIDE

>D>	AP ACCORD HLTHCARE	2MG/ML	A205557	001	Nov 06, 2017	May	DISC
>A>	@	2MG/ML	A205557	001	Nov 06, 2017	May	DISC
>D>	AP	75MG/100ML	A205557	002	Nov 06, 2017	May	DISC
>A>	@	75MG/100ML	A205557	002	Nov 06, 2017	May	DISC
>A>	AP HONG KONG	2MG/ML	A213599	001	May 09, 2024	May	NEWA
>A>	AP	75MG/100ML	A213599	002	May 09, 2024	May	NEWA

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL  
ERGOMAR

!	PANGEA	2MG	A087693	001	Feb 24, 1983	Feb	CAHN
---	--------	-----	---------	-----	--------------	-----	------

ERIBULIN MESYLATE

SOLUTION; INTRAVENOUS  
ERIBULIN MESYLATE

AP	GLAND PHARMA LTD HALAVEN	1MG/2ML (0.5MG/ML)	A218047	001	Apr 05, 2024	Mar	NFTG
AP	+! EISAI INC	1MG/2ML (0.5MG/ML)	N201532	001	Nov 15, 2010	Mar	CFTG

ERLOTINIB HYDROCHLORIDE

TABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

>A>	AB HETERO LABS LTD V	EQ 25MG BASE	A209267	001	May 24, 2024	May	NEWA
>A>	AB	EQ 100MG BASE	A209267	002	May 24, 2024	May	NEWA
>A>	AB	EQ 150MG BASE	A209267	003	May 24, 2024	May	NEWA
	@ NATCO PHARMA LTD	EQ 25MG BASE	A208488	001	Nov 05, 2019	Apr	DISC

ERTAPENEM SODIUM

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
ERTAPENEM SODIUM

@ SUN PHARM EQ 1GM BASE/VIAL A209145 001 May 02, 2023 Jan DISC

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL  
ERYTHROMYCIN

AB AZURITY 250MG A062746 001 Dec 22, 1986 Mar CAHN

OINTMENT; OPHTHALMIC  
ERYTHROMYCIN

AT ! BAUSCH AND LOMB 0.5% A064067 001 Jul 29, 1994 Mar CHRS  
@ PADAGIS US 0.5% A062447 001 Sep 26, 1983 Mar DISC

TABLET; ORAL  
ERYTHROMYCIN

AB AZURITY 250MG A061621 001 Mar CAHN  
AB 500MG A061621 002 Mar CAHN

TABLET, DELAYED RELEASE; ORAL  
ERY-TAB

AB AZURITY 250MG A062298 001 Mar CAHN  
AB 333MG A062298 003 Mar 29, 1982 Mar CAHN  
AB ! 500MG A062298 002 Mar CAHN

ERYTHROMYCIN ETHYLSUCCINATE

GRANULE; ORAL  
ERYTHROMYCIN ETHYLSUCCINATE

>A> @ ENDO OPERATIONS EQ 200MG BASE/5ML A211991 001 Oct 23, 2019 May CAHN  
>A> @ EQ 400MG BASE/5ML A211991 002 Oct 23, 2019 May CAHN  
>D> @ PAR PHARM INC EQ 200MG BASE/5ML A211991 001 Oct 23, 2019 May CAHN  
>D> @ EQ 400MG BASE/5ML A211991 002 Oct 23, 2019 May CAHN

TABLET; ORAL  
E.E.S. 400

@ AZURITY EQ 400MG BASE A061905 001 Mar CAHN  
BX ! EQ 400MG BASE A061905 002 Aug 12, 1982 Mar CAHN

ERYTHROMYCIN ETHYLSUCCINATE

BX ! AZURITY EQ 400MG BASE A061904 001 Mar CAHN

ERYTHROMYCIN STEARATE

TABLET; ORAL  
ERYTHROCIN STEARATE

@ AZURITY EQ 125MG BASE A060359 002 Mar CAHN  
! EQ 250MG BASE A060359 001 Mar CAHN  
@ EQ 500MG BASE A060359 003 Mar CAHN

ESCITALOPRAM OXALATE

TABLET; ORAL  
ESCITALOPRAM OXALATE

@ PHARM ASSOC EQ 5MG BASE A077512 001 Sep 12, 2012 Mar DISC  
@ EQ 10MG BASE A077512 002 Sep 12, 2012 Mar DISC  
@ EQ 20MG BASE A077512 003 Sep 12, 2012 Mar DISC

ESLICARBAZEPINE ACETATE

TABLET; ORAL  
ESLICARBAZEPINE ACETATE

@ APOTEX 200MG A211236 001 Dec 07, 2023 Apr DISC  
@ 400MG A211236 002 Dec 07, 2023 Apr DISC  
@ 600MG A211236 003 Dec 07, 2023 Apr DISC  
@ 800MG A211236 004 Dec 07, 2023 Apr DISC  
AB LUPIN LTD 200MG A211246 001 Mar 27, 2024 Mar NEWA  
AB 400MG A211246 002 Mar 27, 2024 Mar NEWA  
AB 600MG A211246 003 Mar 27, 2024 Mar NEWA  
AB 800MG A211246 004 Mar 27, 2024 Mar NEWA  
@ TORRENT 200MG A211227 001 Feb 27, 2024 Mar DISC  
AB 200MG A211227 001 Feb 27, 2024 Feb NEWA  
@ 400MG A211227 002 Feb 27, 2024 Mar DISC  
AB 400MG A211227 002 Feb 27, 2024 Feb NEWA  
@ 600MG A211227 003 Feb 27, 2024 Mar DISC  
AB 600MG A211227 003 Feb 27, 2024 Feb NEWA  
@ 800MG A211227 004 Feb 27, 2024 Mar DISC  
AB 800MG A211227 004 Feb 27, 2024 Feb NEWA

ESOMEPRAZOLE SODIUM

INJECTABLE; INTRAVENOUS  
ESOMEPRAZOLE SODIUM

>D>	AP	ACCORD HLTHCARE	EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	May DISC
>A>	@		EQ 40MG BASE/VIAL	A205379	001	Sep 25, 2015	May DISC
>D>		GLAND PHARMA LTD	EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	May CHRS
>A>	!		EQ 20MG BASE/VIAL	A203349	001	Apr 01, 2020	May CHRS
>D>	AP	SUN PHARM	EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	May DISC
>A>	@		EQ 40MG BASE/VIAL	A200882	002	Mar 18, 2013	May DISC

ESTRADIOL

GEL, METERED; TRANSDERMAL  
ESTRADIOL

AB		SOLARIS PHARMA CORP	0.06% (1.25GM/ACTIVATION)	A216160	001	Apr 22, 2024	Apr NFTG
AB	+	ASCEND THERAPS US	0.06% (1.25GM/ACTIVATION)	N021166	002	Feb 09, 2004	Apr CFTG

ESTRADIOL CYPIONATE; MEDROXYPROGESTERONE ACETATE

INJECTABLE; INTRAMUSCULAR  
LUNELLE

+	@	PHARMACIA AND UPJOHN	5MG/0.5ML; 25MG/0.5ML	N020874	001	Oct 05, 2000	Feb CRLD
---	---	----------------------	-----------------------	---------	-----	--------------	----------

ESTRADIOL VALERATE

INJECTABLE; INJECTION  
DELESTROGEN

AO	+	ENDO OPERATIONS	10MG/ML	N009402	002		Apr CAHN
AO	+		20MG/ML	N009402	004		Apr CAHN
AO	+		40MG/ML	N009402	003		Apr CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET; ORAL  
ESTRADIOL AND NORETHINDRONE ACETATE

AB		NAARI PTE LTD	1MG; 0.5MG	A210233	001	Feb 28, 2018	Apr CMFD
----	--	---------------	------------	---------	-----	--------------	----------

ESZOPICLONE

TABLET; ORAL  
LUNESTA

AB	+	WAYLIS THERAP	1MG	N021476	001	Dec 15, 2004	Apr CAHN
AB	+		2MG	N021476	002	Dec 15, 2004	Apr CAHN
AB	+		3MG	N021476	003	Dec 15, 2004	Apr CAHN

ETHACRYNATE SODIUM

INJECTABLE; INJECTION  
ETHACRYNATE SODIUM

AP		ENDO OPERATIONS	EQ 50MG BASE/VIAL	A205473	001	Jul 29, 2015	Apr CAHN
AP		STERIMAX	EQ 50MG BASE/VIAL	A208663	001	Jun 09, 2020	Mar CAHN

ETHACRYNIC ACID

TABLET; ORAL  
ETHACRYNIC ACID

>A>	@	ENDO OPERATIONS	25MG	A208501	001	Jul 21, 2017	May CAHN
>D>	@	PAR PHARM INC	25MG	A208501	001	Jul 21, 2017	May CAHN
	@		25MG	A208501	001	Jul 21, 2017	Apr DISC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET; ORAL  
LEVONORGESTREL AND ETHINYL ESTRADIOL

AB		XIROMED	0.03MG; 0.15MG	A200490	001	Apr 21, 2015	Apr CAHN
AB3		MINZOYA					
		LUPIN LTD	0.02MG; 0.1MG	A217087	001	Feb 15, 2024	Feb NEWA

TABLET; ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

>D>	@	MYLAN LABS LTD	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May CAHN
>A>	@	XIROMED	0.02MG; 0.1MG	A202247	001	Dec 08, 2014	Apr CAHN
	@		0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A202970	001	Mar 23, 2018	May CAHN

MYZILRA

>A>	AB	ENDO OPERATIONS	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075MG, 0.125MG	A077502	001	Nov 23, 2011	May CAHN
>D>	AB	VINTAGE PHARMS LLC	0.03MG, 0.04MG, 0.03MG; 0.05MG, 0.075	A077502	001	Nov 23, 2011	May CAHN

TABLET;ORAL-28  
MYZILRA

MG,0.125MG

ORSYTHIA

>A> @ ENDO OPERATIONS 0.02MG;0.1MG A 077099 001 May 11, 2011 May CAHN  
>D> @ VINTAGE PHARMS LLC 0.02MG;0.1MG A 077099 001 May 11, 2011 May CAHN

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-28

CYCLAFEM 0.5/35

@ ENDO OPERATIONS 0.035MG;0.5MG

A 203413 001 Dec 16, 2015 Apr CAHN

CYCLAFEM 1/35

>A> @ ENDO OPERATIONS 0.035MG;1MG A 076337 001 Nov 12, 2010 May CAHN

>D> @ VINTAGE PHARMS LLC 0.035MG;1MG A 076337 001 Nov 12, 2010 May CAHN

CYCLAFEM 7/7/7

>A> @ ENDO OPERATIONS 0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG A 076338 001 Nov 16, 2010 May CAHN

>D> @ VINTAGE PHARMS LLC 0.035MG,0.035MG,0.035MG;0.5MG,0.75 MG,1MG A 076338 001 Nov 16, 2010 May CAHN

GILDAGIA

>A> AB ENDO OPERATIONS 0.035MG;0.4MG A 078376 001 Nov 06, 2012 May CAHN

>D> AB VINTAGE PHARMS 0.035MG;0.4MG A 078376 001 Nov 06, 2012 May CAHN

NORETHINDRONE AND ETHINYL ESTRADIOL

@ XIROMED 0.035MG;0.4MG

A 200897 001 May 11, 2015 Apr CAHN

@ 0.05MG;1MG

A 203006 001 Aug 05, 2013 Apr CAHN

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB +! TEVA BRANDED PHARM 0.025MG;0.8MG N 022573 001 Dec 22, 2010 Mar CAHN

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

@ AMNEAL PHARMS 0.02MG;1MG

A 214292 001 Jul 20, 2021 Feb DISC

TABLET;ORAL

GILDESS 24 FE

>A> AB ENDO OPERATIONS 0.02MG;1MG A 090293 001 Dec 01, 2014 May CAHN

>D> AB VINTAGE PHARMS 0.02MG;1MG A 090293 001 Dec 01, 2014 May CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

@ XIROMED 0.0025MG;0.5MG

A 207260 001 Feb 02, 2017 Apr CAHN

@ 0.005MG;1MG

A 207259 001 Dec 27, 2016 Apr CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>D> @ MYLAN LABS LTD 0.01MG,0.01MG;1MG,N/A A 205049 001 May 31, 2016 May CAHN

>A> @ XIROMED 0.01MG,0.01MG;1MG,N/A A 205049 001 May 31, 2016 May CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

>D> @ MYLAN LABS LTD 0.02MG;1MG A 206120 001 Sep 12, 2017 May CAHN

>A> @ XIROMED 0.02MG;1MG A 206120 001 Sep 12, 2017 May CAHN

>D> OSHIH

>D> AB AUROBINDO PHARMA 0.02MG;1MG A 216558 001 Dec 06, 2023 May DISC

>A> @ 0.02MG;1MG A 216558 001 Dec 06, 2023 May DISC

TABLET;ORAL-21

GILDESS 1.5/30

>A> @ ENDO OPERATIONS 0.03MG;1.5MG A 077075 002 Jul 24, 2012 May CAHN

>D> @ VINTAGE PHARMS LLC 0.03MG;1.5MG A 077075 002 Jul 24, 2012 May CAHN

GILDESS 1/20

>A> @ ENDO OPERATIONS 0.02MG;1MG A 077077 002 Jul 24, 2012 May CAHN

>D> @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 002 Jul 24, 2012 May CAHN

TABLET;ORAL-28

GILDESS FE 1.5/30

>A> @ ENDO OPERATIONS 0.03MG;1.5MG A 077075 001 Apr 28, 2005 May CAHN

>D> @ VINTAGE PHARMS LLC 0.03MG;1.5MG A 077075 001 Apr 28, 2005 May CAHN

GILDESS FE 1/20

>A> @ ENDO OPERATIONS 0.02MG;1MG A 077077 001 May 20, 2005 May CAHN

>D> @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 001 May 20, 2005 May CAHN

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL

AB XIROMED 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A 205069 001 Jun 22, 2018 Apr CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET; ORAL-28

## NORGESTIMATE AND ETHINYL ESTRADIOL

>D>	@ MYLAN	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.25MG	A 201897	001	Jan 27, 2016	May	CAHN
>D>	@ MYLAN LABS LTD	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.25MG	A 202132	001	Sep 09, 2015	May	CAHN
>A>	@ XIROMED	0.025MG, 0.025MG, 0.025MG; 0.18MG, 0.25MG	A 202132	001	Sep 09, 2015	May	CAHN
>A>	@	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.25MG	A 201897	001	Jan 27, 2016	May	CAHN
PREVIFEM							
>A>	AB ENDO OPERATIONS	0.035MG; 0.25MG	A 076334	001	Jan 09, 2004	May	CAHN
>D>	AB VINTAGE PHARMS LLC	0.035MG; 0.25MG	A 076334	001	Jan 09, 2004	May	CAHN
TRI-PREVIFEM							
>A>	@ ENDO OPERATIONS	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.25MG	A 076335	001	Mar 26, 2004	May	CAHN
>D>	@ VINTAGE PHARMS LLC	0.035MG, 0.035MG, 0.035MG; 0.18MG, 0.25MG	A 076335	001	Mar 26, 2004	May	CAHN

ETHOSUXIMIDE

## CAPSULE; ORAL

## ETHOSUXIMIDE

AB	EPIC PHARMA LLC	250MG	A 040686	001	May 28, 2008	Jan	CAHN
----	-----------------	-------	----------	-----	--------------	-----	------

ETODOLAC

## TABLET; ORAL

## ETODOLAC

AB	IPCA LABS LTD	400MG	A 204729	001	May 01, 2024	Apr	NEWA
AB		500MG	A 204729	002	May 01, 2024	Apr	NEWA

ETOMIDATE

## INJECTABLE; INJECTION

## ETOMIDATE

>A>	@ ENDO OPERATIONS	2MG/ML	A 091297	001	Jun 20, 2012	May	CAHN
>D>	@ PAR STERILE PRODUCTS	2MG/ML	A 091297	001	Jun 20, 2012	May	CAHN

EZETIMIBE

## TABLET; ORAL

## EZETIMIBE

AB	MACLEODS PHARMS LTD	10MG	A 211159	001	Apr 29, 2024	Apr	NEWA
----	---------------------	------	----------	-----	--------------	-----	------

EZETIMIBE; SIMVASTATIN

## TABLET; ORAL

## EZETIMIBE AND SIMVASTATIN

AB	AUROBINDO PHARMA USA	10MG; 10MG	A 200082	001	Dec 17, 2020	Mar	CMFD
AB		10MG; 20MG	A 200082	002	Dec 17, 2020	Mar	CMFD
AB		10MG; 40MG	A 200082	003	Dec 17, 2020	Mar	CMFD
AB		10MG; 80MG	A 200082	004	Dec 17, 2020	Mar	CMFD

FAMOTIDINE

## FOR SUSPENSION; ORAL

## FAMOTIDINE

AB	CEROVENE INC	40MG/5ML	A 217605	001	Jan 16, 2024	Jan	NEWA
----	--------------	----------	----------	-----	--------------	-----	------

FAMOTIDINE; IBUPROFEN

## TABLET; ORAL

## FAMOTIDINE AND IBUPROFEN

	@ TORRENT	26.6MG; 800MG	A 215925	001	Mar 18, 2024	Mar	NEWA
AB	! ALKEM LABS LTD	26.6MG; 800MG	A 211890	001	Aug 03, 2021	Feb	CHRS

FEBUXOSTAT

## TABLET; ORAL

## FEBUXOSTAT

	@ LUPIN LTD	40MG	A 205406	001	Jan 17, 2024	Apr	DISC
AB		40MG	A 205406	001	Jan 17, 2024	Jan	NEWA
	@	80MG	A 205406	002	Jan 17, 2024	Apr	DISC
AB		80MG	A 205406	002	Jan 17, 2024	Jan	NEWA



FEDRATINIB HYDROCHLORIDE

CAPSULE;ORAL  
INREBIC

+! BRISTOL-MYERS EQ 100MG BASE N212327 001 Aug 16, 2019 Feb CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL  
FELODIPINE

AB ENDO OPERATIONS 2.5MG A200815 001 Oct 28, 2011 Apr CAHN  
AB 5MG A200815 002 Oct 28, 2011 Apr CAHN  
AB 10MG A200815 003 Oct 28, 2011 Apr CAHN

FENOFIBRATE

CAPSULE;ORAL  
FENOFIBRATE (MICRONIZED)

AB CHARTWELL 67MG A211407 001 Jan 31, 2024 Mar CAHN  
AB 134MG A211407 002 Jan 31, 2024 Mar CAHN  
AB 200MG A211407 003 Jan 31, 2024 Mar CAHN  
@ INVAGEN PHARMS 67MG A207378 001 Mar 28, 2017 Mar DISC  
@ 134MG A207378 002 Mar 28, 2017 Mar DISC  
@ 200MG A207378 003 Mar 28, 2017 Mar DISC  
AB YOUNGTECH PHARMS INC 67MG A211407 001 Jan 31, 2024 Jan NEWA  
AB 134MG A211407 002 Jan 31, 2024 Jan NEWA  
AB 200MG A211407 003 Jan 31, 2024 Jan NEWA

TABLET;ORAL  
FENOFIBRATE

AB ! AUROBINDO PHARMA 145MG A205118 002 May 05, 2016 Mar CHRS  
>D> AB MYLAN PHARMS INC 120MG A204475 002 Jun 23, 2016 May CHRS  
>A> AB ! 120MG A204475 002 Jun 23, 2016 May CHRS  
AB YICHANG HUMANWELL 54MG A218548 001 Apr 24, 2024 Apr NEWA  
AB 160MG A218548 002 Apr 24, 2024 Apr NEWA  
>D> FENOGLIDE  
>D> AB + SALIX 40MG N022118 001 Aug 10, 2007 May DISC  
>A> + @ 40MG N022118 001 Aug 10, 2007 May DISC  
>D> AB +! 120MG N022118 002 Aug 10, 2007 May DISC  
>A> + @ 120MG N022118 002 Aug 10, 2007 May DISC  
TRICOR  
+ @ ABBVIE 145MG N021656 002 Nov 05, 2004 Mar DISC

FENOLDOPAM MESYLATE

INJECTABLE; INJECTION  
CORLOPAM

>D> AP +! HOSPIRA EQ 10MG BASE/ML N019922 001 Sep 23, 1997 May DISC  
>A> + @ EQ 10MG BASE/ML N019922 001 Sep 23, 1997 May DISC  
FENOLDOPAM MESYLATE  
>D> AP HIKMA EQ 10MG BASE/ML A076582 001 Oct 12, 2004 May DISC  
>A> @ EQ 10MG BASE/ML A076582 001 Oct 12, 2004 May DISC  
>D> AP SANDOZ EQ 10MG BASE/ML A077155 001 Feb 15, 2005 May DISC  
>A> @ EQ 10MG BASE/ML A077155 001 Feb 15, 2005 May DISC

FENOPROFEN CALCIUM

CAPSULE;ORAL  
FENOPROFEN CALCIUM

>D> AB MISEMER EQ 200MG BASE A215548 001 May 16, 2023 May CTEC  
>A> EQ 200MG BASE A215548 001 May 16, 2023 May CTEC  
>D> AB RISING EQ 400MG BASE A214475 001 Jul 18, 2022 May CHRS  
>A> AB ! EQ 400MG BASE A214475 001 Jul 18, 2022 May CHRS  
>D> NALFON  
>D> AB + KEY THERAP EQ 200MG BASE N017604 003 May DISC  
>A> + @ EQ 200MG BASE N017604 003 May DISC  
AB + EQ 200MG BASE N017604 003 Apr CAHN  
>D> AB +! EQ 400MG BASE N017604 004 Jul 21, 2009 May DISC  
>A> + @ EQ 400MG BASE N017604 004 Jul 21, 2009 May DISC  
AB +! EQ 400MG BASE N017604 004 Jul 21, 2009 Apr CAHN

TABLET;ORAL  
FENOPROFEN CALCIUM

>D> ! KEY THERAP EQ 600MG BASE A072267 001 Aug 17, 1988 May DISC  
>A> @ EQ 600MG BASE A072267 001 Aug 17, 1988 May DISC  
! EQ 600MG BASE A072267 001 Aug 17, 1988 Apr CAHN

FESOTERODINE FUMARATE

TABLET, EXTENDED RELEASE;ORAL  
 FESOTERODINE FUMARATE  
 @ ANI PHARMS 4MG  
 @ 8MG

A204504 001 Jan 04, 2023 Apr DISC  
 A204504 002 Jan 04, 2023 Apr DISC

FIDAXOMICIN

TABLET;ORAL  
 DIFICID  
 AB +! CUBIST PHARMS LLC 200MG  
 FIDAXOMICIN  
 AB ACTAVIS LABS FL 200MG

N201699 001 May 27, 2011 Jan CFTG  
 A208443 001 Jan 16, 2024 Jan NEWA

FINASTERIDE

TABLET;ORAL  
 FINASTERIDE  
 @ CIPLA 1MG

A077335 001 Nov 20, 2014 Mar DISC

FINASTERIDE; TADALAFIL

CAPSULE;ORAL  
 ENTADFI  
 AB +! BLUE WATER BIOTECH 5MG;5MG  
 FINASTERIDE AND TADALAFIL  
 >D> AB ZYDUS 5MG;5MG  
 AB 5MG;5MG  
 >A> AB ZYDUS LIFESCIENCES 5MG;5MG

N215423 001 Dec 09, 2021 Mar CFTG  
 A218232 001 Mar 15, 2024 May CAHN  
 A218232 001 Mar 15, 2024 Mar NFTG  
 A218232 001 Mar 15, 2024 May CAHN

FINGOLIMOD HYDROCHLORIDE

CAPSULE;ORAL  
 FINGOLIMOD HYDROCHLORIDE  
 AB AUROBINDO PHARMA LTD EQ 0.5MG BASE  
 AB BIOCON LTD EQ 0.5MG BASE

A207983 001 Feb 28, 2024 Feb NEWA  
 A207979 001 Dec 04, 2019 Feb CMFD

FLUDARABINE PHOSPHATE

INJECTABLE;INJECTION  
 FLUDARABINE PHOSPHATE  
 @ RISING 50MG/VIAL

A200648 001 Oct 16, 2012 Feb CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE;INTRAVENOUS  
 FLUDEOXYGLUCOSE F18  
 >D> AP CARDINAL HEALTH 414 20-500mCi/ML  
 >A> AP ! 20-500mCi/ML  
 >D> AP ! SOFIE 20-500mCi/ML  
 >A> @ 20-500mCi/ML

A203603 002 Sep 27, 2018 May CHRS  
 A203603 002 Sep 27, 2018 May CHRS  
 A203665 001 Feb 14, 2013 May DISC  
 A203665 001 Feb 14, 2013 May DISC

FLUOCINOLONE ACETONIDE

OIL;TOPICAL  
 FLUOCINOLONE ACETONIDE  
 @ SAPTALIS PHARMS 0.01%  
 AT TARO 0.01%  
 OIL/DROPS;OTIC  
 FLUOCINOLONE ACETONIDE  
 @ SAPTALIS PHARMS 0.01%  
 >D> SHAMPOO;TOPICAL  
 >D> CAPEX  
 >D> +! GALDERMA LABS LP 0.01%  
 >A> + @ 0.01%

A091514 001 Jun 25, 2015 Feb CAHN  
 A209336 001 May 19, 2016 Jan CAHN  
 A202705 001 Sep 09, 2016 Feb CAHN  
 N020001 001 Aug 27, 1990 May DISC  
 N020001 001 Aug 27, 1990 May DISC

FLUOCINONIDE

CREAM;TOPICAL  
 FLUOCINONIDE  
 @ PADAGIS ISRAEL 0.1%  
 GEL;TOPICAL  
 FLUOCINONIDE  
 >D> AB + ALVOGEN 0.05%  
 >A> + @ 0.05%  
 @ COSETTE 0.05%  
 @ PADAGIS US 0.05%

A090256 001 Jan 14, 2014 Jan DISC  
 N017373 001 May DISC  
 N017373 001 May DISC  
 A072537 001 Feb 07, 1989 Apr DISC  
 A209030 001 Jun 19, 2018 Jan CAHN

SOLUTION;TOPICAL  
FLUOCINONIDE

@ COSETTE 0.05% A071535 001 Dec 02, 1988 Apr DISC

FLUOROURACIL

INJECTABLE; INJECTION  
FLUOROURACIL

AP EUGIA PHARMA SPECLTS 500MG/10ML (50MG/ML) A202668 001 Jul 17, 2012 Apr CMFD  
 AP 1GM/20ML (50MG/ML) A202668 002 Jul 17, 2012 Apr CMFD  
 AP 2.5GM/50ML (50MG/ML) A202669 001 Jul 17, 2012 Apr CMFD  
 AP 5GM/100ML (50MG/ML) A202669 002 Jul 17, 2012 Apr CMFD

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

@ SUN PHARM INDS LTD EQ 40MG BASE A076990 001 Dec 13, 2004 Jan DISC

SOLUTION;ORAL

FLUOXETINE HYDROCHLORIDE

@ BAJAJ EQ 20MG BASE/5ML A075920 001 Jan 29, 2002 Mar CAHN  
 @ SAPTALIS PHARMS EQ 20MG BASE/5ML A075525 001 Jun 27, 2002 Mar CAHN

TABLET;ORAL

FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 10MG BASE A203836 001 Aug 19, 2016 Apr CAHN  
 AB EQ 20MG BASE A203836 002 Aug 19, 2016 Apr CAHN  
 AB EQ 60MG BASE A209419 001 Nov 16, 2017 Apr CAHN  
 AB STRIDES PHARMA EQ 10MG BASE A212684 001 Apr 05, 2024 Mar NEWA  
 AB EQ 20MG BASE A212684 002 Apr 05, 2024 Mar NEWA  
 @ TEVA EQ 10MG BASE A075872 001 Jan 29, 2002 Jan DISC  
 @ EQ 20MG BASE A075872 002 Jan 04, 2019 Jan DISC  
 @ TEVA PHARMS USA EQ 60MG BASE A211051 001 Dec 03, 2018 Jan DISC

FLUOXETINE HYDROCHLORIDE; OLANZAPINE

CAPSULE;ORAL

OLANZAPINE AND FLUOXETINE HYDROCHLORIDE

AB ENDO OPERATIONS EQ 25MG BASE;EQ 3MG BASE A077742 001 Nov 02, 2012 Apr CAHN  
 AB EQ 25MG BASE;EQ 6MG BASE A077742 002 Nov 02, 2012 Apr CAHN  
 AB EQ 25MG BASE;EQ 12MG BASE A077742 003 Nov 02, 2012 Apr CAHN  
 AB EQ 50MG BASE;EQ 6MG BASE A077742 004 Nov 02, 2012 Apr CAHN  
 AB EQ 50MG BASE;EQ 12MG BASE A077742 005 Nov 02, 2012 Apr CAHN

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION

FLUPHENAZINE DECANOATE

AO ENDO OPERATIONS 25MG/ML A203732 001 Jul 03, 2014 Apr CAHN

FLUPHENAZINE HYDROCHLORIDE

TABLET;ORAL

FLUPHENAZINE HYDROCHLORIDE

>A> AB RISING 1MG A218283 001 Jun 07, 2024 May NEWA  
 >A> AB 2.5MG A218283 002 Jun 07, 2024 May NEWA  
 >A> AB 5MG A218283 003 Jun 07, 2024 May NEWA  
 >A> AB 10MG A218283 004 Jun 07, 2024 May NEWA  
 @ TORRENT 1MG A217094 001 Jan 22, 2024 Jan DISC  
 AB 1MG A217094 001 Jan 22, 2024 Jan NEWA  
 @ 2.5MG A217094 002 Jan 22, 2024 Jan DISC  
 AB 2.5MG A217094 002 Jan 22, 2024 Jan NEWA  
 @ 5MG A217094 003 Jan 22, 2024 Jan DISC  
 AB 5MG A217094 003 Jan 22, 2024 Jan NEWA  
 @ 10MG A217094 004 Jan 22, 2024 Jan DISC  
 AB 10MG A217094 004 Jan 22, 2024 Jan NEWA  
 AB ZAMEER PHARMS 1MG A215141 001 Oct 20, 2021 Feb CAHN  
 AB 2.5MG A215141 002 Oct 20, 2021 Feb CAHN  
 AB 5MG A215141 003 Oct 20, 2021 Feb CAHN  
 AB 10MG A215141 004 Oct 20, 2021 Feb CAHN

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

@ HIKMA 0.05MG/SPRAY A077570 001 Jan 16, 2008 Mar DISC

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL  
FLUVOXAMINE MALEATE

AB	ENDO OPERATIONS	100MG	A 091476	001	Mar 13, 2013	Apr	CAHN
AB		150MG	A 091476	002	Mar 13, 2013	Apr	CAHN
TABLET;ORAL							
FLUVOXAMINE MALEATE							
AB	BIONPHARMA	25MG	A 217917	001	Jan 22, 2024	Jan	NEWA
AB		50MG	A 217917	002	Jan 22, 2024	Jan	NEWA
AB		100MG	A 217917	003	Jan 22, 2024	Jan	NEWA

FOLIC ACID

TABLET;ORAL  
FOLIC ACID

>A>	@ ENDO OPERATIONS	1MG	A 040756	001	Jun 04, 2010	May	CAHN
>D>	@ VINTAGE	1MG	A 040756	001	Jun 04, 2010	May	CAHN

FORMOTEROL FUMARATE

SOLUTION;INHALATION  
FORMOTEROL FUMARATE

>D>	AN AUCTA	0.02MG/2ML	A 216486	001	Nov 25, 2022	May	CAHN
>A>	AN RITEDOSE CORP	0.02MG/2ML	A 216486	001	Nov 25, 2022	May	CAHN

FOSAMPRENAVIR CALCIUM

TABLET;ORAL  
FOSAMPRENAVIR CALCIUM

AB	! MYLAN	EQ 700MG BASE	A 204060	001	Apr 15, 2016	Jan	CHRS
	LEXIVA						
	+ @ VIIV HLTHCARE	EQ 700MG BASE	N 021548	001	Oct 20, 2003	Jan	DISC

FOSAPREPITANT DIMEGLUMINE

POWDER;INTRAVENOUS  
FOSAPREPITANT DIMEGLUMINE

>D>	AP ACCORD HLTHCARE	EQ 150MG BASE/VIAL	A 204025	001	Aug 26, 2020	May	DISC
>A>	@	EQ 150MG BASE/VIAL	A 204025	001	Aug 26, 2020	May	DISC

FOSCARNET SODIUM

INJECTABLE;INJECTION  
FOSCARNET SODIUM

AP	AMNEAL	2.4GM/100ML	A 216602	001	Mar 01, 2024	Feb	NEWA
----	--------	-------------	----------	-----	--------------	-----	------

FOSFOMYCIN TROMETHAMINE

FOR SOLUTION;ORAL  
FOSFOMYCIN TROMETHAMINE

AA	AMNEAL	EQ 3GM BASE/PACKET	A 216600	001	Mar 25, 2024	Mar	NEWA
----	--------	--------------------	----------	-----	--------------	-----	------

FROVATRIPTAN SUCCINATE

TABLET;ORAL  
FROVA

AB	+! ENDO OPERATIONS	EQ 2.5MG BASE	N 021006	001	Nov 08, 2001	Apr	CAHN
----	--------------------	---------------	----------	-----	--------------	-----	------

FUROSEMIDE

INJECTABLE;INJECTION  
FUROSEMIDE

AP	SABA ILAC SANAYIVE	10MG/ML	A 215856	001	Apr 02, 2024	Mar	NEWA
----	--------------------	---------	----------	-----	--------------	-----	------

GABAPENTIN

CAPSULE;ORAL  
GABAPENTIN

>D>	AB SUN PHARM INDS LTD	100MG	A 077242	001	Aug 24, 2006	May	DISC
>A>	@	100MG	A 077242	001	Aug 24, 2006	May	DISC
>D>	AB	300MG	A 077242	002	Aug 24, 2006	May	DISC
>A>	@	300MG	A 077242	002	Aug 24, 2006	May	DISC
>D>	AB	400MG	A 077242	003	Aug 24, 2006	May	DISC
>A>	@	400MG	A 077242	003	Aug 24, 2006	May	DISC

SOLUTION;ORAL  
GABAPENTIN

AA	ANNORA PHARMA	250MG/5ML	A 217682	001	Jan 17, 2024	Jan	NEWA
----	---------------	-----------	----------	-----	--------------	-----	------

TABLET;ORAL  
GABAPENTIN

AB1	ACI	600MG	A203244	002	Jul 12, 2013	Jan CTEC	
AB1		800MG	A203244	001	Jul 12, 2013	Jan CTEC	
AB1	ACTAVIS ELIZABETH	600MG	A075694	001	Oct 21, 2004	Jan CTEC	
AB1		800MG	A075694	002	Oct 21, 2004	Jan CTEC	
AB1	ALKEM LABS LTD	600MG	A206402	001	Dec 23, 2015	Jan CTEC	
AB1		800MG	A206402	002	Dec 23, 2015	Jan CTEC	
AB2	ANNORA PHARMA	300MG	A218075	001	Feb 26, 2024	Feb NEWA	
AB2		600MG	A218075	002	Feb 26, 2024	Feb NEWA	
AB1	APOTEX	100MG	A077894	001	Oct 10, 2006	Jan CTEC	
AB1		300MG	A077894	002	Oct 10, 2006	Jan CTEC	
AB1		400MG	A077894	003	Oct 10, 2006	Jan CTEC	
AB1	ASCENT PHARMS INC	600MG	A214957	001	Oct 01, 2021	Jan CTEC	
AB1		800MG	A214957	002	Oct 01, 2021	Jan CTEC	
AB1	AUROBINDO PHARMA LTD	600MG	A200651	001	Oct 06, 2011	Jan CTEC	
AB1		800MG	A200651	002	Oct 06, 2011	Jan CTEC	
AB1	CSPC OUYI	600MG	A207057	001	Oct 26, 2017	Jan CTEC	
AB1		800MG	A207057	002	Oct 26, 2017	Jan CTEC	
AB1	GLENMARK PHARMS LTD	600MG	A077662	001	Aug 18, 2006	Jan CTEC	
AB1		800MG	A077662	002	Aug 18, 2006	Jan CTEC	
AB1	GRANULES	600MG	A217116	001	Mar 28, 2023	Jan CTEC	
AB1		800MG	A217116	002	Mar 28, 2023	Jan CTEC	
AB2	HUMANWELL	300MG	A216252	001	Feb 26, 2024	Feb NEWA	
AB2		600MG	A216252	002	Feb 26, 2024	Feb NEWA	
AB1	@ INVAGEN PHARMS	600MG	A202764	001	Oct 16, 2012	Mar DISC	
AB1		600MG	A202764	001	Oct 16, 2012	Jan CTEC	
AB1	@	800MG	A202764	002	Oct 16, 2012	Mar DISC	
AB1		800MG	A202764	002	Oct 16, 2012	Jan CTEC	
>A>	AB1	IPCA LABS LTD	600MG	A209855	001	May 29, 2024	May NEWA
>A>	AB1		800MG	A209855	002	May 29, 2024	May NEWA
AB1	IVAX SUB TEVA PHARMS	100MG	A076017	001	Apr 28, 2004	Jan CTEC	
AB1		300MG	A076017	002	Apr 28, 2004	Jan CTEC	
AB1		400MG	A076017	003	Apr 28, 2004	Jan CTEC	
AB1	LAURUS	600MG	A217965	001	Apr 08, 2024	Mar NEWA	
AB1		800MG	A217965	002	Apr 08, 2024	Mar NEWA	
AB1	RISING	600MG	A217995	001	Jul 19, 2023	Jan CTEC	
AB1		800MG	A217995	002	Jul 19, 2023	Jan CTEC	
AB1	RUBICON	600MG	A077661	004	Sep 13, 2006	Jan CTEC	
AB1		800MG	A077661	005	Sep 13, 2006	Jan CTEC	
AB1	SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan CTEC	
AB1		800MG	A205101	002	Feb 04, 2016	Jan CTEC	
AB1	STRIDES PHARMA	600MG	A211313	001	Mar 04, 2024	Feb NEWA	
AB1		800MG	A211313	002	Mar 04, 2024	Feb NEWA	
AB1	SUN PHARM INDS LTD	600MG	A077525	001	Aug 24, 2006	Jan CTEC	
AB1		800MG	A077525	002	Aug 24, 2006	Jan CTEC	
AB2	ZYDUS PHARMS	300MG	A203934	001	Jan 24, 2024	Jan NEWA	
AB2		600MG	A203934	002	Jan 24, 2024	Jan NEWA	
AB1	ZYDUS PHARMS USA INC	600MG	A078926	001	Feb 11, 2011	Jan CTEC	
AB1		800MG	A078926	002	Feb 11, 2011	Jan CTEC	
	GRALISE						
AB2	+! ALMATICA	300MG	N022544	001	Jan 28, 2011	Jan CTEC	
AB2	+	600MG	N022544	002	Jan 28, 2011	Jan CTEC	
BX	+	600MG	N022544	002	Jan 28, 2011	Jan CHRS	
	+!	900MG	N022544	005	Apr 18, 2023	Jan CHRS	
	NEURONTIN						
AB1	+ VIATRIS	600MG	N020882	001	Oct 09, 1998	Jan CTEC	
AB1	+!	800MG	N020882	002	Oct 09, 1998	Jan CTEC	

GADODIAMIDE

INJECTABLE;INJECTION  
OMNISCAN

	+ @ GE HEALTHCARE	14.35GM/50ML (287MG/ML)	N022066	001	Sep 05, 2007	Mar CRLD
	+ @	28.7GM/100ML (287MG/ML)	N022066	002	Sep 05, 2007	Mar DISC

GANCICLOVIR SODIUM

INJECTABLE;INJECTION  
GANCICLOVIR SODIUM

>A>	AP	ENDO OPERATIONS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May CAHN
>D>	AP	PAR STERILE PRODUCTS	EQ 500MG BASE/VIAL	A204950	001	Dec 06, 2016	May CAHN

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
GATIFLOXACIN

@ HIKMA 0.5% A203189 001 Sep 03, 2014 Mar DISC

GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION  
GEMCITABINE HYDROCHLORIDE

@ ACCORD HLTHCARE EQ 200MG BASE/VIAL A091594 001 Jul 25, 2011 Apr DISC  
@ EQ 1GM BASE/VIAL A091594 002 Jul 25, 2011 Apr DISC  
@ EQ 2GM BASE/VIAL A091594 003 Jul 25, 2011 Apr DISC

GENTAMICIN SULFATE

SOLUTION/DROPS;OPHTHALMIC  
GENTAK

@ SAPTALIS PHARMS EQ 0.3% BASE A064163 001 Oct 12, 2001 Feb CAHN

GIVINOSTAT HYDROCHLORIDE

SUSPENSION;ORAL  
DUVYZAT

+! ITALFARMACO SPA EQ 8.86MG BASE/ML N217865 001 Mar 21, 2024 Mar NEWA

GLIPIZIDE

TABLET;ORAL  
GLIPIZIDE

>D> AB ACCORD HLTHCARE 5MG A074550 001 Sep 11, 1997 May DISC  
>A> @ 5MG A074550 001 Sep 11, 1997 May DISC  
>D> AB 10MG A074550 002 Sep 11, 1997 May DISC  
>A> @ 10MG A074550 002 Sep 11, 1997 May DISC

TABLET, EXTENDED RELEASE;ORAL  
GLIPIZIDE

>A> @ ENDO OPERATIONS 5MG A076159 002 Sep 20, 2013 May CAHN  
>A> @ 10MG A076159 001 Sep 20, 2013 May CAHN  
>D> @ PAR PHARM 5MG A076159 002 Sep 20, 2013 May CAHN  
>D> @ 10MG A076159 001 Sep 20, 2013 May CAHN

GLUCAGON HYDROCHLORIDE

POWDER;INTRAMUSCULAR, INTRAVENOUS  
GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL N020918 001 Jun 22, 1998 Apr CDFR

POWDER;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS  
GLUCAGEN

+! NOVO NORDISK EQ 1MG BASE/VIAL N020918 002 Jun 22, 1998 Apr CMS1

GLUCAGON

+! FRESENIUS KABI USA EQ 1MG BASE/VIAL N201849 002 Sep 19, 2019 Apr CMS1

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

AB HERITAGE PHARMS 1.25MG;250MG A079009 001 Jun 03, 2009 Feb CMFD  
AB 2.5MG;500MG A079009 002 Jun 03, 2009 Feb CMFD  
AB 5MG;500MG A079009 003 Jun 03, 2009 Feb CMFD

GLYCEROL PHENYLBUTYRATE

LIQUID;ORAL

GLYCEROL PHENYLBUTYRATE

>A> @ ENDO OPERATIONS 1.1GM/ML A205742 001 Dec 02, 2021 May CAHN  
>D> @ PAR PHARM INC 1.1GM/ML A205742 001 Dec 02, 2021 May CAHN

GLYCOPYRROLATE

INJECTABLE; INJECTION  
GLYCOPYRROLATE

AP NIVAGEN PHARMS INC 0.2MG/ML A212591 001 Oct 13, 2021 Feb CAHN

GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS  
PREVDUO

+! AZURITY 0.6MG/3ML (0.2MG/ML);3MG/3ML (1MG/ML) N216903 001 Feb 23, 2023 Feb CAHN

GRISEOFULVIN, MICROSIZE

TABLET;ORAL						
FULVICIN-U/F						
AB	CHARTWELL RX	250MG		A 060569	002	Jan CTEC
		250MG		A 060569	002	Jan CAIN
AB		500MG		A 060569	001	Jan CTEC
		500MG		A 060569	001	Jan CAIN
GRISEOFULVIN						
AB	SANDOZ	250MG		A 091592	001	Aug 07, 2013 Jan CTEC

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL						
FULVICIN P/G						
AB	CHARTWELL RX	125MG		A 061996	001	Jan CTEC
		125MG		A 061996	001	Jan CAIN
AB		250MG		A 061996	002	Jan CTEC
		250MG		A 061996	002	Jan CAIN
FULVICIN P/G 165						
	CHARTWELL RX	165MG		A 061996	003	Apr 06, 1982 Jan CAIN
FULVICIN P/G 330						
	CHARTWELL RX	330MG		A 061996	004	Apr 06, 1982 Jan CAIN

GUANFACINE HYDROCHLORIDE

TABLET;ORAL						
GUANFACINE HYDROCHLORIDE						
AB	XIROMED	EQ 1MG BASE		A 218326	001	Feb 23, 2024 Feb NEWA
AB		EQ 2MG BASE		A 218326	002	Feb 23, 2024 Feb NEWA
TABLET, EXTENDED RELEASE;ORAL						
GUANFACINE HYDROCHLORIDE						
>A>	AB	WANBANG BIOPHARMS	EQ 1MG BASE	A 217638	001	Jun 12, 2024 May NEWA
>A>	AB		EQ 2MG BASE	A 217638	002	Jun 12, 2024 May NEWA
>A>	AB		EQ 3MG BASE	A 217638	003	Jun 12, 2024 May NEWA
>A>	AB		EQ 4MG BASE	A 217638	004	Jun 12, 2024 May NEWA

HALCINONIDE

OINTMENT;TOPICAL						
HALOG						
	+ @ SUN PHARM INDS INC	0.1%		N 017824	001	Jan DISC
SOLUTION;TOPICAL						
HALCINONIDE						
>A>		ENCUBE	0.1%	A 217671	001	May 29, 2024 May NFTG
HALOG						
	+ @ SUN PHARM INDS INC	0.1%		N 017823	001	Jan DISC

HALOBETASOL PROPIONATE

LOTION;TOPICAL						
ULTRAVATE						
>A>	+ @ MICAL PHARMS	0.05%		N 208183	001	Nov 06, 2015 May CAHN
>D>	+! SUN PHARM INDUSTRIES	0.05%		N 208183	001	Nov 06, 2015 May DISC
>A>	+ @	0.05%		N 208183	001	Nov 06, 2015 May DISC

HALOPERIDOL

TABLET;ORAL						
HALOPERIDOL						
AB	AUROBINDO PHARMA LTD	0.5MG		A 218789	001	Apr 19, 2024 Apr NEWA
AB		1MG		A 218789	002	Apr 19, 2024 Apr NEWA
AB		2MG		A 218789	003	Apr 19, 2024 Apr NEWA
AB		5MG		A 218789	004	Apr 19, 2024 Apr NEWA
AB		10MG		A 218789	005	Apr 19, 2024 Apr NEWA
AB		20MG		A 218789	006	Apr 19, 2024 Apr NEWA
AB	CHARTWELL RX	0.5MG		A 071209	002	Nov 17, 1986 Jan CAHN
AB		1MG		A 071209	003	Nov 17, 1986 Jan CAHN
	@	2MG		A 071209	004	Nov 17, 1986 Jan CAHN
AB		5MG		A 071209	001	Nov 17, 1986 Jan CAHN
AB		10MG		A 071210	001	Mar 11, 1988 Jan CAHN
AB		20MG		A 071211	001	Mar 11, 1988 Jan CAHN
AB	MANKIND PHARMA	0.5MG		A 216918	001	Apr 11, 2024 Apr NEWA
AB		1MG		A 216918	002	Apr 11, 2024 Apr NEWA
AB		2MG		A 216918	003	Apr 11, 2024 Apr NEWA
AB		5MG		A 216918	004	Apr 11, 2024 Apr NEWA
AB		10MG		A 216918	005	Apr 11, 2024 Apr NEWA

TABLET; ORAL  
HALOPERIDOL

AB		20MG	A216918	006	Apr 11, 2024	Apr	NEWA
>A>	AB	SCIEGEN PHARMS INC	5MG	A071130	002	Feb 17, 1987	May CMS1
>A>	AB		10MG	A071130	003	May 12, 1987	May CMS1

HALOPERIDOL DECANOATE

INJECTABLE; INJECTION  
HALOPERIDOL DECANOATE

@	TEVA PHARMS USA	EQ 50MG BASE/ML	A075393	001	May 11, 1999	Jan	DISC
@		EQ 100MG BASE/ML	A075393	002	May 11, 1999	Jan	DISC

HALOPERIDOL LACTATE

CONCENTRATE; ORAL  
HALOPERIDOL

AA		RUBICON	EQ 2MG BASE/ML	A218371	001	Jan 31, 2024	Jan	NEWA
----	--	---------	----------------	---------	-----	--------------	-----	------

HEPARIN SODIUM

INJECTABLE; INJECTION  
HEPARIN SODIUM 20,000 UNITS IN DEXTROSE 5%

+	!	FRESENIUS KABI USA	40 UNITS/ML	N017029	021	Aug 24, 2017	Mar	NEWA
		HEPARIN SODIUM 25,000 UNITS IN DEXTROSE 5%						

+	!	FRESENIUS KABI USA	50 UNITS/ML	N017029	022	Aug 24, 2017	Mar	NEWA
+	!		100 UNITS/ML	N017029	023	Aug 24, 2017	Mar	NEWA

		HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45%						
+	!	FRESENIUS KABI USA	50 UNITS/ML	N017029	024	Aug 24, 2017	Mar	NEWA
+	!		100 UNITS/ML	N017029	025	Aug 24, 2017	Mar	NEWA

HISTRELIN ACETATE

IMPLANT; SUBCUTANEOUS  
SUPPRELIN LA

+	!	ENDO OPERATIONS	50MG	N022058	001	May 03, 2007	Apr	CAHN
		VANTAS						

>A>	+	@	ENDO OPERATIONS	50MG	N021732	001	Oct 12, 2004	May	CAHN
>D>	+	@	ENDO PHARM	50MG	N021732	001	Oct 12, 2004	May	CAHN

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL

HYDROCODONE BITARTRATE AND HOMATROPINE METHYLBROMIDE

AA	!	ABHAI LLC	1.5MG/5ML; 5MG/5ML	A207487	001	Feb 21, 2017	Mar	CHRS
		@ GENUS	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Apr	CAHN
		@ PAI HOLDINGS PHARM	1.5MG/5ML; 5MG/5ML	A040613	001	Feb 08, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE

INJECTABLE; INJECTION  
HYDRALAZINE HYDROCHLORIDE

AP		ADRASTEIA PHARMA	20MG/ML	A203110	001	Jun 29, 2015	Feb	CAHN
----	--	------------------	---------	---------	-----	--------------	-----	------

TABLET; ORAL

HYDRALAZINE HYDROCHLORIDE

@	INVAGEN PHARMS	10MG	A090255	001	Dec 15, 2008	Mar	DISC
@		25MG	A090255	002	Dec 15, 2008	Mar	DISC
@		50MG	A090255	003	Dec 15, 2008	Mar	DISC
@		100MG	A090255	004	Dec 15, 2008	Mar	DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

TABLET; ORAL

ISOSORBIDE DINITRATE AND HYDRALAZINE HYDROCHLORIDE

AB		I3 PHARMS	37.5MG; 20MG	A215988	001	Jan 17, 2024	Jan	NEWA
----	--	-----------	--------------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@	GRANULES	12.5MG; 50MG	A218015	001	Sep 29, 2023	Mar	DISC
@		12.5MG; 100MG	A218015	002	Sep 29, 2023	Mar	DISC
@		25MG; 100MG	A218015	003	Sep 29, 2023	Mar	DISC



HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE

## TABLET; ORAL

## METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE

>D>	AB	SUN PHARM INDS	25MG;50MG	A 090654	001	Jan 19, 2012	May	DISC
>A>		@	25MG;50MG	A 090654	001	Jan 19, 2012	May	DISC
>D>	AB		25MG;100MG	A 090654	002	Jan 19, 2012	May	DISC
>A>		@	25MG;100MG	A 090654	002	Jan 19, 2012	May	DISC
>D>	AB		50MG;100MG	A 090654	003	Jan 19, 2012	May	DISC
>A>		@	50MG;100MG	A 090654	003	Jan 19, 2012	May	DISC

HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

>D>	AB	TEVA PHARMS USA	12.5MG;40MG	A 200532	002	Apr 24, 2017	May	DISC
>A>		@	12.5MG;40MG	A 200532	002	Apr 24, 2017	May	DISC

HYDROCHLOROTHIAZIDE; QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

## QUINAPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ INVAGEN PHARMS 12.5MG;EQ 10MG BASE  
 @ 12.5MG;EQ 20MG BASE  
 @ 25MG;EQ 20MG BASE

A 201356 001 Apr 20, 2011 Mar DISC  
 A 201356 002 Apr 20, 2011 Mar DISC  
 A 201356 003 Apr 20, 2011 Mar DISC

HYDROMORPHONE HYDROCHLORIDE

## INJECTABLE; INJECTION

## DILAUDID

AP	+	FRESENIUS KABI USA	0.2MG/ML	N 019034	006	Jan 16, 2020	Feb	CFTG
AP	+		0.5MG/0.5ML	N 019034	007	Feb 10, 2017	Feb	CFTG
	+		0.5MG/0.5ML	N 019034	007	Feb 10, 2017	Jan	NEWA

## HYDROMORPHONE HYDROCHLORIDE

AP		HIKMA	0.2MG/ML	A 216899	001	Feb 09, 2024	Feb	NFTG
AP			0.5MG/0.5ML	A 216899	002	Feb 09, 2024	Feb	NFTG
AP			1MG/ML	A 216899	003	Feb 09, 2024	Feb	NEWA
AP			2MG/ML	A 216899	004	Feb 09, 2024	Feb	NEWA

## SOLUTION; ORAL

## HYDROMORPHONE HYDROCHLORIDE

@ GENUS 5MG/5ML

A 207108 001 Apr 22, 2020 Jan CAHN

## TABLET; ORAL

## HYDROMORPHONE HYDROCHLORIDE

@ GENUS 2MG  
 @ 4MG  
 @ 8MG

A 077471 002 Dec 09, 2009 Jan CAHN  
 A 077471 003 Dec 09, 2009 Jan CAHN  
 A 077471 001 Dec 09, 2009 Jan CAHN

HYDROXYCHLOROQUINE SULFATE

## TABLET; ORAL

## HYDROXYCHLOROQUINE SULFATE

AB		CREEKWOOD PHARMS	200MG	A 040150	001	Jan 27, 1996	Apr	CMFD
		@	200MG	A 040150	001	Jan 27, 1996	Jan	CAHN
AB		SENORES PHARMS	200MG	A 212902	001	May 14, 2020	Feb	CAHN
AB		TEVA PHARMS	200MG	A 040081	001	Sep 30, 1994	Feb	CMFD

HYDROXYUREA

## CAPSULE; ORAL

## HYDROXYUREA

AB		QILU	500MG	A 218021	001	Mar 06, 2024	Feb	NEWA
----	--	------	-------	----------	-----	--------------	-----	------

## SOLUTION; ORAL

## XROMI

	+	NOVA LABS LTD	100MG/ML	N 216593	001	Apr 04, 2024	Apr	NEWA
--	---	---------------	----------	----------	-----	--------------	-----	------

HYDROXYZINE HYDROCHLORIDE

## TABLET; ORAL

## HYDROXYZINE HYDROCHLORIDE

@ INVAGEN PHARMS 10MG  
 @ 25MG  
 @ 50MG

A 040812 001 Mar 12, 2008 Mar DISC  
 A 040812 002 Mar 12, 2008 Mar DISC  
 A 040812 003 Mar 12, 2008 Mar DISC

IBANDRONATE SODIUM

INJECTABLE; INTRAVENOUS  
IBANDRONATE SODIUM

>D>	AP	SUN PHARM	EQ 3MG BASE/3ML	A 090853	001	Feb 14, 2014	May DISC
>A>		@	EQ 3MG BASE/3ML	A 090853	001	Feb 14, 2014	May DISC
		TABLET; ORAL					
		IBANDRONATE SODIUM					
>D>	AB	WATSON LABS TEVA	EQ 150MG BASE	A 079003	001	Mar 20, 2012	May DISC
>A>		@	EQ 150MG BASE	A 079003	001	Mar 20, 2012	May DISC

IBRUTINIB

TABLET; ORAL  
IMBRUVICA

+!		PHARMACYCLICS LLC	420MG	N 210563	003	Feb 16, 2018	Jan CHRS
----	--	-------------------	-------	----------	-----	--------------	----------

IBUPROFEN

TABLET; ORAL  
IBUPROFEN

>A>		@ ENDO OPERATIONS	300MG	A 071230	001	Oct 22, 1986	May CAHN
>A>		@	400MG	A 071231	001	Oct 22, 1986	May CAHN
>A>		@	400MG	A 071644	001	Feb 01, 1988	May CAHN
>A>		@	600MG	A 071232	001	Oct 22, 1986	May CAHN
>A>		@	800MG	A 072004	001	Nov 18, 1987	May CAHN
>D>		@ VINTAGE PHARMS	300MG	A 071230	001	Oct 22, 1986	May CAHN
>D>		@	400MG	A 071231	001	Oct 22, 1986	May CAHN
>D>		@	400MG	A 071644	001	Feb 01, 1988	May CAHN
>D>		@	600MG	A 071232	001	Oct 22, 1986	May CAHN
>D>		@	800MG	A 072004	001	Nov 18, 1987	May CAHN

IBUTILIDE FUMARATE

INJECTABLE; INJECTION  
IBUTILIDE FUMARATE

AP		AVET LIFESCIENCES	0.1MG/ML	A 204146	001	Apr 01, 2024	Mar NEWA
----	--	-------------------	----------	----------	-----	--------------	----------

ICOSAPENT ETHYL

CAPSULE; ORAL  
ICOSAPENT ETHYL

AB		ASCENT PHARMS INC	1GM	A 216811	002	Feb 16, 2024	Feb NEWA
AB		ZYDUS LIFESCIENCES	500MG	A 217656	001	Apr 20, 2023	Apr CAHN
AB			1GM	A 217656	002	Apr 20, 2023	Apr CAHN

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION  
IDARUBICIN HYDROCHLORIDE

@		RISING	1MG/ML	A 200144	001	Oct 11, 2012	Feb CAHN
---	--	--------	--------	----------	-----	--------------	----------

ILOPROST

SOLUTION; INHALATION  
VENTAVIS

+	@	ACTELION	10MCG/ML (10MCG/ML)	N 021779	002	Dec 08, 2005	Mar DISC
+	@		20MCG/ML (20MCG/ML)	N 021779	003	Aug 07, 2009	Mar DISC

SOLUTION; INTRAVENOUS  
AURLUMYN

+!		EICOS SCI	100MCG/ML (100MCG/ML)	N 217933	001	Feb 13, 2024	Feb NEWA
----	--	-----------	-----------------------	----------	-----	--------------	----------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL  
IMIPRAMINE HYDROCHLORIDE

AB	!	LEADING	50MG	A 040903	003	Oct 24, 2012	Apr CHRS
	+	@ SPECGX LLC	10MG	A 087846	002	May 22, 1984	Apr DISC
	+	@	25MG	A 087846	003	May 22, 1984	Apr DISC
		TOFRANIL					
	+	@ SPECGX LLC	50MG	A 087846	001	May 22, 1984	Apr DISC

INDOMETHACIN

SUPPOSITORY; RECTAL  
INDOMETHACIN

AB		ZYDUS LIFESCIENCES	50MG	A 216184	001	Aug 02, 2023	Apr CAHN
----	--	--------------------	------	----------	-----	--------------	----------

SUSPENSION; ORAL  
INDOCIN

AB	+!	ZYLA	25MG/5ML	N018332	001	Oct 10, 1985	Jan CTEC
AB		INDOMETHACIN NOVITIUM PHARMA	25MG/5ML	A217883	001	Jan 12, 2024	Jan NEWA

IOBENGUANE I-131

SOLUTION; INTRAVENOUS  
AZEDRA

	+	@	PROGENICS PHARMS INC	15mCi/ML	N209607	001	Jul 30, 2018	Feb DISC
--	---	---	----------------------	----------	---------	-----	--------------	----------

IOPAMIDOL

INJECTABLE; INJECTION  
IOPAMIDOL

AP		HAINAN POLY	51%	A217134	002	Apr 09, 2024	Mar NEWA
AP			61%	A217134	003	Apr 09, 2024	Mar NEWA
AP			76%	A217134	004	Apr 09, 2024	Mar NEWA
AP	+!	ISOVUE-250 BRACCO	51%	N018735	007	Jul 06, 1992	Mar CTEC
AP	+!	ISOVUE-300 BRACCO	61%	N018735	002	Dec 31, 1985	Mar CTEC
AP	+!	ISOVUE-370 BRACCO	76%	N018735	003	Dec 31, 1985	Mar CTEC

IRBESARTAN

TABLET; ORAL  
IRBESARTAN

>A>	AB		IPCA LABS LTD	75MG	A211056	001	May 22, 2024	May NEWA
>A>	AB			150MG	A211056	002	May 22, 2024	May NEWA
>A>	AB			300MG	A211056	003	May 22, 2024	May NEWA

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION  
ISOPROTERENOL HYDROCHLORIDE

	@	CIPLA	0.2MG/ML	A210322	001	Jun 12, 2018	Mar DISC
--	---	-------	----------	---------	-----	--------------	----------

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL  
DILATRATE-SR

>D>		+	@	AUXILIUM PHARMS LLC	40MG	N019790	001	Sep 02, 1988	May CAHN
>A>		+	@	ENDO OPERATIONS	40MG	N019790	001	Sep 02, 1988	May CAHN

TABLET; ORAL  
ISOSORBIDE DINITRATE

AB			ENDO OPERATIONS	40MG	A211290	001	Nov 23, 2021	Apr CAHN
----	--	--	-----------------	------	---------	-----	--------------	----------

ISOSORBIDE MONONITRATE

TABLET; ORAL  
MONOKET

AB	+		OMNIVIUM PHARMS	10MG	N020215	002	Jun 30, 1993	Jan CAHN
AB	+!			20MG	N020215	001	Jun 30, 1993	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL  
ISOSORBIDE MONONITRATE

AB			CHARTWELL MOLECULAR	120MG	A075155	003	Aug 04, 2000	Mar CHRS
AB	!		RICONPHARMA LLC	120MG	A210918	003	Nov 05, 2018	Mar CHRS
AB			SHANDONG	30MG	A214115	002	Feb 08, 2024	Feb NEWA
AB				60MG	A214115	003	Feb 08, 2024	Feb NEWA
AB				120MG	A214115	001	Apr 29, 2022	Mar CMFD
AB			ZYDUS PHARMS	30MG	A218255	001	Feb 15, 2024	Feb NEWA
AB				60MG	A218255	002	Feb 15, 2024	Feb NEWA
AB				120MG	A218255	003	Feb 15, 2024	Feb NEWA

ISOSULFAN BLUE

INJECTABLE; INJECTION  
ISOSULFAN BLUE

>D>	AP		AM REGENT	1%	A210294	001	May 17, 2023	May CDFR
>D>		@	BELOTECA	1%	A210714	001	Jan 16, 2019	May CDFR
>D>		@	EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	May CDFR
>D>		@	FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	May CDFR
>D>	AP		MEITHEAL	1%	A213130	001	Nov 03, 2021	May CDFR
>D>	AP		MSN	1%	A216090	001	Sep 16, 2022	May CDFR
>D>	AP	!	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May CDFR
>D>		@	SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May CDFR

INJECTABLE; INJECTION		LYMPHAZURIN					
>D>	+ @ COVIDIEN	1%		N018310	001		May CDFR
>A>	SOLUTION; SUBCUTANEOUS						
>A>	ISOSULFAN BLUE						
>A>	AP	AM REGENT	1%	A210294	001	May 17, 2023	May CDFR
>A>	AP		50MG/5ML (10MG/ML)	A210294	001	May 17, 2023	May CPOT
>A>		@ BELOTECA	1%	A210714	001	Jan 16, 2019	May CDFR
>A>		@	50MG/5ML (10MG/ML)	A210714	001	Jan 16, 2019	May CPOT
>A>		@ EUGIA PHARMA	1%	A206831	001	Feb 02, 2016	May CDFR
>A>		@	50MG/5ML (10MG/ML)	A206831	001	Feb 02, 2016	May CPOT
>A>		@ FRESENIUS KABI USA	1%	A211869	001	Sep 08, 2022	May CDFR
>A>		@	50MG/5ML (10MG/ML)	A211869	001	Sep 08, 2022	May CPOT
>A>	AP	MEITHEAL	1%	A213130	001	Nov 03, 2021	May CDFR
>A>	AP		50MG/5ML (10MG/ML)	A213130	001	Nov 03, 2021	May CPOT
>A>	AP	MSN	1%	A216090	001	Sep 16, 2022	May CDFR
>A>	AP		50MG/5ML (10MG/ML)	A216090	001	Sep 16, 2022	May CPOT
>A>	AP	! MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	May CDFR
>A>	AP	!	50MG/5ML (10MG/ML)	A090874	001	Jul 20, 2010	May CPOT
>A>		@ SOMERSET THERAPS LLC	1%	A210558	001	Jul 12, 2019	May CDFR
>A>		@	50MG/5ML (10MG/ML)	A210558	001	Jul 12, 2019	May CPOT
>A>	LYMPHAZURIN						
>A>	+ @ COVIDIEN	1%		N018310	001		May CDFR
>A>	+ @	50MG/5ML (10MG/ML)		N018310	001		May CPOT

ISOTRETINOIN

CAPSULE; ORAL		ISOTRETINOIN					
AB2	AUROBINDO PHARMA	10MG		A218194	001	Jan 29, 2024	Jan NEWA
AB2		20MG		A218194	002	Jan 29, 2024	Jan NEWA
AB2		25MG		A218194	003	Jan 29, 2024	Jan NEWA
AB2		30MG		A218194	004	Jan 29, 2024	Jan NEWA
AB2		35MG		A218194	005	Jan 29, 2024	Jan NEWA
AB2		40MG		A218194	006	Jan 29, 2024	Jan NEWA

ITRACONAZOLE

CAPSULE; ORAL		ITRACONAZOLE					
>D>	AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May DISC
>A>		@	100MG	A205991	001	May 26, 2016	May DISC
>A>		@ RISING	100MG	A205724	001	Dec 13, 2016	Apr CAHN

IVABRADINE HYDROCHLORIDE

TABLET; ORAL		IVABRADINE HYDROCHLORIDE					
>D>		@ INGENUS PHARMS LLC	EQ 5MG BASE	A214051	001	Dec 30, 2021	May CMFD
>A>	AB		EQ 5MG BASE	A214051	001	Dec 30, 2021	May CMFD
>D>		@	EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May CMFD
>A>	AB		EQ 7.5MG BASE	A214051	002	Dec 30, 2021	May CMFD

IVERMECTIN

CREAM; TOPICAL		IVERMECTIN					
AB	ZYDUS LIFESCIENCES	1%		A215210	001	Aug 02, 2022	Mar CAHN

KETOCONAZOLE

AEROSOL, FOAM; TOPICAL		EXTINA					
	+ @ MYLAN	2%		N021738	001	Jun 12, 2007	Feb DISC
AB	! XIROMED	2%		A213601	001	May 21, 2021	Feb CHRS
TABLET; ORAL		KETOCONAZOLE					
AB	SENORES PHARMS	200MG		A075912	001	Jan 10, 2002	Feb CAHN

KETOROLAC TROMETHAMINE

SOLUTION/DROPS; OPHTHALMIC		KETOROLAC TROMETHAMINE					
AT	CAPLIN	0.5%		A218204	001	Mar 26, 2024	Mar NEWA

LABETALOL HYDROCHLORIDE

TABLET; ORAL

LABETALOL HYDROCHLORIDE

AB	ENDO OPERATIONS	100MG	A200908	001	Jul 10, 2012	Apr	CAHN
AB	!	200MG	A200908	002	Jul 10, 2012	Apr	CAHN
AB		300MG	A200908	003	Jul 10, 2012	Apr	CAHN

LACOSAMIDE

SOLUTION; INTRAVENOUS

LACOSAMIDE

AP	DR REDDYS	200MG/20ML (10MG/ML)	A217718	001	Mar 25, 2024	Mar	NEWA
AP	HAINAN POLY	200MG/20ML (10MG/ML)	A217311	001	Feb 13, 2024	Feb	NEWA
AP	HIKMA	200MG/20ML (10MG/ML)	A216806	001	Apr 05, 2024	Mar	NEWA

SOLUTION; ORAL

LACOSAMIDE

	@ AMNEAL PHARMS	10MG/ML	A204839	001	Mar 27, 2024	Apr	DISC
AA		10MG/ML	A204839	001	Mar 27, 2024	Mar	NEWA
AA	AUROBINDO PHARMA LTD	10MG/ML	A209224	001	Jan 24, 2024	Jan	NEWA
>A>	AA CHARTWELL RX	10MG/ML	A215154	001	May 15, 2024	May	NEWA

TABLET; ORAL

LACOSAMIDE

>A>	AB MACLEODS PHARMS LTD	50MG	A208466	001	May 24, 2024	May	NEWA
>A>	AB	100MG	A208466	002	May 24, 2024	May	NEWA
>A>	AB	150MG	A208466	003	May 24, 2024	May	NEWA
>A>	AB	200MG	A208466	004	May 24, 2024	May	NEWA
	AB MEDLEY PHARMS	50MG	A218014	001	Apr 02, 2024	Mar	NEWA
	AB	100MG	A218014	002	Apr 02, 2024	Mar	NEWA
	AB	150MG	A218014	003	Apr 02, 2024	Mar	NEWA
	AB	200MG	A218014	004	Apr 02, 2024	Mar	NEWA
>D>	AB ZYDUS PHARMS	50MG	A204947	001	Dec 15, 2023	May	DISC
>A>	@	50MG	A204947	001	Dec 15, 2023	May	DISC
>D>	AB	100MG	A204947	002	Dec 15, 2023	May	DISC
>A>	@	100MG	A204947	002	Dec 15, 2023	May	DISC
>D>	AB	150MG	A204947	003	Dec 15, 2023	May	DISC
>A>	@	150MG	A204947	003	Dec 15, 2023	May	DISC
>D>	AB	200MG	A204947	004	Dec 15, 2023	May	DISC
>A>	@	200MG	A204947	004	Dec 15, 2023	May	DISC

LACTULOSE

SOLUTION; ORAL

LACTULOSE

	@ HIKMA	10GM/15ML	A074076	001	Jul 03, 1995	Mar	DISC
AA	! PHARM ASSOC	10GM/15ML	A074623	001	Jul 30, 1996	Mar	CHRS

SOLUTION; ORAL, RECTAL

LACTULOSE

@ PAI HOLDINGS PHARM

	10GM/15ML	A074077	001	Jul 03, 1995	Feb	DISC
--	-----------	---------	-----	--------------	-----	------

LAMIVUDINE

SOLUTION; ORAL

EPIVIR-HBV

	+ @ GLAXOSMITHKLINE	5MG/ML	N021004	001	Dec 08, 1998	Apr	DISC
--	---------------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

EPIVIR-HBV

	+ @ GLAXOSMITHKLINE	100MG	N021003	001	Dec 08, 1998	Apr	DISC
--	---------------------	-------	---------	-----	--------------	-----	------

LAMIVUDINE

AB	! APOTEX	100MG	A202941	001	Jan 02, 2014	Apr	CHRS
	@ MYLAN LABS LTD	150MG	A078545	001	Mar 05, 2019	Jan	DISC
	@	300MG	A078545	002	Mar 05, 2019	Jan	DISC

LAMIVUDINE; ZIDOVUDINE

TABLET; ORAL

COMBIVIR

	+ @ VIIV HLTHCARE	150MG; 300MG	N020857	001	Sep 26, 1997	Jan	DISC
--	-------------------	--------------	---------	-----	--------------	-----	------

LAMIVUDINE AND ZIDOVUDINE

AB	! HETERO LABS LTD III	150MG; 300MG	A079124	001	Sep 17, 2015	Jan	CHRS
----	-----------------------	--------------	---------	-----	--------------	-----	------

LAMOTRIGINE

TABLET; ORAL

LAMOTRIGINE

AB	GLENMARK PHARMS LTD	25MG	A090169	001	May 12, 2012	Mar	CAHN
AB		100MG	A090169	002	May 12, 2012	Mar	CAHN
AB		150MG	A090169	003	May 12, 2012	Mar	CAHN
AB		200MG	A090169	004	May 12, 2012	Mar	CAHN

TABLET, EXTENDED RELEASE; ORAL

LAMOTRIGINE

>D>	@ ANCHEN PHARMS	25MG	A201374	001	Dec 26, 2012	May	CAHN
	@	25MG	A201374	001	Dec 26, 2012	Feb	DISC
>D>	@	50MG	A201374	002	Dec 26, 2012	May	CAHN
	@	50MG	A201374	002	Dec 26, 2012	Feb	DISC
>D>	@	100MG	A201374	003	Dec 26, 2012	May	CAHN
	@	100MG	A201374	003	Dec 26, 2012	Feb	DISC
>D>	@	200MG	A201374	004	Dec 26, 2012	May	CAHN
	@	200MG	A201374	004	Dec 26, 2012	Feb	DISC
>D>	@	250MG	A201374	005	Dec 26, 2012	May	CAHN
	@	250MG	A201374	005	Dec 26, 2012	Feb	DISC
>D>	@	300MG	A201374	006	Dec 26, 2012	May	CAHN
	@	300MG	A201374	006	Dec 26, 2012	Feb	DISC
>A>	@ ENDO OPERATIONS	25MG	A201374	001	Dec 26, 2012	May	CAHN
AB		25MG	A201791	001	Jan 18, 2013	Apr	CAHN
>A>	@	50MG	A201374	002	Dec 26, 2012	May	CAHN
AB		50MG	A201791	002	Jan 18, 2013	Apr	CAHN
>A>	@	100MG	A201374	003	Dec 26, 2012	May	CAHN
AB		100MG	A201791	003	Jan 18, 2013	Apr	CAHN
>A>	@	200MG	A201374	004	Dec 26, 2012	May	CAHN
AB		200MG	A201791	004	Jan 18, 2013	Apr	CAHN
>A>	@	250MG	A201374	005	Dec 26, 2012	May	CAHN
AB		250MG	A201791	005	Jan 18, 2013	Apr	CAHN
>A>	@	300MG	A201374	006	Dec 26, 2012	May	CAHN
AB		300MG	A201791	006	Jan 18, 2013	Apr	CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

LAMOTRIGINE

AB	ENDO OPERATIONS	25MG	A204158	001	Oct 27, 2015	Apr	CAHN
AB		50MG	A204158	002	Oct 27, 2015	Apr	CAHN
AB		100MG	A204158	003	Oct 27, 2015	Apr	CAHN
AB		200MG	A204158	004	Oct 27, 2015	Apr	CAHN

LANREOTIDE ACETATE

SOLUTION; SUBCUTANEOUS

LANREOTIDE ACETATE

>A>	AB	INVAGEN PHARMS	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	A217193	001	May 21, 2024	May	NFTG
>A>	AB		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	A217193	002	May 21, 2024	May	NFTG
>A>	AB		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	A217193	003	May 21, 2024	May	NFTG
			SOMATULINE DEPOT					
>D>	+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
>A>	AB	+	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	May	CFTG
>D>	+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
>A>	AB	+	EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	May	CFTG
>D>	+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG
>A>	AB	+	EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	May	CFTG

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

LANSOPRAZOLE

>D>	AB	SUN PHARM	15MG	A202637	001	Sep 13, 2013	May	DISC
>A>	@		15MG	A202637	001	Sep 13, 2013	May	DISC
>D>	AB		30MG	A091509	001	Sep 13, 2013	May	DISC
>A>	@		30MG	A091509	001	Sep 13, 2013	May	DISC

LEFAMULIN ACETATE

SOLUTION; INTRAVENOUS  
XENLETA

+!	NABRIVA	EQ 150MG BASE/15ML (EQ 10MG BASE/ML)	N211673	001	Aug 19, 2019	Apr	CMFD
----	---------	--------------------------------------	---------	-----	--------------	-----	------

LENALIDOMIDE

CAPSULE; ORAL  
LENALIDOMIDE

AB	QILU	2.5MG	A217265	001	Feb 22, 2024	Feb	NEWA
AB		5MG	A217265	002	Feb 22, 2024	Feb	NEWA
AB		10MG	A217265	003	Feb 22, 2024	Feb	NEWA
AB		15MG	A217265	004	Feb 22, 2024	Feb	NEWA
AB		20MG	A217265	005	Feb 22, 2024	Feb	NEWA
AB		25MG	A217265	006	Feb 22, 2024	Feb	NEWA

LEVALBUTEROL HYDROCHLORIDE

SOLUTION; INHALATION  
LEVALBUTEROL HYDROCHLORIDE

AN	!	MYLAN SPECIALITY LP	EQ 0.25% BASE	A078309	001	Mar 20, 2009	Apr	CHRS
>D>	AN	SUN PHARM	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
>A>		@	EQ 0.0103% BASE	A207820	001	Nov 05, 2018	May	DISC
>D>	AN		EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
>A>		@	EQ 0.021% BASE	A207820	002	Nov 05, 2018	May	DISC
>D>	AN		EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
>A>		@	EQ 0.042% BASE	A207820	003	Nov 05, 2018	May	DISC
AN	!	TEVA PHARMS USA	EQ 0.0103% BASE	A090297	001	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.021% BASE	A090297	002	Apr 26, 2013	Apr	CHRS
AN	!		EQ 0.042% BASE	A090297	003	Apr 26, 2013	Apr	CHRS
		XOPENEX						
+	@	HIKMA	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Apr	DISC
+	@		EQ 0.021% BASE	N020837	001	Mar 25, 1999	Apr	DISC
+	@		EQ 0.042% BASE	N020837	002	Mar 25, 1999	Apr	DISC
+	@		EQ 0.25% BASE	N020837	004	Jul 18, 2003	Apr	DISC

LEVAMLODIPINE MALEATE

TABLET; ORAL  
CONJUPRI

+	CSPC OUYI	EQ 2.5MG BASE	N212895	002	Dec 19, 2019	Mar	CMFD
+!		EQ 5MG BASE	N212895	003	Dec 19, 2019	Mar	CMFD

LEVETIRACETAM

INJECTABLE; INTRAVENOUS  
LEVETIRACETAM

AP		ADRASTEA PHARMA	500MG/5ML (100MG/ML)	A091485	001	Aug 05, 2011	Feb	CAHN
>D>	AP	SUN PHARM INDS LTD	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
>A>		@	500MG/5ML (100MG/ML)	A090754	001	Jun 16, 2010	May	DISC
		LEVETIRACETAM IN SODIUM CHLORIDE						
AP		B BRAUN MEDICAL INC	500MG/100ML (5MG/ML)	A209705	001	Feb 27, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A209705	002	Feb 27, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A209705	003	Feb 27, 2024	Feb	NEWA
AP		BAXTER HLTHCARE CORP	500MG/100ML (5MG/ML)	A217059	001	Oct 02, 2023	Feb	CTNA
AP			1GM/100ML (10MG/ML)	A217059	002	Oct 02, 2023	Feb	CTNA
AP			1.5GM/100ML (15MG/ML)	A217059	003	Oct 02, 2023	Feb	CTNA
		@ FRESSENIUS KABI USA	500MG/100ML (5MG/ML)	A208619	001	Jan 31, 2023	Mar	DISC
		@	1GM/100ML (10MG/ML)	A208619	002	Jan 31, 2023	Mar	DISC
		@	1.5GM/100ML (15MG/ML)	A208619	003	Jan 31, 2023	Mar	DISC
AP		HIKMA	500MG/100ML (5MG/ML)	A211356	001	Feb 12, 2024	Feb	NEWA
AP			1GM/100ML (10MG/ML)	A211356	002	Feb 12, 2024	Feb	NEWA
AP			1.5GM/100ML (15MG/ML)	A211356	003	Feb 12, 2024	Feb	NEWA
+	@	HQ SPCLT PHARMA	250MG/50ML (5MG/ML)	N202543	004	Dec 14, 2020	Feb	DISC
		SOLUTION; ORAL						
		LEVETIRACETAM						
		@ HIKMA	100MG/ML	A090601	001	Feb 28, 2012	Mar	DISC
>D>	AA	STRIDES PHARMA	100MG/ML	A214673	001	Nov 20, 2023	May	DISC
>A>		@	100MG/ML	A214673	001	Nov 20, 2023	May	DISC
		TABLET; ORAL						
		LEVETIRACETAM						
>D>	AB	ACCORD HLTHCARE	250MG	A090843	001	Feb 14, 2011	May	DISC
>A>		@	250MG	A090843	001	Feb 14, 2011	May	DISC
>D>	AB		500MG	A090843	002	Feb 14, 2011	May	DISC
>A>		@	500MG	A090843	002	Feb 14, 2011	May	DISC

TABLET;ORAL

LEVETIRACETAM

>D>	AB		750MG	A090843	003	Feb 14, 2011	May	DISC
>A>	@		750MG	A090843	003	Feb 14, 2011	May	DISC
>D>	AB		1GM	A090843	004	Feb 14, 2011	May	DISC
>A>	@		1GM	A090843	004	Feb 14, 2011	May	DISC
	@	GRANULES	250MG	A217878	001	Jun 13, 2023	Mar	DISC
	@		500MG	A217878	002	Jun 13, 2023	Mar	DISC
	@		750MG	A217878	003	Jun 13, 2023	Mar	DISC
	@		1GM	A217878	004	Jun 13, 2023	Mar	DISC
	@	INVAGEN PHARMS	250MG	A078234	001	Jan 15, 2009	Mar	DISC
	@		500MG	A078234	002	Jan 15, 2009	Mar	DISC
	@		750MG	A078234	003	Jan 15, 2009	Mar	DISC

TABLET, EXTENDED RELEASE;ORAL

LEVETIRACETAM

>D>	@	ANCHEN PHARMS	500MG	A091360	001	Oct 04, 2011	May	CAHN
	@		500MG	A091360	001	Oct 04, 2011	Feb	DISC
>D>	@		750MG	A091360	002	Oct 04, 2011	May	CAHN
	@		750MG	A091360	002	Oct 04, 2011	Feb	DISC
>A>	@	ENDO OPERATIONS	500MG	A091360	001	Oct 04, 2011	May	CAHN
>A>	@		750MG	A091360	002	Oct 04, 2011	May	CAHN

LEVOCARNITINE

SOLUTION;ORAL

LEVOCARNITINE

@	HIKMA		1GM/10ML	A077399	001	Oct 25, 2007	Mar	DISC
---	-------	--	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

TABLET;ORAL

LEVOCETIRIZINE DIHYDROCHLORIDE

AB		IPCA LABS LTD	5MG	A204626	001	May 06, 2024	Apr	NEWA
----	--	---------------	-----	---------	-----	--------------	-----	------

LEVOFLOXACIN

INJECTABLE;INJECTION

LEVOFLOXACIN

	@	BAXTER HLTHCARE CORP	EQ 500MG/20ML (EQ 25MG/ML)	A091436	001	Jun 05, 2013	Apr	DISC
			LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP		KNACK	EQ 250MG/50ML (EQ 5MG/ML)	A216164	001	Jan 29, 2024	Jan	NEWA
AP			EQ 500MG/100ML (EQ 5MG/ML)	A216164	002	Jan 29, 2024	Jan	NEWA
AP			EQ 750MG/150ML (EQ 5MG/ML)	A216164	003	Jan 29, 2024	Jan	NEWA

SOLUTION/DROPS;OPHTHALMIC

LEVOFLOXACIN

@	SAPTALIS PHARMS		0.5%	A090268	001	Dec 20, 2010	Mar	CAHN
---	-----------------	--	------	---------	-----	--------------	-----	------

TABLET;ORAL

LEVOFLOXACIN

@	CELLTRION		250MG	A090367	001	Jun 20, 2011	Apr	DISC
@			500MG	A090367	002	Jun 20, 2011	Apr	DISC
@			750MG	A090367	003	Jun 20, 2011	Apr	DISC

LEVOLEUCOVORIN CALCIUM

POWDER;INTRAVENOUS

FUSILEV

>D>	+!	ACROTECH BIOPHARMA	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
>A>	+ @		EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	May	DISC
	+!		EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Mar	CTEC
			LEVOLEUCOVORIN CALCIUM					
	@	MEITHEAL	EQ 50MG BASE/VIAL	A211003	001	Aug 22, 2019	Mar	DISC

LEVONORGESTREL

TABLET;ORAL

LEVONORGESTREL

>D>	@	MYLAN LABS LTD	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
>A>	@	XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN

LEVOTHYROXINE SODIUM

POWDER;INTRAVENOUS

LEVOTHYROXINE SODIUM

>A>	@	ENDO OPERATIONS	200MCG/VIAL	A205366	001	Dec 07, 2015	May	CAHN
>D>	@	PAR STERILE PRODUCTS	200MCG/VIAL	A205366	001	Dec 07, 2015	May	CAHN



LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

## LEVOTHYROXINE SODIUM

AB1, AB2, AB3, AB4	WATSON LABS TEVA	0.025MG	A207588	001	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.05MG	A207588	002	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.075MG	A207588	003	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.088MG	A207588	004	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.1MG	A207588	005	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.112MG	A207588	006	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.125MG	A207588	007	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.137MG	A207588	008	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.15MG	A207588	009	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.175MG	A207588	010	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.2MG	A207588	011	May 10, 2022	Feb CTEC
AB1, AB2, AB3, AB4		0.3MG	A207588	012	May 10, 2022	Feb CTEC

LIDOCAINE

## OINTMENT;TOPICAL

## LIDOCAINE

@ COSETTE	5%	A211019	001	Dec 12, 2018	Apr DISC
-----------	----	---------	-----	--------------	----------

LIDOCAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## LIDOCAINE HYDROCHLORIDE

AP	FRESENIUS KABI USA	1%	A088586	002		Apr CMS1
AP		2%	A088586	003		Apr CMS1

## SOLUTION;ORAL

## LIDOCAINE HYDROCHLORIDE VISCOUS

AT	PAI HOLDINGS PHARM	2%	A218138	001	Feb 20, 2024	Feb NEWA
----	--------------------	----	---------	-----	--------------	----------

## SOLUTION;TOPICAL

## LIDOCAINE HYDROCHLORIDE

AT	THE J MOLNER	4%	A218411	001	Apr 29, 2024	Apr NEWA
----	--------------	----	---------	-----	--------------	----------

LIDOCAINE; PRILOCAINE

## CREAM;TOPICAL

## LIDOCAINE AND PRILOCAINE

@ HIKMA	2.5%;2.5%	A076290	001	Sep 25, 2003	Mar DISC
---------	-----------	---------	-----	--------------	----------

LIFITEGRAST

SOLUTION/DROPS;OPHTHALMIC  
LIFITEGRAST

>D>	AB	EUGIA PHARMA	5%	A215063	001	Nov 07, 2023	May	DISC
>A>		@	5%	A215063	001	Nov 07, 2023	May	DISC
>D>	AB	MICRO LABS	5%	A215081	001	Aug 04, 2023	May	DISC
>A>		@	5%	A215081	001	Aug 04, 2023	May	DISC
		XIIDRA						
>D>	AB	+! BAUSCH AND LOMB INC	5%	N208073	001	Jul 11, 2016	May	CTEC
>A>		+!	5%	N208073	001	Jul 11, 2016	May	CTEC
	AB	+!	5%	N208073	001	Jul 11, 2016	Jan	CAHN

LINCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION  
LINCOMYCIN HYDROCHLORIDE

>D>		@ GENEYORK PHARMS	EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD
>A>	AP		EQ 300MG BASE/ML	A212770	001	Mar 12, 2021	May	CMFD

LIOTHYRONINE SODIUM

INJECTABLE;INJECTION  
TRIOSTAT

>A>		+ @ ENDO OPERATIONS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	May	CAHN
>D>		+ @ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	May	CAHN

TABLET;ORAL

LIOTHYRONINE SODIUM

AB		BIOCON PHARMA	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Mar	CAHN
AB			EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Feb	CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Mar	CAHN
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Feb	CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Mar	CAHN
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Feb	CAHN
AB		CARNEGIE	EQ 0.005MG BASE	A218070	001	Feb 06, 2024	Jan	NEWA
AB			EQ 0.025MG BASE	A218070	002	Feb 06, 2024	Jan	NEWA
AB			EQ 0.05MG BASE	A218070	003	Feb 06, 2024	Jan	NEWA

LIRAGLUTIDE

SOLUTION;SUBCUTANEOUS  
SAXENDA

	+!	NOVO	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Mar	CAIN
		VICTOZA						
	+!	NOVO NORDISK INC	18MG/3ML (6MG/ML)	N022341	001	Jan 25, 2010	Mar	CAIN

LISDEXAMFETAMINE DIMESYLATE

CAPSULE;ORAL

LISDEXAMFETAMINE DIMESYLATE

	@	ACTAVIS ELIZABETH	10MG	A202802	001	Aug 25, 2023	Feb	DISC
	@		20MG	A202802	002	Aug 25, 2023	Feb	DISC
	@		30MG	A202802	003	Aug 25, 2023	Feb	DISC
	@		40MG	A202802	004	Aug 25, 2023	Feb	DISC
	@		50MG	A202802	005	Aug 25, 2023	Feb	DISC
	@		60MG	A202802	006	Aug 25, 2023	Feb	DISC
	@		70MG	A202802	007	Aug 25, 2023	Feb	DISC
AB		HIKMA	10MG	A202827	007	Jan 17, 2024	Jan	NEWA

TABLET, CHEWABLE;ORAL

LISDEXAMFETAMINE DIMESYLATE

AB		MSN	10MG	A218306	001	Feb 02, 2024	Jan	NEWA
AB			20MG	A218306	002	Feb 02, 2024	Jan	NEWA
AB			30MG	A218306	003	Feb 02, 2024	Jan	NEWA
AB			40MG	A218306	004	Feb 02, 2024	Jan	NEWA
AB			50MG	A218306	005	Feb 02, 2024	Jan	NEWA
AB			60MG	A218306	006	Feb 02, 2024	Jan	NEWA
	@	TEVA PHARMS	10MG	A215415	001	Aug 25, 2023	Feb	DISC
	@		20MG	A215415	002	Aug 25, 2023	Feb	DISC
	@		30MG	A215415	003	Aug 25, 2023	Feb	DISC
	@		40MG	A215415	004	Aug 25, 2023	Feb	DISC
	@		50MG	A215415	005	Aug 25, 2023	Feb	DISC
	@		60MG	A215415	006	Aug 25, 2023	Feb	DISC

LISINOPRIL

TABLET; ORAL  
LISINOPRIL

>D>	AB	ACCORD HLTHCARE	2.5MG	A202554	001	Jul 30, 2013	May	DISC
>A>	@		2.5MG	A202554	001	Jul 30, 2013	May	DISC
>D>	AB		5MG	A202554	002	Jul 30, 2013	May	DISC
>A>	@		5MG	A202554	002	Jul 30, 2013	May	DISC
>D>	AB		10MG	A202554	003	Jul 30, 2013	May	DISC
>A>	@		10MG	A202554	003	Jul 30, 2013	May	DISC
>D>	AB		20MG	A202554	004	Jul 30, 2013	May	DISC
>A>	@		20MG	A202554	004	Jul 30, 2013	May	DISC
>D>	AB		30MG	A202554	005	Jul 30, 2013	May	DISC
>A>	@		30MG	A202554	005	Jul 30, 2013	May	DISC
>D>	AB		40MG	A202554	006	Jul 30, 2013	May	DISC
>A>	@		40MG	A202554	006	Jul 30, 2013	May	DISC

LITHIUM CITRATE

SYRUP; ORAL  
LITHIUM CITRATE

	@	PAI HOLDINGS PHARM	EQ 300MG CARBONATE/5ML	A070755	001	May 21, 1986	Feb	DISC
AA	!	RUBICON	EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	NEWA
	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Mar	CTEC
AA	!		EQ 300MG CARBONATE/5ML	A218036	001	Aug 14, 2023	Feb	CHRS
AA		SAPTALIS PHARMS	EQ 300MG CARBONATE/5ML	A217183	001	Mar 18, 2024	Mar	NEWA
AA			EQ 300MG CARBONATE/5ML	A217183	001	Feb 29, 2024	Feb	NEWA

LOMITAPIDE MESYLATE

CAPSULE; ORAL  
JUXTAPID

+		CHIESI	EQ 5MG BASE	N203858	001	Dec 21, 2012	Jan	CAHN
+			EQ 10MG BASE	N203858	002	Dec 21, 2012	Jan	CAHN
+			EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CAHN
+			EQ 30MG BASE	N203858	004	Apr 23, 2015	Jan	CAHN
+	@		EQ 40MG BASE	N203858	005	Apr 23, 2015	Jan	CAHN
+	@		EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CAHN

LOMUSTINE

CAPSULE; ORAL  
GLEOSTINE

+	@	LATINA PHARMA	5MG	N017588	004	Dec 19, 2014	Feb	CAHN
	+		10MG	N017588	001		Feb	CAHN
>D>	+		40MG	N017588	002		May	CHRS
>A>	+!		40MG	N017588	002		May	CHRS
	+		40MG	N017588	002		Feb	CAHN
>D>	+!		100MG	N017588	003		May	CHRS
>A>	+		100MG	N017588	003		May	CHRS
	+!		100MG	N017588	003		Feb	CAHN

LONAFARNIB

CAPSULE; ORAL  
ZOKINVY

>D>	+	EIGER BIOPHARMS	50MG	N213969	001	Nov 20, 2020	May	CAHN
>D>	+!		75MG	N213969	002	Nov 20, 2020	May	CAHN
>A>	+	SENTYNL THERAPS INC	50MG	N213969	001	Nov 20, 2020	May	CAHN
>A>	+!		75MG	N213969	002	Nov 20, 2020	May	CAHN

LOPINAVIR; RITONAVIR

TABLET; ORAL  
LOPINAVIR AND RITONAVIR

AB		MYLAN LABS LTD	100MG;25MG	A079074	001	Feb 07, 2024	Jan	NEWA
AB			200MG;50MG	A079074	002	Feb 07, 2024	Jan	NEWA

LORAZEPAM

CONCENTRATE; ORAL  
LORAZEPAM

@	HIKMA	2MG/ML	A200169	001	Jan 30, 2012	Mar	DISC
---	-------	--------	---------	-----	--------------	-----	------

INJECTABLE; INJECTION  
LORAZEPAM

@	ENDO OPERATIONS	2MG/ML	A074793	001	Mar 16, 2000	Apr	CAHN
@		4MG/ML	A074793	002	Mar 16, 2000	Apr	CAHN

LOSARTAN POTASSIUM

TABLET; ORAL		LOSARTAN POTASSIUM							
	@ AIPING PHARM INC	25MG	A 090544	001	Oct 06, 2010	Feb	CAHN		
	@	50MG	A 090544	002	Oct 06, 2010	Feb	CAHN		
	@	100MG	A 090544	003	Oct 06, 2010	Feb	CAHN		
>A>	AB APOTEX	25MG	A 218551	001	Jun 04, 2024	May	NEWA		
>A>	AB	50MG	A 218551	002	Jun 04, 2024	May	NEWA		
>A>	AB	100MG	A 218551	003	Jun 04, 2024	May	NEWA		
	AB CHARTWELL RX	25MG	A 077424	001	Oct 06, 2010	Jan	CAHN		
	AB	50MG	A 077424	002	Oct 06, 2010	Jan	CAHN		
	AB	100MG	A 077424	003	Oct 06, 2010	Jan	CAHN		

LOTEPREDNOL ETABONATE

GEL; OPHTHALMIC		LOTEPREDNOL ETABONATE							
AB	HIKMA	0.5%	A 213956	001	Nov 29, 2023	Apr	CAHN		
SUSPENSION/DROPS; OPHTHALMIC		LOTEPREDNOL ETABONATE							
AB	LUPIN LTD	0.5%	A 215719	001	Apr 24, 2024	Apr	NEWA		

LUBIPROSTONE

CAPSULE; ORAL		LUBIPROSTONE							
	@ ENDO OPERATIONS	8MCG	A 201442	001	Jun 27, 2022	Apr	CAHN		
	@	24MCG	A 201442	002	Jun 27, 2022	Apr	CAHN		

LURASIDONE HYDROCHLORIDE

TABLET; ORAL		LURASIDONE HYDROCHLORIDE							
AB	SLATE RUN PHARMA	20MG	A 212091	001	Dec 28, 2020	Feb	CAHN		
AB		40MG	A 212091	002	Dec 28, 2020	Feb	CAHN		
AB		60MG	A 212091	003	Dec 28, 2020	Feb	CAHN		
AB		80MG	A 212091	004	Dec 28, 2020	Feb	CAHN		
AB		120MG	A 212091	005	Dec 28, 2020	Feb	CAHN		

MACITENTAN

TABLET; ORAL		MACITENTAN							
>D>	@ APOTEX	10MG	A 211195	001	Jan 09, 2024	Apr	DISC		
>A>	@ ZYDUS	10MG	A 211224	001	Apr 06, 2021	May	CAHN		
>A>	@ ZYDUS LIFESCIENCES	10MG	A 211224	001	Apr 06, 2021	May	CAHN		
	OPSUMIT								
+!	ACTELION	10MG	N 204410	001	Oct 18, 2013	Apr	CTEC		

MACITENTAN; TADALAFIL

TABLET; ORAL		OPSYNVI							
+!	ACTELION	10MG; 20MG	N 218490	001	Mar 22, 2024	Mar	NEWA		
+!		10MG; 40MG	N 218490	002	Mar 22, 2024	Mar	NEWA		

MAFENIDE ACETATE

FOR SOLUTION; TOPICAL		MAFENIDE ACETATE							
>A>	@ ENDO OPERATIONS	5%	A 201511	001	Feb 12, 2013	May	CAHN		
>D>	@ PAR FORM	5%	A 201511	001	Feb 12, 2013	May	CAHN		

MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE

SOLUTION; ORAL		MAGNESIUM SULFATE; POTASSIUM SULFATE; SODIUM SULFATE							
AA	TARO	1.6GM/BOT; 3.13GM/BOT; 17.5GM/BOT	A 206431	001	Mar 19, 2024	Mar	NEWA		

MANNITOL

POWDER; INHALATION		ARIDOL KIT							
>D>	+! ARNA PHARMA	N/A, 5MG, 10MG, 20MG, 40MG	N 022368	001	Oct 05, 2010	May	CAHN		
>A>	+! PHARMAXIS EUROPE	N/A, 5MG, 10MG, 20MG, 40MG	N 022368	001	Oct 05, 2010	May	CAHN		

MARAVIROC

TABLET; ORAL  
SELZENTRY

+ @	VIIV HLTHCARE	25MG	N022128	003	Nov 04, 2016	Jan	DISC
+ @		75MG	N022128	004	Nov 04, 2016	Jan	DISC

MAVORIXAFOR

CAPSULE; ORAL  
XOLREMDI

+!	X4 PHARMS	100MG	N218709	001	Apr 26, 2024	Apr	NEWA
----	-----------	-------	---------	-----	--------------	-----	------

MECLIZINE HYDROCHLORIDE

TABLET; ORAL  
MECLIZINE HYDROCHLORIDE

AA	AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Mar	CHRS
AA	!	50MG	A201451	003	Feb 23, 2011	Feb	CMFD
	@ INVAGEN PHARMS	12.5MG	A200432	001	Feb 17, 2022	Mar	DISC
	@	25MG	A200432	002	Feb 17, 2022	Mar	DISC
	@	50MG	A200432	003	Feb 17, 2022	Mar	DISC

TABLET, CHEWABLE; ORAL  
MECLIZINE HYDROCHLORIDE

@	INVAGEN PHARMS	25MG	A200791	001	Feb 17, 2022	Mar	DISC
---	----------------	------	---------	-----	--------------	-----	------

MEDROXYPROGESTERONE ACETATE

INJECTABLE; INJECTION  
MEDROXYPROGESTERONE ACETATE

AB	HONG KONG	150MG/ML	A076553	001	Jul 28, 2004	Jan	CAHN
----	-----------	----------	---------	-----	--------------	-----	------

MEGESTROL ACETATE

SUSPENSION; ORAL  
MEGACE ES

>A>	AB	+!	ENDO OPERATIONS	125MG/ML	N021778	001	Jul 05, 2005	May	CAHN
>D>	AB	+!	ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	May	CAHN
			MEGESTROL ACETATE						
		@	CHARTWELL	125MG/ML	A204688	001	Dec 01, 2017	Mar	CAHN
		@	HIKMA	40MG/ML	A203960	001	Jun 09, 2017	Mar	DISC
>D>		@	NOVITIUM PHARMA	40MG/ML	A077404	001	Feb 16, 2006	May	CMFD
>A>	AB			40MG/ML	A077404	001	Feb 16, 2006	May	CMFD

MELOXICAM

TABLET; ORAL  
MELOXICAM

AB	SCIEGEN PHARMS INC	7.5MG	A077920	001	Jul 19, 2006	Apr	CMFD
AB		15MG	A077920	002	Jul 19, 2006	Apr	CMFD
AB	!	ZYDUS PHARMS USA	A077921	002	Jul 19, 2006	Jan	CTEC
		MOBIC					
	+ @	BOEHRINGER INGELHEIM	N020938	001	Apr 13, 2000	Jan	DISC
	+ @		N020938	002	Aug 23, 2000	Jan	DISC

MELPHALAN

TABLET; ORAL  
MELPHALAN

>D>	!	ALVOGEN	2MG	A207809	001	Mar 22, 2017	May	DISC
>A>	@		2MG	A207809	001	Mar 22, 2017	May	DISC

MELPHALAN HYDROCHLORIDE

INJECTABLE; INJECTION  
MELPHALAN HYDROCHLORIDE

>A>	@	ENDO OPERATIONS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	May	CAHN
>A>	AP	HETERO LABS	EQ 50MG BASE/VIAL	A215024	001	May 23, 2024	May	NEWA
>D>	@	PAR STERILE PRODUCTS	EQ 50MG BASE/VIAL	A204773	001	Aug 22, 2016	May	CAHN

MEMANTINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL  
MEMANTINE HYDROCHLORIDE

@	ENDO OPERATIONS	7MG	A205784	001	Jun 09, 2017	Apr	CAHN
@		14MG	A205784	002	Jun 09, 2017	Apr	CAHN
@		21MG	A205784	003	Jun 09, 2017	Apr	CAHN
@		28MG	A205784	004	Jun 09, 2017	Apr	CAHN
AB	XIAMEN LP PHARM CO	21MG	A213985	004	Feb 06, 2024	Jan	NEWA

TABLET;ORAL							
MEMANTINE HYDROCHLORIDE							
AB	RENATA	5MG	A209527	001	May 07, 2018	Jan	CAHN
AB		10MG	A209527	002	May 07, 2018	Jan	CAHN
<u>MEPERIDINE HYDROCHLORIDE</u>							
TABLET;ORAL							
MEPERIDINE HYDROCHLORIDE							
AA	!	EPIC PHARMA LLC	50MG	A040331	001	May 28, 1999	Feb CTEC
	!		50MG	A040331	001	May 28, 1999	Feb CHRS
AA		GENUS	50MG	A040893	001	Jun 24, 2009	Feb CMFD
	@		50MG	A040893	001	Jun 24, 2009	Jan CAHN
	@		75MG	A040893	002	Jun 24, 2009	Jan CAHN
	@		100MG	A040893	003	Jun 24, 2009	Jan CAHN
	@		150MG	A040893	004	Jun 24, 2009	Jan CAHN
<u>MESALAMINE</u>							
TABLET, DELAYED RELEASE;ORAL							
MESALAMINE							
AB	ANNORA PHARMA	1.2GM	A216334	001	Feb 05, 2024	Jan	NEWA
<u>MESNA</u>							
INJECTABLE;INTRAVENOUS							
MESNA							
	@	RISING	100MG/ML	A203364	001	Jul 18, 2014	Feb CAHN
<u>METAPROTERENOL SULFATE</u>							
SYRUP;ORAL							
METAPROTERENOL SULFATE							
	!	GENUS	10MG/5ML	A073632	001	Jul 22, 1992	Jan CAHN
<u>METFORMIN HYDROCHLORIDE</u>							
TABLET, EXTENDED RELEASE;ORAL							
METFORMIN HYDROCHLORIDE							
AB3	MACLEODS PHARMS LTD	1GM	A211163	001	Mar 13, 2024	Mar	NEWA
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE</u>							
TABLET;ORAL							
PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE							
	@	CHARTWELL RX	500MG;EQ 15MG BASE	A091273	001	Apr 16, 2013	Jan CAHN
	@		850MG;EQ 15MG BASE	A091273	002	Apr 16, 2013	Jan CAHN
<u>METHADONE HYDROCHLORIDE</u>							
CONCENTRATE;ORAL							
METHADONE HYDROCHLORIDE							
AA	VISTAPHARM LLC	10MG/ML	A040088	001	Nov 30, 1994	Apr	CAHN
TABLET;ORAL							
METHADONE HYDROCHLORIDE							
	@	VISTAPHARM LLC	5MG	A040241	001	May 29, 1998	Apr CAHN
AA			10MG	A040241	002	May 29, 1998	Apr CAHN
AA			10MG	A204166	001	Mar 16, 2020	Apr CAHN
<u>METHENAMINE HIPPURATE</u>							
TABLET;ORAL							
METHENAMINE HIPPURATE							
AB	JUBILANT CADISTA	1GM	A217675	001	Dec 01, 2023	Apr	CAHN
<u>METHOCARBAMOL</u>							
TABLET;ORAL							
METHOCARBAMOL							
AA	DBL PHARMS	500MG	A203550	001	Feb 08, 2017	Feb	CAHN
AA		750MG	A203550	002	Feb 08, 2017	Feb	CAHN
AA	HANGZHOU BINJIANG	500MG	A200958	001	Oct 21, 2011	Mar	CAHN
AA		750MG	A200958	002	Oct 21, 2011	Mar	CAHN
AB	!		1GM	A200958	003	Dec 06, 2021	Mar CAHN
ROBAXIN							
>D>	+	@ AUXILIUM PHARMS LLC	500MG	N011011	004		May CAHN
>A>	+	@ ENDO OPERATIONS	500MG	N011011	004		May CAHN
ROBAXIN-750							
>D>	+	@ AUXILIUM PHARMS LLC	750MG	N011011	006		May CAHN
>A>	+	@ ENDO OPERATIONS	750MG	N011011	006		May CAHN

METHOTREXATE SODIUM

TABLET; ORAL

METHOTREXATE SODIUM

>A>	AB	ALEMBIC	EQ 2.5MG BASE	A217552	001	Jun 03, 2024	May	NEWA
>A>	AB	ELITE LABS INC	EQ 2.5MG BASE	A216453	001	May 16, 2024	May	NEWA
		@ LOTUS PHARM CO LTD	EQ 2.5MG BASE	A209787	001	Apr 23, 2021	Apr	DISC

METHSCOPOLAMINE BROMIDE

TABLET; ORAL

METHSCOPOLAMINE BROMIDE

>D>	AA	AACE PHARMS	2.5MG	A216786	001	Feb 01, 2024	May	CAHN
	AA		2.5MG	A216786	001	Feb 01, 2024	Jan	NEWA
>D>	AA		5MG	A216786	002	Feb 01, 2024	May	CAHN
	AA		5MG	A216786	002	Feb 01, 2024	Jan	NEWA
>A>	AA	NE RX PHARMA	2.5MG	A216786	001	Feb 01, 2024	May	CAHN
>A>	AA		5MG	A216786	002	Feb 01, 2024	May	CAHN

METHYLDOPA

TABLET; ORAL

METHYLDOPA

		@ CHARTWELL RX	250MG	N018934	001	Jun 29, 1984	Feb	DISC
			250MG	N018934	001	Jun 29, 1984	Jan	CMFD
		@	500MG	N018934	002	Jun 29, 1984	Feb	DISC
		!	500MG	N018934	002	Jun 29, 1984	Jan	CMFD

METHYLENE BLUE

SOLUTION; INTRAVENOUS

METHYLENE BLUE

AP		ZYDUS LIFESCIENCES	10MG/2ML (5MG/ML)	A215636	001	Dec 05, 2023	Apr	CAHN
AP			50MG/10ML (5MG/ML)	A215636	002	Dec 05, 2023	Apr	CAHN

METHYLPHENIDATE HYDROCHLORIDE

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

		@ BRECKENRIDGE	5MG/5ML	A201466	001	Nov 12, 2013	Mar	DISC
		@	10MG/5ML	A201466	002	Nov 12, 2013	Mar	DISC

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB		CEDIPROF INC	5MG	A208737	001	Feb 01, 2019	Mar	CMFD
AB			10MG	A208737	002	Feb 01, 2019	Mar	CMFD
AB			20MG	A208737	003	Feb 01, 2019	Mar	CMFD

METHYLPREDNISOLONE

TABLET; ORAL

METHYLPREDNISOLONE

AB		ENDO OPERATIONS	4MG	A040183	001	Dec 22, 1998	Apr	CAHN
		@ PRAXGEN	4MG	A212262	001	Jun 27, 2019	Feb	DISC

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE ACETATE

AB		ENDO OPERATIONS	40MG/ML	A214297	001	Jan 21, 2022	Apr	CAHN
AB			80MG/ML	A214297	002	Jan 21, 2022	Apr	CAHN
AB		HONG KONG	40MG/ML	A040557	001	Feb 23, 2005	Jan	CAHN
AB			80MG/ML	A040557	002	Feb 23, 2005	Jan	CAHN
		@ TEVA PHARMS USA	40MG/ML	A040620	001	Oct 27, 2006	Jan	DISC
		@	80MG/ML	A040620	002	Oct 27, 2006	Jan	DISC

METOCLOPRAMIDE HYDROCHLORIDE

SOLUTION; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AA	!	GENUS	EQ 5MG BASE/5ML	A072744	001	May 28, 1991	Apr	CAHN
----	---	-------	-----------------	---------	-----	--------------	-----	------

METOLAZONE

TABLET; ORAL

METOLAZONE

AB		LEADING	2.5MG	A218606	001	Apr 17, 2024	Apr	NEWA
AB			5MG	A218606	002	Apr 17, 2024	Apr	NEWA
AB			10MG	A218606	003	Apr 17, 2024	Apr	NEWA

METOPROLOL SUCCINATE

		TABLET, EXTENDED RELEASE;ORAL							
		METOPROLOL SUCCINATE							
	@	GRANULES	EQ 25MG TARTRATE	A216509	001	Aug 07, 2023	Mar	DISC	
	@		EQ 50MG TARTRATE	A216509	002	Aug 07, 2023	Mar	DISC	
	@		EQ 100MG TARTRATE	A216509	003	Aug 07, 2023	Mar	DISC	
	@		EQ 200MG TARTRATE	A216509	004	Aug 07, 2023	Mar	DISC	
>A>	AB	SUNSHINE	EQ 25MG TARTRATE	A214004	004	May 23, 2024	May	NEWA	

METOPROLOL TARTRATE

		INJECTABLE; INJECTION							
		METOPROLOL TARTRATE							
	@	HOSPIRA	1MG/ML	A074133	001	Dec 21, 1993	Apr	DISC	

METRONIDAZOLE

		GEL; TOPICAL							
		METROGEL							
>D>	AB	+!	GALDERMA LABS LP	0.75%	N019737	001	Nov 22, 1988	May	DISC
>A>		+ @		0.75%	N019737	001	Nov 22, 1988	May	DISC
		METRONIDAZOLE							
>D>	AB		COSETTE	0.75%	A078178	001	Jan 19, 2011	May	CHRS
>A>	AB	!		0.75%	A078178	001	Jan 19, 2011	May	CHRS
		GEL; VAGINAL							
		METRONIDAZOLE							
	AB		ENCUBE	1.3%	A216795	001	Mar 18, 2024	Mar	NFTG
	AB	+!	CHEMO RESEARCH SL	1.3%	N205223	001	Mar 24, 2014	Mar	CFTG
		TABLET; ORAL							
		METRONIDAZOLE							
	@	FLAMINGO PHARMS	250MG	A207309	001	May 16, 2016	Mar	DISC	
	@		500MG	A207309	002	May 16, 2016	Mar	DISC	

MEXILETINE HYDROCHLORIDE

		CAPSULE; ORAL							
		MEXILETINE HYDROCHLORIDE							
	AB		ZENARA	150MG	A215315	001	Aug 26, 2022	Apr	CAHN
	AB			200MG	A215315	002	Aug 26, 2022	Apr	CAHN
	AB			250MG	A215315	003	Aug 26, 2022	Apr	CAHN

MICAFUNGIN SODIUM

		INJECTABLE; INTRAVENOUS							
		MICAFUNGIN SODIUM							
>A>	AP		BIOCON PHARMA	EQ 50MG BASE/VIAL	A216438	001	May 29, 2024	May	NEWA
>A>	AP			EQ 100MG BASE/VIAL	A216438	002	May 29, 2024	May	NEWA

MIDAZOLAM

		SOLUTION; INTRAVENOUS							
		MIDAZOLAM IN 0.8% SODIUM CHLORIDE							
>D>		+!	EXELA PHARMA	50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC
>A>		+ @		50MG/50ML (1MG/ML)	N215868	001	Jul 20, 2022	May	DISC

MIDAZOLAM HYDROCHLORIDE

		INJECTABLE; INJECTION							
		MIDAZOLAM HYDROCHLORIDE							
	@	FRESENIUS KABI USA	EQ 5MG BASE/ML	A208878	001	Mar 28, 2017	Jan	DISC	

MIDODRINE HYDROCHLORIDE

		TABLET; ORAL							
		MIDODRINE HYDROCHLORIDE							
	AB		ENDO OPERATIONS	2.5MG	A207169	001	Oct 29, 2018	Apr	CAHN
	AB			5MG	A207169	002	Oct 29, 2018	Apr	CAHN
	AB			10MG	A207169	003	Oct 29, 2018	Apr	CAHN

MIDOSTAURIN

		CAPSULE; ORAL							
		MIDOSTAURIN							
>A>	AB		LUPIN	25MG	A216015	001	May 10, 2024	May	NEWA
	AB		TEVA PHARMS	25MG	A216076	001	Apr 29, 2024	Apr	NFTG
		RYDAPT							
	AB	+!	NOVARTIS	25MG	N207997	001	Apr 28, 2017	Apr	CFTG



MINOCYCLINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
MINOCYCLINE HYDROCHLORIDE

@	SUN PHARM INDS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Jan	DISC
@		EQ 65MG BASE	A091118	003	Dec 03, 2019	Jan	DISC
@		EQ 80MG BASE	A091118	004	Sep 25, 2014	Jan	DISC
@		EQ 90MG BASE	A091118	005	Sep 25, 2014	Jan	DISC
@		EQ 105MG BASE	A091118	006	Sep 25, 2014	Jan	DISC
@		EQ 115MG BASE	A091118	007	Dec 03, 2019	Jan	DISC
@		EQ 135MG BASE	A091118	008	Sep 25, 2014	Jan	DISC
@	ZYDUS PHARMS	EQ 45MG BASE	A203553	001	Nov 16, 2017	Jan	DISC
@		EQ 55MG BASE	A203553	002	Jun 16, 2023	Jan	DISC
@		EQ 65MG BASE	A203553	003	Jun 16, 2023	Jan	DISC
@		EQ 80MG BASE	A203553	004	Nov 16, 2017	Jan	DISC
@		EQ 90MG BASE	A203553	005	Nov 16, 2017	Jan	DISC
@		EQ 105MG BASE	A203553	006	Nov 16, 2017	Jan	DISC
@		EQ 115MG BASE	A203553	007	Jun 16, 2023	Jan	DISC
@		EQ 135MG BASE	A203553	008	Nov 16, 2017	Jan	DISC

MINOXIDIL

TABLET;ORAL  
MINOXIDIL

AB	ENDO OPERATIONS	2.5MG	A071826	001	Nov 14, 1988	Apr	CAHN
AB		10MG	A071839	001	Nov 14, 1988	Apr	CAHN

MIRABEGRON

TABLET, EXTENDED RELEASE;ORAL  
MIRABEGRON

AB	ALKEM LABS LTD	25MG	A215948	001	Feb 12, 2024	Feb	NEWA
AB		50MG	A215948	002	Feb 12, 2024	Feb	NEWA
AB	ZYDUS PHARMS	25MG	A209488	001	Sep 29, 2022	Mar	CMFD
AB		50MG	A209488	002	Sep 29, 2022	Mar	CMFD

MITOMYCIN

INJECTABLE;INJECTION  
MITOMYCIN

AP	FRESENIUS KABI USA	5MG/VIAL	A211269	001	Apr 05, 2024	Mar	NEWA
AP		20MG/VIAL	A211269	002	Apr 05, 2024	Mar	NEWA
AP		40MG/VIAL	A211269	003	Apr 05, 2024	Mar	NEWA

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION  
MITOXANTRONE HYDROCHLORIDE

@	RISING	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A201014	001	Dec 11, 2012	Mar	CAHN
---	--------	------------------------------------	---------	-----	--------------	-----	------

MOBOCERTINIB SUCCINATE

CAPSULE;ORAL  
EXKIVITY

+	@ TAKEDA PHARMS USA	EQ 40MG BASE	N215310	001	Sep 15, 2021	Apr	DISC
---	---------------------	--------------	---------	-----	--------------	-----	------

MOMETASONE FUROATE

LOTION;TOPICAL  
MOMETASONE FUROATE

@	COSETTE	0.1%	A077678	001	Nov 21, 2007	Apr	DISC
---	---------	------	---------	-----	--------------	-----	------

SPRAY, METERED;NASAL  
MOMETASONE FUROATE

AB	AUROBINDO PHARMA	0.05MG/SPRAY	A215878	001	Mar 18, 2024	Mar	NEWA
----	------------------	--------------	---------	-----	--------------	-----	------

MONTELUKAST SODIUM

GRANULE;ORAL  
MONTELUKAST SODIUM

@	TEVA PHARMS	EQ 4MG BASE/PACKET	A090955	001	Aug 03, 2012	Jan	DISC
---	-------------	--------------------	---------	-----	--------------	-----	------

MORPHINE SULFATE

INJECTABLE;INJECTION  
MORPHINE SULFATE

@	HOSPIRA	0.5MG/ML	A071849	001	May 11, 1988	Apr	DISC
---	---------	----------	---------	-----	--------------	-----	------

SOLUTION;ORAL  
MORPHINE SULFATE

@	HIKMA	100MG/5ML	A208809	001	Jul 06, 2017	Mar	DISC
AA	WINDER LABS LLC	10MG/5ML	A211454	001	Feb 12, 2021	Jan	CMFD

SOLUTION;ORAL  
MORPHINE SULFATE

AA		20MG/5ML	A211454	002	Feb 12, 2021	Jan	CMFD
AA		100MG/5ML	A211454	003	Feb 12, 2021	Jan	CMFD

MOXIFLOXACIN HYDROCHLORIDE  
SOLUTION/DROPS;OPHTHALMIC  
VIGAMOX

AT1	+	HARROW EYE	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Jan	CAHN
-----	---	------------	--------------	---------	-----	--------------	-----	------

MYCOPHENOLATE MOFETIL

>A>		SUSPENSION;ORAL						
>A>		MYHIBBIN						
>A>	+	AZURITY	200MG/ML	N216482	001	May 01, 2024	May	NEWA
		TABLET;ORAL						
		MYCOPHENOLATE MOFETIL						
	@	AMNEAL	500MG	A090606	001	Jul 16, 2010	Feb	DISC
AB		AUROBINDO PHARMA	500MG	A217937	001	Feb 20, 2024	Feb	NEWA

MYCOPHENOLATE MOFETIL HYDROCHLORIDE

		INJECTABLE;INJECTION						
		MYCOPHENOLATE MOFETIL HYDROCHLORIDE						
AP		ENDO OPERATIONS	500MG/VIAL	A203575	001	Oct 28, 2016	Apr	CAHN

MYCOPHENOLIC SODIUM

		TABLET, DELAYED RELEASE;ORAL						
		MYCOPHENOLIC SODIUM						
AB		AUROBINDO PHARMA LTD	EQ 180MG BASE	A218603	001	Feb 27, 2024	Feb	NEWA
AB			EQ 360MG BASE	A218603	002	Feb 27, 2024	Feb	NEWA
>A>	AB	NOVUGEN	EQ 180MG BASE	A216637	001	May 29, 2024	May	NEWA
>A>	AB		EQ 360MG BASE	A216637	002	May 29, 2024	May	NEWA
AB		SKG PHARMA	EQ 180MG BASE	A217031	001	Nov 29, 2023	Apr	CAHN
AB			EQ 360MG BASE	A217031	002	Nov 29, 2023	Apr	CAHN

NALBUPHINE HYDROCHLORIDE

		INJECTABLE;INJECTION						
		NUBAIN						
>A>	+	@ ENDO OPERATIONS	10MG/ML	N018024	001		May	CAHN
>A>	+	@	20MG/ML	N018024	002	May 27, 1982	May	CAHN
>D>	+	@ PAR PHARM INC	10MG/ML	N018024	001		May	CAHN
>D>	+	@	20MG/ML	N018024	002	May 27, 1982	May	CAHN

NALMEFENE HYDROCHLORIDE

		SOLUTION;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS							
		NALMEFENE HYDROCHLORIDE							
>D>		CHENGDU SHUODE	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC	
>A>	@		EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A216007	001	Nov 15, 2023	May	DISC	
>D>	AP		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC	
>A>	@		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A216007	002	Nov 15, 2023	May	DISC	
>D>	AP	!	PURDUE PHARMA LP	EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC
>A>	!		EQ 2MG BASE/2ML (EQ 1MG BASE/ML)	A212955	001	Feb 08, 2022	May	CTEC	

NALOXONE HYDROCHLORIDE

		INJECTABLE;INJECTION						
		NALOXONE HYDROCHLORIDE						
AP		FRESENIUS KABI USA	0.4MG/ML	A213573	001	Apr 02, 2024	Mar	NEWA
AP			1MG/ML	A213573	002	Apr 02, 2024	Mar	NEWA
AP		HIKMA	0.4MG/ML	A212300	002	Mar 07, 2024	Mar	NEWA
AP		MANKIND PHARMA	0.4MG/ML	A218404	001	Feb 29, 2024	Feb	NEWA
		SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS						
		ZIMHI						
>D>	+	ADAMIS PHARMS CORP	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN
>A>	+	ZMI PHARMA	5MG/0.5ML (5MG/0.5ML)	N212854	001	Oct 15, 2021	May	CAHN
		SPRAY;NASAL						
		REZENOPY						
	+	SUMMIT BIOSCI	10MG/SPRAY	N215487	001	Apr 19, 2024	Apr	NEWA
		SPRAY, METERED;NASAL						
		REXTOVY						
	+	AMPHASTAR PHARMS INC	4MG/SPRAY	N208969	001	Mar 07, 2023	Apr	CMFD

NALTREXONE

FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
NALTREXONE

	@ TEVA PHARMS USA INC	380MG/VIAL	A213195	001	Jul 06, 2023	Jan	DISC
	VIVITROL						
	+! ALKERMES	380MG/VIAL	N021897	001	Apr 13, 2006	Jan	CTEC

NAPROXEN

TABLET;ORAL  
NAPROXEN

	@ INVAGEN PHARMS	250MG	A091305	001	Aug 24, 2011	Mar	DISC
	@	375MG	A091305	002	Aug 24, 2011	Mar	DISC
	@	500MG	A091305	003	Aug 24, 2011	Mar	DISC

TABLET, DELAYED RELEASE;ORAL  
NAPROXEN

>A>	AB	NOVITIUM PHARMA	375MG	A218497	001	Jun 12, 2024	May	NEWA
>A>	AB		500MG	A218497	002	Jun 12, 2024	May	NEWA

NARATRIPTAN HYDROCHLORIDE

TABLET;ORAL  
NARATRIPTAN

>D>	AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC
>A>		@	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	May	DISC

NEBIVOLOL HYDROCHLORIDE

TABLET;ORAL  
NEBIVOLOL HYDROCHLORIDE

>D>	AB	APOTEX	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC
>A>		@	EQ 10MG BASE	A209741	001	Feb 27, 2024	May	DISC
	AB		EQ 10MG BASE	A209741	001	Feb 27, 2024	Feb	NEWA
>D>	AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC
>A>		@	EQ 20MG BASE	A209741	002	Feb 27, 2024	May	DISC
	AB		EQ 20MG BASE	A209741	002	Feb 27, 2024	Feb	NEWA

NEOSTIGMINE METHYLSULFATE

SOLUTION;INTRAVENOUS  
BLOXIVERZ

>D>		+! EXELA PHARMA	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC
>A>		+ @	5MG/5ML (1MG/ML)	N204078	003	Oct 27, 2023	May	DISC

NEOSTIGMINE METHYLSULFATE

	AP	ENDO OPERATIONS	5MG/10ML (0.5MG/ML)	A208405	001	Apr 26, 2017	Apr	CAHN
	AP		10MG/10ML (1MG/ML)	A208405	002	Apr 26, 2017	Apr	CAHN
>D>	AP	EUGIA PHARMA	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
>A>		@	5MG/10ML (0.5MG/ML)	A213244	001	Nov 02, 2023	May	DISC
>D>	AP		10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
>A>		@	10MG/10ML (1MG/ML)	A213244	002	Nov 02, 2023	May	DISC
	AP	NIVAGEN PHARMS INC	5MG/10ML (0.5MG/ML)	A212627	001	Nov 03, 2022	Jan	CAHN
	AP		10MG/10ML (1MG/ML)	A212627	002	Nov 03, 2022	Jan	CAHN

NESIRITIDE

FOR SOLUTION;INTRAVENOUS  
NATRECOR

		+ @ SCIOS LLC	1.5MG/VIAL	N020920	001	Aug 10, 2001	Mar	CAIN
--	--	---------------	------------	---------	-----	--------------	-----	------

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
NICARDIPINE HYDROCHLORIDE

	AB	SKG PHARMA	20MG	A218202	001	Apr 10, 2024	Mar	NEWA
	AB		30MG	A218202	002	Apr 10, 2024	Mar	NEWA

INJECTABLE;INJECTION  
NICARDIPINE HYDROCHLORIDE

	AP	RK PHARMA	25MG/10ML (2.5MG/ML)	A090664	001	Nov 17, 2009	Feb	CMFD
--	----	-----------	----------------------	---------	-----	--------------	-----	------

INJECTABLE;INTRAVENOUS

	AP	+! CHIESI	CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr	CFTG
	AP	+! CHIESI	CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr	CFTG
	AP		NICARDIPINE HYDROCHLORIDE IN 0.83% SODIUM CHLORIDE	40MG/200ML (0.2MG/ML)	A203978	002	Apr 17, 2024	Apr	NFTG

## INJECTABLE; INTRAVENOUS

	NICARDIPINE HYDROCHLORIDE IN 0.86% SODIUM CHLORIDE						
AP	INFORLIFE	20MG/200ML (0.1MG/ML)	A203978	001	Apr 17, 2024	Apr	NFTG

NIFEDIPINE

## TABLET, EXTENDED RELEASE; ORAL

## NIFEDIPINE

>A>	@ ENDO OPERATIONS	30MG	A077899	001	Dec 13, 2006	May	CAHN
>A>	@	60MG	A077899	002	Dec 13, 2006	May	CAHN
>A>	@	90MG	A077899	003	May 25, 2012	May	CAHN
>D>	@ PAR PHARM	30MG	A077899	001	Dec 13, 2006	May	CAHN
>D>	@	60MG	A077899	002	Dec 13, 2006	May	CAHN
>D>	@	90MG	A077899	003	May 25, 2012	May	CAHN

NILOTINIB HYDROCHLORIDE

## CAPSULE; ORAL

## NILOTINIB HYDROCHLORIDE

	@ APOTEX	EQ 50MG BASE	A203640	001	Jan 05, 2024	Apr	DISC
	@	EQ 150MG BASE	A203640	002	Jan 05, 2024	Apr	DISC
	@	EQ 200MG BASE	A203640	003	Jan 05, 2024	Apr	DISC
	TASIGNA						
+	NOVARTIS	EQ 50MG BASE	N022068	003	Mar 22, 2018	Apr	CTEC
+		EQ 150MG BASE	N022068	002	Jun 17, 2010	Apr	CTEC
+	!	EQ 200MG BASE	N022068	001	Oct 29, 2007	Apr	CTEC

NIRAPARIB TOSYLATE

## CAPSULE; ORAL

## ZEJULA

+	@ GLAXOSMITHKLINE	EQ 100MG BASE	N208447	001	Mar 27, 2017	Feb	DISC
---	-------------------	---------------	---------	-----	--------------	-----	------

NIROGACESTAT HYDROBROMIDE

## TABLET; ORAL

## OGSIVEO

+	SPRINGWORKS	EQ 50MG BASE	N217677	001	Nov 27, 2023	Apr	CHRS
+		EQ 100MG BASE	N217677	002	Apr 04, 2024	Apr	NEWA
+	!	EQ 150MG BASE	N217677	003	Apr 04, 2024	Apr	NEWA

NITISINONE

## CAPSULE; ORAL

## NITISINONE

	@ TORRENT	2MG	A215908	001	Jan 09, 2023	Apr	DISC
	@	5MG	A215908	002	Jan 09, 2023	Apr	DISC
	@	10MG	A215908	003	Jan 09, 2023	Apr	DISC
	@	20MG	A215908	004	Jan 09, 2023	Apr	DISC

NITRIC OXIDE

## GAS; INHALATION

## INOMAX

>A>	+	MALLINCKRODT HOSP	4880PPM	N020845	004	Jan 17, 2023	May	NEWA
		NOXIVENT						
>D>		LINDE GAS EQUIP	100PPM	A207141	001	Oct 02, 2018	May	CHRS
>A>	!		100PPM	A207141	001	Oct 02, 2018	May	CHRS

NITROFURANTOIN, MACROCRYSTALLINE

## CAPSULE; ORAL

## NITROFURANTOIN

	@ ACTAVIS LABS FL INC	25MG	A091095	001	Jun 18, 2015	Feb	DISC
	@	50MG	A091095	002	Jun 18, 2015	Feb	DISC
	@	100MG	A091095	003	Jun 18, 2015	Feb	DISC

NITROGLYCERIN

## OINTMENT; INTRA-ANAL

## NITROGLYCERIN

AB	COSETTE	0.4%	A216103	001	Feb 16, 2024	Feb	NFTG	
	RECTIV							
AB	+	ABBVIE	0.4%	N021359	001	Jun 21, 2011	Feb	CFTG

NOREPINEPHRINE BITARTRATE

INJECTABLE; INJECTION

NOREPINEPHRINE BITARTRATE

>A>	AP	DDREG PHARMA	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	NEWA
>A>	AP	RISING	EQ 1MG BASE/ML	A218758	001	May 13, 2024	May	CAHN
SOLUTION; INTRAVENOUS								
NOREPINEPHRINE BITARTRATE IN 0.9% SODIUM CHLORIDE								
+!		LONG GROVE PHARMS	EQ 4MG BASE/250 ML (EQ 16MCG BASE/ML)	N214628	001	Oct 06, 2022	Jan	CMFD
+!			EQ 8MG BASE/250ML (EQ 32MCG BASE/ML)	N214628	002	Oct 06, 2022	Jan	CMFD
+!			EQ 16MG BASE/250ML (EQ 64MCG BASE/ML)	N214628	003	Oct 06, 2022	Jan	CMFD

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL

NORTRIPTYLINE HYDROCHLORIDE

@	RISING	EQ 10MG BASE	A074234	001	Jul 26, 1993	Feb	CAHN
@		EQ 25MG BASE	A074234	002	Jul 26, 1993	Feb	CAHN
@		EQ 50MG BASE	A074234	003	Jul 26, 1993	Feb	CAHN
@		EQ 75MG BASE	A074234	004	Jul 26, 1993	Feb	CAHN

NYSTATIN

POWDER; TOPICAL

NYSTATIN

AT		ADRASTEIA PHARMA	100,000 UNITS/GM	A065175	001	Dec 17, 2004	Mar	CAHN
----	--	------------------	------------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM; 0.1%	A062367	001	May 28, 1985	Apr	DISC
---	---------	------------------------	---------	-----	--------------	-----	------

OINTMENT; TOPICAL

MYKACET

@	COSETTE	100,000 UNITS/GM; 0.1%	A062733	001	Mar 06, 1987	Apr	DISC
---	---------	------------------------	---------	-----	--------------	-----	------

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

OCTREOTIDE ACETATE

AP		SHUANGCHENG	EQ 0.1MG BASE/ML	A217860	001	May 02, 2024	Apr	NEWA
AB		TEVA PHARMS USA INC	EQ 10MG BASE/VIAL	A210317	001	Dec 05, 2023	Jan	CTEC
AB			EQ 20MG BASE/VIAL	A210317	002	Dec 05, 2023	Jan	CTEC
AB			EQ 30MG BASE/VIAL	A210317	003	Dec 05, 2023	Jan	CTEC
SANDOSTATIN LAR								
AB	+	NOVARTIS	EQ 10MG BASE/VIAL	N021008	001	Nov 25, 1998	Jan	CTEC
AB	+		EQ 20MG BASE/VIAL	N021008	002	Nov 25, 1998	Jan	CTEC
AB	+		EQ 30MG BASE/VIAL	N021008	003	Nov 25, 1998	Jan	CTEC

ODEVIXIBAT

CAPSULE; ORAL

BYLVAY

+	IPSEN	0.4MG	N215498	002	Jul 20, 2021	Jan	CAHN
+!		1.2MG	N215498	004	Jul 20, 2021	Jan	CAHN

CAPSULE, PELLETS; ORAL

BYLVAY

+	IPSEN	0.2MG	N215498	001	Jul 20, 2021	Jan	CAHN
+!		0.6MG	N215498	003	Jul 20, 2021	Jan	CAHN

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OFLOXACIN

AT		AMNEAL	0.3%	A211524	001	Mar 01, 2024	Feb	NEWA
AT		CAPLIN	0.3%	A217904	001	Apr 12, 2024	Apr	NEWA

SOLUTION/DROPS; OTIC

OFLOXACIN

@	HIKMA	0.3%	A076616	001	Mar 17, 2008	Mar	DISC
---	-------	------	---------	-----	--------------	-----	------

OLANZAPINE

## TABLET; ORAL

## OLANZAPINE

	@ INDOCO	2.5MG	A206155	001	Jul 31, 2020	Mar	DISC	
	@	5MG	A206155	002	Jul 31, 2020	Mar	DISC	
	@	7.5MG	A206155	003	Jul 31, 2020	Mar	DISC	
	@	10MG	A206155	004	Jul 31, 2020	Mar	DISC	
	@	15MG	A206155	005	Jul 31, 2020	Mar	DISC	
	@	20MG	A206155	006	Jul 31, 2020	Mar	DISC	
>D>	AB	SUN PHARM INDS	2.5MG	A091038	001	Apr 23, 2012	May	DISC
>A>	@		2.5MG	A091038	001	Apr 23, 2012	May	DISC
>D>	AB		5MG	A091038	002	Apr 23, 2012	May	DISC
>A>	@		5MG	A091038	002	Apr 23, 2012	May	DISC
>D>	AB		7.5MG	A091038	003	Apr 23, 2012	May	DISC
>A>	@		7.5MG	A091038	003	Apr 23, 2012	May	DISC
>D>	AB		10MG	A091038	004	Apr 23, 2012	May	DISC
>A>	@		10MG	A091038	004	Apr 23, 2012	May	DISC
>D>	AB		15MG	A091038	005	Apr 23, 2012	May	DISC
>A>	@		15MG	A091038	005	Apr 23, 2012	May	DISC
>D>	AB		20MG	A091038	006	Apr 23, 2012	May	DISC
>A>	@		20MG	A091038	006	Apr 23, 2012	May	DISC

## TABLET, ORALLY DISINTEGRATING; ORAL

## OLANZAPINE

>D>	AB	SUN PHARM INDS	5MG	A090881	001	Feb 28, 2012	May	DISC
>A>	@		5MG	A090881	001	Feb 28, 2012	May	DISC
>D>	AB		10MG	A090881	002	Feb 28, 2012	May	DISC
>A>	@		10MG	A090881	002	Feb 28, 2012	May	DISC
>D>	AB		15MG	A090881	003	Feb 28, 2012	May	DISC
>A>	@		15MG	A090881	003	Feb 28, 2012	May	DISC
>D>	AB		20MG	A090881	004	Feb 28, 2012	May	DISC
>A>	@		20MG	A090881	004	Feb 28, 2012	May	DISC

OLMESARTAN MEDOXOMIL

## TABLET; ORAL

## OLMESARTAN MEDOXOMIL

AB		BRECKENRIDGE	5MG	A206227	001	Jan 25, 2024	Jan	NEWA
AB			20MG	A206227	002	Jan 25, 2024	Jan	NEWA
AB			40MG	A206227	003	Jan 25, 2024	Jan	NEWA
AB		CHARTWELL RX	5MG	A206227	001	Jan 25, 2024	Mar	CAHN
AB			20MG	A206227	002	Jan 25, 2024	Mar	CAHN
AB			40MG	A206227	003	Jan 25, 2024	Mar	CAHN
>D>	@	INVENTIA	5MG	A208659	001	May 18, 2020	May	CMFD
>A>	AB		5MG	A208659	001	May 18, 2020	May	CMFD
>D>	@		20MG	A208659	002	May 18, 2020	May	CMFD
>A>	AB		20MG	A208659	002	May 18, 2020	May	CMFD
>D>	@		40MG	A208659	003	May 18, 2020	May	CMFD
>A>	AB		40MG	A208659	003	May 18, 2020	May	CMFD

OLOPATADINE HYDROCHLORIDE

## SPRAY, METERED; NASAL

## OLOPATADINE HYDROCHLORIDE

	@ HIKMA	0.665MG/SPRAY	A213757	001	Aug 19, 2020	Mar	DISC
--	---------	---------------	---------	-----	--------------	-----	------

OMEGA-3-ACID ETHYL ESTERS

## CAPSULE; ORAL

## OMEGA-3-ACID ETHYL ESTERS

AB		CHARTWELL	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A206455	001	Aug 07, 2019	Mar	CAHN
----	--	-----------	--	---------	-----	--------------	-----	------

OMEPRAZOLE; SODIUM BICARBONATE

## CAPSULE; ORAL

## OMEPRAZOLE AND SODIUM BICARBONATE

AB	!	AJANTA PHARMA LTD	40MG;1.1GM	A204228	002	Jul 15, 2016	Mar	CHRS
		ZEGERID						
	+	@ SALIX	20MG;1.1GM	N021849	001	Feb 27, 2006	Mar	DISC
	+	@	40MG;1.1GM	N021849	002	Feb 27, 2006	Mar	DISC
		FOR SUSPENSION; ORAL						
		OMEPRAZOLE AND SODIUM BICARBONATE						
AB	!	AJANTA PHARMA LTD	40MG/PACKET;1.68GM/PACKET	A205545	002	Jul 27, 2016	Mar	CHRS

FOR SUSPENSION;ORAL  
ZEGERID

+ @ SALIX	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Mar	DISC
+ @	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Mar	DISC

ONDANSETRON

TABLET, ORALLY DISINTEGRATING;ORAL  
ONDANSETRON

@ SUN PHARM INDS LTD	4MG	A078602	001	Feb 24, 2011	Jan	DISC
@	8MG	A078602	002	Feb 24, 2011	Jan	DISC

ONDANSETRON HYDROCHLORIDE

INJECTABLE; INJECTION

ONDANSETRON HYDROCHLORIDE

@ AM REGENT	EQ 2MG BASE/ML	A077582	001	Dec 26, 2006	Apr	CAHN
-------------	----------------	---------	-----	--------------	-----	------

ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE

>D> AP	ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	May	DISC
>A>	@	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	May	DISC
	@ AM REGENT	EQ 2MG BASE/ML	A077387	001	Dec 26, 2006	Apr	CAHN

SOLUTION;ORAL

ONDANSETRON HYDROCHLORIDE

>D> AA	@ PHARM ASSOC	EQ 4MG BASE/5ML	A078127	001	Jun 25, 2007	Feb	DISC
	TARO	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007	May	DISC
>A>	@	EQ 4MG BASE/5ML	A077009	001	Nov 30, 2007	May	DISC

OPICAPONE

CAPSULE;ORAL

ONGENTYS

+ AMNEAL	25MG	N212489	001	Apr 24, 2020	Apr	CAHN
+!	50MG	N212489	002	Apr 24, 2020	Apr	CAHN

OSELTAMIVIR PHOSPHATE

CAPSULE;ORAL

OSELTAMIVIR PHOSPHATE

AB	LAURUS	EQ 30MG BASE	A218565	001	May 01, 2024	Apr	NEWA
AB		EQ 45MG BASE	A218565	002	May 01, 2024	Apr	NEWA
AB		EQ 75MG BASE	A218565	003	May 01, 2024	Apr	NEWA

FOR SUSPENSION;ORAL

OSELTAMIVIR PHOSPHATE

>A> AB	AUROBINDO PHARMA LTD	EQ 6MG BASE/ML	A218131	001	May 10, 2024	May	NEWA
--------	----------------------	----------------	---------	-----	--------------	-----	------

OSPEMIFENE

TABLET;ORAL

OSPEMIFENE

AB	HETERO LABS LTD V	60MG	A215574	001	Feb 13, 2024	Feb	NFTG
----	-------------------	------	---------	-----	--------------	-----	------

AB	+! DUCHESNAY	60MG	N203505	001	Feb 26, 2013	Feb	CFTG
----	--------------	------	---------	-----	--------------	-----	------

OXALIPLATIN

INJECTABLE; INTRAVENOUS

OXALIPLATIN

AP	KINDOS	50MG/10ML (5MG/ML)	A217348	001	Jan 11, 2024	Jan	NEWA
AP		100MG/20ML (5MG/ML)	A217348	002	Jan 11, 2024	Jan	NEWA

OXAPROZIN

TABLET;ORAL

OXAPROZIN

@ TEVA	600MG	A075849	001	Jul 03, 2002	Jan	DISC
--------	-------	---------	-----	--------------	-----	------

OXCARBAZEPINE

SUSPENSION;ORAL

OXCARBAZEPINE

AB	ALKEM LABS LTD	300MG/5ML	A213183	001	Mar 18, 2023	Mar	NEWA
AB	BIOCON PHARMA	300MG/5ML	A218278	001	Mar 01, 2024	Apr	CAHN
AB	CARNEGIE	300MG/5ML	A218278	001	Mar 01, 2024	Feb	NEWA
AB	MEDLEY PHARMS	300MG/5ML	A217782	001	Feb 14, 2024	Feb	NEWA
AB	RISING	300MG/5ML	A218278	001	Mar 01, 2024	Mar	CAHN

TABLET;ORAL

OXCARBAZEPINE

AB	RUBICON	150MG	A207717	001	Mar 05, 2024	Feb	NEWA
AB		300MG	A207717	002	Mar 05, 2024	Feb	NEWA

TABLET;ORAL

OXCARBAZEPINE

AB		600MG	A207717	003	Mar 05, 2024	Feb NEWA
	@ ZYDUS	150MG	A211747	001	Jul 03, 2023	Jan DISC
	@	300MG	A211747	002	Jul 03, 2023	Jan DISC
	@	600MG	A211747	003	Jul 03, 2023	Jan DISC

TABLET, EXTENDED RELEASE;ORAL

OXCARBAZEPINE

AB	AJANTA PHARMA LTD	150MG	A217659	001	Feb 22, 2024	Feb NEWA
AB		300MG	A217659	002	Feb 22, 2024	Feb NEWA
AB		600MG	A217659	003	Feb 22, 2024	Feb NEWA
	OXTELLAR XR					
AB	+ SUPERNUS PHARMS	150MG	N202810	001	Oct 19, 2012	Feb CTEC
AB	+	300MG	N202810	002	Oct 19, 2012	Feb CTEC
AB	+!	600MG	N202810	003	Oct 19, 2012	Feb CTEC

OXYBUTYNIN CHLORIDE

SYRUP;ORAL

OXYBUTYNIN CHLORIDE

	@ PHARM ASSOC	5MG/5ML	A075137	001	Dec 18, 1998	Feb DISC
--	---------------	---------	---------	-----	--------------	----------

TABLET;ORAL

OXYBUTYNIN CHLORIDE

	@ EYWA	5MG	A211062	001	Feb 06, 2019	Mar DISC
--	--------	-----	---------	-----	--------------	----------

OXYCODONE HYDROCHLORIDE

SOLUTION;ORAL

OXYCODONE HYDROCHLORIDE

	@ HIKMA	5MG/5ML	A208817	001	Aug 10, 2017	Mar DISC
	@	100MG/5ML	A208795	001	Aug 07, 2017	Mar DISC
	+ @ VISTAPHARM LLC	5MG/5ML	N201194	001	Jan 12, 2012	Apr CAHN
	@ XTTRIUM LABS INC	5MG/5ML	A206456	001	Jun 16, 2015	Mar CAHN

OXYMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

OPANA ER

>A>	+ @ ENDO OPERATIONS	5MG	N021610	001	Jun 22, 2006	May CAHN
>A>	+ @	7.5MG	N021610	005	Feb 29, 2008	May CAHN
>A>	+ @	10MG	N021610	002	Jun 22, 2006	May CAHN
>A>	+ @	15MG	N021610	006	Feb 29, 2008	May CAHN
>A>	+ @	20MG	N021610	003	Jun 22, 2006	May CAHN
>A>	+ @	30MG	N021610	007	Feb 29, 2008	May CAHN
>A>	+ @	40MG	N021610	004	Jun 22, 2006	May CAHN
>D>	+ @ ENDO PHARMS	5MG	N021610	001	Jun 22, 2006	May CAHN
>D>	+ @	7.5MG	N021610	005	Feb 29, 2008	May CAHN
>D>	+ @	10MG	N021610	002	Jun 22, 2006	May CAHN
>D>	+ @	15MG	N021610	006	Feb 29, 2008	May CAHN
>D>	+ @	20MG	N021610	003	Jun 22, 2006	May CAHN
>D>	+ @	30MG	N021610	007	Feb 29, 2008	May CAHN
>D>	+ @	40MG	N021610	004	Jun 22, 2006	May CAHN

OZANIMOD HYDROCHLORIDE

CAPSULE;ORAL

ZEPOSIA

	+ BRISTOL	EQ 0.23MG BASE	N209899	001	Mar 25, 2020	Jan CAHN
	+	EQ 0.46MG BASE	N209899	002	Mar 25, 2020	Jan CAHN
	+!	EQ 0.92MG BASE	N209899	003	Mar 25, 2020	Jan CAHN

PACLITAXEL

POWDER; INTRAVENOUS

ABRAXANE

AB	+! BRISTOL-MYERS	100MG/VIAL	N021660	001	Jan 07, 2005	Jan CTEC
	PACLITAXEL					
AB	+! AM REGENT	100MG/VIAL	N211875	001	Jul 27, 2022	Apr CTEC
AB	+! TEVA PHARMS INC	100MG/VIAL	N216338	001	May 11, 2023	Jan CMFD

PALBOCICLIB

TABLET;ORAL

IBRANCE

>D>	+ PFIZER	75MG	N212436	001	Nov 01, 2019	May CFTG
>A>	AB +	75MG	N212436	001	Nov 01, 2019	May CFTG
	+	75MG	N212436	001	Nov 01, 2019	Jan CTEC
>D>	+	100MG	N212436	002	Nov 01, 2019	May CFTG



TABLET;ORAL  
IBRANCE

>A>	AB	+	100MG	N212436	002	Nov 01, 2019	May	CFTG
		+	100MG	N212436	002	Nov 01, 2019	Jan	CTEC
>D>		+	125MG	N212436	003	Nov 01, 2019	May	CFTG
>A>	AB	+	125MG	N212436	003	Nov 01, 2019	May	CFTG
		+	125MG	N212436	003	Nov 01, 2019	Jan	CTEC

PALBOCICLIB

>D>	AB		75MG	A215570	001	Aug 28, 2023	May	NFTG
>A>	AB		75MG	A215570	001	Jun 05, 2024	May	NFTG
>D>	AB		100MG	A215570	002	Aug 28, 2023	May	NFTG
>A>	AB		100MG	A215570	002	Jun 05, 2024	May	NFTG
>D>	AB		125MG	A215570	003	Aug 28, 2023	May	NFTG
>A>	AB		125MG	A215570	003	Jun 05, 2024	May	NFTG

PALIPERIDONE

TABLET, EXTENDED RELEASE;ORAL  
INVEGA

+	@	JANSSEN PHARMS	1.5MG	N021999	006	Aug 26, 2008	Mar	DISC
---	---	----------------	-------	---------	-----	--------------	-----	------

PALIPERIDONE PALMITATE

SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR  
INVEGA SUSTENNA

>D>	+	JANSSEN PHARMS	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
>A>	AB	+	39MG/0.25ML (39MG/0.25ML)	N022264	001	Jul 31, 2009	May	CTEC
>D>	+		78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
>A>	AB	+	78MG/0.5ML (78MG/0.5ML)	N022264	002	Jul 31, 2009	May	CTEC
>D>	+		117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
>A>	AB	+	117MG/0.75ML (117MG/0.75ML)	N022264	003	Jul 31, 2009	May	CTEC
>D>	+		156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
>A>	AB	+	156MG/ML (156MG/ML)	N022264	004	Jul 31, 2009	May	CTEC
>D>	+		234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC
>A>	AB	+	234MG/1.5ML (156MG/ML)	N022264	005	Jul 31, 2009	May	CTEC

PALIPERIDONE PALMITATE

>D>	@	TEVA PHARMS USA	39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
>A>	AB		39MG/0.25ML (39MG/0.25ML)	A211149	001	Jul 06, 2021	May	CMFD
>D>	@		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
>A>	AB		78MG/0.5ML (78MG/0.5ML)	A211149	002	Jul 06, 2021	May	CMFD
>D>	@		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
>A>	AB		117MG/0.75ML (117MG/0.75ML)	A211149	003	Jul 06, 2021	May	CMFD
>D>	@		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
>A>	AB		156MG/ML (156MG/ML)	A211149	004	Jul 06, 2021	May	CMFD
>D>	@		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD
>A>	AB		234MG/1.5ML (156MG/ML)	A211149	005	Jul 06, 2021	May	CMFD

PALONOSETRON HYDROCHLORIDE

SOLUTION;INTRAVENOUS  
PALONOSETRON HYDROCHLORIDE

@	AVYXA HOLDINGS	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	N203050	001	Mar 01, 2016	Apr	CAHN
@		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	N203050	002	Mar 01, 2016	Apr	CAHN

PANCURONIUM BROMIDE

INJECTABLE;INJECTION  
PANCURONIUM BROMIDE

>D>	AP	!	DR REDDYS	1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
>A>		!		1MG/ML	A072759	001	Jul 31, 1990	May	CTEC
>D>	AP		HOSPIRA	1MG/ML	A072320	001	Jan 19, 1989	May	DISC
>A>		@		1MG/ML	A072320	001	Jan 19, 1989	May	DISC

PANTOPRAZOLE SODIUM

INJECTABLE;INTRAVENOUS  
PANTOPRAZOLE SODIUM

AP			HANGZHOU ZHONGMEI	EQ 40MG BASE/VIAL	A209524	001	Aug 30, 2021	Mar	CAHN
			@ SUN PHARM	EQ 40MG BASE/VIAL	A077674	001	Aug 19, 2019	Feb	DISC

SOLUTION;INTRAVENOUS  
PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE

+	!	BAXTER HLTHCARE CORP	EQ 40MG BASE/100ML (EQ 0.4MG BASE/ML)	N217512	001	Feb 14, 2024	Feb	NEWA
+	!		EQ 40MG BASE/50ML (EQ 0.8MG BASE/ML)	N217512	002	Feb 14, 2024	Feb	NEWA
+	!		EQ 80MG BASE/100ML (EQ 0.8MG	N217512	003	Feb 14, 2024	Feb	NEWA

SOLUTION;INTRAVENOUS  
 PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE  
 BASE/ML)

TABLET, DELAYED RELEASE;ORAL  
 PANTOPRAZOLE SODIUM

AB MANKIND PHARMA EQ 20MG BASE A215880 002 Apr 25, 2024 Apr NEWA

PARICALCITOL

SOLUTION;INTRAVENOUS  
 PARICALCITOL

>D> AP HOSPIRA 0.002MG/ML (0.002MG/ML) N201657 001 Oct 21, 2014 May DISC  
 >A> @ 0.002MG/ML (0.002MG/ML) N201657 001 Oct 21, 2014 May DISC  
 >D> AP 0.005MG/ML (0.005MG/ML) N201657 002 Oct 21, 2014 May DISC  
 >A> @ 0.005MG/ML (0.005MG/ML) N201657 002 Oct 21, 2014 May DISC  
 >D> AP 0.01MG/2ML (0.005MG/ML) N201657 003 Oct 21, 2014 May DISC  
 >A> @ 0.01MG/2ML (0.005MG/ML) N201657 003 Oct 21, 2014 May DISC

PATIROMER SORBITE X CALCIUM

POWDER;ORAL  
 VELTASSA

+ @ VIFOR PHARMA EQ 1GM BASE/PACKET N205739 004 Oct 02, 2023 Feb DISC

PAZOPANIB HYDROCHLORIDE

TABLET;ORAL  
 PAZOPANIB HYDROCHLORIDE

AB NOVUGEN EQ 200MG BASE A218231 001 Apr 23, 2024 Apr NEWA

PEGULICIANINE ACETATE

POWDER;INTRAVENOUS  
 LUMISIGHT

+! LUMICELL EQ 40MG BASE/VIAL N214511 001 Apr 17, 2024 Apr NEWA

PENBUTOLOL SULFATE

TABLET;ORAL  
 LEVATOL

>D> + @ AUXILIUM PHARMS LLC 10MG N018976 001 Dec 30, 1987 May CAHN  
 >D> + @ 20MG N018976 004 Jan 05, 1989 May CAHN  
 >A> + @ ENDO OPERATIONS 10MG N018976 001 Dec 30, 1987 May CAHN  
 >A> + @ 20MG N018976 004 Jan 05, 1989 May CAHN

PENICILLAMINE

CAPSULE;ORAL  
 PENICILLAMINE

AB ENDO OPERATIONS 250MG A211231 001 Dec 23, 2019 Apr CAHN

TABLET;ORAL  
 PENICILLAMINE

AB ENDO OPERATIONS 250MG A211196 001 Dec 23, 2019 Apr CAHN

PENICILLIN V POTASSIUM

TABLET;ORAL  
 PENICILLIN V POTASSIUM

AB ! AUROBINDO PHARMA EQ 500MG BASE A065435 002 Apr 29, 2008 Jan CHRS  
 @ SANDOZ EQ 250MG BASE A064071 001 Nov 30, 1995 Jan DISC  
 @ EQ 500MG BASE A064071 002 Nov 30, 1995 Jan DISC

PENTOBARBITAL

ELIXIR;ORAL  
 NEMBUTAL

@ SAPTALIS PHARMS 18.2MG/5ML A083244 001 Apr CAHN

PENTOBARBITAL SODIUM

SUPPOSITORY;RECTAL  
 NEMBUTAL

@ SAPTALIS PHARMS 30MG A083247 001 Jan 25, 1982 Mar CAHN  
 @ 60MG A083247 002 Jan 25, 1982 Mar CAHN  
 @ 120MG A083247 003 Jan 25, 1982 Mar CAHN  
 @ 200MG A083247 004 Jan 25, 1982 Mar CAHN

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL  
PENTOXIFYLLINE

AB ANI PHARMS 400MG A074878 001 Jul 09, 1997 Jan CMFD

PERMETHRIN

CREAM; TOPICAL  
PERMETHRIN

@ DR REDDYS LABS EU 5% A209732 001 Aug 01, 2023 Jan DISC

PERPHENAZINE

TABLET; ORAL  
PERPHENAZINE

AB ENDO OPERATIONS 2MG A040226 001 Dec 31, 1998 Apr CAHN  
 AB 4MG A040226 002 Dec 31, 1998 Apr CAHN  
 AB 8MG A040226 003 Dec 31, 1998 Apr CAHN  
 AB 16MG A040226 004 Dec 31, 1998 Apr CAHN  
 AB MACLEODS PHARMS LTD 2MG A212545 001 May 06, 2024 Apr NEWA  
 AB 4MG A212545 002 May 06, 2024 Apr NEWA  
 AB 8MG A212545 003 May 06, 2024 Apr NEWA  
 AB 16MG A212545 004 May 06, 2024 Apr NEWA

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL  
PHENOXYBENZAMINE HYDROCHLORIDE

>A> AB ! ENDO OPERATIONS 10MG A204522 001 Jan 24, 2017 May CAHN  
 >D> AB ! PAR PHARM INC 10MG A204522 001 Jan 24, 2017 May CAHN

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL  
ADIPEX-P

+ @ TEVA 37.5MG A088023 001 Aug 02, 1983 Feb DISC  
 PHENTERMINE HYDROCHLORIDE  
 @ INVAGEN PHARMS 15MG A202858 001 Feb 14, 2014 Mar DISC  
 @ 30MG A202858 002 Feb 14, 2014 Mar DISC  
 @ 30MG A204414 001 May 05, 2014 Mar DISC  
 @ 37.5MG A202846 001 Feb 05, 2014 Mar DISC  
 AA ! NUVO PHARM 37.5MG A205017 001 Sep 25, 2014 Feb CHRS  
 TABLET; ORAL  
 PHENTERMINE HYDROCHLORIDE  
 @ INVAGEN PHARMS 37.5MG A202942 001 Feb 05, 2014 Mar DISC

PHENTERMINE HYDROCHLORIDE; TOPIRAMATE

CAPSULE, EXTENDED RELEASE; ORAL  
QSYMIA

>D> + VIVUS EQ 3.75MG BASE; 23MG N022580 001 Jul 17, 2012 May CAHN  
 >D> + EQ 7.5MG BASE; 46MG N022580 002 Jul 17, 2012 May CAHN  
 >D> + EQ 11.25MG BASE; 69MG N022580 003 Jul 17, 2012 May CAHN  
 >D> +! EQ 15MG BASE; 92MG N022580 004 Jul 17, 2012 May CAHN  
 >A> + VIVUS LLC EQ 3.75MG BASE; 23MG N022580 001 Jul 17, 2012 May CAHN  
 >A> + EQ 7.5MG BASE; 46MG N022580 002 Jul 17, 2012 May CAHN  
 >A> + EQ 11.25MG BASE; 69MG N022580 003 Jul 17, 2012 May CAHN  
 >A> +! EQ 15MG BASE; 92MG N022580 004 Jul 17, 2012 May CAHN

PHENTOLAMINE MESYLATE

SOLUTION; OPHTHALMIC  
RYZUMVI

+! FAMYGEN LIFE SCI EQ 0.75% BASE N217064 001 Sep 25, 2023 Jan CAHN

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; INTRAVENOUS  
PHENYLEPHRINE HYDROCHLORIDE

>D> AP1 ACCORD HLTHCARE 10MG/ML (10MG/ML) A213237 001 Jul 01, 2020 May DISC  
 >A> @ 10MG/ML (10MG/ML) A213237 001 Jul 01, 2020 May DISC  
 >D> AP1 50MG/5ML (10MG/ML) A213237 002 Jul 01, 2020 May DISC  
 >A> @ 50MG/5ML (10MG/ML) A213237 002 Jul 01, 2020 May DISC  
 >D> AP1 100MG/10ML (10MG/ML) A213237 003 Jul 01, 2020 May DISC  
 >A> @ 100MG/10ML (10MG/ML) A213237 003 Jul 01, 2020 May DISC  
 >A> AP1 ASPIRO 10MG/ML (10MG/ML) A218110 001 May 10, 2024 May NEWA  
 >A> AP1 50MG/5ML (10MG/ML) A218110 002 May 10, 2024 May NEWA  
 >A> AP1 100MG/10ML (10MG/ML) A218110 003 May 10, 2024 May NEWA

SOLUTION;INTRAVENOUS

PHENYLEPHRINE HYDROCHLORIDE

	@ ENDO OPERATIONS	10MG/ML (10MG/ML)	A210025	001	Dec 21, 2018	Apr CAHN
AP1		50MG/5ML (10MG/ML)	A210025	002	Dec 21, 2018	Apr CAHN
AP1		100MG/10ML (10MG/ML)	A210025	003	Dec 21, 2018	Apr CAHN
AP1	HAINAN POLY	10MG/ML (10MG/ML)	A218412	001	Mar 14, 2024	Mar NEWA
AP1		50MG/5ML (10MG/ML)	A218412	002	Mar 14, 2024	Mar NEWA
AP1		100MG/10ML (10MG/ML)	A218412	003	Mar 14, 2024	Mar NEWA

SOLUTION/DROPS;OPHTHALMIC

PHENYLEPHRINE HYDROCHLORIDE

>A>	AT	CAPLIN	2.5%	A215183	001	May 23, 2024	May NEWA
>A>	AT		10%	A215183	002	May 23, 2024	May NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

AA	!	GENUS	5MG/5ML;6.25MG/5ML	A040654	001	Dec 07, 2006	Apr CAHN
		@ HIKMA	5MG/5ML;6.25MG/5ML	A040675	001	Dec 23, 2014	Mar DISC

PHENYTOIN

SUSPENSION;ORAL

PHENYTOIN

	@ PAI HOLDINGS PHARM	125MG/5ML	A040420	001	Apr 19, 2002	Feb DISC
	@ VISTAPHARM	125MG/5ML	A040342	001	Jan 31, 2001	Apr DISC
	@	125MG/5ML	A040342	002	Aug 18, 2005	Apr DISC

TABLET, CHEWABLE;ORAL

PHENYTOIN

AB		TARO	50MG	A200565	001	Apr 17, 2014	Apr CAHN
----	--	------	------	---------	-----	--------------	----------

PIMAVANSERIN TARTRATE

CAPSULE;ORAL

NUPLAZID

AB	+	ACADIA PHARMS INC	EQ 34MG BASE	N210793	001	Jun 28, 2018	Jan CFTG
		PIMAVANSERIN					
		@ MSN	EQ 34MG BASE	A214925	001	Jan 16, 2024	Feb DISC
AB			EQ 34MG BASE	A214925	001	Jan 16, 2024	Jan NEWA
AB		ZYDUS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan CAHN
AB		ZYDUS PHARMS	EQ 34MG BASE	A214493	001	Jan 16, 2024	Jan NEWA

TABLET;ORAL

NUPLAZID

AB	+	ACADIA PHARMS INC	EQ 10MG BASE	N207318	002	Jun 28, 2018	Jan CFTG
		PIMAVANSERIN					
AB		ZYDUS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan CAHN
AB		ZYDUS PHARMS	EQ 10MG BASE	A214502	001	Jan 16, 2024	Jan NEWA

PIMOZIDE

TABLET;ORAL

PIMOZIDE

		ENDO OPERATIONS	1MG	A204521	001	Sep 28, 2015	Apr CAHN
	!		2MG	A204521	002	Sep 28, 2015	Apr CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE;INJECTION

PIPERACILLIN AND TAZOBACTAM

	@ ASTRAL	EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL	A212287	001	Jul 29, 2019	Apr DISC
	@	EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL	A212287	002	Jul 29, 2019	Apr DISC
	@	EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL	A212287	003	Jul 29, 2019	Apr DISC
	@ EUGIA PHARMA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A217409	002	Oct 12, 2023	Apr DISC
	@	EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL	A217409	001	Oct 12, 2023	Apr DISC
	@ FRESENIUS KABI USA	EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL	A206204	001	May 11, 2018	Feb DISC

PIROXICAM

CAPSULE;ORAL

PIROXICAM

	@ FLAMINGO PHARMS	10MG	A207938	001	Sep 09, 2016	Mar DISC
	@	20MG	A207938	002	Sep 09, 2016	Mar DISC

PITAVASTATIN CALCIUM

TABLET;ORAL

PITAVASTATIN CALCIUM

AB	HETERO LABS LTD V	EQ 1MG BASE	A205977	001	Apr 30, 2024	Apr	NEWA
AB		EQ 2MG BASE	A205977	002	Apr 30, 2024	Apr	NEWA
AB		EQ 4MG BASE	A205977	003	Apr 30, 2024	Apr	NEWA

PIVMECILLINAM HYDROCHLORIDE

TABLET;ORAL

PIVYA

+!	UTILITY THERAP	EQ 185MG BASE	N216483	001	Apr 24, 2024	Apr	NEWA
----	----------------	---------------	---------	-----	--------------	-----	------

PLERIXAFOR

SOLUTION;SUBCUTANEOUS

PLERIXAFOR

AP	GLAND PHARMA LTD	24MG/1.2ML (20MG/ML)	A206644	001	May 03, 2024	Apr	NEWA
>D>	AP ZYDUS PHARMS	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC
>A>	@	24MG/1.2ML (20MG/ML)	A208980	001	Jul 26, 2023	May	DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE WITH FLAVOR PACKS

@	MYLAN SPECIALITY LP	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	N018983	012	Oct 08, 1998	Apr	DISC
---	---------------------	--	---------	-----	--------------	-----	------

PEG 3350 AND ELECTROLYTES

	NOVEL LABS INC	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A090186	001	Jun 01, 2009	Apr	CTEC
--	----------------	--	---------	-----	--------------	-----	------

POLYMYXIN B SULFATE

INJECTABLE;INJECTION

POLYMYXIN B SULFATE

AP	ADRASTEIA PHARMA	EQ 500,000 UNITS BASE/VIAL	A063000	001	Sep 30, 1994	Feb	CAHN
----	------------------	----------------------------	---------	-----	--------------	-----	------

POMALIDOMIDE

CAPSULE;ORAL

POMALIDOMIDE

>A>	AB	APOTEX	1MG	A210164	001	Jun 11, 2024	May	NEWA
>A>	AB		2MG	A210164	002	Jun 11, 2024	May	NEWA
>A>	AB		3MG	A210164	003	Jun 11, 2024	May	NEWA
>A>	AB		4MG	A210164	004	Jun 11, 2024	May	NEWA

POMALYST

>D>	+	BRISTOL	1MG	N204026	001	Feb 08, 2013	May	CTEC
>A>	AB	+	1MG	N204026	001	Feb 08, 2013	May	CTEC
>D>	+		2MG	N204026	002	Feb 08, 2013	May	CTEC
>A>	AB	+	2MG	N204026	002	Feb 08, 2013	May	CTEC
>D>	+		3MG	N204026	003	Feb 08, 2013	May	CTEC
>A>	AB	+	3MG	N204026	003	Feb 08, 2013	May	CTEC
>D>	+		4MG	N204026	004	Feb 08, 2013	May	CTEC
>A>	AB	+	4MG	N204026	004	Feb 08, 2013	May	CTEC

PONESIMOD

TABLET;ORAL

PONVORY

>D>	+	JANSSEN PHARMS	2MG	N213498	001	Mar 18, 2021	May	CAHN
>D>	+		3MG	N213498	002	Mar 18, 2021	May	CAHN
>D>	+		4MG	N213498	003	Mar 18, 2021	May	CAHN
>D>	+		5MG	N213498	004	Mar 18, 2021	May	CAHN
>D>	+		6MG	N213498	005	Mar 18, 2021	May	CAHN
>D>	+		7MG	N213498	006	Mar 18, 2021	May	CAHN
>D>	+		8MG	N213498	007	Mar 18, 2021	May	CAHN
>D>	+		9MG	N213498	008	Mar 18, 2021	May	CAHN
>D>	+		10MG	N213498	009	Mar 18, 2021	May	CAHN
>D>	+		20MG	N213498	010	Mar 18, 2021	May	CAHN
>A>	+	VANDA PHARMS INC	2MG	N213498	001	Mar 18, 2021	May	CAHN
>A>	+		3MG	N213498	002	Mar 18, 2021	May	CAHN
>A>	+		4MG	N213498	003	Mar 18, 2021	May	CAHN
>A>	+		5MG	N213498	004	Mar 18, 2021	May	CAHN
>A>	+		6MG	N213498	005	Mar 18, 2021	May	CAHN
>A>	+		7MG	N213498	006	Mar 18, 2021	May	CAHN
>A>	+		8MG	N213498	007	Mar 18, 2021	May	CAHN
>A>	+		9MG	N213498	008	Mar 18, 2021	May	CAHN

TABLET;ORAL  
PONVORY

>A> + 10MG N213498 009 Mar 18, 2021 May CAHN  
>A> + 20MG N213498 010 Mar 18, 2021 May CAHN

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

>D> @ ANCHEN PHARMS 8MEQ A202886 001 Dec 26, 2013 May CAHN  
>D> @ 8MEQ A202886 001 Dec 26, 2013 Feb DISC  
>D> @ 10MEQ A202886 002 Dec 26, 2013 May CAHN  
>D> @ 10MEQ A202886 002 Dec 26, 2013 Feb DISC  
>A> @ ENDO OPERATIONS 8MEQ A202886 001 Dec 26, 2013 May CAHN  
>A> @ 10MEQ A202886 002 Dec 26, 2013 May CAHN

SOLUTION;ORAL  
POTASSIUM CHLORIDE

AA STRIDES PHARMA 20MEQ/15ML A211665 002 Jan 16, 2024 Jan NEWA

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CHLORIDE

>A> @ CHARTWELL RX 10MEQ A206630 001 Mar 29, 2019 May CAHN  
>A> @ 15MEQ A206630 002 Mar 29, 2019 May CAHN  
>A> @ 20MEQ A206630 003 Mar 29, 2019 May CAHN  
>A> AB1 MACLEODS PHARMS LTD 10MEQ A216269 001 May 09, 2024 May NEWA  
>A> AB1 15MEQ A216269 002 May 09, 2024 May NEWA  
>A> AB1 20MEQ A216269 003 May 09, 2024 May NEWA  
>D> @ STRIDES PHARMA 10MEQ A206630 001 Mar 29, 2019 May CAHN  
>D> @ 15MEQ A206630 002 Mar 29, 2019 May CAHN  
>D> @ 20MEQ A206630 003 Mar 29, 2019 May CAHN

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE;ORAL  
POTASSIUM CITRATE

AB @ TORRENT 5MEQ A213986 001 Feb 06, 2024 Feb DISC  
AB @ 5MEQ A213986 001 Feb 06, 2024 Jan NEWA  
AB @ 10MEQ A213986 002 Feb 06, 2024 Feb DISC  
AB @ 10MEQ A213986 002 Feb 06, 2024 Jan NEWA  
AB @ 15MEQ A213986 003 Feb 06, 2024 Feb DISC  
AB @ 15MEQ A213986 003 Feb 06, 2024 Jan NEWA

PRALSETINIB

CAPSULE;ORAL  
GAVRETO

+! BLUEPRINT MEDICINES 100MG N213721 001 Sep 04, 2020 Feb CAHN

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB GLENMARK PHARMS LTD 0.125MG A090781 001 Oct 08, 2010 Mar CAHN  
AB ! 0.25MG A090781 002 Oct 08, 2010 Mar CAHN  
AB 0.5MG A090781 003 Oct 08, 2010 Mar CAHN  
AB 0.75MG A090781 006 Sep 11, 2015 Mar CAHN  
AB 1MG A090781 004 Oct 08, 2010 Mar CAHN  
AB 1.5MG A090781 005 Oct 08, 2010 Mar CAHN

TABLET, EXTENDED RELEASE;ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

>D> @ ANCHEN PHARMS 0.375MG A202206 001 Feb 06, 2014 May CAHN  
>D> @ 0.75MG A202206 002 Feb 06, 2014 May CAHN  
>D> @ 1.5MG A202206 003 Feb 06, 2014 May CAHN  
>D> @ 2.25MG A202206 004 Feb 06, 2014 May CAHN  
>D> @ 3MG A202206 005 Feb 06, 2014 May CAHN  
>D> @ 3.75MG A202206 006 Feb 06, 2014 May CAHN  
>D> @ 4.5MG A202206 007 Feb 06, 2014 May CAHN  
>A> @ ENDO OPERATIONS 0.375MG A202206 001 Feb 06, 2014 May CAHN  
>A> @ 0.75MG A202206 002 Feb 06, 2014 May CAHN  
>A> @ 1.5MG A202206 003 Feb 06, 2014 May CAHN  
>A> @ 2.25MG A202206 004 Feb 06, 2014 May CAHN  
>A> @ 3MG A202206 005 Feb 06, 2014 May CAHN  
>A> @ 3.75MG A202206 006 Feb 06, 2014 May CAHN  
>A> @ 4.5MG A202206 007 Feb 06, 2014 May CAHN

PRAZIQUANTEL

TABLET;ORAL  
 PRAZIQUANTEL  
 AB ENDO OPERATIONS 600MG A208820 001 Nov 27, 2017 Apr CAHN

PREDNISOLONE

SYRUP;ORAL  
 PREDNISOLONE  
 @ HIKMA 15MG/5ML A040401 001 Feb 27, 2003 Mar DISC  
 @ PHARM ASSOC 15MG/5ML A040399 001 Mar 05, 2003 Feb DISC  
 TABLET;ORAL  
 PREDNISOLONE  
 AB ZHEJIANG XIANJU 5MG A218083 001 May 02, 2024 Apr NEWA

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION;ORAL  
 PREDNISOLONE SODIUM PHOSPHATE  
 >A> @ ENDO OPERATIONS EQ 15MG BASE/5ML A079010 001 May 26, 2009 May CAHN  
 @ HIKMA EQ 5MG BASE/5ML A075183 001 Mar 26, 2003 Mar DISC  
 @ PHARM ASSOC EQ 30MG BASE/5ML A204962 001 Mar 11, 2020 Mar DISC  
 >D> @ VINTAGE EQ 15MG BASE/5ML A079010 001 May 26, 2009 May CAHN

PREDNISONE

SOLUTION;ORAL  
 PREDNISONE INTENSOL  
 +! HIKMA 5MG/ML A088810 001 Feb 20, 1985 Jan CRLD  
 TABLET;ORAL  
 PREDNISONE  
 AB ENDO OPERATIONS 1MG A040584 001 Dec 21, 2004 Apr CAHN  
 AB 2.5MG A040581 001 Dec 21, 2004 Apr CAHN  
 AB 5MG A040256 001 Jul 12, 2002 Apr CAHN  
 AB 10MG A040256 002 Jul 12, 2002 Apr CAHN  
 AB 20MG A040392 001 Feb 12, 2003 Apr CAHN  
 @ GENEYORK PHARMS 1MG A211496 001 Dec 28, 2018 Feb DISC  
 @ 2.5MG A210525 004 Dec 07, 2018 Feb DISC  
 @ 5MG A210525 005 Dec 07, 2018 Feb DISC  
 @ 10MG A210525 001 Dec 04, 2018 Feb DISC  
 @ 20MG A210525 002 Dec 04, 2018 Feb DISC  
 @ 50MG A210525 003 Dec 04, 2018 Feb DISC

PREGABALIN

CAPSULE;ORAL  
 PREGABALIN  
 AB ACI 25MG A215755 001 Apr 26, 2023 Feb CMFD  
 AB 50MG A215755 002 Apr 26, 2023 Feb CMFD  
 AB 75MG A215755 003 Apr 26, 2023 Feb CMFD  
 AB 100MG A215755 004 Apr 26, 2023 Feb CMFD  
 AB 150MG A215755 005 Apr 26, 2023 Feb CMFD  
 AB 200MG A215755 006 Apr 26, 2023 Feb CMFD  
 AB 225MG A215755 007 Apr 26, 2023 Feb CMFD  
 AB 300MG A215755 008 Apr 26, 2023 Feb CMFD  
 @ CADILA PHARMS LTD 25MG A206452 001 Jul 12, 2023 Jan DISC  
 @ 50MG A206452 002 Jul 12, 2023 Jan DISC  
 @ 75MG A206452 003 Jul 12, 2023 Jan DISC  
 @ 100MG A206452 004 Jul 12, 2023 Jan DISC  
 @ 150MG A206452 005 Jul 12, 2023 Jan DISC  
 @ 200MG A206452 006 Jul 12, 2023 Jan DISC  
 @ 225MG A206452 007 Jul 12, 2023 Jan DISC  
 @ 300MG A206452 008 Jul 12, 2023 Jan DISC  
 >D> AB CIPLA 25MG A212280 001 Jan 10, 2020 May DISC  
 >A> @ 25MG A212280 001 Jan 10, 2020 May DISC  
 >D> AB 50MG A212280 002 Jan 10, 2020 May DISC  
 >A> @ 50MG A212280 002 Jan 10, 2020 May DISC  
 >D> AB 75MG A212280 003 Jan 10, 2020 May DISC  
 >A> @ 75MG A212280 003 Jan 10, 2020 May DISC  
 >D> AB 100MG A212280 004 Jan 10, 2020 May DISC  
 >A> @ 100MG A212280 004 Jan 10, 2020 May DISC  
 >D> AB 150MG A212280 005 Jan 10, 2020 May DISC  
 >A> @ 150MG A212280 005 Jan 10, 2020 May DISC  
 >D> AB 200MG A212280 006 Jan 10, 2020 May DISC  
 >A> @ 200MG A212280 006 Jan 10, 2020 May DISC  
 >D> AB 225MG A212280 007 Jan 10, 2020 May DISC

CAPSULE;ORAL		PREGABALIN							
>A>	@	225MG		A212280	007	Jan 10, 2020	May	DISC	
>D>	AB	300MG		A212280	008	Jan 10, 2020	May	DISC	
>A>	@	300MG		A212280	008	Jan 10, 2020	May	DISC	
>A>	AB	INDOCO	25MG	A208113	001	May 17, 2024	May	NEWA	
>A>	AB		50MG	A208113	002	May 17, 2024	May	NEWA	
>A>	AB		75MG	A208113	004	May 17, 2024	May	NEWA	
>A>	AB		100MG	A208113	005	May 17, 2024	May	NEWA	
>A>	AB		150MG	A208113	003	May 17, 2024	May	NEWA	
>A>	AB		200MG	A208113	006	May 17, 2024	May	NEWA	
>A>	AB		225MG	A208113	007	May 17, 2024	May	NEWA	
>A>	AB		300MG	A208113	008	May 17, 2024	May	NEWA	
AB		STRIDES PHARMA	25MG	A209883	001	Jan 24, 2024	Jan	NEWA	
AB			50MG	A209883	002	Jan 24, 2024	Jan	NEWA	
AB			75MG	A209883	003	Jan 24, 2024	Jan	NEWA	
AB			100MG	A209883	004	Jan 24, 2024	Jan	NEWA	
AB			150MG	A209883	005	Jan 24, 2024	Jan	NEWA	
AB			200MG	A209883	006	Jan 24, 2024	Jan	NEWA	
AB			225MG	A209883	007	Jan 24, 2024	Jan	NEWA	
AB			300MG	A209883	008	Jan 24, 2024	Jan	NEWA	
	@	SUN PHARM	25MG	A091157	001	Nov 29, 2019	Jan	DISC	
	@		50MG	A091157	002	Nov 29, 2019	Jan	DISC	
	@		75MG	A091157	003	Nov 29, 2019	Jan	DISC	
	@		100MG	A091157	004	Nov 29, 2019	Jan	DISC	
	@		150MG	A091157	005	Nov 29, 2019	Jan	DISC	
	@		200MG	A091157	006	Nov 29, 2019	Jan	DISC	
	@		225MG	A091157	007	Nov 29, 2019	Jan	DISC	
	@		300MG	A091157	008	Nov 29, 2019	Jan	DISC	

PRIMIDONE

SUSPENSION;ORAL		MYSOLINE							
+	@	FHTA	250MG/5ML	N010401	001		Jan	CAHN	
TABLET;ORAL		PRIMIDONE							
AB		CARNEGIE	50MG	A218366	001	Jan 23, 2024	Jan	NEWA	
AB			250MG	A218366	002	Jan 23, 2024	Jan	NEWA	

PROCHLORPERAZINE MALEATE

TABLET;ORAL		PROCHLORPERAZINE MALEATE							
AB		AJANTA PHARMA LTD	EQ 5MG BASE	A218515	001	May 09, 2024	Apr	NEWA	
AB			EQ 10MG BASE	A218515	002	May 09, 2024	Apr	NEWA	

PROPAPENONE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		PROPAPENONE HYDROCHLORIDE							
>D>	BX	SINOTHERAPEUTICS INC	225MG	A210339	001	Jan 04, 2019	May	CTEC	
>A>	AB		225MG	A210339	001	Jan 04, 2019	May	CTEC	
>D>	BX		325MG	A210339	002	Jan 04, 2019	May	CTEC	
>A>	AB		325MG	A210339	002	Jan 04, 2019	May	CTEC	
>D>	BX		425MG	A210339	003	Jan 04, 2019	May	CTEC	
>A>	AB		425MG	A210339	003	Jan 04, 2019	May	CTEC	
AB		TWI PHARMS	225MG	A212928	001	Jun 18, 2020	Mar	CAHN	
AB			325MG	A212928	002	Jun 18, 2020	Mar	CAHN	
AB			425MG	A212928	003	Jun 18, 2020	Mar	CAHN	

PROPRANOLOL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL		PROPRANOLOL HYDROCHLORIDE							
	@	LUPIN LTD	60MG	A204349	001	Jan 12, 2024	Apr	DISC	
AB			60MG	A204349	001	Jan 12, 2024	Jan	NEWA	
	@		80MG	A204349	002	Jan 12, 2024	Apr	DISC	
AB			80MG	A204349	002	Jan 12, 2024	Jan	NEWA	
	@		120MG	A204349	003	Jan 12, 2024	Apr	DISC	
AB			120MG	A204349	003	Jan 12, 2024	Jan	NEWA	
	@		160MG	A204349	004	Jan 12, 2024	Apr	DISC	
AB			160MG	A204349	004	Jan 12, 2024	Jan	NEWA	

SOLUTION;ORAL

HEMANGEOL									
>A>	+	PIERRE FABRE	4.28MG/ML	N205410	001	Mar 14, 2014	May	CAHN	
>D>	+	PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	May	CAHN	



TABLET;ORAL

PROPRANOLOL HYDROCHLORIDE

AB	ENDO OPERATIONS	10MG	A070221	002	Aug 01, 1986	Apr	CAHN
AB		20MG	A070221	003	Aug 01, 1986	Apr	CAHN
AB		40MG	A070221	004	Aug 01, 1986	Apr	CAHN
AB		60MG	A070221	005	Sep 24, 1986	Apr	CAHN
AB		80MG	A070221	001	Apr 14, 1986	Apr	CAHN

PROPYLTHIOURACIL

TABLET;ORAL

PROPYLTHIOURACIL

AB	+!	ENDO OPERATIONS	50MG	N006188	001		Apr	CAHN
----	----	-----------------	------	---------	-----	--	-----	------

PYRIDOSTIGMINE BROMIDE

TABLET;ORAL

PYRIDOSTIGMINE BROMIDE

AB	ANI PHARMS	60MG	A040512	001	Oct 08, 2003	Jan	CMFD
AB	MLV	30MG	A211181	002	May 14, 2019	Mar	CAHN
AB		60MG	A211181	001	Jul 20, 2018	Mar	CAHN

QUETIAPINE FUMARATE

TABLET;ORAL

QUETIAPINE FUMARATE

>A>	AB	IPCA LABS LTD	EQ 25MG BASE	A205983	001	May 20, 2024	May	NEWA
>A>	AB		EQ 50MG BASE	A205983	002	May 20, 2024	May	NEWA
>A>	AB		EQ 100MG BASE	A205983	003	May 20, 2024	May	NEWA
>A>	AB		EQ 200MG BASE	A205983	004	May 20, 2024	May	NEWA
>A>	AB		EQ 300MG BASE	A205983	005	May 20, 2024	May	NEWA
>A>	AB		EQ 400MG BASE	A205983	006	May 20, 2024	May	NEWA

TABLET, EXTENDED RELEASE;ORAL

QUETIAPINE FUMARATE

>D>	@	ANCHEN PHARMS	EQ 150MG BASE	A090757	001	Dec 01, 2017	May	CAHN
>D>	@		EQ 200MG BASE	A090757	002	Dec 01, 2017	May	CAHN
>D>	@		EQ 300MG BASE	A090757	003	Dec 01, 2017	May	CAHN
>D>	@		EQ 400MG BASE	A090757	004	Dec 01, 2017	May	CAHN
>A>	@	ENDO OPERATIONS	EQ 50MG BASE	A090482	001	May 09, 2017	May	CAHN
>A>	@		EQ 150MG BASE	A090482	002	May 09, 2017	May	CAHN
>A>	@		EQ 150MG BASE	A090757	001	Dec 01, 2017	May	CAHN
>A>	@		EQ 200MG BASE	A090482	003	May 09, 2017	May	CAHN
>A>	@		EQ 200MG BASE	A090757	002	Dec 01, 2017	May	CAHN
>A>	@		EQ 300MG BASE	A090482	004	May 09, 2017	May	CAHN
>A>	@		EQ 300MG BASE	A090757	003	Dec 01, 2017	May	CAHN
>A>	@		EQ 400MG BASE	A090482	005	May 09, 2017	May	CAHN
>A>	@		EQ 400MG BASE	A090757	004	Dec 01, 2017	May	CAHN
>D>	@	PAR PHARM	EQ 50MG BASE	A090482	001	May 09, 2017	May	CAHN
	@		EQ 50MG BASE	A090482	001	May 09, 2017	Feb	DISC
>D>	@		EQ 150MG BASE	A090482	002	May 09, 2017	May	CAHN
	@		EQ 150MG BASE	A090482	002	May 09, 2017	Feb	DISC
>D>	@		EQ 200MG BASE	A090482	003	May 09, 2017	May	CAHN
	@		EQ 200MG BASE	A090482	003	May 09, 2017	Feb	DISC
>D>	@		EQ 300MG BASE	A090482	004	May 09, 2017	May	CAHN
	@		EQ 300MG BASE	A090482	004	May 09, 2017	Feb	DISC
>D>	@		EQ 400MG BASE	A090482	005	May 09, 2017	May	CAHN
	@		EQ 400MG BASE	A090482	005	May 09, 2017	Feb	DISC
AB		PRINSTON INC	EQ 400MG BASE	A208781	005	Mar 11, 2024	Mar	NEWA

QUINAPRIL HYDROCHLORIDE

TABLET;ORAL

QUINAPRIL HYDROCHLORIDE

@	INVAGEN PHARMS	EQ 5MG BASE	A078457	001	Aug 24, 2007	Mar	DISC
@		EQ 10MG BASE	A078457	002	Aug 24, 2007	Mar	DISC
@		EQ 20MG BASE	A078457	003	Aug 24, 2007	Mar	DISC
@		EQ 40MG BASE	A078457	004	Aug 24, 2007	Mar	DISC

RABEPRAZOLE SODIUM

TABLET, DELAYED RELEASE;ORAL

ACIPHEX

AB	+ @	WAYLIS THERAP	10MG	N020973	001	May 29, 2002	Apr	CAHN
AB	+!		20MG	N020973	002	Aug 19, 1999	Apr	CAHN

RAMIPRIL

CAPSULE;ORAL

RAMIPRIL

>D>	AB	ACCORD HLTHCARE	1.25MG	A202392	001	Apr 15, 2014	May DISC
>A>	@		1.25MG	A202392	001	Apr 15, 2014	May DISC
>D>	AB		2.5MG	A202392	002	Apr 15, 2014	May DISC
>A>	@		2.5MG	A202392	002	Apr 15, 2014	May DISC
>D>	AB		5MG	A202392	003	Apr 15, 2014	May DISC
>A>	@		5MG	A202392	003	Apr 15, 2014	May DISC
>D>	AB		10MG	A202392	004	Apr 15, 2014	May DISC
>A>	@		10MG	A202392	004	Apr 15, 2014	May DISC

RANITIDINE HYDROCHLORIDE

SYRUP;ORAL

RANITIDINE HYDROCHLORIDE

@ LANNETT CO INC EQ 15MG BASE/ML  
 @ PHARM ASSOC EQ 15MG BASE/ML

A091288 001 Dec 09, 2010 Mar DISC  
 A077405 001 Sep 21, 2007 Mar DISC

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

>A>	@	ENDO OPERATIONS	EQ 150MG BASE	A075180	001	Jan 28, 1999	May CAHN
>A>	@		EQ 300MG BASE	A075180	002	Jan 28, 1999	May CAHN
>D>	@	PAR PHARM	EQ 150MG BASE	A075180	001	Jan 28, 1999	May CAHN
	@		EQ 150MG BASE	A075180	001	Jan 28, 1999	Feb DISC
>D>	@		EQ 300MG BASE	A075180	002	Jan 28, 1999	May CAHN
	@		EQ 300MG BASE	A075180	002	Jan 28, 1999	Feb DISC

RANOLAZINE

TABLET, EXTENDED RELEASE;ORAL

RANOLAZINE

@ PIRAMAL HLTHCARE UK 500MG  
 @ 1GM

A213085 001 Jul 25, 2023 Jan DISC  
 A213085 002 Jul 25, 2023 Jan DISC

RASAGILINE MESYLATE

TABLET;ORAL

RASAGILINE MESYLATE

AB SKG PHARMA EQ 0.5MG BASE  
 AB EQ 1MG BASE

A218163 001 Apr 09, 2024 Mar NEWA  
 A218163 002 Apr 09, 2024 Mar NEWA

RESMETIROM

TABLET;ORAL

REZDIFFRA

+ MADRIGAL 60MG  
 + 80MG  
 +! 100MG

N217785 001 Mar 14, 2024 Mar NEWA  
 N217785 002 Mar 14, 2024 Mar NEWA  
 N217785 003 Mar 14, 2024 Mar NEWA

RETAPAMULIN

OINTMENT;TOPICAL

ALTABAX

>D>	+!	ALMIRALL	1%	N022055	001	Apr 12, 2007	May DISC
>A>	+ @		1%	N022055	001	Apr 12, 2007	May DISC

RIFAMPIN

CAPSULE;ORAL

RIFAMPIN

@ HIKMA 150MG  
 @ 300MG

A065028 001 Mar 14, 2001 Mar DISC  
 A065028 002 Mar 14, 2001 Mar DISC

RILPIVIRINE HYDROCHLORIDE

TABLET, FOR SUSPENSION;ORAL

EDURANT PED

+! JANSSEN PRODS EQ 2.5MG BASE

N219016 001 Mar 15, 2024 Mar NEWA

RILUZOLE

TABLET;ORAL

RILUTEK

>D>							
>D>	AB	+!	COVIS	50MG	N020599	001	Dec 12, 1995
>A>		+ @		50MG	N020599	001	Dec 12, 1995
			RILUZOLE				
>D>	AB		ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016
>A>	AB	!		50MG	A204048	001	Mar 30, 2016

RISPERIDONE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
RISVAN

+ LABS FARMS ROVI SA 75MG N214835 001 Mar 29, 2024 Mar NEWA  
+! 100MG N214835 002 Mar 29, 2024 Mar NEWA

INJECTABLE; INTRAMUSCULAR  
RISPERDAL CONSTA

AB + JANSSEN PHARMS 12.5MG/VIAL N021346 004 Apr 12, 2007 Jan CMS1  
AB +! 25MG/VIAL N021346 001 Oct 29, 2003 Jan CMS1  
AB + 37.5MG/VIAL N021346 002 Oct 29, 2003 Jan CMS1  
AB + 50MG/VIAL N021346 003 Oct 29, 2003 Jan CMS1  
RISPERIDONE  
AB TEVA PHARMS USA INC 12.5MG/VIAL A214068 001 Dec 05, 2023 Jan CMS1  
AB 25MG/VIAL A214068 002 Dec 05, 2023 Jan CMS1  
AB 37.5MG/VIAL A214068 003 Dec 05, 2023 Jan CMS1  
AB 50MG/VIAL A214068 004 Dec 05, 2023 Jan CMS1

SOLUTION; ORAL  
RISPERIDONE

@ HIKMA 1MG/ML A076904 001 Jul 29, 2009 Mar DISC  
@ PHARM ASSOC 1MG/ML A077719 001 Jul 29, 2009 Feb DISC

TABLET; ORAL  
RISPERIDONE

AB RENATA 0.25MG A078707 001 Dec 29, 2008 Feb CAHN  
AB 0.5MG A078707 002 Dec 29, 2008 Feb CAHN  
AB 1MG A078707 003 Dec 29, 2008 Feb CAHN  
AB 2MG A078707 004 Dec 29, 2008 Feb CAHN  
AB 3MG A078707 005 Dec 29, 2008 Feb CAHN  
AB 4MG A078707 006 Dec 29, 2008 Feb CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
RISPERIDONE

ENDO OPERATIONS 0.25MG A077494 001 Apr 30, 2009 Apr CAHN  
AB 0.5MG A077494 002 Apr 30, 2009 Apr CAHN  
AB 1MG A077494 003 Oct 26, 2009 Apr CAHN  
AB 2MG A077494 004 Apr 30, 2009 Apr CAHN  
AB 3MG A077494 005 Apr 30, 2009 Apr CAHN  
AB 4MG A077494 006 Apr 30, 2009 Apr CAHN

RITONAVIR

CAPSULE; ORAL  
RITONAVIR

MYLAN 100MG A205024 001 Feb 16, 2024 Feb NEWA

RIVASTIGMINE TARTRATE

SOLUTION; ORAL  
EXELON

+ @ NOVARTIS EQ 2MG BASE/ML N021025 001 Apr 21, 2000 Apr CRLD

RIZATRIPTAN BENZOATE

TABLET; ORAL

RIZATRIPTAN BENZOATE

@ INVAGEN PHARMS EQ 5MG BASE A204339 001 Jul 01, 2013 Apr DISC  
@ EQ 10MG BASE A204339 002 Jul 01, 2013 Apr DISC

ROPIVACAINE HYDROCHLORIDE

SOLUTION; INJECTION

ROPIVACAINE HYDROCHLORIDE

>A> AP CAPLIN 200MG/100ML (2MG/ML) A212808 005 May 23, 2024 May NEWA  
>A> AP 400MG/200ML (2MG/ML) A212808 006 May 23, 2024 May NEWA  
>D> AP HOSPIRA 20MG/10ML (2MG/ML) A090194 001 Sep 23, 2014 May DISC  
>A> @ 20MG/10ML (2MG/ML) A090194 001 Sep 23, 2014 May DISC  
>D> AP 40MG/20ML (2MG/ML) A090194 005 Sep 23, 2014 May DISC  
>A> @ 40MG/20ML (2MG/ML) A090194 005 Sep 23, 2014 May DISC  
>D> AP 100MG/10ML (10MG/ML) A090194 004 Sep 23, 2014 May DISC  
>A> @ 100MG/10ML (10MG/ML) A090194 004 Sep 23, 2014 May DISC  
>D> AP 150MG/30ML (5MG/ML) A090194 002 Sep 23, 2014 May DISC  
>A> @ 150MG/30ML (5MG/ML) A090194 002 Sep 23, 2014 May DISC  
>D> AP 150MG/20ML (7.5MG/ML) A090194 003 Sep 23, 2014 May DISC  
>A> @ 150MG/20ML (7.5MG/ML) A090194 003 Sep 23, 2014 May DISC  
>D> AP 200MG/20ML (10MG/ML) A090194 006 Sep 23, 2014 May DISC  
>A> @ 200MG/20ML (10MG/ML) A090194 006 Sep 23, 2014 May DISC

ROSUVASTATIN CALCIUM

TABLET; ORAL

ROSUVASTATIN CALCIUM

@ SANDOZ	EQ 5MG BASE	A079171	001	Jul 19, 2016	Jan	DISC
@	EQ 10MG BASE	A079171	002	Jul 19, 2016	Jan	DISC
@	EQ 20MG BASE	A079171	003	Jul 19, 2016	Jan	DISC
@	EQ 40MG BASE	A079171	004	Jul 19, 2016	Jan	DISC

SACUBITRIL; VALSARTAN

CAPSULE, PELLETS; ORAL

ENTRESTO SPRINKLE

+ NOVARTIS	6MG; 6MG	N218591	001	Apr 12, 2024	Apr	NEWA
+!	15MG; 16MG	N218591	002	Apr 12, 2024	Apr	NEWA

TABLET; ORAL

ENTRESTO

>D>	+ NOVARTIS PHARMS CORP	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
>A> AB	+	24MG; 26MG	N207620	001	Jul 07, 2015	May	CFTG
>D>	+	49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
>A> AB	+	49MG; 51MG	N207620	002	Jul 07, 2015	May	CFTG
>D>	+!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG
>A> AB	+!	97MG; 103MG	N207620	003	Jul 07, 2015	May	CFTG
>A>	SACUBITRIL AND VALSARTAN						
>A> AB	ALEMBIC	24MG; 26MG	A213682	001	May 28, 2024	May	NFTG
>A> AB		49MG; 51MG	A213682	002	May 28, 2024	May	NFTG
>A> AB		97MG; 103MG	A213682	003	May 28, 2024	May	NFTG
>A> AB	CRYSTAL	24MG; 26MG	A213605	001	May 28, 2024	May	NFTG
>A> AB		49MG; 51MG	A213605	002	May 28, 2024	May	NFTG
>A> AB		97MG; 103MG	A213605	003	May 28, 2024	May	NFTG
>A> AB	LAURUS	24MG; 26MG	A213676	001	May 28, 2024	May	NFTG
>A> AB		49MG; 51MG	A213676	002	May 28, 2024	May	NFTG
>A> AB		97MG; 103MG	A213676	003	May 28, 2024	May	NFTG

SAFINAMIDE MESYLATE

TABLET; ORAL

SAFINAMIDE MESYLATE

AB	PRINSTON INC	EQ 50MG BASE	A215739	001	Apr 25, 2024	Apr	NEWA
AB		EQ 100MG BASE	A215739	002	Apr 25, 2024	Apr	NEWA
	XADAGO						
AB	+ MDD US	EQ 50MG BASE	N207145	001	Mar 21, 2017	Apr	CTEC
AB	+!	EQ 100MG BASE	N207145	002	Mar 21, 2017	Apr	CTEC

SAXAGLIPTIN HYDROCHLORIDE

TABLET; ORAL

SAXAGLIPTIN

@ AMNEAL	EQ 2.5MG BASE	A205941	001	Jul 31, 2023	Feb	DISC
@	EQ 5MG BASE	A205941	002	Jul 31, 2023	Feb	DISC

SCOPOLAMINE

SYSTEM; TRANSDERMAL

SCOPOLAMINE

AB	RHODES PHARMS	1MG/72HR	A215329	001	May 06, 2024	Apr	NEWA
----	---------------	----------	---------	-----	--------------	-----	------

SELEGILINE HYDROCHLORIDE

TABLET; ORAL

SELEGILINE HYDROCHLORIDE

>D>	@ BAYSHORE PHARMS LLC	5MG	A074912	001	Apr 30, 1998	May	CAHN
>A>	@ KENTON	5MG	A074912	001	Apr 30, 1998	May	CAHN

SELEXIPAG

TABLET; ORAL

SELEXIPAG

>D>	@ ZYDUS	0.2MG	A214302	001	Dec 21, 2022	May	CAHN
>D>	@	0.4MG	A214302	002	Dec 21, 2022	May	CAHN
>D>	@	0.6MG	A214302	003	Dec 21, 2022	May	CAHN
>D>	@	0.8MG	A214302	004	Dec 21, 2022	May	CAHN
>D>	@	1MG	A214302	005	Dec 21, 2022	May	CAHN
>D>	@	1.2MG	A214302	006	Dec 21, 2022	May	CAHN
>D>	@	1.4MG	A214302	007	Dec 21, 2022	May	CAHN
>D>	@	1.6MG	A214302	008	Dec 21, 2022	May	CAHN
>A>	@ ZYDUS LIFESCIENCES	0.2MG	A214302	001	Dec 21, 2022	May	CAHN
>A>	@	0.4MG	A214302	002	Dec 21, 2022	May	CAHN

TABLET;ORAL							
SELEXIPAG							
>A>	@	0.6MG	A214302	003	Dec 21, 2022	May	CAHN
>A>	@	0.8MG	A214302	004	Dec 21, 2022	May	CAHN
>A>	@	1MG	A214302	005	Dec 21, 2022	May	CAHN
>A>	@	1.2MG	A214302	006	Dec 21, 2022	May	CAHN
>A>	@	1.4MG	A214302	007	Dec 21, 2022	May	CAHN
>A>	@	1.6MG	A214302	008	Dec 21, 2022	May	CAHN

SELPERCATINIB

TABLET;ORAL  
RETEVMO

+	LOXO ONCOL ELI LILLY	40MG	N218160	001	Apr 10, 2024	Apr	NEWA
+		80MG	N218160	002	Apr 10, 2024	Apr	NEWA
+		120MG	N218160	003	Apr 10, 2024	Apr	NEWA
+	!	160MG	N218160	004	Apr 10, 2024	Apr	NEWA

SERTRALINE HYDROCHLORIDE

TABLET;ORAL  
SERTRALINE HYDROCHLORIDE

>A>	@ APPCO	EQ 25MG BASE	A077713	001	Feb 06, 2007	May	CAHN
>A>	@	EQ 50MG BASE	A077713	002	Feb 06, 2007	May	CAHN
>A>	@	EQ 100MG BASE	A077713	003	Feb 06, 2007	May	CAHN
>D>	@ FOSUN PHARMA	EQ 25MG BASE	A077713	001	Feb 06, 2007	May	CAHN
>D>	@	EQ 50MG BASE	A077713	002	Feb 06, 2007	May	CAHN
>D>	@	EQ 100MG BASE	A077713	003	Feb 06, 2007	May	CAHN

SEVELAMER CARBONATE

FOR SUSPENSION;ORAL  
SEVELAMER CARBONATE

AB	MACLEODS PHARMS LTD	800MG/PACKET	A207291	001	Apr 25, 2024	Apr	NEWA
AB		2.4GM/PACKET	A207291	002	Apr 25, 2024	Apr	NEWA
TABLET;ORAL							
SEVELAMER CARBONATE							
>A>	@ ANXIN	800MG	A212970	001	Apr 09, 2020	Apr	DISC
>A>	AB STRIDES PHARMA	800MG	A211915	001	May 09, 2024	May	NEWA

SILDENAFIL CITRATE

TABLET;ORAL  
SILDENAFIL CITRATE

@ MYLAN PHARMS INC	EQ 20MG BASE	A201150	001	Nov 09, 2012	Apr	DISC
--------------------	--------------	---------	-----	--------------	-----	------

SILODOSIN

CAPSULE;ORAL  
SILODOSIN

AB	CHARTWELL RX	4MG	A204726	001	Mar 31, 2017	Mar	CAHN
AB		8MG	A204726	002	Mar 31, 2017	Mar	CAHN

SILVER SULFADIAZINE

CREAM;TOPICAL  
SSD

AB	! DR REDDYS LA	1%	N018578	001	Feb 25, 1982	Jan	CRLD
AB	!	1%	N018578	001	Feb 25, 1982	Jan	CHRS

SIMVASTATIN

SUSPENSION;ORAL  
FLOLIPID

+	SALERNO PHARMS	20MG/5ML	N206679	001	Apr 21, 2016	Apr	CAHN
+	!	40MG/5ML	N206679	002	Apr 21, 2016	Apr	CAHN

SINCALIDE

>D> INJECTABLE;INJECTION  
>D> KINEVAC

>D>	+	BRACCO	0.005MG/VIAL	N017697	001		May	CTEC
>A>	AP	+	0.005MG/VIAL	N017697	001		May	CTEC

>A> POWDER;INTRAVENOUS  
>A> KINEVAC

>A>	AP	+	BRACCO	0.005MG/VIAL	N017697	001		May	CDFR
-----	----	---	--------	--------------	---------	-----	--	-----	------

>D> +! MAIA PHARMS INC  
>A> AP +!

		0.005MG/VIAL	N210850	001	Nov 22, 2022	May	CTEC
		0.005MG/VIAL	N210850	001	Nov 22, 2022	May	CTEC

SODIUM ACETATE

	INJECTABLE; INJECTION						
	SODIUM ACETATE						
AP	FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CPOT
AP	MILLA PHARMS	400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CPOT
	SOLUTION; INTRAVENOUS						
	SODIUM ACETATE						
AP	! FRESENIUS KABI USA	400MEQ/100ML (4MEQ/ML)	A206687	001	Oct 30, 2017	Apr	CDFR
AP	HIKMA	40MEQ/20ML (2MEQ/ML)	A216920	001	Mar 15, 2024	Mar	NEWA
AP		100MEQ/50ML (2MEQ/ML)	A216920	002	Mar 15, 2024	Mar	NEWA
AP		200MEQ/100ML (2MEQ/ML)	A216920	003	Mar 15, 2024	Mar	NEWA
AP	+! HOSPIRA	2MEQ/ML	N018893	001	May 04, 1983	Mar	CDFR
AP	+!	40MEQ/20ML (2MEQ/ML)	N018893	001	May 04, 1983	Mar	CPOT
AP	+!	100MEQ/50ML (2MEQ/ML)	N018893	002	Sep 02, 2014	Mar	CMS1
AP	+!	200MEQ/100ML (2MEQ/ML)	N018893	003	Sep 02, 2014	Mar	CMS1
AP	MILLA PHARMS	2MEQ/ML	A214805	001	May 04, 2021	Mar	CDFR
AP		40MEQ/20ML (2MEQ/ML)	A214805	004	Jan 22, 2024	Mar	CMS1
AP		100MEQ/50ML (2MEQ/ML)	A214805	001	May 04, 2021	Mar	CPOT
AP		200MEQ/100ML (2MEQ/ML)	A214805	003	May 04, 2021	Mar	CMS1
AP		400MEQ/100ML (4MEQ/ML)	A214805	002	Aug 25, 2023	Apr	CDFR

SODIUM BICARBONATE

	INJECTABLE; INJECTION						
	SODIUM BICARBONATE						
AP	STERISCIENCE	1MEQ/ML	A217594	001	Jun 28, 2023	Apr	CMFD
	@	1MEQ/ML	A217594	001	Jun 28, 2023	Jan	DISC

SODIUM CHLORIDE

	SOLUTION; INJECTION						
	SODIUM CHLORIDE 0.9%						
	@ HIKMA	90MG/10ML (9MG/ML)	A201850	001	Jan 20, 2012	Mar	DISC

SODIUM FLUORIDE F-18

	INJECTABLE; INTRAVENOUS						
	SODIUM FLUORIDE F-18						
AP	! PETNET	10-200mCi/ML	A203890	001	Sep 28, 2015	Jan	CHRS

SODIUM PHENYL BUTYRATE

	POWDER; ORAL						
	SODIUM PHENYL BUTYRATE						
AB	ENDO OPERATIONS	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Apr	CAHN
	TABLET; ORAL						
	SODIUM PHENYL BUTYRATE						
AB	ENDO OPERATIONS	500MG	A204395	001	Apr 15, 2016	Apr	CAHN

SOLIFENACIN SUCCINATE

	TABLET; ORAL						
	SOLIFENACIN SUCCINATE						
AB	MACLEODS PHARMS LTD	5MG	A204374	001	Feb 20, 2024	Feb	NEWA
AB		10MG	A204374	002	Feb 20, 2024	Feb	NEWA

SOTALOL HYDROCHLORIDE

	TABLET; ORAL						
	SOTALOL HYDROCHLORIDE						
	@ RISING	80MG	A075725	001	Dec 19, 2000	Feb	CAHN
	@	120MG	A075725	002	Dec 19, 2000	Feb	CAHN
	@	160MG	A075725	003	Dec 19, 2000	Feb	CAHN
	@	240MG	A075725	004	Dec 19, 2000	Feb	CAHN

STERILE WATER FOR INJECTION

	LIQUID; N/A						
	STERILE WATER FOR INJECTION						
AP	AM REGENT	100% (5ML)	A217341	003	Feb 09, 2024	Feb	NEWA

SUCCINYLCHOLINE CHLORIDE

	INJECTABLE; INJECTION						
	SUCCINYLCHOLINE CHLORIDE						
>D> AP	ACCORD HLTHCARE	20MG/ML	A213705	001	May 20, 2020	May	DISC
>A>	@	20MG/ML	A213705	001	May 20, 2020	May	DISC
	@ EUGIA PHARMA	20MG/ML	A217808	001	Oct 16, 2023	Apr	DISC
	@ NEXUS	20MG/ML	A213552	001	Oct 27, 2020	Mar	DISC

INJECTABLE; INJECTION  
SUCCINYLCHOLINE CHLORIDE

AP	NIVAGEN PHARMS INC	20MG/ML	A211625	001	May 19, 2020	Jan	CAHN
SOLUTION; INTRAMUSCULAR, INTRAVENOUS							
SUCCINYLCHOLINE CHLORIDE							
AP	DR REDDYS	100MG/5ML (20MG/ML)	A218467	001	Jan 17, 2024	Jan	NEWA
AP	+! HIKMA	100MG/5ML (20MG/ML)	N215143	001	Aug 20, 2021	Jan	CFTG

SUCRALFATE

SUSPENSION; ORAL  
SUCRALFATE

AB	ABON PHARMS LLC	1GM/10ML	A216726	001	Mar 21, 2024	Mar	NEWA
AB	PD PARTNERS	1GM/10ML	A213549	001	Jan 17, 2024	Jan	NEWA
>A>	AB STRIDES PHARMA	1GM/10ML	A216474	001	May 21, 2024	May	NEWA
AB	VISTAPHARM LLC	1GM/10ML	A211884	001	Mar 15, 2022	Apr	CAHN

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS  
SUGAMMADEX SODIUM

@	ZYDUS PHARMS	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	A214290	001	Oct 04, 2023	Mar	DISC
@		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	A214290	002	Oct 04, 2023	Mar	DISC

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL  
SULFAMETHOXAZOLE AND TRIMETHOPRIM

AB	! AUROBINDO PHARMA	200MG/5ML; 40MG/5ML	A091348	001	Jun 08, 2010	Mar	CHRS
	@ HIKMA	200MG/5ML; 40MG/5ML	A074650	001	Dec 29, 1997	Mar	DISC

SUMATRIPTAN SUCCINATE

INJECTABLE; SUBCUTANEOUS  
IMITREX

+ @	GLAXOSMITHKLINE	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N020080	001	Dec 28, 1992	Jan	DISC
-----	-----------------	-------------------------------------	---------	-----	--------------	-----	------

SUMATRIPTAN SUCCINATE

>A>	@ ENDO OPERATIONS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May	CAHN
>A>	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May	CAHN
AP	! EUGIA PHARMA	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A202758	001	Apr 23, 2013	Jan	CHRS
>D>	@ PAR PHARM	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	May	CAHN
	@	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077332	001	Oct 09, 2009	Feb	DISC
>D>	@ PAR STERILE PRODUCTS	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A077871	001	Jul 09, 2009	May	CAHN

SUMAVEL DOSEPRO

>A>	+ @ ENDO OPERATIONS	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	CAHN
>A>	+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May	CAHN
>D>	+ @ ENDO VENTURES LTD	EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)	N022239	002	Nov 26, 2013	May	CAHN
>D>	+ @	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	N022239	001	Jul 15, 2009	May	CAHN

SUNITINIB MALATE

CAPSULE; ORAL  
SUNITINIB MALATE

AB	EUGIA PHARMA	EQ 12.5MG BASE	A218615	001	Mar 14, 2024	Mar	NEWA
AB		EQ 25MG BASE	A218615	002	Mar 14, 2024	Mar	NEWA
AB		EQ 37.5MG BASE	A218615	003	Mar 14, 2024	Mar	NEWA
AB		EQ 50MG BASE	A218615	004	Mar 14, 2024	Mar	NEWA
>D>	@ NOVUGEN	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
>A>	AB	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	May	CMFD
	@	EQ 12.5MG BASE	A218012	001	Aug 21, 2023	Feb	DISC
>D>	@	EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
>A>	AB	EQ 25MG BASE	A218012	002	Aug 21, 2023	May	CMFD
	@	EQ 25MG BASE	A218012	002	Aug 21, 2023	Feb	DISC
>D>	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
>A>	AB	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	May	CMFD
	@	EQ 37.5MG BASE	A218012	003	Aug 21, 2023	Feb	DISC
>D>	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
>A>	AB	EQ 50MG BASE	A218012	004	Aug 21, 2023	May	CMFD
	@	EQ 50MG BASE	A218012	004	Aug 21, 2023	Feb	DISC

TACROLIMUS

		CAPSULE, EXTENDED RELEASE;ORAL							
		ASTAGRAF XL							
AB	+	ASTELLAS	EQ 0.5MG BASE	N204096	001	Jul 19, 2013	Jan	CFTG	
AB	+		EQ 1MG BASE	N204096	002	Jul 19, 2013	Jan	CFTG	
AB	+	!	EQ 5MG BASE	N204096	003	Jul 19, 2013	Jan	CFTG	
		TACROLIMUS							
AB		CHENGDU	EQ 0.5MG BASE	A215012	001	Jan 25, 2024	Jan	NFTG	
AB			EQ 1MG BASE	A215012	002	Jan 25, 2024	Jan	NFTG	
AB			EQ 5MG BASE	A215012	003	Jan 25, 2024	Jan	NFTG	

TADALAFIL

		TABLET;ORAL							
		TADALAFIL							
AB1		HANGZHOU BINJIANG	2.5MG	A208824	001	Oct 27, 2020	Mar	CAHN	
AB1			5MG	A208824	002	Oct 27, 2020	Mar	CAHN	
AB1			10MG	A208824	003	Oct 27, 2020	Mar	CAHN	
AB1			20MG	A208824	004	Oct 27, 2020	Mar	CAHN	
AB1		SHANDONG	20MG	A216279	001	Mar 04, 2024	Feb	NEWA	

TAFLUPROST

		SOLUTION/DROPS;OPHTHALMIC							
		TAFLUPROST							
>D>	AT	INGENUS PHARMS LLC	0.0015%	A218002	001	Apr 05, 2024	May	DISC	
>A>		@	0.0015%	A218002	001	Apr 05, 2024	May	DISC	
	AT		0.0015%	A218002	001	Apr 05, 2024	Mar	NEWA	

TALAZOPARIB TOSYLATE

		CAPSULE;ORAL							
		TALZENNA							
	+	PFIZER	EQ 0.1MG BASE	N217439	001	Mar 07, 2024	Mar	NEWA	
	+		EQ 0.25MG BASE	N217439	002	Mar 07, 2024	Mar	NEWA	
	+		EQ 0.35MG BASE	N217439	003	Mar 07, 2024	Mar	NEWA	
	+		EQ 0.5MG BASE	N217439	004	Mar 07, 2024	Mar	NEWA	
	+		EQ 0.75MG BASE	N217439	005	Mar 07, 2024	Mar	NEWA	
	+	!	EQ 1MG BASE	N217439	006	Mar 07, 2024	Mar	NEWA	

TAMSULOSIN HYDROCHLORIDE

		CAPSULE;ORAL							
		TAMSULOSIN HYDROCHLORIDE							
>D>		@ ANCHEN PHARMS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN	
>A>		@ ENDO OPERATIONS	0.4MG	A202010	001	Jan 04, 2013	May	CAHN	

TAVABOROLE

		SOLUTION;TOPICAL							
		KERYDIN							
	+	@ ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Mar	DISC	
		TAVABOROLE							
AB	!	ENCUBE	5%	A211297	001	Oct 13, 2020	Mar	CHRS	

TEDUGLUTIDE

		POWDER;SUBCUTANEOUS							
		GATTEX KIT							
	+	!	TAKEDA PHARMS USA	5MG/VIAL	N203441	001	Dec 21, 2012	Mar	CAIN

TEMAZEPAM

		CAPSULE;ORAL							
		TEMAZEPAM							
AB		CHARTWELL RX	15MG	A071427	001	Jan 12, 1988	Jan	CAHN	
AB			30MG	A071428	001	Jan 12, 1988	Jan	CAHN	

TENAPANOR HYDROCHLORIDE

		TABLET;ORAL							
		XPHOZAH							
	+	@ ARDELYX INC	EQ 10MG BASE	N213931	001	Oct 17, 2023	Apr	DISC	



TENOFOVIR ALAFENAMIDE FUMARATE

TABLET;ORAL

TENOFOVIR ALAFENAMIDE FUMARATE

>D>	AB	APOTEX	EQ 25MG BASE	A213867	001	Mar 21, 2024	May DISC
>A>		@	EQ 25MG BASE	A213867	001	Mar 21, 2024	May DISC
	AB		EQ 25MG BASE	A213867	001	Mar 21, 2024	Mar NEWA

TENOFOVIR DISOPROXIL FUMARATE

TABLET;ORAL

TENOFOVIR DISOPROXIL FUMARATE

	AB	MYLAN LABS LTD	300MG	A079071	001	Feb 29, 2024	Feb NEWA
--	----	----------------	-------	---------	-----	--------------	----------

TERAZOSIN HYDROCHLORIDE

CAPSULE;ORAL

TERAZOSIN HYDROCHLORIDE

	AB	BIONPHARMA	EQ 1MG BASE	A075667	001	Jul 28, 2000	Jan CMFD
	AB		EQ 2MG BASE	A075667	002	Jul 28, 2000	Jan CMFD
	AB		EQ 5MG BASE	A075667	003	Jul 28, 2000	Jan CMFD
	AB		EQ 10MG BASE	A075667	004	Jul 28, 2000	Jan CMFD

TERBINAFINE

GEL;TOPICAL

LAMISIL

@ KARO HLTHCARE 1%

				N020846	001	Apr 29, 1998	Feb CAHN
--	--	--	--	---------	-----	--------------	----------

TERBINAFINE HYDROCHLORIDE

SOLUTION;TOPICAL

LAMISIL

@ KARO HLTHCARE 1%

				N020749	001	Oct 17, 1997	Feb CAHN
--	--	--	--	---------	-----	--------------	----------

TABLET;ORAL

TERBINAFINE HYDROCHLORIDE

@ CIPLA EQ 250MG BASE

				A077137	001	Jul 02, 2007	Mar DISC
--	--	--	--	---------	-----	--------------	----------

TERBUTALINE SULFATE

INJECTABLE;INJECTION

TERBUTALINE SULFATE

	AP	AREVA PHARMS	1MG/ML	A200122	001	Nov 08, 2013	Apr CAHN
--	----	--------------	--------	---------	-----	--------------	----------

TERIFLUNOMIDE

TABLET;ORAL

TERIFLUNOMIDE

>D>	AB	AMNEAL PHARMS CO	7MG	A209613	001	Sep 28, 2018	May DISC
>A>		@	7MG	A209613	001	Sep 28, 2018	May DISC
>D>	AB		14MG	A209613	002	Sep 28, 2018	May DISC
>A>		@	14MG	A209613	002	Sep 28, 2018	May DISC
		@ MYLAN	7MG	A209702	001	Feb 28, 2020	Apr DISC
		@	14MG	A209702	002	Feb 28, 2020	Apr DISC
	AB	TORRENT	7MG	A209697	001	Apr 04, 2024	Mar NEWA
	AB		14MG	A209697	002	Apr 04, 2024	Mar NEWA

TESTOSTERONE

GEL;TRANSDERMAL

TESTIM

	AB2	+!	ENDO OPERATIONS	50MG/5GM PACKET	N021454	001	Oct 31, 2002	Apr CAHN
--	-----	----	-----------------	-----------------	---------	-----	--------------	----------

GEL, METERED;TRANSDERMAL

FORTESTA

+ @ ENDO OPERATIONS 10MG/0.5GM ACTUATION

				N021463	001	Dec 29, 2010	Apr CAHN
--	--	--	--	---------	-----	--------------	----------

+ @ ENDO PHARMS 10MG/0.5GM ACTUATION

				N021463	001	Dec 29, 2010	Jan DISC
--	--	--	--	---------	-----	--------------	----------

TESTOSTERONE

! ACTAVIS LABS UT INC 10MG/0.5GM ACTUATION

				A204571	001	Aug 05, 2015	Jan CTEC
--	--	--	--	---------	-----	--------------	----------

AB ! 10MG/0.5GM ACTUATION

				A204571	001	Aug 05, 2015	Jan CHRS
--	--	--	--	---------	-----	--------------	----------

AB1 ! 12.5MG/1.25GM ACTUATION

				A076737	003	Mar 09, 2015	Apr CTEC
--	--	--	--	---------	-----	--------------	----------

AB1 ENCUBE 12.5MG/1.25GM ACTUATION

				A212984	002	Feb 09, 2024	Apr NEWA
--	--	--	--	---------	-----	--------------	----------

PELLET;IMPLANTATION

TESTOPEL

! ENDO OPERATIONS 75MG

				A080911	001		Apr CAHN
--	--	--	--	---------	-----	--	----------

SOLUTION, METERED;TRANSDERMAL

TESTOSTERONE

AT ENCUBE 30MG/1.5ML ACTUATION

				A212301	001	Jan 11, 2021	Apr CAHN
--	--	--	--	---------	-----	--------------	----------

AT FEMPHARM 30MG/1.5ML ACTUATION

				A212301	001	Jan 11, 2021	Mar CAHN
--	--	--	--	---------	-----	--------------	----------

TESTOSTERONE ENANTHATE

	INJECTABLE; INJECTION					
	TESTOSTERONE ENANTHATE					
AO	EUGIA PHARMA	200MG/ML	A212659	001	Feb 28, 2024	Feb NEWA
AO		200MG/ML	A212659	001	Feb 28, 2024	Feb NEWA

TESTOSTERONE UNDECANOATE

	CAPSULE; ORAL					
	TLANDO					
+!	VERITY	112.5MG	N208088	001	Mar 28, 2022	Jan CAHN
	INJECTABLE; INTRAMUSCULAR					
	AVEED					
+!	ENDO OPERATIONS	750MG/3ML (250MG/ML)	N022219	001	Mar 05, 2014	Apr CAHN

TETRABENAZINE

	TABLET; ORAL					
	TETRABENAZINE					
AB	SLATE RUN PHARMA	12.5MG	A213316	001	Jan 22, 2020	Feb CAHN
AB		25MG	A213316	002	Jan 22, 2020	Feb CAHN

TETRACYCLINE HYDROCHLORIDE

	SUSPENSION; ORAL					
	SUMYCIN					
>A>	@ ENDO OPERATIONS	125MG/5ML	A060400	001		May CAHN
>D>	@ PAR PHARM	125MG/5ML	A060400	001		May CAHN
	TABLET; ORAL					
	SUMYCIN					
	STRIDES PHARMA	250MG	A061147	001		Jan CMFD
	!	500MG	A061147	004		Jan CMFD

THEOPHYLLINE

	CAPSULE, EXTENDED RELEASE; ORAL					
	THEO-24					
	ENDO OPERATIONS	100MG	A087943	002	Aug 22, 1983	Apr CAHN
+		200MG	A087943	001	Aug 22, 1983	Apr CAHN
		300MG	A087943	003	Aug 22, 1983	Apr CAHN
!		400MG	A087943	004	Feb 28, 1992	Apr CAHN
	TABLET, EXTENDED RELEASE; ORAL					
	THEOPHYLLINE					
>A> AB	ZYDUS LIFESCIENCES	300MG	A218063	001	May 21, 2024	May CAHN
>A> AB		450MG	A218063	002	May 21, 2024	May CAHN
>A> AB	ZYDUS PHARMS	300MG	A218063	001	May 21, 2024	May NEWA
>A> AB		450MG	A218063	002	May 21, 2024	May NEWA

TIGECYCLINE

	POWDER; INTRAVENOUS					
	TIGECYCLINE					
>D>	ACCORD HLTHCARE INC	50MG/VIAL	N208744	001	Jan 18, 2018	May DISC
>A>	@	50MG/VIAL	N208744	001	Jan 18, 2018	May DISC

TIMOLOL MALEATE

	SOLUTION, GEL FORMING/DROPS; OPHTHALMIC					
	TIMOLOL MALEATE					
>A> AB	AMNEAL	EQ 0.25% BASE	A216343	001	May 23, 2024	May NEWA
>A> AB		EQ 0.5% BASE	A216343	002	May 23, 2024	May NEWA
	SOLUTION/DROPS; OPHTHALMIC					
	TIMOLOL MALEATE					
>D>	@ AKORN	EQ 0.5% BASE	A074466	001	Mar 25, 1997	May CAHN
>A>	@ SAPTALIS PHARMS	EQ 0.5% BASE	A074466	001	Mar 25, 1997	May CAHN

TIOPRONIN

	TABLET, DELAYED RELEASE; ORAL					
	THIOLA EC					
AB	+ MISSION PHARMACAL	100MG	N211843	001	Jun 28, 2019	Jan CFTG
	TIOPRONIN					
AB	TORRENT	100MG	A216990	001	Jan 30, 2024	Jan NFTG
AB		300MG	A216990	002	Jan 30, 2024	Jan NEWA

TIRZEPATIDE

SOLUTION;SUBCUTANEOUS  
MOUNJARO

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	007	Jul 28, 2023	Jan NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	008	Jul 28, 2023	Jan NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	009	Jul 28, 2023	Jan NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	010	Jul 28, 2023	Jan NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	011	Jul 28, 2023	Jan NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	012	Jul 28, 2023	Jan NEWA

MOUNJARO (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N215866	001	May 13, 2022	Jan CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N215866	002	May 13, 2022	Jan CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N215866	003	May 13, 2022	Jan CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N215866	004	May 13, 2022	Jan CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N215866	005	May 13, 2022	Jan CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N215866	006	May 13, 2022	Jan CTNA

ZEPBOUND

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	007	Mar 28, 2024	Mar NEWA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	008	Mar 28, 2024	Mar NEWA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	009	Mar 28, 2024	Mar NEWA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	010	Mar 28, 2024	Mar NEWA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	011	Mar 28, 2024	Mar NEWA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	012	Mar 28, 2024	Mar NEWA

ZEPBOUND (AUTOINJECTOR)

+!	ELI LILLY AND CO	2.5MG/0.5ML (2.5MG/0.5ML)	N217806	001	Nov 08, 2023	Mar CTNA
+!		5MG/0.5ML (5MG/0.5ML)	N217806	002	Nov 08, 2023	Mar CTNA
+!		7.5MG/0.5ML (7.5MG/0.5ML)	N217806	003	Nov 08, 2023	Mar CTNA
+!		10MG/0.5ML (10MG/0.5ML)	N217806	004	Nov 08, 2023	Mar CTNA
+!		12.5MG/0.5ML (12.5MG/0.5ML)	N217806	005	Nov 08, 2023	Mar CTNA
+!		15MG/0.5ML (15MG/0.5ML)	N217806	006	Nov 08, 2023	Mar CTNA

TIZANIDINE HYDROCHLORIDE

CAPSULE;ORAL

TIZANIDINE HYDROCHLORIDE

>A>	AB	APPCO	EQ 4MG BASE	A213365	001	May 13, 2024	May NEWA
>A>	AB		EQ 6MG BASE	A213365	002	May 13, 2024	May NEWA
>A>		@ ENDO OPERATIONS	EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
>A>		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
>A>		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN
>D>		@ PAR PHARM INC	EQ 2MG BASE	A207199	001	Mar 14, 2017	May CAHN
>D>		@	EQ 4MG BASE	A207199	002	Mar 14, 2017	May CAHN
>D>		@	EQ 6MG BASE	A207199	003	Mar 14, 2017	May CAHN

TABLET;ORAL

TIZANIDINE HYDROCHLORIDE

>A>		@ ENDO OPERATIONS	EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
>A>		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN
>D>		@ PAR PHARM INC	EQ 2MG BASE	A207170	001	Jan 26, 2017	May CAHN
>D>		@	EQ 4MG BASE	A207170	002	Jan 26, 2017	May CAHN

TOBRAMYCIN

SOLUTION/DROPS;OPHTHALMIC

TOBRAMYCIN

AT	!	SOMERSET THERAPS LLC	0.3%	A207444	001	Jun 28, 2017	Apr CHRS
		TOBEX					
	+	@ NOVARTIS	0.3%	N050541	001		Apr DISC

TOFACITINIB CITRATE

SOLUTION;ORAL

TOFACITINIB CITRATE

AA		HIKMA	EQ 1MG BASE/ML	A216878	001	Sep 25, 2023	Apr CAHN
----	--	-------	----------------	---------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

TOFACITINIB

>A>	AB	AUROBINDO PHARMA LTD	EQ 11MG BASE	A218462	001	Jun 03, 2024	May NEWA
		XELJANZ XR					
>D>	+	PFIZER	EQ 11MG BASE	N208246	001	Feb 23, 2016	May CTEC
>A>	AB	+	EQ 11MG BASE	N208246	001	Feb 23, 2016	May CTEC

TOLCAPONE

## TABLET; ORAL

## TOLCAPONE

>A>	@ ENDO OPERATIONS	100MG	A204584	001	Mar 26, 2015	May	CAHN
>D>	@ PAR PHARM INC	100MG	A204584	001	Mar 26, 2015	May	CAHN
	@	100MG	A204584	001	Mar 26, 2015	Mar	DISC

TOPIRAMATE

## CAPSULE; ORAL

## TOPIRAMATE

AB	STRIDES PHARMA	15MG	A078418	001	Oct 14, 2009	Apr	CMFD
AB		25MG	A078418	002	Oct 14, 2009	Apr	CMFD

## CAPSULE, EXTENDED RELEASE; ORAL

## TOPIRAMATE

## @ AJANTA PHARMA LTD

	@	25MG	A215663	001	Aug 15, 2023	Feb	DISC
	@	50MG	A215663	002	Aug 15, 2023	Feb	DISC
	@	100MG	A215663	003	Aug 15, 2023	Feb	DISC
	@	200MG	A215663	004	Aug 15, 2023	Feb	DISC

## TABLET; ORAL

## TOPIRAMATE

## @ AIPING PHARM INC

	@	25MG	A078499	001	Jan 07, 2010	Feb	CAHN
	@	50MG	A078499	002	Jan 07, 2010	Feb	CAHN
	@	100MG	A078499	003	Jan 07, 2010	Feb	CAHN
	@	200MG	A078499	004	Jan 07, 2010	Feb	CAHN
	@ SUN PHARM INDS LTD	25MG	A076327	001	Mar 27, 2009	Jan	DISC
	@	100MG	A076327	002	Mar 27, 2009	Jan	DISC
	@	200MG	A076327	003	Mar 27, 2009	Jan	DISC

TOPOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## TOPOTECAN HYDROCHLORIDE

	@ RISING	EQ 4MG BASE/VIAL	A091542	001	Aug 28, 2012	Mar	CAHN
--	----------	------------------	---------	-----	--------------	-----	------

TORSEMIDE

## SOLUTION; INTRAVENOUS

## DEMADEX

+	@ ROCHE	50MG/5ML (10MG/ML)	N020137	002	Aug 23, 1993	Mar	CDFR
+	@	20MG/2ML (10MG/ML)	N020137	001	Aug 23, 1993	Mar	CDFR

## TORSEMIDE

## @ AM REGENT

	@	20MG/2ML (10MG/ML)	A090656	001	Apr 21, 2010	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A090656	002	Apr 21, 2010	Mar	CDFR
	@ WEST-WARD PHARMS INT	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Mar	CDFR
	@	50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Mar	CDFR

TOVORAFENIB

## FOR SUSPENSION; ORAL

## OJEMDA

+	!	DAY ONE BIOPHARMS	25MG/ML	N218033	001	Apr 23, 2024	Apr	NEWA
---	---	-------------------	---------	---------	-----	--------------	-----	------

## TABLET; ORAL

## OJEMDA

+	!	DAY ONE BIOPHARMS	100MG	N217700	001	Apr 23, 2024	Apr	NEWA
---	---	-------------------	-------	---------	-----	--------------	-----	------

TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

## TRAMADOL HYDROCHLORIDE

## RUBICON

		75MG	A208708	004	Apr 04, 2024	Mar	NFTG
--	--	------	---------	-----	--------------	-----	------

## TABLET, EXTENDED RELEASE; ORAL

## TRAMADOL HYDROCHLORIDE

## @ ENDO OPERATIONS

	@	100MG	A200491	001	Jun 27, 2012	Apr	CAHN
	@	200MG	A200491	002	Jun 27, 2012	Apr	CAHN
	@	300MG	A200491	003	Jun 27, 2012	Apr	CAHN

>D>	!	SUN PHARM	100MG	A091607	001	Dec 30, 2011	May	DISC
>A>	@		100MG	A091607	001	Dec 30, 2011	May	DISC
>D>			300MG	A091607	003	Dec 30, 2011	May	DISC
>A>	@		300MG	A091607	003	Dec 30, 2011	May	DISC

TRANEXAMIC ACID

SOLUTION;INTRAVENOUS  
TRANEXAMIC ACID

AP	GLAND PHARMA LTD	1GM/100ML (10MG/ML)	A218599	001	Apr 16, 2024	Apr NEWA
AP	NEXUS	1GM/100ML (10MG/ML)	A216877	001	Apr 16, 2024	Apr NEWA

TABLET;ORAL  
TRANEXAMIC ACID

>A>	AB	RUBICON	650MG	A218320	001	Jun 11, 2024	May NEWA
-----	----	---------	-------	---------	-----	--------------	----------

TRAVOPROST

SOLUTION/DROPS;OPHTHALMIC  
TRAVOPROST

AT	LUPIN LTD	0.004%	A207040	001	May 03, 2024	Apr NEWA
----	-----------	--------	---------	-----	--------------	----------

TRAZODONE HYDROCHLORIDE

TABLET;ORAL  
TRAZODONE HYDROCHLORIDE

>A>	AB	CROSSMEDIKA SA	50MG	A211116	001	May 20, 2024	May NEWA
>A>	AB		100MG	A211116	002	May 20, 2024	May NEWA
>A>	AB		150MG	A211116	003	May 20, 2024	May NEWA
>A>	AB		300MG	A211116	004	May 20, 2024	May NEWA

TRETINOIN

CAPSULE;ORAL  
TRETINOIN

AB	ENDO OPERATIONS	10MG	A201687	001	Oct 24, 2012	Apr CAHN
----	-----------------	------	---------	-----	--------------	----------

CREAM;TOPICAL  
TRETINOIN

AB	ALEMBIC	0.1%	A217804	001	Apr 29, 2024	Apr NEWA
AB	ZYDUS LIFESCIENCES	0.1%	A218561	001	Apr 25, 2024	Apr NEWA

TRIAMCINOLONE ACETONIDE

OINTMENT;TOPICAL  
TRIAMCINOLONE ACETONIDE

@	AUROBINDO PHARMA LTD	0.1%	A211315	001	Mar 18, 2020	Jan CAHN
@		0.5%	A211315	002	Mar 18, 2020	Jan CAHN
@	COSETTE	0.5%	A208925	001	Oct 06, 2017	Apr DISC

SPRAY;TOPICAL  
TRIAMCINOLONE ACETONIDE

AT	SAPTALIS PHARMS	0.147MG/GM	A207094	001	Dec 07, 2016	Feb CAHN
----	-----------------	------------	---------	-----	--------------	----------

TRIAZOLAM

TABLET;ORAL  
TRIAZOLAM

@	HIKMA	0.125MG	A074224	001	Jun 01, 1994	Feb DISC
@		0.25MG	A074224	002	Jun 01, 1994	Feb DISC

TRIENTINE HYDROCHLORIDE

CAPSULE;ORAL  
TRIENTINE HYDROCHLORIDE

AB	ENDO OPERATIONS	250MG	A210096	001	Sep 25, 2019	Apr CAHN
----	-----------------	-------	---------	-----	--------------	----------

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION  
TIGAN

+	!	ENDO OPERATIONS	100MG/ML	N017530	001		Apr CAHN
---	---	-----------------	----------	---------	-----	--	----------

TRIMIPRAMINE MALEATE

CAPSULE;ORAL  
TRIMIPRAMINE MALEATE

AB	BRECKENRIDGE	EQ 25MG BASE	A208127	001	Apr 15, 2016	Mar CAHN
AB	!	EQ 50MG BASE	A208127	002	Apr 15, 2016	Mar CAHN
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Mar CAHN

TROSPIUM CHLORIDE

TABLET;ORAL  
TROSPIUM CHLORIDE

AB	ZAMEER PHARMS	20MG	A215781	001	Feb 16, 2022	Feb CAHN
----	---------------	------	---------	-----	--------------	----------

UMECLIDINIUM BROMIDE

POWDER; INHALATION  
INCRUSE ELLIPTA

+! GLAXO GRP ENGLAND EQ 0.0625MG BASE/INH N205382 001 Apr 30, 2014 Jan CPOT

UPADACITINIB

SOLUTION; ORAL  
RINVOQ LQ

+! ABBVIE 1MG/ML N218347 001 Apr 26, 2024 Apr NEWA

URSODIOL

TABLET; ORAL  
URSODIOL

AB ENDO OPERATIONS 250MG A202540 001 Feb 14, 2013 Apr CAHN  
AB 500MG A202540 002 Feb 14, 2013 Apr CAHN

VADADUSTAT

TABLET; ORAL  
VAFSEO

+ AKEBIA 150MG N215192 001 Mar 27, 2024 Mar NEWA  
+ 300MG N215192 002 Mar 27, 2024 Mar NEWA  
+! 450MG N215192 003 Mar 27, 2024 Mar NEWA

VALACYCLOVIR HYDROCHLORIDE

TABLET; ORAL  
VALACYCLOVIR HYDROCHLORIDE

@ CIPLA EQ 500MG BASE A077135 001 May 24, 2010 Apr DISC  
@ EQ 1GM BASE A077135 002 May 24, 2010 Apr DISC

VALBENAZINE TOSYLATE

CAPSULE; ORAL  
INGREZZA

AB + NEUROCRINE EQ 40MG BASE N209241 001 Apr 11, 2017 Mar CFTG  
AB +! EQ 80MG BASE N209241 002 Oct 04, 2017 Mar CFTG  
INGREZZA SPRINKLE  
+ NEUROCRINE EQ 40MG BASE N218390 001 Apr 30, 2024 Apr NEWA  
+ EQ 60MG BASE N218390 002 Apr 30, 2024 Apr NEWA  
+! EQ 80MG BASE N218390 003 Apr 30, 2024 Apr NEWA  
VALBENAZINE TOSYLATE  
AB LUPIN LTD EQ 40MG BASE A216064 001 Apr 05, 2024 Mar NFTG  
AB EQ 80MG BASE A216064 002 Apr 05, 2024 Mar NFTG

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL  
VALGANCICLOVIR HYDROCHLORIDE

>A> AB GPP EQ 450MG BASE A212876 001 Jun 11, 2024 May NEWA

VALPROIC ACID

CAPSULE; ORAL  
VALPROIC ACID

@ EYWA 250MG A207611 001 Aug 05, 2019 Mar DISC  
>D> AB SUN PHARM INDS LTD 250MG A091037 001 Feb 22, 2013 May DISC  
>A> @ 250MG A091037 001 Feb 22, 2013 May DISC

SYRUP; ORAL  
VALPROIC ACID

@ HIKMA 250MG/5ML A074060 001 Jan 13, 1995 Mar DISC  
AA QUAGEN 250MG/5ML A090517 001 May 28, 2010 Jan CAHN

VALRUBICIN

SOLUTION; INTRAVESICAL  
VALSTAR PRESERVATIVE FREE

AO +! ENDO OPERATIONS 40MG/ML N020892 001 Sep 25, 1998 Apr CAHN

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL  
VANCOMYCIN HYDROCHLORIDE

@ PAI HOLDINGS PHARM EQ 125MG BASE A065478 001 Apr 09, 2012 Feb DISC  
@ EQ 250MG BASE A065478 002 Apr 09, 2012 Feb DISC

INJECTABLE; INJECTION

VANCOMYCIN HYDROCHLORIDE

@ PHARM ASSOC	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	Feb	DISC
@	EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	Feb	DISC
@ SANDOZ INC	EQ 5GM BASE/VIAL	A201048	001	Aug 10, 2012	Apr	DISC
@	EQ 10GM BASE/VIAL	A201048	002	Aug 10, 2012	Apr	DISC
VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER						
+! BAXTER HLTHCARE	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CTNA
+!	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CTNA
+!	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CTNA

SOLUTION; INTRAVENOUS

VANCOMYCIN HYDROCHLORIDE IN PLASTIC CONTAINER

+! BAXTER HLTHCARE	EQ 500MG BASE/100ML (EQ 5MG BASE/ML)	N050671	001	Apr 29, 1993	Feb	CPOT
+!	EQ 500MG BASE/100ML	N050671	001	Apr 29, 1993	Feb	CDFR
+!	EQ 750MG BASE/150ML (EQ 5MG BASE/ML)	N050671	002	Dec 20, 2010	Feb	CPOT
+!	EQ 750MG BASE/150ML	N050671	002	Dec 20, 2010	Feb	CDFR
+!	EQ 1GM BASE/200ML (EQ 5MG BASE/ML)	N050671	003	Mar 01, 1999	Feb	CPOT
+!	EQ 1GM BASE/200ML	N050671	003	Mar 01, 1999	Feb	CDFR
+!	EQ 1.25GM BASE/250ML (EQ 5MG BASE/ML)	N050671	004	Jan 25, 2024	Feb	NEWA
+!	EQ 1.5GM BASE/300ML (EQ 5MG BASE/ML)	N050671	005	Jan 25, 2024	Feb	NEWA

VARENICLINE TARTRATE

TABLET; ORAL

VARENICLINE TARTRATE

AB	AJANTA PHARMA LTD	EQ 0.5MG BASE	A213019	001	Mar 19, 2024	Mar	NEWA
AB		EQ 1MG BASE	A213019	002	Mar 19, 2024	Mar	NEWA
AB	AVALANCHE PHARM	EQ 0.5MG BASE	A217283	001	Mar 06, 2024	Feb	NEWA
AB		EQ 1MG BASE	A217283	002	Mar 06, 2024	Feb	NEWA
AB	MYLAN	EQ 0.5MG BASE	A202019	001	Feb 28, 2024	Feb	NEWA
AB		EQ 1MG BASE	A202019	002	Feb 28, 2024	Feb	NEWA

VASOPRESSIN

SOLUTION; INTRAVENOUS

VASOPRESSIN

AP	DR REDDYS	20UNITS/ML (20UNITS/ML)	A213988	001	May 08, 2024	Apr	NEWA
AP	GLAND PHARMA LTD	20UNITS/ML (20UNITS/ML)	A216963	001	Feb 09, 2024	Feb	NEWA

VENLAFAXINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

VENLAFAXINE HYDROCHLORIDE

>A> AB	ALEMBIC	EQ 37.5MG BASE	A217767	001	Jun 06, 2024	May	NEWA
>A> AB		EQ 75MG BASE	A217767	002	Jun 06, 2024	May	NEWA
>A> AB		EQ 150MG BASE	A217767	003	Jun 06, 2024	May	NEWA
>D>	@ ANCHEN PHARMS	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
>A>	@	EQ 37.5MG BASE	A078087	001	Mar 16, 2012	May	CAHN
>D>	@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
>A>	@	EQ 75MG BASE	A078087	002	Mar 16, 2012	May	CAHN
>D>	@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
>A>	@	EQ 150MG BASE	A078087	003	Mar 16, 2012	May	CAHN
>D> AB	NOSTRUM PHARMS LLC	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
>A>	@	EQ 37.5MG BASE	A200430	001	Apr 04, 2023	May	DISC
>D> AB		EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
>A>	@	EQ 75MG BASE	A200430	002	Apr 04, 2023	May	DISC
>D> AB		EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC
>A>	@	EQ 150MG BASE	A200430	003	Apr 04, 2023	May	DISC

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HYDROCHLORIDE

>D> AP	FRESENIUS KABI USA	2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
>A>	@	2.5MG/ML	A216471	001	Apr 23, 2024	May	DISC
AP		2.5MG/ML	A216471	001	Apr 23, 2024	Apr	NEWA

SOLUTION; INTRAVENOUS

VERAPAMIL HYDROCHLORIDE

AP	NEPHRON	5MG/2ML (2.5MG/ML)	A213352	002	Sep 16, 2020	Apr	CAHN
AP		10MG/4ML (2.5MG/ML)	A213352	001	Mar 17, 2020	Apr	CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE  
@ RISING

EQ 10MG BASE/ML

A200148 001 Aug 31, 2012 Mar CAHN

>D> VORAPAXAR SULFATE

>D> TABLET; ORAL  
>D> ZONTIVITY

>D> +! KEY THERAP

EQ 2.08MG BASE

N204886 001 May 08, 2014 May DISC

>A> + @

EQ 2.08MG BASE

N204886 001 May 08, 2014 May DISC

>A> +!

EQ 2.08MG BASE

N204886 001 May 08, 2014 Apr CAHN

VORICONAZOLE

INJECTABLE; INTRAVENOUS  
VORICONAZOLE

AP ASPIRO

200MG/VIAL

A218533 001 Apr 03, 2024 Mar NEWA

ZIDOVUDINE

TABLET; ORAL  
ZIDOVUDINE

@ MYLAN PHARMS INC

300MG

A078922 001 Feb 14, 2008 Apr DISC

ZINC SULFATE

SOLUTION; INTRAVENOUS  
ZINC SULFATE

>A> AP APOTEX

EQ 25MG BASE/5ML (EQ 5MG BASE/ML)

A218059 001 Jun 10, 2024 May NEWA

ZOLEDRONIC ACID

INJECTABLE; INTRAVENOUS  
ZOLEDRONIC ACID

>D> AP HOSPIRA

EQ 4MG BASE/5ML

A090621 001 Mar 19, 2015 May DISC

>A> @

EQ 4MG BASE/5ML

A090621 001 Mar 19, 2015 May DISC

ZOLMITRIPTAN

SPRAY; NASAL  
ZOLMITRIPTAN

AB ! PADAGIS ISRAEL

5MG/SPRAY

A212469 002 Sep 30, 2021 Feb CHRS

TABLET; ORAL  
ZOLMITRIPTAN

@ INVAGEN PHARMS

2.5MG

A204284 001 Apr 09, 2014 Mar DISC

@

5MG

A204284 002 Apr 09, 2014 Mar DISC

ZOLPIDEM TARTRATE

TABLET; ORAL  
ZOLPIDEM TARTRATE

@ INVAGEN PHARMS

5MG

A078184 001 Sep 07, 2007 Mar DISC

@

10MG

A078184 002 Sep 07, 2007 Mar DISC

TABLET; SUBLINGUAL  
ZOLPIDEM TARTRATE

AB ENDO OPERATIONS

1.75MG

A204229 001 Sep 11, 2017 Apr CAHN

AB

3.5MG

A204229 002 Sep 11, 2017 Apr CAHN

>A> AB

5MG

A201509 001 Aug 01, 2016 May CAHN

>A> AB

10MG

A201509 002 Aug 01, 2016 May CAHN

>D> AB

PAR FORM

5MG

A201509 001 Aug 01, 2016 May CAHN

>D> AB

10MG

A201509 002 Aug 01, 2016 May CAHN

TABLET, EXTENDED RELEASE; ORAL  
ZOLPIDEM TARTRATE

>D> @ ANCHEN PHARMS

6.25MG

A078148 002 Apr 14, 2011 May CAHN

>D> @

12.5MG

A078148 001 Dec 03, 2010 May CAHN

>A> @ ENDO OPERATIONS

6.25MG

A078148 002 Apr 14, 2011 May CAHN

>A> @

12.5MG

A078148 001 Dec 03, 2010 May CAHN



ACETAMINOPHEN

SUPPOSITORY;RECTAL

ACEPHEN

@ COSETTE	120MG	N018060	001		Mar	DISC
@	325MG	A072344	001	Mar 27, 1992	Mar	DISC
@	650MG	A072237	001	Mar 27, 1992	Mar	DISC

ACETAMINOPHEN; IBUPROFEN

TABLET;ORAL

ACETAMINOPHEN AND IBUPROFEN

AUROBINDO PHARMA LTD	250MG;125MG	A218359	001	Mar 26, 2024	Apr	CTNA
	250MG;125MG	A218359	001	Mar 26, 2024	Mar	NEWA
GLENMARK PHARMS LTD	250MG;125MG	A218311	001	Apr 26, 2024	Apr	NEWA

ALCAFTADINE

SOLUTION/DROPS;OPHTHALMIC

ALCAFTADINE

GLAND PHARMA LTD	0.25%	A209706	001	Mar 01, 2024	Feb	NEWA
------------------	-------	---------	-----	--------------	-----	------

AZELASTINE HYDROCHLORIDE

SPRAY, METERED;NASAL

AZELASTINE HYDROCHLORIDE

>A>	AMNEAL	0.2055MG/SPRAY	A216576	001	Jun 05, 2024	May	NEWA
>D>	PADAGIS ISRAEL	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
>A>	@	0.2055MG/SPRAY	A216801	001	May 08, 2024	May	DISC
		0.2055MG/SPRAY	A216801	001	May 08, 2024	Apr	NEWA
	AZELASTINE HYDROCHLORIDE	ALLERGY					
>A>	APOTEX	0.2055MG/SPRAY	A216421	001	May 29, 2024	May	NEWA
	AZELASTINE HYDROCHLORIDE	CHILDREN'S ALLERGY					
>A>	APOTEX	0.2055MG/SPRAY	A216421	002	May 29, 2024	May	NEWA

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC

BRIMONIDINE TARTRATE

DR REDDYS LABS SA	0.025%	A216361	001	Feb 16, 2024	Feb	NFTG
LUMIFY PRESERVATIVE FREE						
+! BAUSCH AND LOMB INC	0.025%	N218424	001	Apr 19, 2024	Apr	NEWA

CETIRIZINE HYDROCHLORIDE

SOLUTION;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

AMNEAL PHARMS	5MG/5ML	A090765	002	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	002	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	002	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	001	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	001	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	002	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Feb	CDFR
HETERO LABS LTD III	5MG/5ML	A210622	001	Mar 13, 2019	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A204226	001	Sep 09, 2013	Feb	CDFR
	5MG/5ML	A090254	002	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	002	Apr 22, 2008	Feb	CDFR
QUAGEN	5MG/5ML	A212266	001	May 16, 2019	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	002	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	002	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	001	May 20, 2011	Feb	CDFR
@ TRIS PHARMA INC	5MG/5ML	A090572	001	Nov 16, 2012	Feb	CDFR
	CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF					
AMNEAL PHARMS	5MG/5ML	A090765	001	Oct 07, 2009	Feb	CDFR
@ APOZEAL PHARMS	5MG/5ML	A090474	001	Mar 30, 2009	Feb	CDFR
AUROBINDO PHARMA	5MG/5ML	A090750	001	Feb 02, 2010	Feb	CDFR
BAJAJ	5MG/5ML	A091327	002	Oct 17, 2011	Feb	CDFR
CHARTWELL MOLECULAR	5MG/5ML	A091130	002	Apr 22, 2011	Feb	CDFR
@ CHARTWELL RX	5MG/5ML	A090378	001	May 09, 2008	Feb	CDFR
@ CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Feb	CDFR
PERRIGO R AND D	5MG/5ML	A090254	001	Apr 09, 2008	Feb	CDFR
@ PHARM ASSOC	5MG/5ML	A090188	001	Apr 22, 2008	Feb	CDFR
@ RANBAXY LABS LTD	5MG/5ML	A090183	001	Apr 24, 2008	Feb	CDFR
TARO	5MG/5ML	A090182	001	Apr 22, 2008	Feb	CDFR
	5MG/5ML	A201546	002	May 20, 2011	Feb	CDFR

<u>SOLUTION;ORAL</u>									
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
	@ TRIS PHARMA INC	5MG/5ML	A090572	002	Nov 16, 2012	Feb	CDFR		
CHILDREN'S ZYRTEC ALLERGY									
+!	J AND J CONSUMER INC	5MG/5ML	N022155	002	Nov 16, 2007	Feb	CDFR		
CHILDREN'S ZYRTEC HIVES RELIEF									
+!	J AND J CONSUMER INC	5MG/5ML	N022155	001	Nov 16, 2007	Feb	CDFR		
<u>TABLET, CHEWABLE;ORAL</u>									
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY									
	@ SUN PHARM	5MG	A090142	001	Aug 30, 2011	Mar	DISC		
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF									
	@ SUN PHARM	5MG	A090142	003	Aug 30, 2011	Mar	DISC		
<u>CLOTRIMAZOLE</u>									
<u>CREAM;VAGINAL</u>									
TRIVAGIZOLE 3									
	TARO	2%	N021143	001	Apr 12, 2000	Mar	CAHN		
<u>DICLOFENAC SODIUM</u>									
<u>GEL;TOPICAL</u>									
DICLOFENAC SODIUM									
	@ HIKMA	1%	A209484	001	Nov 21, 2018	Mar	DISC		
<u>DIPHENHYDRAMINE CITRATE; IBUPROFEN</u>									
<u>TABLET;ORAL</u>									
IBUPROFEN AND DIPHENHYDRAMINE CITRATE									
	PLD ACQUISITIONS LLC	38MG;200MG	A211404	001	Apr 11, 2024	Apr	NEWA		
<u>DOCOSANOL</u>									
<u>CREAM;TOPICAL</u>									
DOCOSANOL									
	AUROBINDO PHARMA LTD	10%	A217090	001	Mar 01, 2024	Feb	NEWA		
	P AND L DEVELOPMENT	10%	A212385	001	Oct 07, 2022	Mar	CAHN		
<u>ESOMEPRAZOLE MAGNESIUM</u>									
<u>CAPSULE, DELAYED RELEASE;ORAL</u>									
ESOMEPRAZOLE MAGNESIUM									
	DR REDDYS	EQ 20MG BASE	A207198	001	Apr 30, 2024	Apr	NEWA		
>A>	GLENMARK SPECLT	EQ 20MG BASE	A218092	001	Jun 11, 2024	May	NEWA		
	GUARDIAN DRUG	EQ 20MG BASE	A216149	001	Mar 15, 2023	Feb	CAHN		
<u>TABLET, DELAYED RELEASE;ORAL</u>									
ESOMEPRAZOLE MAGNESIUM									
	AUROBINDO PHARMA LTD	EQ 20MG BASE	A214473	001	Jul 12, 2023	Apr	CMFD		
	@	EQ 20MG BASE	A214473	001	Jul 12, 2023	Jan	DISC		
<u>FAMOTIDINE</u>									
<u>TABLET;ORAL</u>									
FAMOTIDINE									
>A>	CONTRACT PHARMACAL	10MG	A218003	001	May 28, 2024	May	NEWA		
>A>		20MG	A218003	002	May 28, 2024	May	NEWA		
	GRAVITI PHARMS	10MG	A218461	001	Mar 14, 2024	Mar	NEWA		
		20MG	A218461	002	Mar 14, 2024	Mar	NEWA		
	@ SUN PHARM INDS LTD	10MG	A090283	001	Nov 17, 2009	Apr	DISC		
	@	20MG	A090283	002	Nov 17, 2009	Apr	DISC		
<u>FLUTICASONE PROPIONATE</u>									
<u>SPRAY, METERED;NASAL</u>									
FLUTICASONE PROPIONATE									
>A>	AUROBINDO PHARMA LTD	0.05MG/SPRAY	A217088	001	May 10, 2024	May	NEWA		
	@ HIKMA	0.05MG/SPRAY	A208024	001	Apr 17, 2019	Mar	DISC		
<u>IBUPROFEN</u>									
<u>CAPSULE;ORAL</u>									
IBUPROFEN									
	@ AUROBINDO PHARMA LTD	EQ 200MG FREE ACID AND POTASSIUM SALT	A215777	001	Sep 14, 2023	Mar	DISC		
	PATHEON SOFTGELS	EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Mar	CAHN		
		EQ 200MG FREE ACID AND POTASSIUM SALT	A217236	001	Feb 13, 2024	Feb	NEWA		

SUSPENSION/DROPS;ORAL

## IBUPROFEN

	AUROBINDO PHARMA LTD	40MG/ML	A213506	001	Apr 08, 2024	Mar	NEWA
--	----------------------	---------	---------	-----	--------------	-----	------

TABLET;ORAL

## IBUPROFEN

>A>	ENDO OPERATIONS	200MG	A071229	001	Apr 01, 1987	May	CAHN
>A>	@	200MG	A071639	001	Feb 02, 1988	May	CAHN
>A>	@	200MG	A072249	001	Jan 10, 1989	May	CAHN
>D>	VINTAGE PHARMS	200MG	A071229	001	Apr 01, 1987	May	CAHN
>D>	@	200MG	A071639	001	Feb 02, 1988	May	CAHN
>D>	@	200MG	A072249	001	Jan 10, 1989	May	CAHN

LEVONORGESTRELTABLET;ORAL

## LEVONORGESTREL

>D>	@ MYLAN LABS LTD	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
>D>		1.5MG	A202739	001	Oct 31, 2014	May	CAHN
	NAARI PTE LTD	1.5MG	A207660	001	May 02, 2019	Apr	CMFD
>A>	@ XIROMED	0.75MG	A202740	001	Sep 02, 2016	May	CAHN
>A>		1.5MG	A202739	001	Oct 31, 2014	May	CAHN

LOPERAMIDE HYDROCHLORIDESOLUTION;ORAL

## LOPERAMIDE HYDROCHLORIDE

	@ SAPTALIS PHARMS	1MG/5ML	A074352	001	Nov 17, 1995	Jan	CAHN
--	-------------------	---------	---------	-----	--------------	-----	------

LOPERAMIDE HYDROCHLORIDE; SIMETHICONETABLET;ORAL

## LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE

>D>	SUN PHARM INDS LTD	2MG;125MG	A077500	001	Sep 06, 2006	May	DISC
>A>	@	2MG;125MG	A077500	001	Sep 06, 2006	May	DISC

LORATADINE; PSEUDOEPHEDRINE SULFATETABLET, EXTENDED RELEASE;ORAL

## LORATADINE AND PSEUDOEPHEDRINE SULFATE

>A>	BIONPHARMA	10MG;240MG	A218017	001	May 14, 2024	May	NEWA
-----	------------	------------	---------	-----	--------------	-----	------

MICONAZOLE NITRATECREAM;VAGINAL

## MICONAZOLE NITRATE

	@ COSETTE	2%	A074366	001	Feb 22, 1996	Apr	DISC
--	-----------	----	---------	-----	--------------	-----	------

SUPPOSITORY;VAGINAL

## MICONAZOLE NITRATE

	@ COSETTE	100MG	A074414	001	Apr 30, 1997	Apr	DISC
--	-----------	-------	---------	-----	--------------	-----	------

MINOXIDILAEROSOL, FOAM;TOPICAL

## MINOXIDIL (FOR MEN)

	AUROBINDO PHARMA	5%	A218616	001	Apr 22, 2024	Apr	NEWA
--	------------------	----	---------	-----	--------------	-----	------

## MINOXIDIL (FOR WOMEN)

	AUROBINDO PHARMA	5%	A218616	002	Apr 22, 2024	Apr	NEWA
--	------------------	----	---------	-----	--------------	-----	------

MOMETASONE FUROATESPRAY, METERED;NASAL

## MOMETASONE FUROATE

	APOTEX	0.05MG/SPRAY	A217438	001	Apr 23, 2024	Apr	NEWA
--	--------	--------------	---------	-----	--------------	-----	------

NALOXONE HYDROCHLORIDESPRAY, METERED;NASAL

## NALOXONE HYDROCHLORIDE

	AMNEAL	4MG/SPRAY	A217992	001	Apr 23, 2024	Apr	NEWA
--	--------	-----------	---------	-----	--------------	-----	------

NAPROXEN SODIUMTABLET;ORAL

## NAPROXEN SODIUM

	@ SUN PHARM INDS LTD	220MG	A091183	001	May 20, 2011	Jan	DISC
--	----------------------	-------	---------	-----	--------------	-----	------

NICOTINE POLACRILEXTROCHE/LOZENGE; ORAL  
NICORETTE

+	HALEON US HOLDINGS	EQ 2MG BASE	N022360	001	May 18, 2009	Jan	CAHN
+	!	EQ 4MG BASE	N022360	002	May 18, 2009	Jan	CAHN

NORGESTRELTABLET; ORAL  
OPILL

+	!	LABORATOIRE HRA	0.075MG	N017031	001		Feb	CMFD
---	---	-----------------	---------	---------	-----	--	-----	------

OLOPATADINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

@	SAPTALIS PHARMS	EQ 0.2% BASE	A204723	001	Dec 05, 2017	Jan	CAHN
	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Apr	CMKT

OMEPRAZOLE; SODIUM BICARBONATEFOR SUSPENSION; ORAL  
OMEPRAZOLE AND SODIUM BICARBONATE

>A>		DR REDDYS	20MG/PACKET; 1.68GM/PACKET	A217784	001	May 09, 2024	May	NFTG
-----	--	-----------	----------------------------	---------	-----	--------------	-----	------

POVIDONE-IODINESPONGE; TOPICAL  
E-Z SCRUB 201

+	@	BECTON DICKINSON	20%	N019240	001	Nov 29, 1985	Feb	DISC
---	---	------------------	-----	---------	-----	--------------	-----	------

E-Z SCRUB 241

+	@	BECTON DICKINSON	10%	N019476	001	Jan 07, 1987	Feb	DISC
---	---	------------------	-----	---------	-----	--------------	-----	------

TERBINAFINEGEL; TOPICAL  
LAMISIL AT

+	!	KARO HLTHCARE	1%	N021958	001	Jul 24, 2006	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

TERBINAFINE HYDROCHLORIDECREAM; TOPICAL  
LAMISIL

+	!	KARO HLTHCARE	1%	N020980	001	Mar 09, 1999	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

SOLUTION; TOPICAL  
LAMISIL AT

+	!	KARO HLTHCARE	1%	N021124	001	Mar 17, 2000	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

SPRAY; TOPICAL  
LAMISIL AT

+	!	KARO HLTHCARE	1%	N021124	002	Mar 17, 2000	Feb	CAHN
---	---	---------------	----	---------	-----	--------------	-----	------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND  
RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 5 MAY 2024**

NO MAY 2024 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of Orphan Designations and Approvals is available at:

[https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products.](https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products)

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO MAY 2024 APPROVALS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABALOPARATIDE - TYMLOS</u>						
N 208743 001	>A> 11977067	Apr 30, 2038	DP			
<u>ACETAMINOPHEN; IBUPROFEN - ACETAMINOPHEN AND IBUPROFEN</u>						
A 218311 001					>A> PC	Nov 03, 2024
<u>ACETAMINOPHEN; IBUPROFEN - ADVIL DUAL ACTION WITH ACETAMINOPHEN</u>						
N 211733 001	11918693	Jul 09, 2041	DP			
<u>ACETAMINOPHEN; IBUPROFEN SODIUM - COMBOGESIC IV</u>						
N 215320 001	11896567	Oct 26, 2031	U-3744			
	11896567	Oct 26, 2031	U-3745			
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 001					>A> NP	Feb 13, 2027
<u>ACETYLCYSTEINE LYSINE - LEGUBETI</u>						
N 215040 002					>A> NP	Feb 13, 2027
<u>ACYCLOVIR - ACYCLOVIR</u>						
A 212361 001					CGT	Jun 12, 2024
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001					>A> I-947 >A> ODE-477	Apr 18, 2027 Apr 18, 2031
<u>ALPELISIB - PIORAY</u>						
N 212526 001	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 002	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - PIORAY</u>						
N 212526 003	8227462	Apr 29, 2033	DS DP U-3809		I-937	Jan 18, 2027
<u>ALPELISIB - VIJOICE</u>						
N 218466 001	>A> 8227462	Apr 29, 2033	DS DP			
	>A> 8476268	Sep 10, 2029	DS DP			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 001	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - GOCOVRI</u>						
N 208944 002	11903908	Jun 17, 2034	U-3822			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 001	11890261	Feb 15, 2038	U-2497			
<u>AMANTADINE HYDROCHLORIDE - OSMOLEX ER</u>						
N 209410 002	11890261	Feb 15, 2038	U-2497			
<u>AMLODIPINE BENZOATE - KATERZIA</u>						
N 211340 001	11918685	Oct 06, 2037	U-3447			
	11918685	Oct 06, 2037	U-3448			
<u>AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA</u>						
N 213004 001	11878011	May 27, 2042	U-3816			
	11931463	Feb 12, 2034	DP U-3866			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	9839619	Jun 28, 2032	DP			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 001	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 002	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 003	11896562	Mar 10, 2037	U-3299			
<u>AMPHETAMINE SULFATE - EVEKEO ODT</u>						
N 209905 004	11896562	Mar 10, 2037	U-3299			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 001	>A> 11963952	Jan 30, 2040	U-3901			
<u>APALUTAMIDE - ERLEADA</u>						
N 210951 002	>A> 11963952	Jan 30, 2040	U-3901			
<u>APREMILAST - OTEZLA</u>						
N 205437 001	10092541	May 29, 2034	U-2403		>A> I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		>A> M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			>A> NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		>A> ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			>A> PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		>A> PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		>A> PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 002	10092541	May 29, 2034	U-2403		>A> I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		>A> M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			>A> NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		>A> ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			>A> PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		>A> PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		>A> PED	Oct 25, 2027
	9872854*PED	Nov 29, 2034				
<u>APREMILAST - OTEZLA</u>						
N 205437 003	10092541	May 29, 2034	U-2403		>A> I-884	Dec 20, 2024
	10092541	May 29, 2034	U-2659		>A> M-299	Jul 20, 2026
	10092541*PED	Nov 29, 2034			>A> NPP	Apr 25, 2027
	7427638	Feb 16, 2028	DS DP		>A> ODE-248	Jul 19, 2026
	7427638*PED	Aug 16, 2028			>A> PED	Jan 19, 2027
	9872854	May 29, 2034	U-2232		>A> PED	Jan 20, 2027
	9872854	May 29, 2034	U-2233		>A> PED	Oct 25, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	9872854*PED	Nov 29, 2034				
<u>APREPITANT - APONVIE</u>						
N 216457 001	11878074	Sep 18, 2035	U-3787			
<u>APROCITENTAN - TRYVIO</u>						
N 217686 001	10919881	Feb 26, 2038	DS DP		NCE	Mar 22, 2029
	11174247	Nov 06, 2037	U-3879			
	11680058	Jul 26, 2038	U-3878			
	11787782	Mar 02, 2038	U-3877			
	8324232	Sep 21, 2029	DS DP U-3878			
<u>ASCIMINIB HYDROCHLORIDE - SCEMBLIX</u>						
N 215358 003	>A> 11407735	May 14, 2040	DS		>A> NCE	Oct 29, 2026
	>A> 8829195	May 13, 2033	DS U-1374		>A> ODE*	Oct 29, 2028
<u>ATORVASTATIN CALCIUM - ATORVALIO</u>						
N 213260 001	11925704	Jun 07, 2037	DP U-3853			
<u>ATROPINE SULFATE - ATROPINE SULFATE</u>						
A 217791 001					>A> CGT	Dec 04, 2024
<u>AVACOPAN - TAVNEOS</u>						
N 214487 001	11951214	Nov 27, 2039	DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 001	11964980	Apr 10, 2040	DS DP			
	>A> 11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 002	11964980	Apr 10, 2040	DS DP			
	>A> 11999744	Apr 10, 2040	U-3168			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 003	11964980	Apr 10, 2040	DS DP			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 004	11964980	Apr 10, 2040	DS DP			
	>A> 11999744	Apr 10, 2040	U-3168			
	>A> 11999744	Apr 10, 2040	U-3506			
<u>AVAPRITINIB - AYVAKIT</u>						
N 212608 005	11964980	Apr 10, 2040	DS DP			
	>A> 11999744	Apr 10, 2040	U-3168			
<u>AVATROMBOPAG MALEATE - DOPTELET</u>						
N 210238 001	7638536	Jul 28, 2027	DS DP			
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001	7112592	Jan 07, 2026	DS DP U-2244		NPP	Jan 26, 2027
	7112592	Jan 07, 2026	DS DP U-2508			
	7112592	Jan 07, 2026	DS DP U-282			
	7112592	Jan 07, 2026	DS DP U-3818			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 001	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BACLOFEN - LYVISPAH</u>						
N 215422 002	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BACLOFEN - LYVISPAH</u>						
N 215422 003	11850225	Sep 29, 2041	DP U-3488			
	11850225	Sep 29, 2041	DP U-3489			
	11931328	Jul 29, 2039	DP			
<u>BALOXAVIR MARBOXIL - XOFLUZA</u>						
N 214410 001	11925648	Apr 21, 2041	DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 001	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 002	8158616	May 31, 2032	DS DP			
<u>BARICITINIB - OLUMIANT</u>						
N 207924 003	8158616	May 31, 2032	DS DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 001	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	>A> 11957832	May 05, 2041	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR REDIHALER</u>						
N 207921 002	11865247	Jan 26, 2038	DP			
	11896759	Jan 26, 2038	DP			
	>A> 11957832	May 05, 2041	DP			
<u>BELZUTIFAN - WELIREG</u>						
N 215383 001	>A> RE49948	Sep 05, 2034	DS DP U-3201		I-931	Dec 14, 2026
	>A> RE49948	Sep 05, 2034	DS DP U-3780			
<u>BEMPEDOIC ACID - NEXLETOL</u>						
N 211616 001	11744816	Mar 14, 2036	U-3883		>A> I-943	Mar 22, 2027
	11926584	Jun 19, 2040	U-3873		>A> I-944	Mar 22, 2027
	>A> 7335799	Dec 03, 2030	DS			
<u>BEMPEDOIC ACID; EZETIMIBE - NEXLIZET</u>						
N 211617 001	10912751	Mar 14, 2036	U-3224		>A> I-943	Mar 22, 2027
	10912751	Mar 14, 2036	U-3884		>A> I-945	Mar 22, 2027
	11744816	Mar 14, 2036	U-3692			
	11744816	Mar 14, 2036	U-3883			
	11926584	Jun 19, 2040	U-3873			
	>A> 7335799	Dec 03, 2030	DS			
<u>BENDAMUSTINE HYDROCHLORIDE - BELRAPZO</u>						
N 205580 001	11872214	Jan 28, 2031	DP			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	11872214	Jan 28, 2031	DP			
<u>BENZOYL PEROXIDE - EPSOLAY</u>						
N 214510 001	11865100	Feb 19, 2040	U-3357			
	11877997	Feb 19, 2040	U-3356			
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10258564	Nov 22, 2034	U-3797		NCE	Jan 05, 2029
	10258564	Nov 22, 2034	U-3798			
	10258564	Nov 22, 2034	U-3799			
	10265334	Jul 03, 2032	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BERDAZIMER SODIUM - ZELSUVMI</u>						
N 217424 001	10322081	Jul 10, 2035	U-3793			
	10322081	Jul 10, 2035	U-3794			
	10322081	Jul 10, 2035	U-3795			
	10322081	Jul 10, 2035	U-3796			
	10376538	Aug 20, 2030	DP			
	10736839	Jul 10, 2035	U-3790			
	10736839	Jul 10, 2035	U-3791			
	10736839	Jul 10, 2035	U-3792			
	11040006	Jul 10, 2035	DP U-3789			
	11285098	Feb 28, 2034	DP			
	11723858	Jul 10, 2035	DP U-3788			
	8282967	May 30, 2026	DS			
	8956658	May 30, 2026	DS			
	9289442	Jul 03, 2032	DP U-3803			
	9526738	Sep 03, 2031	DP			
	9737561	Aug 20, 2030	U-3802			
	9855211	Feb 27, 2034	DP U-3800			
	9855211	Feb 27, 2034	DP U-3801			
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 001					I-942 M-305 ODE-468	Feb 23, 2027 Apr 24, 2027 Feb 23, 2031
<u>BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY</u>						
N 210251 002	7390791	Apr 17, 2025	DS DP		I-942 ODE-468	Feb 23, 2027 Feb 23, 2031
	7390791*PED	Oct 17, 2025				
	8754065	Aug 15, 2032	DS DP U-257			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-257			
	9296769*PED	Feb 15, 2033				
<u>BINIMETINIB - MEKTOVI</u>						
N 210498 001	7777050	Mar 13, 2025	DS DP			
<u>BIRCH TRITERPENES - FILSUVEZ</u>						
N 215064 001	11083733	Jan 04, 2039	DP		NCE ODE-460	Dec 18, 2028 Dec 18, 2030
	11266660	Jan 04, 2039	U-3811			
	8828444	Jun 21, 2025	DP			
	9352041	Nov 24, 2030	U-3811			
	9827214	Nov 24, 2030	U-3811			
<u>BIVALIRUDIN - ANGIOMAX RTU</u>						
N 211215 001	11903993	May 20, 2039	U-3817			
	11918622	May 20, 2039	U-3817			
	>A> 11992514	May 20, 2039	DP			
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 001	>A> 10307419	Oct 12, 2032	DP		>A> I-913	May 10, 2026
	>A> 10307419*PED	Apr 12, 2033			>A> M-14	May 08, 2027
	>A> 7888362	Apr 12, 2026	DS	Y	>A> PED	Nov 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8349840*PED	Oct 12, 2026				
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 002	>A> 10307419	Oct 12, 2032	DP		>A> I-913	May 10, 2026
	>A> 10307419*PED	Apr 12, 2033			>A> M-14	May 08, 2027
	>A> 7888362	Apr 12, 2026	DS	Y	>A> PED	Nov 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8349840*PED	Oct 12, 2026				
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 003	>A> 10307419	Oct 12, 2032	DP		>A> I-913	May 10, 2026
	>A> 10307419*PED	Apr 12, 2033			>A> M-14	May 08, 2027
	>A> 7888362	Apr 12, 2026	DS	Y	>A> PED	Nov 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8349840*PED	Oct 12, 2026				
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 004	>A> 10307419	Oct 12, 2032	DP		>A> I-913	May 10, 2026
	>A> 10307419*PED	Apr 12, 2033			>A> M-14	May 08, 2027
	>A> 7888362	Apr 12, 2026	DS	Y	>A> PED	Nov 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8349840*PED	Oct 12, 2026				
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 005	>A> 10307419	Oct 12, 2032	DP		>A> I-913	May 10, 2026
	>A> 10307419*PED	Apr 12, 2033			>A> M-14	May 08, 2027
	>A> 7888362	Apr 12, 2026	DS	Y	>A> PED	Nov 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529			
	>A> 8349840*PED	Oct 12, 2026				
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BREXPIRAZOLE - REXULTI</u>						
N 205422 006	>A> 7888362	Apr 12, 2026	DS	Y	>A> I-913	May 10, 2026
	>A> 7888362*PED	Oct 12, 2026			>A> M-14	May 08, 2027
	>A> 8349840	Apr 12, 2026	DP U-1529		>A> PED	Nov 10, 2026
	>A> 8349840*PED	Oct 12, 2026			>A> PED	Nov 08, 2027
	>A> 8618109	Apr 12, 2026	U-3281			
	>A> 8618109	Apr 12, 2026	U-543			
	>A> 8618109*PED	Oct 12, 2026				
	>A> 9839637	Apr 12, 2026	DP U-1529			
	>A> 9839637	Apr 12, 2026	DP U-3281			
	>A> 9839637	Apr 12, 2026	DP U-543			
	>A> 9839637*PED	Oct 12, 2026				
	>A> RE48059	Dec 23, 2028	DS			
	>A> RE48059*PED	Jun 23, 2029				
<u>BRIMONIDINE TARTRATE - LUMIFY PRESERVATIVE FREE</u>						
N 218424 001	>A> 11596600	Jul 27, 2029	U-2222			
	>A> 8293742	Jul 14, 2030	U-2222			
	>A> 9259425	Jul 14, 2030	U-2222			
<u>BROMFENAC SODIUM - BROMFENAC SODIUM</u>						
A 206027 001					PC	Jul 06, 2024
<u>BUDESONIDE - EOHILIA</u>						
N 213976 001	10293052	Nov 22, 2028	DP		NP	Feb 09, 2027
	11197822	Nov 09, 2026	DP		ODE-466	Feb 09, 2031
	11260064	Jan 10, 2039	DP			
	11357859	Nov 12, 2028	U-3820			
	11413296	Nov 09, 2026	DP			
	11564934	Jan 10, 2039	U-3820			
	8324192	Aug 03, 2029	U-3820			
	8497258	Nov 09, 2026	U-3820			
	8679545	Nov 09, 2026	DP			
	8975243	Nov 09, 2026	U-3820			
	9050368	Aug 01, 2029	DP			
	9119863	Nov 09, 2026	U-3820			
<u>BUDESONIDE - TARPEYO</u>						
N 215935 001	11896719	Jan 23, 2043	U-3810		ODE-464	Dec 20, 2030
	8491932	May 07, 2029	DP U-3269			
	8491932	May 07, 2029	DP U-3781			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	11918565	Feb 02, 2043	U-3841		I-929	Nov 09, 2026
	11925706	Jan 22, 2041	DP U-3380			
	11931459	Mar 17, 2042	U-3839			
	11931459	Mar 17, 2042	U-3840			
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 001					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 002					I-933	Jan 23, 2027
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988 003					I-933	Jan 23, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE; MELOXICAM - ZYNRELEF KIT</u>						
N 211988	004				I-933	Jan 23, 2027
<u>BUPROPION HYDROCHLORIDE; DEXTROMETHORPHAN HYDROBROMIDE - AUVELITY</u>						
N 215430	001	11883373	Jan 23, 2043	U-3419		
		11896563	Dec 01, 2041	U-3419		
		11925636	Jan 20, 2043	U-3419		
		11969421	Nov 05, 2034	U-3419		
	>A>	11986444	Feb 15, 2043	U-3419		
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010	001	11154509	Apr 25, 2028	U-3815		
		9498486	Apr 25, 2028	U-3814		
<u>CANNABIDIOL - EPIDIOLEX</u>						
N 210365	001	11865102	Apr 26, 2039	DS DP U-2781		
		11865102	Apr 26, 2039	DS DP U-3236		
		11865102	Apr 26, 2039	DS DP U-3277		
	>A>	11963937	Jun 17, 2035	U-2780		
	>A>	11963937	Jun 17, 2035	U-2781		
<u>CANTHARIDIN - YCANTH</u>						
N 212905	001				NCE	Jul 21, 2028
<u>CEDAZURIDINE; DECITABINE - INQOVI</u>						
N 212576	001	>A> 11963971	Feb 24, 2041	DP		
<u>CEFEPIME HYDROCHLORIDE; ENMETAZOACTAM - EXBLIFEP</u>						
N 216165	001	11124526	Nov 07, 2034	U-3852	NCE	Feb 22, 2029
		7687488	Dec 03, 2027	DS DP U-3851	GAIN	Feb 22, 2034
<u>CEFTOBIPROLE MEDOCARIL SODIUM - ZEVTERA</u>						
N 218275	001				NCE GAIN	Apr 03, 2029 Apr 03, 2034
<u>CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO</u>						
N 212819	001	>A> 8487093	Mar 21, 2033	DS DP U-2586		
		>A> 8487093	Mar 21, 2033	DS DP U-2587		
		>A> 8487093	Mar 21, 2033	DS DP U-2840		
<u>CLASCOTERONE - WINLEVI</u>						
N 213433	001	>A> 11938141	Jul 24, 2028	DP		
		>A> 8865690	Jul 24, 2025	U-2942		
		>A> 9211295	May 31, 2025	DP		
<u>CLOBETASOL PROPIONATE - CLOBETASOL PROPIONATE</u>						
N 218158	001	10588913	May 09, 2036	DP	NP	Mar 04, 2027
		11376262	May 09, 2036	DP U-19		
<u>CLONIDINE HYDROCHLORIDE - ONYDA XR</u>						
N 217645	001	>A> 11918689	Jul 28, 2041	DP U-3944		
		>A> 8062667	Mar 29, 2029	DP		
<u>COLCHICINE - LODOCO</u>						
N 215727	001	10130585	May 09, 2034	U-3642		
		10206891	Nov 01, 2033	U-3641		
		10265281	Nov 01, 2033	U-3639		
		10842762	Nov 01, 2033	U-3640		
		11026899	Nov 01, 2033	U-3639		
		11026900	Nov 01, 2033	U-3639		
		11026901	Nov 01, 2033	U-3638		
		11944594	Nov 01, 2033	U-3864		
		11944595	Nov 01, 2033	U-3867		
		11944595	Nov 01, 2033	U-3868		
		9744144	Nov 01, 2033	U-3643		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>COLCHICINE - IODOCO</u>						
N 215727 001	10130585	May 09, 2034	U-3642			
	10206891	Nov 01, 2033	U-3641			
	10265281	Nov 01, 2033	U-3639			
	10842762	Nov 01, 2033	U-3640			
	11026899	Nov 01, 2033	U-3639			
	11026900	Nov 01, 2033	U-3639			
	11026901	Nov 01, 2033	U-3638			
	11944594	Nov 01, 2033	U-3864			
	11944595	Nov 01, 2033	U-3867			
	11944595	Nov 01, 2033	U-3868			
	9744144	Nov 01, 2033	U-3643			
<u>CORTICOTROPIN - PURIFIED CORTROPHIN GEL</u>						
N 008975 002	>A> 11975047	Oct 27, 2043	U-3904			
	>A> 11975047	Oct 27, 2043	U-3905			
	>A> 11975047	Oct 27, 2043	U-3906			
	>A> 11975047	Oct 27, 2043	U-3907			
	>A> 11975047	Oct 27, 2043	U-3908			
	>A> 11975047	Oct 27, 2043	U-3909			
	>A> 11975047	Oct 27, 2043	U-3910			
	>A> 11975047	Oct 27, 2043	U-3911			
	>A> 11975047	Oct 27, 2043	U-3912			
	>A> 11975047	Oct 27, 2043	U-3913			
	>A> 11975047	Oct 27, 2043	U-3914			
	>A> 11975047	Oct 27, 2043	U-3915			
	>A> 11975047	Oct 27, 2043	U-3916			
	>A> 11975047	Oct 27, 2043	U-3917			
	>A> 11975047	Oct 27, 2043	U-3918			
	>A> 11975047	Oct 27, 2043	U-3919			
	>A> 11975047	Oct 27, 2043	U-3920			
	>A> 11975047	Oct 27, 2043	U-3921			
	>A> 11975047	Oct 27, 2043	U-3922			
	>A> 11975047	Oct 27, 2043	U-3923			
	>A> 11975047	Oct 27, 2043	U-3924			
	>A> 11975047	Oct 27, 2043	U-3925			
	>A> 11975047	Oct 27, 2043	U-3926			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 001	11975022	Jul 01, 2041	U-3899			
	>A> 11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT</u>						
N 209376 002	11975022	Jul 01, 2041	U-3899			
	>A> 11998565	Jul 01, 2041	DP			
<u>CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRY5</u>						
N 209376 003	11975022	Jul 01, 2041	U-3900			
	>A> 11998565	Jul 01, 2041	DP			
<u>CYCLOSPORINE - RESTASIS MULTIDOSE</u>						
N 050790 002	8629111	Aug 27, 2024	DP		Y	
	8633162	Aug 27, 2024	U-1479		Y	
	8642556	Aug 27, 2024	DP		Y	
	8648048	Aug 27, 2024	U-1483		Y	
	8685930	Aug 27, 2024	DP		Y	
	9248191	Aug 27, 2024	U-1479		Y	
<u>CYCLOSPORINE - CEQUA</u>						
N 210913 001	11951153	Feb 28, 2037	U-1483			
<u>CYSTEINE HYDROCHLORIDE - ELCYS</u>						
N 210660 001	>A> 11969439	Jan 15, 2039	U-2752			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CYSTEINE HYDROCHLORIDE - NOURESS</u>						
N 212535 001	>A> 11642370	Jan 15, 2039	DP			
	>A> 11648262	Jan 15, 2039	DP			
	>A> 11679125	Jan 15, 2039	DP			
	>A> 11684636	Jan 15, 2039	DP			
	>A> 11826383	Jan 15, 2039	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002					I-908 ODE-428 PED PED	Mar 16, 2026 Mar 16, 2030 Sep 16, 2026 Sep 16, 2030
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 217514 001	11504333	Jun 29, 2038	DP		NP ODE-428	Mar 16, 2026 Mar 16, 2030
	11504333*PED	Dec 29, 2038				
	7994185	Jan 20, 2030	DS DP		PED	Sep 16, 2026
	7994185*PED	Jul 20, 2030			PED	Sep 16, 2030
	8415345	Jan 20, 2030	DS DP			
	8415345*PED	Jul 20, 2030				
	8703781	Oct 15, 2030	DS DP U-3565			
	8703781*PED	Apr 15, 2031				
	8835443	Jun 10, 2025		U-3565		
	8835443*PED	Dec 10, 2025				
<u>DANICOPAN - VOYDEYA</u>						
N 218037 001	>A> 9796741	Feb 25, 2035	DS U-3933		NCE ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DANICOPAN - VOYDEYA</u>						
N 218037 002	>A> 9796741	Feb 25, 2035	DS U-3933		NCE ODE-476	Mar 29, 2029 Mar 29, 2031
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	>A> 6515117	Oct 04, 2025	DS DP U-2139		>A> M-298	May 08, 2026
	>A> 6515117	Oct 04, 2025	DS DP U-493		>A> PED	Nov 08, 2026
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7456254	Jun 30, 2025		U-2139		
	>A> 7456254*PED	Dec 30, 2025				
	>A> 7851502	Aug 19, 2028		DP		
	>A> 7851502*PED	Feb 19, 2029				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8221786	Mar 21, 2028		DP		
	>A> 8221786*PED	Sep 21, 2028				
	>A> 8329648	Aug 18, 2026		U-2139		
	>A> 8329648	Aug 18, 2026		U-2212		
	>A> 8329648	Aug 18, 2026		U-2213		
	>A> 8329648*PED	Feb 18, 2027				
	>A> 8361972	Mar 21, 2028		U-2139		
	>A> 8361972	Mar 21, 2028		U-493		
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8431685	Apr 13, 2025		U-2139		
	>A> 8431685*PED	Oct 13, 2025				
	>A> 8461105	Apr 13, 2025		U-2139		
	>A> 8461105*PED	Oct 13, 2025				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030		U-1522		
	>A> 8685934*PED	Nov 26, 2030				
	>A> 8716251	Mar 21, 2028	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 001	>A> 8716251*PED	Sep 21, 2028				
	>A> 8721615	Jan 18, 2030	DP	Y		
	>A> 8721615*PED	Jul 18, 2030				
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293 002	>A> 10973836	Mar 09, 2040	U-3127		>A> M-298	May 08, 2026
	>A> 10973836*PED	Sep 09, 2040			>A> PED	Nov 08, 2026
	>A> 11826376	Jul 18, 2039	U-3766			
	>A> 11826376*PED	Jan 18, 2040				
	>A> 11903955	Mar 09, 2040	U-3825			
	>A> 11903955*PED	Sep 09, 2040				
	>A> 6515117	Oct 04, 2025	DS DP U-2139			
	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7456254	Jun 30, 2025	U-2139			
	>A> 7456254*PED	Dec 30, 2025				
	>A> 7851502	Aug 19, 2028	DP			
	>A> 7851502*PED	Feb 19, 2029				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8221786	Mar 21, 2028	DP			
	>A> 8221786*PED	Sep 21, 2028				
	>A> 8329648	Aug 18, 2026	U-2139			
	>A> 8329648	Aug 18, 2026	U-2212			
	>A> 8329648	Aug 18, 2026	U-2213			
	>A> 8329648*PED	Feb 18, 2027				
	>A> 8361972	Mar 21, 2028	U-2139			
	>A> 8361972	Mar 21, 2028	U-493			
	>A> 8361972*PED	Sep 21, 2028				
	>A> 8431685	Apr 13, 2025	U-2139			
	>A> 8431685*PED	Oct 13, 2025				
	>A> 8461105	Apr 13, 2025	U-2139			
	>A> 8461105*PED	Oct 13, 2025				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 8716251	Mar 21, 2028	DP			
	>A> 8716251*PED	Sep 21, 2028				
	>A> 8721615	Jan 18, 2030	DP	Y		
	>A> 8721615*PED	Jul 18, 2030				
	>A> 8906851	Aug 18, 2026	U-2139			
	>A> 8906851*PED	Feb 18, 2027				
	>A> 9238076	Apr 15, 2024	U-2139			
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 001	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 002	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 003	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 005	>A> 6515117	Oct 04, 2025	DS DP U-493			
	>A> 6515117*PED	Apr 04, 2026				
	>A> 7919598	Dec 16, 2029	DS			
	>A> 7919598*PED	Jun 16, 2030				
	>A> 8501698	Jun 20, 2027	DP U-493			
	>A> 8501698*PED	Dec 20, 2027				
	>A> 8685934	May 26, 2030	U-1522			
	>A> 8685934*PED	Nov 26, 2030				
	>A> 9616028	Nov 12, 2030	DP			
	>A> 9616028*PED	May 12, 2031				
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 001	>A> 11963995	May 21, 2029	U-2327			
<u>DESMOPRESSIN ACETATE - NOCDURNA</u>						
N 022517 002	>A> 11963995	May 21, 2029	U-2327			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 001	11890272	Jul 17, 2040	U-3756			
	>A> 11998529	Jul 17, 2040	U-3935			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - IGALMI</u>						
N 215390 002	11890272	Jul 17, 2040	U-3756			
	>A> 11998529	Jul 17, 2040	U-3935			
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 001	>A> 11273131	Jun 18, 2038	DP	>A> NP		Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 002	>A> 11273131	Jun 18, 2038	DP	>A> NP		Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 003	>A> 11273131	Jun 18, 2038	DP	>A> NP		Apr 26, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 004	>A> 11273131	Jun 18, 2038	DP		>A> NP	Apr 26, 2027
<u>DIAZEPAM - LIBERVANT</u>						
N 218623 005	>A> 11273131	Jun 18, 2038	DP		>A> NP	Apr 26, 2027
<u>DOLUTEGRAVIR SODIUM; LAMIVUDINE - DOVATO</u>						
N 211994 001					>A> NPP	Apr 05, 2027
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 001	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 002	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE - NAMZARIC</u>						
N 206439 004	8168209	Nov 22, 2025	DP		Y	
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-1641		Y	
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-1641		Y	
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP		Y	
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-1641		Y	
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP		Y	
	8598233*PED	May 22, 2026				
<u>DROSPIRENONE - SLYND</u>						
N 211367 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE - DROSPIRENONE</u>						
N 216285 001	11951213	Jun 28, 2031	U-2553			
<u>DROSPIRENONE; ESTETROL - NEXTSTELLIS</u>						
N 214154 001	11957694	Jun 17, 2036	DP			
	11964055	Jun 17, 2036	DP			
<u>EDARAVONE - RADICAVA ORS</u>						
N 215446 001	11957660	Nov 01, 2039	DP		ODE-144	May 12, 2029
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 001					M-14	Oct 18, 2026
<u>EDOXABAN TOSYLATE - SAVAYSA</u>						
N 206316 002					M-14	Oct 18, 2026

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EDOXYBAN TOSYLATE - SAVAYSA</u>						
N 206316	003				M-14	Oct 18, 2026
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567	001	11872218	Jan 03, 2028	U-1969		
<u>EFLORNITHINE HYDROCHLORIDE - IWILFIN</u>						
N 215500	001				NP ODE-462	Dec 13, 2026 Dec 13, 2030
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	001	7419983	Jul 06, 2029	DS DP U-2360		
<u>ELAGOLIX SODIUM - ORILISSA</u>						
N 210450	002	7419983	Jul 06, 2029	DS DP U-2360		
<u>ELAGOLIX SODIUM, ESTRADIOL, NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED)</u>						
N 213388	001	7419983	Jul 06, 2029	DS DP		
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774	001	>A> 11072586	Nov 05, 2038	DS DP U-3936		
		>A> 11072586	Nov 05, 2038	DS DP U-3937		
		>A> 11072586	Nov 05, 2038	DS DP U-3938		
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774	002	>A> 11072586	Nov 05, 2038	DS DP U-3936		
		>A> 11072586	Nov 05, 2038	DS DP U-3937		
		>A> 11072586	Nov 05, 2038	DS DP U-3938		
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774	003	>A> 11072586	Nov 05, 2038	DS DP U-3936		
		>A> 11072586	Nov 05, 2038	DS DP U-3937		
		>A> 11072586	Nov 05, 2038	DS DP U-3938		
<u>ELTROMBOPAG CHOLINE - ALVAIZ</u>						
N 216774	004	>A> 11072586	Nov 05, 2038	DS DP U-3936		
		>A> 11072586	Nov 05, 2038	DS DP U-3937		
		>A> 11072586	Nov 05, 2038	DS DP U-3938		
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215	002				ODE-457	Jan 07, 2029
<u>EPLONTERSEN SODIUM - WAINUA (AUTOINJECTOR)</u>						
N 217388	001	10683499	Aug 25, 2034	DS DP U-2378	NCE	Dec 21, 2028
		8101743	Apr 01, 2025	DS DP	ODE-461	Dec 21, 2030
		9127276	May 01, 2034	DS		
		9181549	May 01, 2034	DS		
<u>ERDAFITINIB - BALVERSA</u>						
N 212018	001	>A> 10478494	Aug 13, 2036	U-3902	I-930	Jan 19, 2027
		10898482	Feb 09, 2036	DP U-2518		
		10898482	Feb 09, 2036	DP U-3065		
		10898482	Feb 09, 2036	DP U-3066		
		10898482	Feb 09, 2036	DP U-3067		
		10898482	Feb 09, 2036	DP U-3805		
		10898482	Feb 09, 2036	DP U-3806		
		10898482	Feb 09, 2036	DP U-3807		
		11077106	Feb 02, 2038	U-3196		
		11077106	Feb 02, 2038	U-3808		
		11684620	Feb 09, 2036	U-3805		
		11684620	Feb 09, 2036	U-3806		
		11684620	Feb 09, 2036	U-3807		
		9464071	Apr 28, 2031	U-3805		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 002 >A>	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ERDAFITINIB - BALVERSA</u>						
N 212018 003 >A>	10478494	Aug 13, 2036	U-3902		I-930	Jan 19, 2027
	10898482	Feb 09, 2036	DP U-2518			
	10898482	Feb 09, 2036	DP U-3065			
	10898482	Feb 09, 2036	DP U-3066			
	10898482	Feb 09, 2036	DP U-3067			
	10898482	Feb 09, 2036	DP U-3805			
	10898482	Feb 09, 2036	DP U-3806			
	10898482	Feb 09, 2036	DP U-3807			
	11077106	Feb 02, 2038	U-3196			
	11077106	Feb 02, 2038	U-3808			
	11684620	Feb 09, 2036	U-3805			
	11684620	Feb 09, 2036	U-3806			
	11684620	Feb 09, 2036	U-3807			
	9464071	Apr 28, 2031	U-3805			
<u>ESKETAMINE HYDROCHLORIDE - SPRAVATO</u>						
N 211243 001	11883526	Feb 18, 2040	U-3812			
	11883526	Feb 18, 2040	U-3813			
<u>ESTRADIOL - ESTRADIOL</u>						
A 216160 001				>A> CGT		Oct 23, 2024
<u>ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE</u>						
N 214846 001	11957684	Sep 29, 2037	U-3129			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 001	11865179	Nov 21, 2032	DS DP			
<u>ESTRADIOL; PROGESTERONE - BIJUVA</u>						
N 210132 002	11865179	Nov 21, 2032	DS DP			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 001 >A>	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 002 >A>	11959486	Jun 27, 2034	DP U-2014			
<u>ETELCALCETIDE - PARSABIV</u>						
N 208325 003 >A>	11959486	Jun 27, 2034	DP U-2014			
<u>ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA</u>						
N 209627 001	11850251	Jun 21, 2039	U-3785			
<u>ETRASIMOD ARGININE - VELSIPITY</u>						
N 216956 001	11884626	Jun 21, 2036	U-3731			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 002	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 003	7612109	Feb 05, 2025	DS DP			
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 004	7612109	Feb 05, 2025	DS DP			
<u>FIDAXOMICIN - DIFICID</u>						
N 213138 001	8586551*PED	Jan 15, 2024				
<u>FINERENONE - KERENDIA</u>						
N 215341 001	RE49826	Jul 29, 2035	DS			
<u>FINERENONE - KERENDIA</u>						
N 215341 002	RE49826	Jul 29, 2035	DS			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001	>A> 11980674	Apr 23, 2042		U-2450		
<u>FLUOROMETHOLONE - FLUOROMETHOLONE</u>						
A 216348 001					CGT	Jul 07, 2024
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP	Y		
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 001	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 002	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 003	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 004	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 005	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 006	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK</u>						
N 208798 007	>A> 11969544	Aug 20, 2039	DP			
<u>FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER</u>						
N 208798 008	>A> 11969544	Aug 20, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE PROPIONATE - XHANCE</u>						
N 209022	001				I-940	Mar 15, 2027
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	001	>A> 11969544	Aug 20, 2039	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	002	>A> 11969544	Aug 20, 2039	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK</u>						
N 208799	003	>A> 11969544	Aug 20, 2039	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799	004	>A> 11969544	Aug 20, 2039	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799	005	>A> 11969544	Aug 20, 2039	DP		
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER</u>						
N 208799	006	>A> 11969544	Aug 20, 2039	DP		
<u>FOSTEMSAVIR TROMETHAMINE - RUKOBIA</u>						
N 212950	001	8168615	Jul 13, 2029	DP		
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564	001				NCE	Nov 30, 2028
<u>FRUQUINTINIB - FRUZAOLA</u>						
N 217564	002				NCE	Nov 30, 2028
<u>GILTERITINIB FUMARATE - XOSPATA</u>						
N 211349	001	11938130	Jul 01, 2036	DP		
		11938131	Jul 01, 2036	DP		
		11938132	Jul 01, 2036	DP		
		11938133	Jul 01, 2036	DP		
		11944620	Jul 01, 2036	DP		
		8969336	Nov 28, 2032	DS DP		
<u>GIVINOSTAT HYDROCHLORIDE - DUVYZAT</u>						
N 217865	001	10688047	Oct 28, 2036	DP U-3885	NCE	Mar 21, 2029
		7329689	Jan 15, 2025	DS DP	ODE-473	Mar 21, 2031
		9421184	Feb 03, 2032	U-3885		
		9867799	Feb 03, 2032	U-3885		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	001	11891372	Apr 13, 2036	U-3254		
<u>GLASDEGIB MALEATE - DAURISMO</u>						
N 210656	002	11891372	Apr 13, 2036	U-3254		
<u>GLYCEROL PHENYL BUTYRATE - RAVICTI</u>						
N 203284	001	8404215	Mar 09, 2032	U-1383	Y	
		9254278	Sep 22, 2030	U-1816		
		9326966	Sep 22, 2030	U-1816		
<u>GLYCOPYRROLATE; NEOSTIGMINE METHYLSULFATE - PREVDUO</u>						
N 216903	001	11938217	Oct 25, 2038	DP		
<u>GOLODIRSEN - VYONDYS 53</u>						
N 211970	001	>A> RE47691	Jun 28, 2028	DP		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HALOBETASOL PROPIONATE - HALOBETASOL PROPIONATE</u>						
A 215266	001				PC	Jun 24, 2024
<u>HALOBETASOL PROPIONATE - BRYHALI</u>						
N 209355	001	>A> 11957753	Nov 02, 2031	DP		
		>A> 11986527	Nov 02, 2031	U-2625		
<u>HALOBETASOL PROPIONATE; TAZAROTENE - DUOBRII</u>						
N 209354	001	>A> 11957753	Nov 02, 2031	DP		
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520	001				NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HEPARIN SODIUM; TAUROLIDINE - DEFENCATH</u>						
N 214520	002				NCE GAIN	Nov 15, 2028 Nov 15, 2033
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899	002				>A> PC	Nov 11, 2024
<u>HYDROMORPHONE HYDROCHLORIDE - HYDROMORPHONE HYDROCHLORIDE</u>						
A 216899	003				>A> PC	Dec 02, 2024
<u>HYDROXYUREA - XROMI</u>						
N 216593	001				ODE-470	Apr 04, 2031
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	001	8754090	Jun 03, 2031	U-1456	Y	
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552	002	8754090	Jun 03, 2031	U-1456	Y	
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	001	8754090	Jun 03, 2031	U-1456	Y	
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	002	8754090	Jun 03, 2031	U-1456	Y	
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 210563	003	8754090	Jun 03, 2031	U-1456	Y	
		8754090*PED	Dec 03, 2031			
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003	001	10004746	Jun 03, 2031	U-3846		
		10004746	Jun 03, 2031	U-3847		
		10004746	Jun 03, 2031	U-3848		
		10004746	Jun 03, 2031	U-3849		
		10016435	Jun 03, 2031	U-3845		
		10463668	Oct 24, 2034	U-2970		
		10478439	Jun 03, 2031	U-2666		
		10478439	Jun 03, 2031	U-2970		
		10478439	Jun 03, 2031	U-3422		
		10478439	Jun 03, 2031	U-3842		
		10478439	Jun 03, 2031	U-3843		
		10478439	Jun 03, 2031	U-3844		
		10478439	Jun 03, 2031	U-3845		
		10478439*PED	Dec 03, 2031			
		10695350	Oct 24, 2034	U-2970		
		10751342	Jun 03, 2031	U-2666		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IBRUTINIB - IMBRUVICA</u>						
N 217003 001	10751342	Jun 03, 2031	U-3842			
	10751342	Jun 03, 2031	U-3843			
	10751342	Jun 03, 2031	U-3844			
	11672803	Jun 03, 2031	U-2666			
	11672803	Jun 03, 2031	U-3842			
	11672803	Jun 03, 2031	U-3843			
	11672803	Jun 03, 2031	U-3844			
	8476284	Dec 28, 2026	U-3843			
	8476284	Dec 28, 2026	U-3844			
	8476284	Dec 28, 2026	U-3845			
	8497277	Dec 28, 2026	U-2666			
	8497277	Dec 28, 2026	U-2970			
	8497277	Dec 28, 2026	U-3422			
	8497277	Dec 28, 2026	U-3842			
	8497277	Dec 28, 2026	U-3843			
	8497277	Dec 28, 2026	U-3844			
	8497277	Dec 28, 2026	U-3845			
	8497277*PED	Jun 28, 2027				
	8563563	Apr 26, 2027	U-2666			
	8563563	Apr 26, 2027	U-3842			
	8563563	Apr 26, 2027	U-3843			
	8563563	Apr 26, 2027	U-3844			
	8563563	Apr 26, 2027	U-3845			
	8703780	Dec 28, 2026	U-2666			
	8703780	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-2666			
	8952015	Dec 28, 2026	U-3842			
	8952015	Dec 28, 2026	U-3843			
	8952015	Dec 28, 2026	U-3844			
	8952015	Dec 28, 2026	U-3845			
	8999999	Jun 03, 2031	U-2666			
	8999999	Jun 03, 2031	U-3842			
	8999999	Jun 03, 2031	U-3843			
	8999999	Jun 03, 2031	U-3844			
	9125889	Jun 03, 2031	U-3845			
	9795604	Oct 24, 2034	U-2970			
	9795604	Oct 24, 2034	U-3422			
	9795604*PED	Apr 24, 2035				
	9801881	Jun 03, 2031	U-3846			
	9801881	Jun 03, 2031	U-3847			
	9801883	Jun 03, 2031	U-2666			
	9801883	Jun 03, 2031	U-3842			
	9801883	Jun 03, 2031	U-3843			
	9801883	Jun 03, 2031	U-3844			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 001					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002					NPP	May 11, 2026
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 003					NPP	May 11, 2026
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003					I-939	Apr 02, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					I-939	Apr 02, 2027
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					I-939	Apr 02, 2027
<u>ILOPROST - AURLUMYN</u>						
N 217933 001					NP ODE-465	Feb 13, 2027 Feb 13, 2031
<u>IMIQUIMOD - ZYCLARA</u>						
N 022483 001	11850245	Apr 30, 2030	U-1455			
	11850245	Apr 30, 2030	U-172			
<u>INDOMETHACIN - INDOMETHACIN</u>						
A 217883 001					CGT	Jul 10, 2024
<u>IPTACOPAN HYDROCHLORIDE - FABHALTA</u>						
N 218276 001	11951101	Jul 15, 2041	U-3895		NCE ODE-456	Dec 05, 2028 Dec 05, 2030
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	11344552	Aug 19, 2036	U-3824		I-932 ODE-463	Feb 13, 2027 Feb 13, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 001					NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207500 002					NPP ODE-454 ODE-458 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>ISAVUCONAZONIUM SULFATE - CRESEMBA</u>						
N 207501 001					NPP ODE-453 ODE-459 PED PED PED	Dec 08, 2026 Dec 08, 2030 Dec 08, 2030 Jun 08, 2027 Jun 08, 2031 Jun 08, 2031
<u>IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED)</u>						
N 210491 001	11951212	Apr 14, 2035	DP U-3894			
<u>LANSOPRAZOLE - LANSOPRAZOLE</u>						
N 208025 001	>A> 11986554	Apr 21, 2036	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LATANOPROST - IYUZEH</u>						
N 216472 001	8637054	Jul 08, 2031	DP U-446			
<u>LATANOPROSTENE BUNOD - VYZULTA</u>						
N 207795 001	8058467	Feb 21, 2029	DS U-2144			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 001	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LEMBOREXANT - DAYVIGO</u>						
N 212028 002	10702529	Oct 21, 2035	DP			
	11026944	Oct 21, 2035	DP			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215973 001	11944611	Jun 04, 2041	U-3507			
<u>LENACAPAVIR SODIUM - SUNLENCA</u>						
N 215974 001	11944611	Jun 04, 2041	DS DP U-3507			
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-269	Jul 21, 2024
	10407393	Aug 26, 2035	DS		M-272	Dec 19, 2024
	10407393*PED	Feb 26, 2036			ODE-196	Aug 15, 2025
	11090386	Feb 23, 2036		U-3519	PED	Feb 15, 2026
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002	10259791	Aug 26, 2035	DS		I-868	Aug 10, 2024
	10259791*PED	Feb 26, 2036			M-269	Jul 21, 2024
	10407393	Aug 26, 2035	DS		M-272	Dec 19, 2024
	10407393*PED	Feb 26, 2036			ODE-196	Aug 15, 2025
	11090386	Feb 23, 2036		U-3519	PED	Feb 15, 2026
	11090386*PED	Aug 23, 2036				
	11186547	Aug 26, 2035	DS			
	11186547*PED	Feb 26, 2036				
	7253286	Oct 24, 2025	DS DP			
	7253286*PED	Apr 24, 2026				
	7612208	Sep 19, 2026	DS DP			
	7612208*PED	Mar 19, 2027				
	9006256	Jul 27, 2027		U-1695		
	9006256*PED	Jan 27, 2028				
<u>LETERMOVIR - PREVMIS</u>						
N 209939 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209939 002	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209940 001	RE46791	Jan 18, 2029	DS DP			
<u>LETERMOVIR - PREVMIS</u>						
N 209940 002	RE46791	Jan 18, 2029	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021343 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021379 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021488 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - ELIGARD KIT</u>						
N 021731 001	11931559	Dec 22, 2041	DS			
<u>LEUPROLIDE ACETATE - FENSOLVI KIT</u>						
N 213150 001	11931559	Dec 22, 2041	DS			
<u>LEVOKETOCONAZOLE - RECORLEY</u>						
N 214133 001	11903940	Mar 02, 2040	U-3821			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003					M-304	Mar 24, 2026
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004					M-304	Mar 24, 2026
<u>LEVONORGESTREL - MIRENA</u>						
N 021225 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - SKYLA</u>						
N 203159 001	11850182	Sep 14, 2029	DP U-3819			
<u>LEVONORGESTREL - KYLEENA</u>						
N 208224 001	11850182	Sep 14, 2029	DP U-3819			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	11911388	Apr 10, 2030	U-3854			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	11911388	Apr 10, 2030	U-3854			
<u>LOTEPREDNOL ETABONATE - INVELTYS</u>						
N 210565 001	11872318	May 03, 2033	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOTEPREDNOL ETABONATE - EYSUVIS</u>						
N 210933 001	11872318	May 03, 2033	DP			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 001	>A> 11980617	Oct 27, 2039	U-3940			
	8598119	Dec 28, 2029	U-543	Y		
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 002	>A> 11980617	Oct 27, 2039	U-3940			
<u>LUMATEPERONE TOSYLATE - CAPLYTA</u>						
N 209500 003	>A> 11980617	Oct 27, 2039	U-3940			
<u>LUTETIUM LU 177 DOTATATE - LUTATHERA</u>						
N 208700 001	10596276	Jul 25, 2038	DP		ODE-166	Jan 26, 2025
	10596276*PED	Jan 25, 2039			>A> ODE-479	Apr 23, 2031
	10596278	Jul 25, 2038	DP		PED	Jul 26, 2025
	10596278*PED	Jan 25, 2039			>A> PED	Oct 23, 2031
	11904027	Jul 25, 2038	DP			
	11904027*PED	Jan 25, 2039				
<u>LUTETIUM LU-177 VIPIVOTIDE TETRAKETAN - PLUVICTO</u>						
N 215833 001	>A> 11951190	Nov 12, 2035	U-3345			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 001	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MACITENTAN; TADALAFIL - OPSYNVI</u>						
N 218490 002	10946015	Sep 11, 2026	DP U-3881		NP	Mar 22, 2027
	7094781	Dec 05, 2025	DS DP		ODE-475	Mar 22, 2031
	8268847	Apr 18, 2029	DP U-3882			
<u>MARALIXIBAT CHLORIDE - LIVMARLI</u>						
N 214662 001	10512657	Oct 26, 2032	U-3850		I-938	Mar 13, 2027
	11229661	Oct 26, 2032	U-3850		ODE-471	Mar 13, 2031
	11918578	Feb 12, 2040	U-3290			
<u>MAVORIXAFOR - XOLREMDI</u>						
N 218709 001	>A> 10548889	Dec 11, 2038	DP		>A> NCE	Apr 26, 2029
	>A> 10610527	Dec 22, 2036	U-3932		>A> ODE-480	Apr 26, 2031
	>A> 10953003	Dec 14, 2036	DP			
	>A> 11045461	Dec 11, 2038	DP			
	>A> 11219621	Dec 22, 2036	U-3932			
<u>METAXALONE - METAXALONE</u>						
N 022503 001	11918559	Jul 29, 2039	DP			
<u>METHOTREXATE SODIUM - XATMEP</u>						
N 208400 001	>A> 11969503	Jan 02, 2033	DP			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					M-303	Jan 08, 2027
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 002					M-303	Jan 08, 2027
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 001	11911518	Mar 23, 2032	U-2357			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 002	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 003	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 004	11911518	Mar 23, 2032	U-2357			
<u>METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM</u>						
N 209311 005	11911518	Mar 23, 2032	U-2357			
<u>MIFEPRISTONE - MIFEPRISTONE</u>						
A 211436 001					PC	Jul 17, 2024
<u>MIFEPRISTONE - KORLYM</u>						
N 202107 001	>A> 11969435	Jun 19, 2037	U-1643			
<u>MIGALASTAT HYDROCHLORIDE - GALAFOLD</u>						
N 208623 001	11903938	Aug 17, 2038	DS U-2371			
	>A> RE48608	Oct 20, 2031	U-2371			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	11944634	Oct 16, 2032	DP			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 001	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 002	11878049	Jul 31, 2041	U-3782			
<u>MITAPIVAT SULFATE - PYRUKYND</u>						
N 216196 003	11878049	Jul 31, 2041	U-3782			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 001	>A> 11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 002	>A> 11963962	Dec 02, 2040	U-3928			
<u>MOMELOTINIB DIHYDROCHLORIDE - OJJAARA</u>						
N 216873 003	>A> 11963962	Dec 02, 2040	U-3928			
<u>MONOMETHYL FUMARATE - BAFIERTAM</u>						
N 210296 001	11903918	Feb 27, 2035	U-1384			
<u>MYCOPHENOLATE MOFETIL - MYHIBBIN</u>						
N 216482 001	>A> 11931455	Aug 16, 2039	DP U-1752			
<u>NALOXONE HYDROCHLORIDE - KLOXXADO</u>						
N 212045 001					NP	Apr 29, 2024
<u>NALOXONE HYDROCHLORIDE - REZENOPY</u>						
N 215487 001				>A> NP		Apr 19, 2027
<u>NALOXONE HYDROCHLORIDE - RIVIVE</u>						
N 217722 001	11806428	May 11, 2032	DP			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11872211	May 19, 2043	U-3754		NCE	Nov 27, 2028
	11884634	Aug 09, 2039	DP		ODE-452	Nov 27, 2030
	11884635	Aug 09, 2039	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 001	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043	U-3754			
	11925620	May 19, 2043	U-3754			
	11938116	May 19, 2043	U-3754			
	11951096	May 19, 2043	U-3754			
	11957662	May 19, 2043	U-3754			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 002	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NIROGACESTAT HYDROBROMIDE - OGSIVEO</u>						
N 217677 003	10590087	Aug 09, 2039	DS		NCE	Nov 27, 2028
	10710966	Aug 09, 2039	DS	U-3754	ODE*	Nov 27, 2030
	10941118	Aug 09, 2039	DS	U-3754		
	11504354	Jul 08, 2042	DP			
	11612588	Jul 08, 2042	DP	U-3754		
	11807611	Sep 08, 2042	DP	U-3754		
	11820748	Aug 09, 2039	DP			
	11844780	Sep 08, 2042	DP	U-3754		
	11845732	Aug 09, 2039	DS	U-3754		
	11872211	May 19, 2043		U-3754		
	11884634	Aug 09, 2039	DP			
	11884635	Aug 09, 2039	DP			
	11905255	Aug 09, 2039	DP			
	11925619	May 19, 2043		U-3754		
	11925620	May 19, 2043		U-3754		
	11938116	May 19, 2043		U-3754		
	11951096	May 19, 2043		U-3754		
	11957662	May 19, 2043		U-3754		
	7342118	Aug 18, 2025	DS			
	7795447	Aug 18, 2025	DS			
	7951958	Mar 11, 2025	DS			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	>A> 11931377	Jun 03, 2029	DS DP	U-3903		
	>A> 11931377*PED	Dec 03, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 004	>A> 11931377	Jun 03, 2029	DS DP	U-3903		
<u>NITROGLYCERIN - NITROGLYCERIN</u>						
A 216103 001					CGT	Aug 21, 2024
<u>NUSINERSEN SODIUM - SPINRAZA</u>						
N 209531 001	8361977	Dec 23, 2030	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OCTREOTIDE ACETATE - MYCAPSSA</u>						
N 208232 001	11857595	Feb 03, 2036	U-3784		ODE-474	Jun 26, 2027
	11890316	Dec 28, 2040	U-3232			
	11969471	Sep 17, 2029	DP			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 001	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 002	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 003	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI</u>						
N 213378 004	11951111	Nov 12, 2041	U-3886			
	11951111	Nov 12, 2041	U-3887			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 001	>A> 11970530	Oct 25, 2041	U-3929			
	>A> 11970530	Oct 25, 2041	U-3930			
	>A> 11970530	Oct 25, 2041	U-3931			
	>A> 11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLAPARIB - LYNPARZA</u>						
N 208558 002	>A> 11970530	Oct 25, 2041	U-3929			
	>A> 11970530	Oct 25, 2041	U-3930			
	>A> 11970530	Oct 25, 2041	U-3931			
	>A> 11975001	Oct 07, 2029	DP			
	7449464	Sep 08, 2027	DS DP			
<u>OLICERIDINE - OLINVYK</u>						
N 210730 001	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 002	11931350	Mar 23, 2032	DS	U-2986		
<u>OLICERIDINE - OLINVYK</u>						
N 210730 003	11931350	Mar 23, 2032	DS	U-2986		
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209816 001	>A> 7553828	Jun 02, 2025	DS			
<u>OMADACYCLINE TOSYLATE - NUZYRA</u>						
N 209817 001	>A> 7553828	Jun 02, 2025	DS			
<u>OMAVELOXOLONE - SKYCLARYS</u>						
N 216718 001	11919838	Apr 20, 2029	U-3862			
	11919838	Apr 20, 2029	U-3863			
<u>OMEPRAZOLE; SODIUM BICARBONATE - KONVOMEF</u>						
N 213593 001	11911473	Jul 16, 2039	U-623			
	11911473	Jul 16, 2039	U-624			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OPICAPONE - ONGENTYS</u>						
N 212489 001	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OPICAPONE - ONGENTYS</u>						
N 212489 002	10583130	Mar 31, 2030	U-3869			
	8168793	Apr 02, 2029	DS DP U-3869			
	8524746	Jul 14, 2029	U-3869			
	9550759	Jul 26, 2026	U-3870			
	9550759	Jul 26, 2026	U-3871			
	9550759	Jul 26, 2026	U-3872			
	9630955	Dec 12, 2032	DS DP U-3869			
	9745290	Oct 10, 2027	DP U-3869			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002	10183020	Jan 02, 2035	DP U-1777		I-941	Feb 16, 2027
	10183020	Jan 02, 2035	DP U-2289			
	10183020	Jan 02, 2035	DP U-3016			
	10183020	Jan 02, 2035	DP U-3823			
	8946235	Aug 08, 2032	DS DP U-1777			
	8946235	Aug 08, 2032	DS DP U-2289			
	8946235	Aug 08, 2032	DS DP U-3016			
	8946235	Aug 08, 2032	DS DP U-3823			
	9732058	Jul 25, 2032	DS DP U-1777			
	9732058	Jul 25, 2032	DS DP U-2289			
	9732058	Jul 25, 2032	DS DP U-3016			
	9732058	Jul 25, 2032	DS DP U-3823			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	11896599	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	11896599	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	11964056	Aug 24, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	11964056	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200534 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 001					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 200535 002					M-14	Jul 21, 2024
<u>OXYCODONE HYDROCHLORIDE - OXYCODONE HYDROCHLORIDE</u>						
N 201194 001					M-14	Jul 21, 2024
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 001	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 002	10239846	Nov 15, 2030	U-3740			
<u>OZANIMOD HYDROCHLORIDE - ZEPOSIA</u>						
N 209899 003	10239846	Nov 15, 2030	U-3740			
<u>PEGCETACOPLAN - EMPAVELI</u>						
N 215014 001	11844841	Dec 09, 2038	DP U-3172			
	11844841	Dec 09, 2038	DP U-3173			
	11844841	Dec 09, 2038	DP U-3174			
<u>PEGCETACOPLAN - SYFOVRE</u>						
N 217171 001	11903994	Feb 22, 2037	U-3826			
	11903994	Feb 22, 2037	U-3827			
	11903994	Feb 22, 2037	U-3828			
<u>PEGULICIANINE ACETATE - LUMISIGHT</u>						
N 214511 001	10285759	Dec 08, 2031	U-3890		>A> NCE	Apr 17, 2029
	9032965	Dec 08, 2031	U-3890			
	9155471	Oct 12, 2031	U-3890			
	9532835	Dec 08, 2031	U-3890			
	9763577	Sep 14, 2034	DS DP U-3890			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	May 23, 2025	DS DP U-106			
	6949571	May 23, 2025	DS DP U-2088			
	6949571	May 23, 2025	DS DP U-2089			
	6949571	May 23, 2025	DS DP U-2428			
	6949571	May 23, 2025	DS DP U-2429			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PERFLUTREN - DEFINITY RT</u>						
N 021064 002	11857646	Mar 16, 2037		U-665		
	11925695	Mar 16, 2037		U-665		
<u>PHENTOLAMINE MESYLATE - RYZUMVI</u>						
N 217064 001	10278918	Jan 31, 2034	DP			
	10772829	Jan 31, 2034	DP			
	11090261	Jan 31, 2034	DP			
	11400077	Oct 25, 2039		U-3804		
	11844858	Jan 31, 2034	DP			
	9795560	Jan 31, 2034	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE; TROPICAMIDE - MYDCOMBI</u>						
N 215352 001	11839487	Jul 15, 2031		U-3685		
<u>PIFLUFOLASTAT F-18 - PYLARIFY</u>						
N 214793 001	11851407	Jun 09, 2037	DS DP U-3130			
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 001					ODE-451	Dec 01, 2030
<u>PIRTOBRUTINIB - JAYPIRCA</u>						
N 216059 002					ODE-451	Dec 01, 2030

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 001					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 002					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 003					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONATINIB HYDROCHLORIDE - ICLUSIG</u>						
N 203469 004					I-934 ODE-472	Mar 19, 2027 Mar 19, 2031
<u>PONESIMOD - PONVORY</u>						
N 213498 001	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 002	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 003	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 004	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 005	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 006	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 007	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 008	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 009	11951097	Oct 10, 2042	U-3891			
<u>PONESIMOD - PONVORY</u>						
N 213498 010	11951097	Oct 10, 2042	U-3891			
<u>PRALSETINIB - GAVRETO</u>						
N 213721 001	11872192	Apr 03, 2039	U-2952			
	>A> 11963958	Apr 03, 2039	U-2828			
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10675296	Jul 10, 2038	DP		NCE	Oct 22, 2025
	10675296*PED	Jan 10, 2039			NPP	Apr 25, 2025
	10695361	Sep 16, 2036	U-3831		PED	Jul 21, 2025
	10695361	Sep 16, 2036	U-3832		PED	Oct 25, 2025
	10695361*PED	Mar 16, 2037			PED	Apr 22, 2026
	11007208	Sep 16, 2036	U-3831		PED	Jan 13, 2027
	11007208	Sep 16, 2036	U-3832			
	11007208*PED	Mar 16, 2037				
	11266681	Jul 10, 2038	U-3831			
	11266681	Jul 10, 2038	U-3832			
	11266681*PED	Jan 10, 2039				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>REMDESIVIR - VEKLURY</u>						
N 214787 001	11382926	Sep 16, 2036	U-3831			
	11382926	Sep 16, 2036	U-3832			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3835			
	11491169	May 28, 2041	U-3836			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3835			
	11903953	May 28, 2041	U-3836			
	11903953*PED	Nov 28, 2041				
>A>	11975012	May 28, 2041	U-3835			
>A>	11975012	May 28, 2041	U-3836			
>A>	11975017	Jul 10, 2038	DP			
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMDESIVIR - VEKLURY</u>						
N 214787 002	10065958	Sep 16, 2031	DS		D-183	Jan 21, 2025
	10065958*PED	Mar 16, 2032			M-301	Jul 13, 2026
	10695361	Sep 16, 2036	U-3829		NCE	Oct 22, 2025
	10695361	Sep 16, 2036	U-3830		NPP	Apr 25, 2025
	10695361*PED	Mar 16, 2037			PED	Jul 21, 2025
	11007208	Sep 16, 2036	U-3829		PED	Oct 25, 2025
	11007208	Sep 16, 2036	U-3830		PED	Apr 22, 2026
	11007208*PED	Mar 16, 2037			PED	Jan 13, 2027
	11382926	Sep 16, 2036	U-3829			
	11382926	Sep 16, 2036	U-3830			
	11382926*PED	Mar 16, 2037				
	11491169	May 28, 2041	U-3833			
	11491169	May 28, 2041	U-3834			
	11491169*PED	Nov 28, 2041				
	11492353	Dec 08, 2031	DS			
	11492353*PED	Jun 08, 2032				
	11903953	May 28, 2041	U-3837			
	11903953	May 28, 2041	U-3838			
	11903953*PED	Nov 28, 2041				
>A>	11975012	May 28, 2041	U-3833			
>A>	11975012	May 28, 2041	U-3834			
	8008264	Sep 06, 2029	DS DP			
	8008264*PED	Mar 06, 2030				
	8318682	Apr 22, 2029	DS DP			
	8318682*PED	Oct 22, 2029				
	9724360	Oct 29, 2035	DS DP			
	9724360*PED	Apr 29, 2036				
	9949994	Oct 29, 2035	DS			
	9949994*PED	Apr 29, 2036				
	RE46762	Apr 22, 2029	DS DP			
	RE46762*PED	Oct 22, 2029				
<u>REMIMAZOLAM BESYLATE - BYFAVO</u>						
N 212295 001	>A> 9827251	Jan 13, 2034	U-2968			
<u>REPOTRECTINIB - AUGTYRO</u>						
N 218213 001					NCE	Nov 15, 2028
					ODE-455	Nov 15, 2030

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 001	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	>A> 11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 002	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	>A> 11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RESMETIROM - REZDIFFRA</u>						
N 217785 003	10376517	Sep 17, 2033	U-3861		NCE	Mar 14, 2029
	11564926	Sep 17, 2033	DS DP U-3861			
	>A> 11986481	Sep 17, 2033	U-3861			
	7452882	Sep 12, 2026	DS DP			
	9266861	Sep 17, 2033	DS DP			
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT</u>						
N 202022 001	7125879	Apr 21, 2025	DS DP U-1153			
	7125879	Apr 21, 2025	DS DP U-1307			
	7125879	Apr 21, 2025	DS DP U-1740			
	7125879	Apr 21, 2025	DS DP U-3353			
	7125879	Apr 21, 2025	DS DP U-3874			
	7125879*PED	Oct 21, 2025				
<u>RILPIVIRINE HYDROCHLORIDE - EDURANT PED</u>						
N 219016 001	11065198	Oct 23, 2037	DP			
	7125879	Apr 21, 2025	DS DP U-3874			
<u>RIPRETINIB - QINLOCK</u>						
N 213973 001	11896585	Dec 30, 2040	DP			
	11903933	Dec 30, 2040	DP			
	11911370	Dec 30, 2040	DP			
	11918564	Dec 30, 2040	DP			
	11969414	Feb 08, 2041	U-3897			
	11969415	Dec 30, 2040	U-3219			
<u>RISDIPLAM - EVRYSDI</u>						
N 213535 001	11938136	Nov 08, 2036	DP			
<u>RISPERIDONE - RISVAN</u>						
N 214835 001	>A> 10058504	May 31, 2031	DP		NP	Mar 29, 2027
	>A> 10085936	May 31, 2031	DP			
	>A> 10182982	May 31, 2031	U-3943			
	>A> 10195138	May 31, 2031	U-3943			
	>A> 10335366	May 31, 2031	DP			
	>A> 10463607	May 31, 2031	DP			
	>A> 10881605	May 31, 2031	DP			
	>A> 11007139	May 31, 2031	U-3942			
	>A> 11173110	May 31, 2031	U-3941			
	>A> 11241377	May 31, 2031	U-3939			
	>A> 11752092	May 31, 2031	U-3941			
	>A> 11752093	May 31, 2031	DP			
	>A> 11759416	May 31, 2031	U-3939			
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	>A> 10058504	May 31, 2031	DP		NP	Mar 29, 2027
	>A> 10085936	May 31, 2031	DP			
	>A> 10182982	May 31, 2031	U-3943			
	>A> 10195138	May 31, 2031	U-3943			
	>A> 10335366	May 31, 2031	DP			
	>A> 10463607	May 31, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RISPERIDONE - RISVAN</u>						
N 214835 002	>A> 10881605	May 31, 2031	DP			
	>A> 11007139	May 31, 2031	U-3942			
	>A> 11173110	May 31, 2031	U-3941			
	>A> 11241377	May 31, 2031	U-3939			
	>A> 11752092	May 31, 2031	U-3941			
	>A> 11752093	May 31, 2031	DP			
	>A> 11759416	May 31, 2031	U-3939			
<u>RIVAROXABAN - XARELTO</u>						
N 215859 001	7157456	Aug 28, 2024	DS DP			
	7157456*PED	Feb 28, 2025				
<u>ROFLUMILAST - ZORYVE</u>						
N 217242 001					NP	Dec 15, 2026
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 001	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SACUBITRIL; VALSARTAN - ENTRESTO SPRINKLE</u>						
N 218591 002	10722471	Feb 02, 2037	DP U-3896			
	8101659	Jan 15, 2025	DP			
	8877938	May 27, 2027	DS DP			
	9388134	Nov 08, 2026	U-1723			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 001	>A> 11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 002	>A> 11998565	Jul 01, 2041	DP			
<u>SELENIOS ACID - SELENIOS ACID</u>						
N 209379 003	>A> 11998565	Jul 01, 2041	DP			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 001	10112942	Oct 10, 2037	DS DP	>A> NCE		May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10112942	Oct 10, 2037	DS DP	>A> NCE		May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 002	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 003	10112942	Oct 10, 2037	DS DP		>A> NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELPERCATINIB - RETEVMO</u>						
N 218160 004	10112942	Oct 10, 2037	DS DP		>A> NCE	May 08, 2025
	10137124	Oct 10, 2037	U-3450			
	10137124	Oct 10, 2037	U-3451			
	10137124	Oct 10, 2037	U-3452			
	10137124	Oct 10, 2037	U-3453			
	10172851	Oct 10, 2037	U-3450			
	10172851	Oct 10, 2037	U-3451			
	10172851	Oct 10, 2037	U-3452			
	10172851	Oct 10, 2037	U-3453			
	10584124	Oct 10, 2038	DS U-3450			
	10584124	Oct 10, 2038	DS U-3451			
	10584124	Oct 10, 2038	DS U-3452			
	10584124	Oct 10, 2038	DS U-3453			
	10786489	Oct 10, 2038	DP U-3450			
	10786489	Oct 10, 2038	DP U-3451			
	10786489	Oct 10, 2038	DP U-3452			
	10786489	Oct 10, 2038	DP U-3453			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 001	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SELUMETINIB SULFATE - KOSELUGO</u>						
N 213756 002	7425637	Mar 13, 2025	DS			
	8178693	Mar 13, 2025	DS DP			
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 001					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 002					I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256 003					I-935	Mar 08, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	004				I-935	Mar 08, 2027
<u>SEMAGLUTIDE - WEGOVY</u>						
N 215256	005				I-935	Mar 08, 2027
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845	001				ODE-469	Jan 31, 2030
<u>SIPONIMOD - MAYZENT</u>						
N 209884	001	11944602	Jul 24, 2036	U-3889		
<u>SIPONIMOD - MAYZENT</u>						
N 209884	002	11944602	Jul 24, 2036	U-3889		
<u>SIPONIMOD - MAYZENT</u>						
N 209884	003	11944602	Jul 24, 2036	U-3889		
<u>SODIUM ACETATE - SODIUM ACETATE</u>						
A 216920	001				>A> CGT	Nov 16, 2024
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	001	11896572	Jul 21, 2037	DP		
	>A>	11986451	Jul 21, 2037	U-3934		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	002	11896572	Jul 21, 2037	DP		
	>A>	11986451	Jul 21, 2037	U-3934		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	003	11896572	Jul 21, 2037	DP		
	>A>	11986451	Jul 21, 2037	U-3934		
<u>SODIUM OXYBATE - LUMRYZ</u>						
N 214755	004	11896572	Jul 21, 2037	DP		
	>A>	11986451	Jul 21, 2037	U-3934		
<u>SODIUM THIOSULFATE - PEDMARK</u>						
N 212937	001	11964018	Jul 01, 2039	U-3898		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	001	11857528	Mar 19, 2040	U-3521		
		11865098	Jun 01, 2038	U-2548		
		11872203	Dec 30, 2042	U-3693		
		11872204	Dec 30, 2042	U-3693		
		11969404	Mar 19, 2040	U-3892		
	>A>	11986454	Mar 19, 2040	U-3775		
	>A>	11986455	Mar 19, 2040	U-3521		
	>A>	11998639	Sep 05, 2037	DP U-2548		
<u>SOLRIAMFETOL HYDROCHLORIDE - SUNOSI</u>						
N 211230	002	11857528	Mar 19, 2040	U-3521		
		11865098	Jun 01, 2038	U-2548		
		11872203	Dec 30, 2042	U-3693		
		11872204	Dec 30, 2042	U-3693		
		11969404	Mar 19, 2040	U-3892		
	>A>	11986454	Mar 19, 2040	U-3775		
	>A>	11986455	Mar 19, 2040	U-3521		
	>A>	11998639	Sep 05, 2037	DP U-2548		
<u>SUVOREXANT - BELSOMRA</u>						
N 204569	001	>A> 11980623	May 29, 2033	DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002 >A>	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003 >A>	11980623	May 29, 2033	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004 >A>	11980623	May 29, 2033	DP			
<u>TADALAFIL - TADLIQ</u>						
N 214522 001 >A>	11975006	Dec 24, 2038	DP U-3397			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 001	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 002	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 003	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 004	10189837	Oct 20, 2031	DS DP		I-920	Jun 20, 2026
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 005	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TALAZOPARIB TOSYLATE - TALZENNA</u>						
N 217439 006	10189837	Oct 20, 2031	DS DP			
	10780088	Jul 27, 2029	U-3651			
	8012976	Oct 19, 2029	DS DP			
	8420650	Jul 27, 2029	DS DP			
	8735392	Oct 20, 2031	DS DP			
	9820985	Jul 27, 2029	U-2437			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11826339	Jan 25, 2033	U-3342			
	11826339	Jan 25, 2033	U-3343			
	11918556	Jan 25, 2033	U-3342			
	11918556	Jan 25, 2033	U-3343			
	11918557	Apr 07, 2033	U-3003			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	11918557	Apr 07, 2033	U-3865			
<u>TASIMELTEON - HETLIOZ LO</u>						
N 214517 001	11826339	Jan 25, 2033	U-3342			
	11918556	Jan 25, 2033	U-3342			
	11918557	Apr 07, 2033	U-3003			
<u>TAZEMETOSTAT HYDROBROMIDE - TAZVERIK</u>						
N 211723 001	10155002	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2736			
	10420775	Sep 12, 2031	U-2852			
	10420775	Sep 12, 2031	U-2853			
	11052093	Apr 13, 2032	DS DP U-2736			
	11052093	Apr 13, 2032	DS DP U-2852			
	11052093	Apr 13, 2032	DS DP U-2853			
	11491163	Apr 11, 2033	U-2736			
	11491163	Apr 11, 2033	U-2852			
	11491163	Apr 11, 2033	U-2853			
	8765732	Sep 12, 2031	U-2852			
	8765732	Sep 12, 2031	U-2853			
	9090562	Sep 12, 2031	DS DP			
	9549931	Sep 12, 2031	U-2736			
	9549931	Sep 12, 2031	U-2852			
	9549931	Sep 12, 2031	U-2853			
	9855275	Sep 12, 2031	U-2736			
<u>TECOVIRIMAT - TPOXX</u>						
N 208627 001	11890270	Aug 08, 2032	U-2346			
<u>TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY</u>						
N 208464 001	8754065	Aug 15, 2032	DS DP U-1275			
	8754065	Aug 15, 2032	DS DP U-3880			
	8754065	Aug 15, 2032	DS DP U-999			
	8754065*PED	Feb 15, 2033				
	9296769	Aug 15, 2032	DS DP U-1275			
	9296769	Aug 15, 2032	DS DP U-3880			
	9296769	Aug 15, 2032	DS DP U-999			
	9296769*PED	Feb 15, 2033				
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 001	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 002	11844804	Jun 04, 2033	U-2418			
<u>TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR)</u>						
N 209863 003	11844804	Jun 04, 2033	U-2418			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 007	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 008	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 009	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 010	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 011	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - MOUNJARO</u>						
N 215866 012	11357820	Jun 14, 2039	DS DP		NCE	May 13, 2027
	9474780	Jan 05, 2036	DS DP U-3378			
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 001	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 002	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 003	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 004	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 005	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND (AUTOINJECTOR)</u>						
N 217806 006	11918623	Jun 14, 2039		U-3855		
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 007	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 008	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 009	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 010	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 011	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIRZEPATIDE - ZEPBOUND</u>						
N 217806 012	11357820	Jun 14, 2039	DP		NCE	May 13, 2027
	11918623	Jun 14, 2039	U-3855			
	9474780	Jan 05, 2036	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 001	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TIVOZANIB HYDROCHLORIDE - FOTIVDA</u>						
N 212904 002	6821987	Apr 26, 2025	DS DP U-3100			
	7166722	Nov 16, 2024	DS DP			
<u>TOPIRAMATE - EPRONTIA</u>						
N 214679 001	11911362	Aug 21, 2040	DP U-3413			
	11911362	Aug 21, 2040	DP U-3414			
	11911362	Aug 21, 2040	DP U-3415			
<u>TOVORAFENIB - OJEMDA</u>						
N 217700 001	10426782	Jun 23, 2035	DP		>A> NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		>A> ODE-478	Apr 23, 2031
<u>TOVORAFENIB - OJEMDA</u>						
N 218033 001	10426782	Jun 23, 2035	DP		>A> NCE	Apr 23, 2029
	8293752	Aug 04, 2031	DS DP		>A> ODE-478	Apr 23, 2031
<u>TRAVOPROST - IDOSE TR</u>						
N 218010 001					NP	Dec 13, 2026
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 001	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 002	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 003	11826327	Feb 03, 2042	U-3749			
<u>TREPROSTINIL - TYVASO DPI</u>						
N 214324 004	11826327	Feb 03, 2042	U-3749			
<u>TUCATINIB - TUKYSA</u>						
N 213411 001	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>TUCATINIB - TUKYSA</u>						
N 213411 002	11207324	Apr 27, 2038	U-3783			
	11666572	Apr 27, 2038	U-3783			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 001	11857542	Dec 22, 2041	U-3786			
	11925709	Jan 30, 2035	DP			
<u>UBROGEPANT - UBRELVY</u>						
N 211765 002	11925709	Jan 30, 2035	DP			
<u>UPADACITINIB - RINVOO</u>						
N 211675 001	>A> RE47221	Aug 16, 2033	DS		>A> I-946	Apr 26, 2027
					>A> NPP	Apr 24, 2027
					>A> ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 002	>A> RE47221	Aug 16, 2033	DS		>A> I-946	Apr 26, 2027
					>A> NPP	Apr 24, 2027
					>A> ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO</u>						
N 211675 003	>A> RE47221	Aug 16, 2033	DS		>A> I-946	Apr 26, 2027
					>A> NPP	Apr 24, 2027

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>UPADACITINIB - RINVOO</u>						
N 211675	003				>A> ODE-481	Apr 26, 2031
<u>UPADACITINIB - RINVOO LO</u>						
N 218347	001	>A> RE47221	Aug 16, 2033	DS	>A> NCE >A> NP >A> ODE-481	Aug 16, 2024 Apr 26, 2027 Apr 26, 2031
<u>VADADUSTAT - VAFSEO</u>						
N 215192	001	10149842	Nov 14, 2034	DS DP	NCE	Mar 27, 2029
		11065237	Nov 14, 2034	DS DP	U-3876	
		11324734	Mar 31, 2036	DP		
		11844756	Mar 31, 2036		U-3876	
		11857543	Jun 09, 2034		U-3876	
		7811595	Mar 13, 2028	DS DP		
		8323671	Apr 03, 2028		U-3876	
		8343952	Aug 14, 2027	DS DP		
		8598210	Jun 26, 2027	DS DP		
		8940773	Jun 26, 2027		U-3876	
		9701636	Nov 14, 2034	DS DP		
		9987262	Nov 14, 2034		U-3876	
		RE47437	Jun 26, 2027	DS DP		
<u>VADADUSTAT - VAFSEO</u>						
N 215192	002	10149842	Nov 14, 2034	DS DP	NCE	Mar 27, 2029
		11065237	Nov 14, 2034	DS DP	U-3876	
		11324734	Mar 31, 2036	DP		
		11844756	Mar 31, 2036		U-3876	
		11857543	Jun 09, 2034		U-3876	
		7811595	Mar 13, 2028	DS DP		
		8323671	Apr 03, 2028		U-3876	
		8343952	Aug 14, 2027	DS DP		
		8598210	Jun 26, 2027	DS DP		
		8940773	Jun 26, 2027		U-3876	
		9701636	Nov 14, 2034	DS DP		
		9987262	Nov 14, 2034		U-3876	
		RE47437	Jun 26, 2027	DS DP		
<u>VADADUSTAT - VAFSEO</u>						
N 215192	003	10149842	Nov 14, 2034	DS DP	NCE	Mar 27, 2029
		11065237	Nov 14, 2034	DS DP	U-3876	
		11324734	Mar 31, 2036	DP		
		11844756	Mar 31, 2036		U-3876	
		11857543	Jun 09, 2034		U-3876	
		7811595	Mar 13, 2028	DS DP		
		8323671	Apr 03, 2028		U-3876	
		8343952	Aug 14, 2027	DS DP		
		8598210	Jun 26, 2027	DS DP		
		8940773	Jun 26, 2027		U-3876	
		9701636	Nov 14, 2034	DS DP		
		9987262	Nov 14, 2034		U-3876	
		RE47437	Jun 26, 2027	DS DP		
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390	001	>A> 10065952	Oct 28, 2036	DS DP	U-1995	>A> I-925
		>A> 10065952	Oct 28, 2036	DS DP	U-3055	Aug 18, 2026
		>A> 10844058	Oct 28, 2036	DS DP	U-1995	
		>A> 10844058	Oct 28, 2036	DS DP	U-3055	
		>A> 10851103	Oct 28, 2036	DS DP	U-1995	
		>A> 10851103	Oct 28, 2036	DS DP	U-3055	
		>A> 10851104	Oct 28, 2036	DS	U-1995	
		>A> 10851104	Oct 28, 2036	DS	U-3055	
		>A> 10857137	Oct 10, 2037		U-1995	
		>A> 10857148	Oct 10, 2037		U-1995	
		>A> 10874648	Oct 10, 2037		U-1995	
		>A> 10874648	Oct 10, 2037		U-3046	
		>A> 10874648	Oct 10, 2037		U-3055	
		>A> 10906902	Dec 22, 2036	DS DP		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 001	>A> 10906903	Dec 22, 2036	DS DP			
	>A> 10912771	Oct 10, 2037			U-1995	
	>A> 10912771	Oct 10, 2037			U-3055	
	>A> 10912771	Oct 10, 2037			U-3076	
	>A> 10919892	Dec 22, 2036	DS DP			
	>A> 10940141	Aug 10, 2040			U-1995	
	>A> 10952997	Oct 10, 2037			U-1995	
	>A> 10993941	Oct 10, 2037			U-1995	
	>A> 11026931	Aug 14, 2039			U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-3055	
	>A> 11040029	Oct 10, 2037			U-1995	
	>A> 11311532	Sep 18, 2038	DP		U-1995	
	>A> 11311532	Sep 18, 2038	DP		U-3055	
	>A> 11439629	Oct 10, 2037			U-3055	
	>A> 11654142	Nov 14, 2038			U-3055	
	>A> 8039627	Apr 11, 2031	DS DP			
	>A> 8357697	Nov 08, 2027			U-1995	
	>A> 8357697	Nov 08, 2027			U-3055	
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 002	>A> 10065952	Oct 28, 2036	DS DP		U-1995	>A> I-925
	>A> 10065952	Oct 28, 2036	DS DP		U-3055	Aug 18, 2026
	>A> 10844058	Oct 28, 2036	DS DP		U-1995	
	>A> 10844058	Oct 28, 2036	DS DP		U-3055	
	>A> 10851103	Oct 28, 2036	DS DP		U-1995	
	>A> 10851103	Oct 28, 2036	DS DP		U-3055	
	>A> 10851104	Oct 28, 2036	DS		U-1995	
	>A> 10851104	Oct 28, 2036	DS		U-3055	
	>A> 10857137	Oct 10, 2037			U-1995	
	>A> 10857148	Oct 10, 2037			U-1995	
	>A> 10874648	Oct 10, 2037			U-1995	
	>A> 10874648	Oct 10, 2037			U-3046	
	>A> 10874648	Oct 10, 2037			U-3055	
	>A> 10906902	Dec 22, 2036	DS DP			
	>A> 10906903	Dec 22, 2036	DS DP			
	>A> 10912771	Oct 10, 2037			U-1995	
	>A> 10912771	Oct 10, 2037			U-3055	
	>A> 10912771	Oct 10, 2037			U-3076	
	>A> 10919892	Dec 22, 2036	DS DP			
	>A> 10940141	Aug 10, 2040			U-1995	
	>A> 10952997	Oct 10, 2037			U-1995	
	>A> 10993941	Oct 10, 2037			U-1995	
	>A> 11026931	Aug 14, 2039			U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-1995	
	>A> 11026939	Sep 18, 2038	DP		U-3055	
	>A> 11040029	Oct 10, 2037			U-1995	
	>A> 11311532	Sep 18, 2038	DP		U-1995	
	>A> 11311532	Sep 18, 2038	DP		U-3055	
	>A> 11439629	Oct 10, 2037			U-3055	
	>A> 11654142	Nov 14, 2038			U-3055	
	>A> 8039627	Apr 11, 2031	DS DP			
	>A> 8357697	Nov 08, 2027			U-1995	
	>A> 8357697	Nov 08, 2027			U-3055	
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	>A> 10065952	Oct 28, 2036	DS DP		U-1995	>A> I-925
	>A> 10065952	Oct 28, 2036	DS DP		U-3055	Aug 18, 2026
	>A> 10844058	Oct 28, 2036	DS DP		U-1995	
	>A> 10844058	Oct 28, 2036	DS DP		U-3055	
	>A> 10851103	Oct 28, 2036	DS DP		U-1995	
	>A> 10851103	Oct 28, 2036	DS DP		U-3055	
	>A> 10851104	Oct 28, 2036	DS		U-1995	
	>A> 10851104	Oct 28, 2036	DS		U-3055	
	>A> 10857137	Oct 10, 2037			U-1995	
	>A> 10857148	Oct 10, 2037			U-1995	
	>A> 10874648	Oct 10, 2037			U-1995	
	>A> 10874648	Oct 10, 2037			U-3046	



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VALBENAZINE TOSYLATE - INGREZZA SPRINKLE</u>						
N 218390 003	>A> 10874648	Oct 10, 2037	U-3055			
	>A> 10906902	Dec 22, 2036	DS DP			
	>A> 10906903	Dec 22, 2036	DS DP			
	>A> 10912771	Oct 10, 2037	U-1995			
	>A> 10912771	Oct 10, 2037	U-3055			
	>A> 10912771	Oct 10, 2037	U-3076			
	>A> 10919892	Dec 22, 2036	DS DP			
	>A> 10940141	Aug 10, 2040	U-1995			
	>A> 10952997	Oct 10, 2037	U-1995			
	>A> 10993941	Oct 10, 2037	U-1995			
	>A> 11026931	Aug 14, 2039	U-1995			
	>A> 11026939	Sep 18, 2038	DP U-1995			
	>A> 11026939	Sep 18, 2038	DP U-3055			
	>A> 11040029	Oct 10, 2037	U-1995			
	>A> 11311532	Sep 18, 2038	DP U-1995			
	>A> 11311532	Sep 18, 2038	DP U-3055			
	>A> 11439629	Oct 10, 2037	U-3055			
	>A> 11654142	Nov 14, 2038	U-3055			
	>A> 8039627	Apr 11, 2031	DS DP			
	>A> 8357697	Nov 08, 2027	U-1995			
	>A> 8357697	Nov 08, 2027	U-3055			
<u>VAMOROLONE - AGAMREE</u>						
N 215239 001	11690853	Mar 07, 2033	U-3747			
<u>VARENICLINE TARTRATE - TYRVAYA</u>						
N 213978 001	11903941	Oct 19, 2035	U-1900			
	11903942	Oct 19, 2035	DP			
	11903943	Oct 19, 2035	U-1900			
	11911380	Oct 19, 2035	U-1900			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 001	>A> 10646550	Aug 01, 2036	DP U-3927			
	>A> 11590204	Aug 01, 2036	DP U-3927			
	>A> 11911446	Aug 01, 2036	U-3927			
	>A> 8198242	Jun 11, 2030	DS DP U-3927			
	>A> RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 002	>A> 10646550	Aug 01, 2036	DP U-3927			
	>A> 11590204	Aug 01, 2036	DP U-3927			
	>A> 11911446	Aug 01, 2036	U-3927			
	>A> 8198242	Jun 11, 2030	DS DP U-3927			
	>A> RE48267	May 20, 2030	U-3927			
<u>VOSORITIDE - VOXZOGO</u>						
N 214938 003	>A> 10646550	Aug 01, 2036	DP U-3927			
	>A> 11590204	Aug 01, 2036	DP U-3927			
	>A> 11911446	Aug 01, 2036	U-3927			
	>A> 8198242	Jun 11, 2030	DS DP U-3927			
	>A> RE48267	May 20, 2030	U-3927			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 001	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 213137 002	11944612	Dec 02, 2036	U-3893			
<u>VOXELOTOR - OXBRYTA</u>						
N 216157 001	11944612	Dec 02, 2036	U-3893			
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-1745		I-936	Mar 07, 2027
	10570139	Apr 22, 2034	U-2145		ODE-467	Mar 07, 2031
	10570139	Apr 22, 2034	U-2537			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZANUBRUTINIB - BRUKINSA</u>						
N 213217 001	10570139	Apr 22, 2034	U-2666			
	10570139	Apr 22, 2034	U-3063			
	10570139	Apr 22, 2034	U-3486			
	10570139	Apr 22, 2034	U-3860			
	11142528	Apr 22, 2034	DP U-1745			
	11142528	Apr 22, 2034	DP U-2145			
	11142528	Apr 22, 2034	DP U-2537			
	11142528	Apr 22, 2034	DP U-2666			
	11142528	Apr 22, 2034	DP U-3063			
	11142528	Apr 22, 2034	DP U-3486			
	11142528	Apr 22, 2034	DP U-3860			
	11701357	Jun 24, 2039	U-3860			
	11786531	Jan 19, 2043	U-3715			
	11786531	Jan 19, 2043	U-3716			
	11786531	Jan 19, 2043	U-3717			
	11786531	Jan 19, 2043	U-3718			
	11786531	Jan 19, 2043	U-3719			
	11786531	Jan 19, 2043	U-3720			
	11786531	Jan 19, 2043	U-3875			
	11851437	Aug 15, 2037	DS DP			
	11884674	Aug 15, 2037	U-1745			
	11884674	Aug 15, 2037	U-2145			
	11884674	Aug 15, 2037	U-2537			
	11884674	Aug 15, 2037	U-2666			
	11884674	Aug 15, 2037	U-3063			
	11884674	Aug 15, 2037	U-3486			
	11884674	Aug 15, 2037	U-3860			
	11896596	Jan 19, 2043	U-3715			
	11896596	Jan 19, 2043	U-3716			
	11896596	Jan 19, 2043	U-3717			
	11896596	Jan 19, 2043	U-3718			
	11896596	Jan 19, 2043	U-3719			
	11896596	Jan 19, 2043	U-3720			
	11896596	Jan 19, 2043	U-3875			
	11911386	Jan 19, 2043	U-3715			
	11911386	Jan 19, 2043	U-3716			
	11911386	Jan 19, 2043	U-3717			
	11911386	Jan 19, 2043	U-3718			
	11911386	Jan 19, 2043	U-3719			
	11911386	Jan 19, 2043	U-3720			
	11911386	Jan 19, 2043	U-3875			
	>A> 11970500	Aug 15, 2037	U-1745			
	>A> 11970500	Aug 15, 2037	U-2145			
	>A> 11970500	Aug 15, 2037	U-2537			
	>A> 11970500	Aug 15, 2037	U-2666			
	>A> 11970500	Aug 15, 2037	U-3063			
	>A> 11970500	Aug 15, 2037	U-3486			
	>A> 11970500	Aug 15, 2037	U-3860			
	9447106	Apr 22, 2034	DS DP U-1745			
	9447106	Apr 22, 2034	DS DP U-2145			
	9447106	Apr 22, 2034	DS DP U-2537			
	9447106	Apr 22, 2034	DS DP U-2666			
	9447106	Apr 22, 2034	DS DP U-3063			
	9447106	Apr 22, 2034	DS DP U-3486			
	9447106	Apr 22, 2034	DS DP U-3860			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 001	>A> 11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 002	>A> 11965040	Jun 12, 2035	DP			
<u>ZILUCOPLAN SODIUM - ZILBRYSO</u>						
N 216834 003	>A> 11965040	Jun 12, 2035	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 05 - May 2024

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 001	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 002	11884696	Dec 24, 2037	U-2552			
<u>ZURANOLONE - ZURZUVAE</u>						
N 217369 003	11884696	Dec 24, 2037	U-2552			

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 44<sup>TH</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_patent.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm)

The current complete list of exclusivity terms is available at [http://www.accessdata.fda.gov/scripts/cder/ob/results\\_exclusivity.cfm](http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfm)